<SEC-DOCUMENT>0001472375-23-000142.txt : 20231108
<SEC-HEADER>0001472375-23-000142.hdr.sgml : 20231108
<ACCEPTANCE-DATETIME>20231108115609
ACCESSION NUMBER:		0001472375-23-000142
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		44
CONFORMED PERIOD OF REPORT:	20230930
FILED AS OF DATE:		20231108
DATE AS OF CHANGE:		20231108

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			REGENEREX PHARMA, INC.
		CENTRAL INDEX KEY:			0001357878
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				980479983
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			0331

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-53230
		FILM NUMBER:		231386763

	BUSINESS ADDRESS:	
		STREET 1:		5348 VEGAS DRIVE, SUITE 177
		CITY:			LAS VEGAS
		STATE:			NV
		ZIP:			89108
		BUSINESS PHONE:		305-927-5191

	MAIL ADDRESS:	
		STREET 1:		5348 VEGAS DRIVE, SUITE 177
		CITY:			LAS VEGAS
		STATE:			NV
		ZIP:			89108

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PEPTIDE TECHNOLOGIES, INC.
		DATE OF NAME CHANGE:	20180309

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Eternelle Skincare Products Inc.
		DATE OF NAME CHANGE:	20170621

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PEPTIDE TECHNOLOGIES, INC.
		DATE OF NAME CHANGE:	20111007
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>ixform10q.htm
<DESCRIPTION>QUARTERLY REPORT FOR THE PERIOD ENDED SEPTEMBER 30, 2023
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:us-roles="http://fasb.org/us-roles/2023" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:RGPX="http://regenerexpharmainc.com/20230930">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
<body>
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2023-04-01to2023-09-30" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2023-04-01to2023-09-30" name="dei:DocumentFiscalYearFocus">2023</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2023-04-01to2023-09-30" name="dei:DocumentFiscalPeriodFocus">Q2</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2023-04-01to2023-09-30" name="dei:CurrentFiscalYearEndDate">--03-31</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2023-04-01to2023-09-30" name="dei:EntityCentralIndexKey">0001357878</ix:nonNumeric>
  <ix:nonFraction name="us-gaap:PrepaidExpenseCurrent" contextRef="AsOf2023-03-31" id="xdx2ixbrl0046" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2023-03-31" id="xdx2ixbrl0062" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NotesPayableCurrent" contextRef="AsOf2023-03-31" id="xdx2ixbrl0089" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2023-03-31" id="xdx2ixbrl0092" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NotesPayable" contextRef="AsOf2023-03-31" id="xdx2ixbrl0104" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2023-03-31" id="xdx2ixbrl0107" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="AsOf2023-09-30" id="xdx2ixbrl0112" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="AsOf2023-03-31" id="xdx2ixbrl0113" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2022-07-012022-09-30" id="xdx2ixbrl0152" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2022-04-012022-09-30" id="xdx2ixbrl0154" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2022-04-012022-09-30" id="xdx2ixbrl0214" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PaymentsToAcquireIntangibleAssets" contextRef="From2022-04-012022-09-30" id="xdx2ixbrl0217" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" contextRef="From2022-04-012022-09-30" id="xdx2ixbrl0220" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PaymentsToAcquireFurnitureAndFixtures" contextRef="From2022-04-012022-09-30" id="xdx2ixbrl0241" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2022-04-012022-09-30" id="xdx2ixbrl0244" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:RepaymentsOfNotesPayable" contextRef="From2022-04-012022-09-30_us-gaap_OtherAffiliatesMember" id="xdx2ixbrl0253" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:RepaymentsOfNotesPayable" contextRef="From2022-04-012022-09-30_custom_ShareholderMember" id="xdx2ixbrl0256" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfWarrants" contextRef="From2022-04-012022-09-30" id="xdx2ixbrl0262" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxesPaid" contextRef="From2023-04-01to2023-09-30" id="xdx2ixbrl0279" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxesPaid" contextRef="From2022-04-012022-09-30" id="xdx2ixbrl0280" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:InterestPaid" contextRef="From2023-04-01to2023-09-30" id="xdx2ixbrl0282" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:InterestPaid" contextRef="From2022-04-012022-09-30" id="xdx2ixbrl0283" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="RGPX:OperatingLeasesRouAssetAndLiabilities" contextRef="From2022-04-012022-09-30" id="xdx2ixbrl0292" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1" contextRef="From2023-04-01to2023-09-30" id="xdx2ixbrl0294" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="RGPX:NoncashOrPartNoncashAcquisitionOfIntangibleAssetsExcludingGoodwill" contextRef="From2022-04-012022-09-30" id="xdx2ixbrl0298" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-04-012022-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0306" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-04-012022-06-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0307" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-07-012022-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl0323" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-07-012022-09-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0324" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2023-04-012023-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0342" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2023-04-012023-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0348" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-04-012023-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0352" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-04-012023-06-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0353" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-07-012023-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0371" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2023-07-012023-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0377" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-07-012023-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl0381" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-07-012023-09-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0382" unitRef="USD" xs:nil="true"></ix:nonFraction>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="rgpx-20230930.xsd" xlink:type="simple" />
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2023-04-01to2023-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357878</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-11-08">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357878</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-11-08</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357878</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357878</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012023-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357878</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012022-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357878</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-012022-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357878</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012023-09-30_us-gaap_OtherAffiliatesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357878</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:OtherAffiliatesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-012022-09-30_us-gaap_OtherAffiliatesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357878</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:OtherAffiliatesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012023-09-30_custom_ShareholderMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357878</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">RGPX:ShareholderMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-012022-09-30_custom_ShareholderMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357878</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">RGPX:ShareholderMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357878</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357878</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357878</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357878</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357878</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357878</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357878</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357878</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357878</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357878</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357878</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357878</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357878</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357878</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357878</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357878</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-012022-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357878</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-012022-06-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357878</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-012022-06-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357878</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-012022-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357878</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012022-09-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357878</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012022-09-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357878</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012022-09-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357878</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012023-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357878</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012023-06-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357878</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012023-06-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357878</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012023-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357878</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012023-09-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357878</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012023-09-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357878</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012023-09-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357878</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-09-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357878</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-09-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357878</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-09-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357878</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-09-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357878</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-09-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357878</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-09-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357878</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-11-15_custom_PurchaseIntellectualPropertyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357878</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">RGPX:PurchaseIntellectualPropertyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-11-15</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-11-15">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357878</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-11-15</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-09-30_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357878</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-09-30_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357878</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-09-30_srt_ChiefFinancialOfficerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357878</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefFinancialOfficerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012023-09-30_custom_AffiliatesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357878</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">RGPX:AffiliatesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-012022-09-30_custom_AffiliatesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357878</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">RGPX:AffiliatesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-09-30_srt_ChiefExecutiveOfficerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357878</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_custom_ChiefExecutiveOfficerAndChiefFinancialOfficerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357878</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">RGPX:ChiefExecutiveOfficerAndChiefFinancialOfficerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012023-09-30_custom_ChiefExecutiveOfficerAndChiefFinancialOfficerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357878</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">RGPX:ChiefExecutiveOfficerAndChiefFinancialOfficerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-012022-09-30_custom_ChiefExecutiveOfficerAndChiefFinancialOfficerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357878</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">RGPX:ChiefExecutiveOfficerAndChiefFinancialOfficerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-09-30_us-gaap_MajorityShareholderMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357878</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:MajorityShareholderMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_us-gaap_MajorityShareholderMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357878</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:MajorityShareholderMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-09-30_custom_ReissuedNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357878</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">RGPX:ReissuedNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012023-09-30_custom_ShareholderMember_custom_PromissoryNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357878</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">RGPX:ShareholderMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">RGPX:PromissoryNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-09-30_custom_ShareholderMember_custom_Promissory1NotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357878</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">RGPX:ShareholderMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">RGPX:Promissory1NotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-09-30_custom_AggregateInterestExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357878</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">RGPX:AggregateInterestExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-09-30_custom_AggregateInterestExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357878</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">RGPX:AggregateInterestExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-11-012021-11-15">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357878</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-11-01</xbrli:startDate>
        <xbrli:endDate>2021-11-15</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012023-09-30_custom_ChiefExecutiveOfficerAndChiefFinancialOfficerMember397223531">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357878</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AssetsSoldUnderAgreementsToRepurchaseAxis">RGPX:ChiefExecutiveOfficerAndChiefFinancialOfficerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-012023-03-31_custom_ChiefExecutiveOfficerAndChiefFinancialOfficerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357878</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AssetsSoldUnderAgreementsToRepurchaseAxis">RGPX:ChiefExecutiveOfficerAndChiefFinancialOfficerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-09-30_custom_AssetPurchaseAgreementLiabilityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357878</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">RGPX:AssetPurchaseAgreementLiabilityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_custom_AssetPurchaseAgreementLiabilityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357878</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">RGPX:AssetPurchaseAgreementLiabilityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-09-30_custom_OfficeLeaseMember_custom_MonthlyRentalPaymentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357878</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertySubjectToOrAvailableForOperatingLeaseAxis">RGPX:OfficeLeaseMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">RGPX:MonthlyRentalPaymentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-09-30_custom_OfficeLeaseMember_custom_SecurityDepositMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357878</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertySubjectToOrAvailableForOperatingLeaseAxis">RGPX:OfficeLeaseMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">RGPX:SecurityDepositMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-09-30_custom_PlantFacilityMember_custom_MonthlyRentalPaymentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357878</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertySubjectToOrAvailableForOperatingLeaseAxis">RGPX:PlantFacilityMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">RGPX:MonthlyRentalPaymentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_custom_PlantFacilityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357878</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertySubjectToOrAvailableForOperatingLeaseAxis">RGPX:PlantFacilityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012023-09-30_custom_OperatingLeaseCostMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357878</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">RGPX:OperatingLeaseCostMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-012022-09-30_custom_OperatingLeaseCostMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357878</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">RGPX:OperatingLeaseCostMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012023-09-30_custom_BoardMembersAndConsultantsMember_custom_ServicesRenderedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357878</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">RGPX:BoardMembersAndConsultantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">RGPX:ServicesRenderedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-09-30_custom_BoardMembersAndConsultantsMember_custom_ServicesRenderedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357878</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">RGPX:BoardMembersAndConsultantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">RGPX:ServicesRenderedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012023-09-30_custom_BoardMembersAndConsultantsMember_custom_ServicesRenderedMember_custom_WarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357878</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">RGPX:BoardMembersAndConsultantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">RGPX:ServicesRenderedMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">RGPX:WarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-09-30_custom_BoardMembersAndConsultantsMember_custom_ServicesRenderedMember_custom_WarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357878</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">RGPX:BoardMembersAndConsultantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">RGPX:ServicesRenderedMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">RGPX:WarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-10-01_us-gaap_SubsequentEventMember_custom_ReissuedNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357878</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">RGPX:ReissuedNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-10-01</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-11-01_us-gaap_SubsequentEventMember_custom_ReissuedNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357878</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">RGPX:ReissuedNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-11-01</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-11-012023-11-30_us-gaap_SubsequentEventMember_custom_ReissuedNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357878</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">RGPX:ReissuedNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-11-01</xbrli:startDate>
        <xbrli:endDate>2023-11-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="Pure">
      <xbrli:measure>xbrli:pure</xbrli:measure>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<hr style="border-top: black 0 solid; border-bottom: black 0 dashed; border-right-width: 0; border-left-width: 0; border-top-width: 4px; border-bottom-width: 1px; background-color: transparent; height: 3px; margin-bottom: 20px" />

<p style="margin: 0px; text-align: center; font-size: 15pt">&#160;<b>UNITED STATES</b></p>

<p style="margin: 0px; text-align: center; font-size: 15pt"><b>SECURITIES AND EXCHANGE
COMMISSION</b></p>

<p style="margin: 0px; text-align: center; font-size: 10pt"><b>WASHINGTON,
D.C. 20549</b></p>

<p style="margin: 0px; text-align: center; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0px; text-align: center; font-size: 15pt"><b>FORM <ix:nonNumeric contextRef="From2023-04-01to2023-09-30" name="dei:DocumentType">10-Q</ix:nonNumeric></b><b></b></p>

<p style="margin: 0px; text-align: center; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0px; text-align: center; font-size: 10pt"><b><ix:nonNumeric contextRef="From2023-04-01to2023-09-30" format="ixt:booleantrue" name="dei:DocumentQuarterlyReport">[X]</ix:nonNumeric> QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D)
OF THE SECURITIES EXCHANGE ACT OF 1934</b></p>

<p style="margin: 0px; text-align: center; font-size: 10pt">&#160;</p>

<p style="margin: 0px; text-align: center; font-size: 10pt">For the quarterly period
ended <ix:nonNumeric contextRef="From2023-04-01to2023-09-30" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate">September 30, 2023</ix:nonNumeric></p>

<p style="margin: 0px; text-align: center; font-size: 10pt">&#160;</p>

<p style="margin: 0px; text-align: center; font-size: 10pt"><b><ix:nonNumeric contextRef="From2023-04-01to2023-09-30" format="ixt:booleanfalse" name="dei:DocumentTransitionReport">[ ]</ix:nonNumeric> TRANSITION REPORT PURSUANT TO SECTION
13 OR 15(D) OF THE SECURITIES EXCHANGE ACT</b></p>

<p style="margin: 0px; text-align: center; font-size: 10pt">&#160;</p>

<p style="margin: 0px; text-align: center; font-size: 10pt">Commission File No.
<ix:nonNumeric contextRef="From2023-04-01to2023-09-30" name="dei:EntityFileNumber">000-53230</ix:nonNumeric></p>

<p style="margin: 0px; font-size: 10pt">&#160;</p>

<p style="margin: 0px; text-align: center; font-size: 10pt"><img src="regenerexlogo.gif" alt="" /><br /></p>

<p style="margin: 0px; font-size: 10pt">&#160;</p>

<p style="margin: 0px; text-align: center; font-size: 15pt"><b><span style="text-decoration: underline"><ix:nonNumeric contextRef="From2023-04-01to2023-09-30" name="dei:EntityRegistrantName">REGENEREX PHARMA, INC.</ix:nonNumeric></span></b><span style="text-decoration: underline"></span></p>

<p style="margin: 0px; text-align: center; font-size: 10pt">(Exact name of registrant as
specified in its charter)</p>

<p style="margin: 0px; text-align: center; font-size: 10pt">&#160;</p>

<p style="margin: 0px; text-align: center; font-size: 10pt">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse">
  <tbody>
  <tr>
    <td style="border-bottom: black 1.01px solid; vertical-align: top; width: 49%"><p style="margin: 0px; text-align: center; font-size: 10pt"><b><ix:nonNumeric contextRef="From2023-04-01to2023-09-30" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode">Nevada</ix:nonNumeric></b></p></td>
    <td style="padding: 0cm 0cm 1.5pt; vertical-align: top"><p style="margin: 0px">&#160;</p></td>
    <td style="border-bottom: black 1.01px solid; vertical-align: top; width: 49%"><p style="margin: 0px; text-align: center; font-size: 10pt"><b><ix:nonNumeric contextRef="From2023-04-01to2023-09-30" name="dei:EntityTaxIdentificationNumber">98-0479983</ix:nonNumeric></b></p></td>
  </tr>
  <tr>
    <td style="vertical-align: top"><p style="margin: 0px; text-align: center; font-size: 10pt">(State or other
  jurisdiction of</p></td>
    <td style="vertical-align: top"><p style="margin: 0px">&#160;</p></td>
    <td style="vertical-align: top"><p style="margin: 0px; text-align: center; font-size: 10pt">(IRS Employer</p></td>
  </tr>
  <tr>
    <td style="vertical-align: top"><p style="margin: 0px; text-align: center; font-size: 10pt">incorporation or
  organization)</p></td>
    <td style="vertical-align: top"><p style="margin: 0px">&#160;</p></td>
    <td style="vertical-align: top"><p style="margin: 0px; text-align: center; font-size: 10pt">Identification No.)</p></td>
  </tr>
</tbody>
</table>

<p style="margin: 0px; text-align: center; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0px; text-align: center; font-size: 10pt"><b><span style="text-decoration: underline"><ix:nonNumeric contextRef="From2023-04-01to2023-09-30" name="dei:EntityAddressAddressLine1">5348 Vegas Drive #177</ix:nonNumeric></span></b></p>

<p style="margin: 0px; text-align: center; font-size: 10pt"><b><span style="text-decoration: underline"><ix:nonNumeric contextRef="From2023-04-01to2023-09-30" name="dei:EntityAddressCityOrTown">Las Vegas</ix:nonNumeric>, <ix:nonNumeric contextRef="From2023-04-01to2023-09-30" name="dei:EntityAddressStateOrProvince">NV</ix:nonNumeric> <ix:nonNumeric contextRef="From2023-04-01to2023-09-30" name="dei:EntityAddressPostalZipCode">89108</ix:nonNumeric></span></b></p>

<p style="margin: 0px; text-align: center; font-size: 10pt">(Address of principal
executive offices)</p>

<p style="margin: 0px; text-align: center; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0px; text-align: center; font-size: 10pt"><b><span style="text-decoration: underline"><ix:nonNumeric contextRef="From2023-04-01to2023-09-30" name="dei:CityAreaCode">(877)</ix:nonNumeric> <ix:nonNumeric contextRef="From2023-04-01to2023-09-30" name="dei:LocalPhoneNumber">761-7479</ix:nonNumeric></span></b></p>

<p style="margin: 0px; text-align: center; font-size: 10pt">Registrant&#8217;s telephone
number, including area code</p>

<p style="margin: 0px; text-align: center; font-size: 10pt">&#160;</p>

<p style="margin: 0px; text-align: justify; font-size: 10pt">Indicate by check mark
whether the Registrant (1) has filed all reports required by Section 13 or
15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or
for such shorter period that the Registrant was required to file such reports)
and (2) has been subject to such filing requirements for the past 90 days:</p>

<p style="margin: 0px; text-align: justify; text-indent: 26.66px; font-size: 10pt"><ix:nonNumeric contextRef="From2023-04-01to2023-09-30" name="dei:EntityCurrentReportingStatus">Yes</ix:nonNumeric> [X ] No [&#160;&#160; ]</p>

<p style="margin: 0px; text-align: justify; font-size: 10pt">&#160;</p>

<p style="margin: 0px; text-align: justify; font-size: 10pt">Indicate by check mark
whether the registrant has submitted electronically and posted on its corporate
Web site, if any, every Interactive Data File required to be submitted and
posted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during
the preceding 12 months (or for such shorter period that the registrant was
required to submit and post such files).</p>

<p style="margin: 0px; text-align: justify; text-indent: 26.66px; font-size: 10pt"><ix:nonNumeric contextRef="From2023-04-01to2023-09-30" name="dei:EntityInteractiveDataCurrent">Yes</ix:nonNumeric> [X] No [&#160;&#160;]</p>

<p style="margin: 0px; text-align: justify; font-size: 10pt">&#160;</p>

<p style="margin: 0px; text-align: justify; font-size: 10pt">Indicate by check mark
whether the registrant is a large accelerated filer, an accelerated filer, a
non-accelerated filer, a smaller reporting company, or an emerging growth
company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221;
&#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the
Exchange Act.</p>

<table border="0" cellspacing="0" cellpadding="0" style="width: 100%; page-break-after: always">
  <tbody>
  <tr>
    <td style="border-bottom: black 4px solid"><p style="margin: 0; font-size: 10pt">&#160;</p></td>
  </tr>
</tbody>
</table>

<p style="margin: 0; font-size: 10pt">&#160;<span style="font-size: 10pt; text-align: justify">&#160;</span></p>

<table border="0" cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse">
  <tbody>
  <tr>
    <td style="width: 38%; vertical-align: top"><p style="margin: 0px; text-indent: 13.33px; font-size: 10pt">Large accelerated filer</p></td>
    <td style="width: 20%; vertical-align: top"><p style="margin: 0px; font-size: 10pt">[&#160;&#160;]</p></td>
    <td style="width: 31%; vertical-align: top"><p style="margin: 0px; font-size: 10pt">Accelerated
  filer</p></td>
    <td style="width: 11%; vertical-align: top"><p style="margin: 0px; font-size: 10pt">[&#160;&#160;
  ]</p></td>
  </tr>
  <tr>
    <td style="vertical-align: top"><p style="margin: 0px; text-indent: 13.33px; font-size: 10pt"><ix:nonNumeric contextRef="From2023-04-01to2023-09-30" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory">Non-Accelerated filer</ix:nonNumeric></p></td>
    <td style="vertical-align: top"><p style="margin: 0px; font-size: 10pt">[&#160;&#160;]</p></td>
    <td style="vertical-align: top"><p style="margin: 0px; font-size: 10pt">Smaller
  reporting company</p></td>
    <td style="vertical-align: top"><p style="margin: 0px; font-size: 10pt"><ix:nonNumeric contextRef="From2023-04-01to2023-09-30" format="ixt:booleantrue" name="dei:EntitySmallBusiness">[X]</ix:nonNumeric></p></td>
  </tr>
  <tr>
    <td style="vertical-align: top"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="vertical-align: top"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="vertical-align: top"><p style="margin: 0px; font-size: 10pt">Emerging
  growth company</p></td>
    <td style="vertical-align: top"><p style="margin: 0px; font-size: 10pt"><ix:nonNumeric contextRef="From2023-04-01to2023-09-30" format="ixt:booleantrue" name="dei:EntityEmergingGrowthCompany">[X]</ix:nonNumeric></p></td>
  </tr>
</tbody>
</table>

<p style="margin: 0px; font-size: 10pt">&#160;</p>

<p style="margin: 0px; text-align: justify; font-size: 10pt">If an emerging growth
company, indicate by check mark if the registrant has elected not to use the
extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160; <ix:nonNumeric contextRef="From2023-04-01to2023-09-30" format="ixt:booleanfalse" name="dei:EntityExTransitionPeriod">[ ]</ix:nonNumeric></p>

<p style="margin: 0px; text-align: justify; font-size: 10pt">&#160;</p>

<p style="margin: 0px; text-align: justify; font-size: 10pt">Indicate by check mark
whether the registrant is a shell company (as defined in Rule 12b&#8211;2 of the
Exchange Act).</p>

<p style="margin: 0px; text-align: justify; text-indent: 26.66px; font-size: 10pt">Yes <ix:nonNumeric contextRef="From2023-04-01to2023-09-30" format="ixt:booleanfalse" name="dei:EntityShellCompany">[ ]</ix:nonNumeric> No [X]</p>

<p style="margin: 0px; text-indent: -9.6px; font-size: 10pt">&#160;</p>

<p style="margin: 0px; font-size: 10pt">Securities
registered pursuant to Section 12(b) of the Act: None</p>

<p style="margin: 0px; font-size: 10pt">&#160;</p>

<p style="margin: 0px; text-align: justify; font-size: 10pt">Indicate the number of
shares outstanding of each of the issuer&#8217;s classes of common stock, as of the
latest practicable date.</p>

<p style="margin: 0px; font-size: 10pt">&#160;&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse">
  <tbody>
  <tr>
    <td style="border-bottom: black 1.01px solid; vertical-align: top; width: 49%"><p style="margin: 0px; text-align: center; font-size: 10pt">Class</p></td>
    <td style="vertical-align: top"><p style="margin: 0px">&#160;</p></td>
    <td style="border-bottom: black 1.01px solid; vertical-align: top; width: 49%"><p style="margin: 0px; text-align: center; font-size: 10pt">Outstanding at November 08,
  2023</p></td>
  </tr>
  <tr>
    <td style="vertical-align: top; background-color: #e6efff"><p style="margin: 0px; text-align: center; font-size: 10pt">Common stock, $0.001 par   value</p></td>
    <td style="vertical-align: top; background-color: #e6efff"><p style="margin: 0px">&#160;</p></td>
    <td style="vertical-align: bottom; background-color: #e6efff"><p style="margin: 0px; text-align: center; font-size: 10pt"><ix:nonFraction name="dei:EntityCommonStockSharesOutstanding" contextRef="AsOf2023-11-08" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">277,915,910</ix:nonFraction></p></td>
  </tr>
</tbody>
</table>

<p style="margin: 0px; text-align: justify; font-size: 10pt">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="width: 100%; page-break-after: always">
  <tbody>
  <tr>
    <td style="border-bottom: black 4px solid"><p style="margin: 0; font-size: 10pt">&#160;</p></td>
  </tr>
</tbody>
</table>

<p style="margin: 0; font-size: 10pt">&#160;<span style="font-size: 10pt; text-align: justify">&#160;</span></p>

<p style="margin: 0px; text-align: justify; font-size: 10pt"><span style="float: none">&#8220;Explanatory Note Regarding Forward-Looking Statements:&#8221;</span></p>

<p style="margin: 0px; text-align: justify; font-size: 10pt"><br /></p>

<p style="margin: 0px; text-align: justify; font-size: 10pt">This Quarterly Report on
Form 10-Q contains forward-looking statements which are made pursuant to the
safe harbor provisions of Section 27A of the Securities Act of 1933, as amended
(the &#8220;Securities Act&#8221;), and Section 21E of the Securities Exchange Act of 1934,
as amended (the &#8220;Exchange Act&#8221;). These statements may be identified by such
forward-looking terminology as &#8220;may,&#8221; &#8220;should,&#8221; &#8220;expects,&#8221; &#8220;intends,&#8221; &#8220;plans,&#8221;
&#8220;anticipates,&#8221; &#8220;believes,&#8221; &#8220;estimates,&#8221; &#8220;predicts,&#8221; &#8220;potential,&#8221; &#8220;continue&#8221; or
the negative of these terms or other comparable terminology. Our
forward-looking statements are based on a series of expectations, assumptions,
estimates and projections about our company, are not guarantees of future
results or performance and involve substantial risks and uncertainty. We may
not actually achieve the plans, intentions or expectations disclosed in these
forward-looking statements. Actual results or events could differ materially
from the plans, intentions and expectations disclosed in these forward-looking
statements. Our business and our forward-looking statements involve substantial
known and unknown risks and uncertainties, including the risks and
uncertainties inherent in our statements regarding:</p>

<p style="margin: 0px; text-align: justify; font-size: 10pt">&#160;</p>

<table cellpadding="0" cellspacing="0" border="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">
  <tbody>
  <tr>
    <td style="width: 0.5in; vertical-align: top"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="text-align: justify; vertical-align: top"><p style="margin: 0px; font-size: 10pt">&#9679;&#160;&#160;&#160;&#160; our ability to
add new customers.</p></td>
  </tr>
  <tr>
    <td style="width: 0.5in; vertical-align: top"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="text-align: justify; vertical-align: top"><p style="margin: 0px; font-size: 10pt">&#9679;&#160;&#160;&#160;&#160; the impacts of
COVID-19, or other future pandemics on our business, results of operations,
financial position, and cash flows.</p></td>
  </tr>
  <tr>
    <td style="width: 0.5in; vertical-align: top"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="text-align: justify; vertical-align: top"><p style="margin: 0px; font-size: 10pt">&#9679;&#160;&#160;&#160;&#160; the potential
benefits of and our ability to maintain our relationships and establish or
maintain future collaborations or strategic relationships or obtain additional funding.</p></td>
  </tr>
  <tr>
    <td style="width: 0.5in; vertical-align: top"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="text-align: justify; vertical-align: top"><p style="margin: 0px; font-size: 10pt">&#9679;&#160;&#160;&#160;&#160; our marketing
capabilities and strategy.</p></td>
  </tr>
  <tr>
    <td style="width: 0.5in; vertical-align: top"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="text-align: justify; vertical-align: top"><p style="margin: 0px; font-size: 10pt">&#9679;&#160;&#160;&#160;&#160; our ability to
maintain a cost-effective program.</p></td>
  </tr>
  <tr>
    <td style="width: 0.5in; vertical-align: top"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="text-align: justify; vertical-align: top"><p style="margin: 0px; font-size: 10pt">&#9679;&#160;&#160;&#160;&#160; our ability to
retain the continued service of our key professionals and to identify, hire and
retain additional qualified professionals.</p></td>
  </tr>
  <tr>
    <td style="width: 0.5in; vertical-align: top"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="text-align: justify; vertical-align: top"><p style="margin: 0px; font-size: 10pt">&#9679;&#160;&#160;&#160;&#160; our competitive
position, and developments and projections relating to our competitors and our industry.</p></td>
  </tr>
  <tr>
    <td style="width: 0.5in; vertical-align: top"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="text-align: justify; vertical-align: top"><p style="margin: 0px; font-size: 10pt">&#9679;&#160;&#160;&#160;&#160; our estimates
regarding expenses, future revenue, capital requirements and needs for
additional financing; and</p></td>
  </tr>
  <tr>
    <td style="width: 0.5in; vertical-align: top"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="text-align: justify; vertical-align: top"><p style="margin: 0px; font-size: 10pt">&#9679;&#160;&#160;&#160;&#160; the impact of
laws and regulations.</p></td>
  </tr>
</tbody>
</table>

<p style="margin-left: 48px; text-align: justify; text-indent: -24px; margin-top: 0px; margin-bottom: 0px; font-size: 10pt"><span style="font-size: 10pt">&#160;</span></p>

<p style="margin: 0px; text-align: justify; font-size: 10pt">All of our forward-looking
statements are as of the date of this Quarterly Report on Form 10-Q only. In
each case, actual results may differ materially from such forward-looking
information. We can give no assurance that such expectations or forward-looking
statements will prove to be correct. An occurrence of, or any material adverse
change in, one or more of the risk factors or risks and uncertainties referred
to in this Quarterly Report on Form 10-Q or included in our other public
disclosures or our other periodic reports or other documents or filings filed
with or furnished to the U.S. Securities and Exchange Commission (the &#8220;SEC&#8221;)
could materially and adversely affect our business, prospects, financial
condition and results of operations. Except as required by law, we do not
undertake or plan to update or revise any such forward-looking statements to
reflect actual results, changes in plans, assumptions, estimates or projections
or other circumstances affecting such forward-looking statements occurring
after the date of this Quarterly Report on Form 10-Q, even if such results,
changes or circumstances make it clear that any forward-looking information
will not be realized. Any public statements or disclosures by us following this
Quarterly Report on Form 10-Q that modify or impact any of the forward-looking
statements contained in this Quarterly Report on Form 10-Q will be deemed to
modify or supersede such statements in this Quarterly Report on Form 10-Q.</p>

<table border="0" cellspacing="0" cellpadding="0" style="width: 100%; page-break-after: always">
  <tbody>
  <tr>
    <td style="border-bottom: black 4px solid"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
  </tr>
</tbody>
</table>

<p style="margin: 0px; text-align: justify; font-size: 10pt">&#160;</p>

<p style="margin: 0px; text-align: center; font-size: 10pt"><b>REGENEREX PHARMA, INC.</b></p>

<p style="margin: 0px; text-align: center; font-size: 10pt"><b>INDEX TO FORM 10-Q FILING</b></p>

<p style="margin: 0px; text-align: center; font-size: 10pt"><b>FOR THE SIX MONTHS ENDED SEPTEMBER
30, 2023 AND 2022</b></p>

<p style="margin: 0px; text-align: center; font-size: 10pt"><b>TABLE OF CONTENTS</b></p>

<p style="margin: 0px; text-align: center; font-size: 10pt">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse">
  <tbody>
  <tr>
    <td colspan="2" style="padding: 0cm 0cm 1.5pt; vertical-align: top"><p style="margin: 0px">&#160;</p></td>
    <td style="border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: top; width: 72px"><p style="margin: 0px; text-align: center; font-size: 10pt"><b>PAGE</b></p></td>
  </tr>
  <tr>
    <td colspan="2" style="vertical-align: top"><p style="margin: 0px; font-size: 10pt"><b>PART
  I - FINANCIAL INFORMATION</b></p></td>
    <td style="vertical-align: top; width: 48px"><p style="margin: 0px">&#160;</p></td>
  </tr>
  <tr>
    <td colspan="2" style="vertical-align: top"><p style="margin: 0px">&#160;</p></td>
    <td style="vertical-align: top; width: 48px"><p style="margin: 0px">&#160;</p></td>
  </tr>
  <tr>
    <td style="width: 72px; vertical-align: top; background-color: rgb(238, 238, 238)"><p style="margin: 0px; font-size: 10pt"><a href="#page_1">Item   1.</a></p></td>
    <td style="vertical-align: top; background-color: rgb(238, 238, 238)"><p style="margin: 0px; font-size: 10pt"><a href="#page_1">Financial   Statements (Unaudited)</a></p></td>
    <td style="width: 48px; vertical-align: top; background-color: rgb(238, 238, 238)"><p style="margin: 0px; text-align: center; font-size: 10pt"><a href="#page_1">1</a></p></td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 72px"><p style="margin: 0px">&#160;</p></td>
    <td style="padding: 0cm 0cm 0cm 20pt; vertical-align: top"><p style="margin: 0px; font-size: 10pt"><a href="#page_1">Balance   Sheets</a></p></td>
    <td style="vertical-align: top; width: 48px"><p style="margin: 0px; text-align: center; font-size: 10pt"><a href="#page_1">1</a></p></td>
  </tr>
  <tr>
    <td style="vertical-align: top; background-color: rgb(238, 238, 238); width: 72px"><p style="margin: 0px">&#160;</p></td>
    <td style="padding: 0cm 0cm 0cm 20pt; vertical-align: top; background-color: #eeeeee"><p style="margin: 0px; font-size: 10pt"><a href="#page_2">Statements   of Operations</a></p></td>
    <td style="vertical-align: top; background-color: rgb(238, 238, 238); width: 48px"><p style="margin: 0px; text-align: center; font-size: 10pt"><a href="#page_2">2</a></p></td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 72px"><p style="margin: 0px">&#160;</p></td>
    <td style="padding: 0cm 0cm 0cm 20pt; vertical-align: top"><p style="margin: 0px; font-size: 10pt"><a href="#page_3">Statements   of Cash Flows</a></p></td>
    <td style="vertical-align: top; width: 48px"><p style="margin: 0px; text-align: center; font-size: 10pt"><a href="#page_3">3</a></p></td>
  </tr>
  <tr>
    <td style="vertical-align: top; background-color: rgb(238, 238, 238); width: 72px"><p style="margin: 0px">&#160;</p></td>
    <td style="padding: 0cm 0cm 0cm 20pt; vertical-align: top; background-color: #eeeeee"><p style="margin: 0px; font-size: 10pt"><a href="#page_4">Statements   of Stockholders&#8217; Deficit</a></p></td>
    <td style="vertical-align: top; background-color: rgb(238, 238, 238); width: 48px"><p style="margin: 0px; text-align: center; font-size: 10pt"><a href="#page_4">4</a></p></td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 72px"><p style="margin: 0px">&#160;</p></td>
    <td style="padding: 0cm 0cm 0cm 20pt; vertical-align: top"><p style="margin: 0px; font-size: 10pt"><a href="#page_5">Notes   to Financial Statements</a></p></td>
    <td style="vertical-align: top; width: 48px"><p style="margin: 0px; text-align: center; font-size: 10pt"><a href="#page_5">5</a></p></td>
  </tr>
  <tr>
    <td style="vertical-align: top; background-color: rgb(238, 238, 238); width: 72px"><p style="margin: 0px; font-size: 10pt"><a href="#page_12">Item   2.</a></p></td>
    <td style="vertical-align: top; background-color: #eeeeee"><p style="margin: 0px; font-size: 10pt"><a href="#page_12">Management   Discussion &amp; Analysis of Financial Condition and Results of Operations</a></p></td>
    <td style="vertical-align: top; background-color: rgb(238, 238, 238); width: 48px"><p style="margin: 0px; text-align: center; font-size: 10pt"><a href="#page_12">12</a></p></td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 72px"><p style="margin: 0px; font-size: 10pt"><a href="#page_17">Item   3</a></p></td>
    <td style="vertical-align: top"><p style="margin: 0px; font-size: 10pt"><a href="#page_17">Quantitative   and Qualitative Disclosures About Market Risk</a></p></td>
    <td style="vertical-align: top; width: 48px"><p style="margin: 0px; text-align: center; font-size: 10pt"><a href="#page_17">17</a></p></td>
  </tr>
  <tr>
    <td style="vertical-align: top; background-color: rgb(238, 238, 238); width: 72px"><p style="margin: 0px; font-size: 10pt"><a href="#page_17">Item   4.</a></p></td>
    <td style="vertical-align: top; background-color: #eeeeee"><p style="margin: 0px; font-size: 10pt"><a href="#page_17">Controls   and Procedures</a></p></td>
    <td style="vertical-align: top; background-color: rgb(238, 238, 238); width: 48px"><p style="margin: 0px; text-align: center; font-size: 10pt"><a href="#page_17">17</a></p></td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 72px"><p style="margin: 0px">&#160;</p></td>
    <td style="vertical-align: top"><p style="margin: 0px">&#160;</p></td>
    <td style="vertical-align: top; width: 48px"><p style="margin: 0px">&#160;</p></td>
  </tr>
  <tr>
    <td colspan="2" style="vertical-align: top; background-color: #eeeeee"><p style="margin: 0px; font-size: 10pt"><b>PART
  II - OTHER INFORMATION</b></p></td>
    <td style="vertical-align: top; background-color: rgb(238, 238, 238); width: 48px"><p style="margin: 0px">&#160;</p></td>
  </tr>
  <tr>
    <td colspan="2" style="vertical-align: top"><p style="margin: 0px">&#160;</p></td>
    <td style="vertical-align: top; width: 48px"><p style="margin: 0px">&#160;</p></td>
  </tr>
  <tr>
    <td style="vertical-align: top; background-color: rgb(238, 238, 238); width: 72px"><p style="margin: 0px; font-size: 10pt"><a href="#page_19">Item   1.</a></p></td>
    <td style="vertical-align: top; background-color: #eeeeee"><p style="margin: 0px; font-size: 10pt"><a href="#page_19">Legal   Proceedings</a></p></td>
    <td style="vertical-align: top; background-color: rgb(238, 238, 238); width: 48px"><p style="margin: 0px; text-align: center; font-size: 10pt"><a href="#page_19">19</a></p></td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 72px"><p style="margin: 0px; font-size: 10pt"><a href="#page_19">Item   2.</a></p></td>
    <td style="vertical-align: top"><p style="margin: 0px; font-size: 10pt"><a href="#page_19">Unregistered   Sales of Equity Securities and Use of Proceeds</a></p></td>
    <td style="vertical-align: top; width: 48px"><p style="margin: 0px; text-align: center; font-size: 10pt"><a href="#page_19">19</a></p></td>
  </tr>
  <tr>
    <td style="vertical-align: top; background-color: rgb(238, 238, 238); width: 72px"><p style="margin: 0px; font-size: 10pt"><a href="#page_19">Item   3.</a></p></td>
    <td style="vertical-align: top; background-color: #eeeeee"><p style="margin: 0px; font-size: 10pt"><a href="#page_19">Defaults   Upon Senior Securities</a></p></td>
    <td style="vertical-align: top; background-color: rgb(238, 238, 238); width: 48px"><p style="margin: 0px; text-align: center; font-size: 10pt"><a href="#page_19">19</a></p></td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 72px"><p style="margin: 0px; font-size: 10pt"><a href="#page_19">Item   4.</a></p></td>
    <td style="vertical-align: top"><p style="margin: 0px; font-size: 10pt"><a href="#page_19">Mining   Safety Disclosures</a></p></td>
    <td style="vertical-align: top; width: 48px"><p style="margin: 0px; text-align: center; font-size: 10pt"><a href="#page_19">19</a></p></td>
  </tr>
  <tr>
    <td style="vertical-align: top; background-color: rgb(238, 238, 238); width: 72px"><p style="margin: 0px; font-size: 10pt"><a href="#page_19">Item   5</a></p></td>
    <td style="vertical-align: top; background-color: #eeeeee"><p style="margin: 0px; font-size: 10pt"><a href="#page_19">Other   Information</a></p></td>
    <td style="vertical-align: top; background-color: rgb(238, 238, 238); width: 48px"><p style="margin: 0px; text-align: center; font-size: 10pt"><a href="#page_19">19</a></p></td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 72px"><p style="margin: 0px; font-size: 10pt"><a href="#page_19">Item   6.</a></p></td>
    <td style="vertical-align: top"><p style="margin: 0px; font-size: 10pt"><a href="#page_19">Exhibits</a></p></td>
    <td style="vertical-align: top; width: 48px"><p style="margin: 0px; text-align: center; font-size: 10pt"><a href="#page_19">19</a></p></td>
  </tr>
  <tr>
    <td style="vertical-align: top; background-color: rgb(238, 238, 238); width: 72px"><p style="margin: 0px">&#160;</p></td>
    <td style="vertical-align: top; background-color: #eeeeee"><p style="margin: 0px">&#160;</p></td>
    <td style="vertical-align: top; background-color: rgb(238, 238, 238); width: 48px"><p style="margin: 0px">&#160;</p></td>
  </tr>
  <tr>
    <td colspan="2" style="vertical-align: top"><p style="margin: 0px; font-size: 10pt"><b>CERTIFICATIONS</b></p></td>
    <td style="vertical-align: top; width: 48px"><p style="margin: 0px">&#160;</p></td>
  </tr>
  <tr>
    <td colspan="2" style="vertical-align: top; background-color: #eeeeee"><p style="margin: 0px">&#160;</p></td>
    <td style="vertical-align: top; background-color: rgb(238, 238, 238); width: 48px"><p style="margin: 0px">&#160;</p></td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 72px"><p style="margin: 0px; font-size: 10pt">31.1</p></td>
    <td style="vertical-align: top"><p style="margin: 0px; font-size: 10pt">Certification
  of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act</p></td>
    <td style="vertical-align: top; width: 48px"><p style="margin: 0px">&#160;</p></td>
  </tr>
  <tr>
    <td style="vertical-align: top; background-color: rgb(238, 238, 238); width: 72px"><p style="margin: 0px; font-size: 10pt">31.2</p></td>
    <td style="vertical-align: top; background-color: #eeeeee"><p style="margin: 0px; font-size: 10pt">Certification of Chief Financial Officer Pursuant
  to Section 302 of the Sarbanes-Oxley Act</p></td>
    <td style="vertical-align: top; background-color: rgb(238, 238, 238); width: 48px"><p style="margin: 0px">&#160;</p></td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 72px"><p style="margin: 0px; font-size: 10pt">32.1</p></td>
    <td style="vertical-align: top"><p style="margin: 0px; font-size: 10pt">Certification
  of Chief Executive Officer Pursuant to Section 906 of the Sarbanes-Oxley Act</p></td>
    <td style="vertical-align: top; width: 48px"><p style="margin: 0px">&#160;</p></td>
  </tr>
  <tr>
    <td style="vertical-align: top; background-color: rgb(238, 238, 238); width: 72px"><p style="margin: 0px; font-size: 10pt">32.2</p></td>
    <td style="vertical-align: top; background-color: #eeeeee"><p style="margin: 0px; font-size: 10pt">Certification
  of Chief Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act</p></td>
    <td style="vertical-align: top; background-color: rgb(238, 238, 238); width: 48px"><p style="margin: 0px">&#160;</p></td>
  </tr>
</tbody>
</table>

<p style="margin: 0px; text-align: right; font-size: 10pt">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="width: 100%; page-break-after: always">
  <tbody>
  <tr>
    <td style="border-bottom: black 4px solid"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
  </tr>
</tbody>
</table>



<p style="margin-top: 0pt; margin-bottom: 0pt"><span id="page_1" class="adv_highlightanchor adv_pagination"></span></p>

<p style="margin: 0px; text-align: justify; font-size: 10pt">&#160;</p>

<p style="margin: 0px; text-align: center; font-size: 10pt">&#160;<b>PART
I</b></p>

<p style="margin: 0px; text-align: center; font-size: 10pt"><b>FINANCIAL INFORMATION</b></p>

<p style="margin: 0px; text-align: center; font-size: 10pt">&#160;</p>

<p style="margin: 0px; font-size: 10pt"><b>ITEM 1. </b><b>FINANCIAL STATEMENTS</b></p>

<p style="margin: 0px; text-align: center; font-size: 10pt"><b>&#160;REGENEREX
PHARMA, INC.</b></p>

<p style="margin: 0px; text-align: center; font-size: 10pt"><b>BALANCE
SHEETS</b></p>

<p style="margin: 0px; text-align: center; font-size: 10pt"><b>(UNAUDITED)</b></p>

<p style="margin: 0px; text-align: center; font-size: 10pt">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
  <tbody>
  <tr>
    <td style="vertical-align: bottom"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="border-bottom: black 1.01px solid; width: 0.1in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="border-bottom: black 1.01px solid; vertical-align: bottom; width: 1.2in"><p style="margin: 0px; text-align: center; font-size: 10pt"><b>September 30, 2023</b></p></td>
    <td style="width: 0.2in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="border-bottom: black 1.01px solid; width: 0.1in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="border-bottom: black 1.01px solid; vertical-align: bottom; width: 1.2in"><p style="margin: 0px; text-align: center; font-size: 10pt"><b>March 31, 2023</b></p></td>
    <td style="width: 0.2in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom"><p style="margin: 0px; text-align: center; font-size: 10pt"><b>ASSETS</b></p></td>
    <td style="width: 0.1in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="vertical-align: bottom"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.2in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.1in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="vertical-align: bottom"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.2in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.1in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="vertical-align: bottom"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.2in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.1in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="vertical-align: bottom"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.2in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom"><p style="margin: 0px; font-size: 10pt"><b>Current   Assets-</b></p></td>
    <td style="width: 0.1in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="vertical-align: bottom"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.2in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.1in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="vertical-align: bottom"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.2in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; background-color: rgb(230, 239, 255); padding-left: 12px"><p style="margin-top: 0px; margin-bottom: 0px; font-size: 10pt">Cash and equivalents</p></td>
    <td style="vertical-align: bottom; text-align: right; width: 0.1in; background-color: rgb(230, 239, 255)"><p style="margin: 0px; font-size: 10pt">$</p></td>
    <td style="vertical-align: bottom; text-align: right; width: 1.2in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,080</ix:nonFraction></p></td>
    <td style="width: 0.2in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="vertical-align: bottom; text-align: right; width: 0.1in; background-color: rgb(230, 239, 255)"><p style="margin: 0px; font-size: 10pt">$</p></td>
    <td style="vertical-align: bottom; text-align: right; width: 1.2in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,135</ix:nonFraction></p></td>
    <td style="width: 0.2in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; padding-left: 12px"><p style="margin-top: 0px; margin-bottom: 0px; font-size: 10pt">Prepaid expenses</p></td>
    <td style="width: 0.1in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="border-bottom: black 1.01px solid; vertical-align: bottom; text-align: right; width: 1.2in"><p style="margin: 0px; font-size: 10pt"><ix:nonFraction name="us-gaap:PrepaidExpenseCurrent" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,250</ix:nonFraction></p></td>
    <td style="width: 0.2in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.1in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="border-bottom: black 1.01px solid; vertical-align: bottom; text-align: right; width: 1.2in"><p style="margin: 0px; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0046">&#8212;</span></p></td>
    <td style="width: 0.2in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">Total Current Assets</p></td>
    <td style="width: 0.1in; background-color: rgb(230, 239, 255)"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="border-bottom: black 1.01px solid; vertical-align: bottom; text-align: right; width: 1.2in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">19,330</ix:nonFraction></p></td>
    <td style="width: 0.2in; background-color: rgb(230, 239, 255)"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.1in; background-color: rgb(230, 239, 255)"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="border-bottom: black 1.01px solid; vertical-align: bottom; text-align: right; width: 1.2in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,135</ix:nonFraction></p></td>
    <td style="width: 0.2in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.1in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 1.2in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.2in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.1in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 1.2in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.2in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">Website,   net of accumulated amortization of $<ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">27,834</ix:nonFraction> and $<ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">26,397</ix:nonFraction>, as of September 30,   2023 and March 31, 2023, respectively</p></td>
    <td style="width: 0.1in; background-color: rgb(230, 239, 255)"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="vertical-align: bottom; text-align: right; width: 1.2in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,766</ix:nonFraction></p></td>
    <td style="width: 0.2in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.1in; background-color: rgb(230, 239, 255)"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="vertical-align: bottom; text-align: right; width: 1.2in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,203</ix:nonFraction></p></td>
    <td style="width: 0.2in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom"><p style="margin: 0px; font-size: 10pt">Furniture and computer equipment, net of   accumulated depreciation of $<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">735</ix:nonFraction> and $<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">197</ix:nonFraction> as of September 30, 2023 and March   31, 2023, respectively</p></td>
    <td style="width: 0.1in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="vertical-align: bottom; text-align: right; width: 1.2in"><p style="margin: 0px; font-size: 10pt"><ix:nonFraction name="us-gaap:MachineryAndEquipmentGross" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,962</ix:nonFraction></p></td>
    <td style="width: 0.2in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.1in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="vertical-align: bottom; text-align: right; width: 1.2in"><p style="margin: 0px; font-size: 10pt"><ix:nonFraction name="us-gaap:MachineryAndEquipmentGross" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,201</ix:nonFraction></p></td>
    <td style="width: 0.2in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">Right of use asset</p></td>
    <td style="width: 0.1in; background-color: rgb(230, 239, 255)"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="border-bottom: black 1.01px solid; vertical-align: bottom; text-align: right; width: 1.2in; background-color: rgb(230, 239, 255)"><p style="margin: 0px; font-size: 10pt"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">903,586</ix:nonFraction></p></td>
    <td style="width: 0.2in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.1in; background-color: rgb(230, 239, 255)"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="border-bottom: black 1.01px solid; vertical-align: bottom; text-align: right; width: 1.2in; background-color: rgb(230, 239, 255)"><p style="margin: 0px; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0062">&#8212;</span></p></td>
    <td style="width: 0.2in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom"><p style="margin-left: 37.79px; margin-top: 0px; margin-bottom: 0px; font-size: 10pt"><b>Total Assets</b></p></td>
    <td style="vertical-align: bottom; text-align: right; width: 0.1in"><p style="margin: 0px; font-size: 10pt">$</p></td>
    <td style="border-bottom: black 3px double; vertical-align: bottom; text-align: right; width: 1.2in"><p style="margin: 0px; font-size: 10pt"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">932,644</ix:nonFraction></p></td>
    <td style="width: 0.2in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="vertical-align: bottom; text-align: right; width: 0.1in"><p style="margin: 0px; font-size: 10pt">$</p></td>
    <td style="border-bottom: black 3px double; vertical-align: bottom; text-align: right; width: 1.2in"><p style="margin: 0px; font-size: 10pt"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,539</ix:nonFraction></p></td>
    <td style="width: 0.2in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.1in; background-color: rgb(230, 239, 255)"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 1.2in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.2in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.1in; background-color: rgb(230, 239, 255)"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 1.2in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.2in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom"><p style="margin: 0px; text-align: center; font-size: 10pt"><b>LIABILITIES AND   STOCKHOLDERS&#8217; DEFICIT</b></p></td>
    <td style="width: 0.1in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 1.2in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.2in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.1in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 1.2in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.2in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.1in; background-color: rgb(230, 239, 255)"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 1.2in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.2in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.1in; background-color: rgb(230, 239, 255)"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 1.2in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.2in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom"><p style="margin: 0px; font-size: 10pt"><b>Current Liabilities</b></p></td>
    <td style="width: 0.1in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 1.2in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.2in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.1in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 1.2in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.2in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; background-color: rgb(230, 239, 255); padding-left: 12px"><p style="margin: 0px; font-size: 10pt">Accounts   payable</p></td>
    <td style="vertical-align: bottom; text-align: right; width: 0.1in; background-color: rgb(230, 239, 255)"><p style="margin: 0px; font-size: 10pt">$</p></td>
    <td style="vertical-align: bottom; text-align: right; width: 1.2in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">89,840</ix:nonFraction></p></td>
    <td style="width: 0.2in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="vertical-align: bottom; text-align: right; width: 0.1in; background-color: rgb(230, 239, 255)"><p style="margin: 0px; font-size: 10pt">$</p></td>
    <td style="vertical-align: bottom; text-align: right; width: 1.2in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">75,145</ix:nonFraction></p></td>
    <td style="width: 0.2in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; padding-left: 12px"><p style="margin: 0px; font-size: 10pt">Related   party advances</p></td>
    <td style="width: 0.1in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="vertical-align: bottom; text-align: right; width: 1.2in"><p style="margin: 0px; font-size: 10pt"><ix:nonFraction name="RGPX:RelatedPartyAdvances" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,637</ix:nonFraction></p></td>
    <td style="width: 0.2in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.1in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="vertical-align: bottom; text-align: right; width: 1.2in"><p style="margin: 0px; font-size: 10pt"><ix:nonFraction name="RGPX:RelatedPartyAdvances" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">131,887</ix:nonFraction></p></td>
    <td style="width: 0.2in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; background-color: rgb(230, 239, 255); padding-left: 12px"><p style="margin: 0px; font-size: 10pt">Accrued   compensation</p></td>
    <td style="width: 0.1in; background-color: rgb(230, 239, 255)"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="vertical-align: bottom; text-align: right; width: 1.2in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt"><ix:nonFraction name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">318,077</ix:nonFraction></p></td>
    <td style="width: 0.2in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.1in; background-color: rgb(230, 239, 255)"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="vertical-align: bottom; text-align: right; width: 1.2in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt"><ix:nonFraction name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">221,192</ix:nonFraction></p></td>
    <td style="width: 0.2in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; padding-left: 12px"><p style="margin: 0px; font-size: 10pt">Other   accrued liabilities</p></td>
    <td style="width: 0.1in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="vertical-align: bottom; text-align: right; width: 1.2in"><p style="margin: 0px; font-size: 10pt"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">82,034</ix:nonFraction></p></td>
    <td style="width: 0.2in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.1in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="vertical-align: bottom; text-align: right; width: 1.2in"><p style="margin: 0px; font-size: 10pt"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">125,787</ix:nonFraction></p></td>
    <td style="width: 0.2in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; background-color: rgb(230, 239, 255); padding-left: 12px"><p style="margin: 0px; font-size: 10pt">Current   portion of notes payable to shareholder</p></td>
    <td style="width: 0.1in; background-color: rgb(230, 239, 255)"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="vertical-align: bottom; text-align: right; width: 1.2in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt"><ix:nonFraction name="us-gaap:OtherNotesPayableCurrent" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">282,786</ix:nonFraction></p></td>
    <td style="width: 0.2in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.1in; background-color: rgb(230, 239, 255)"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="vertical-align: bottom; text-align: right; width: 1.2in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt"><ix:nonFraction name="us-gaap:OtherNotesPayableCurrent" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">222,771</ix:nonFraction></p></td>
    <td style="width: 0.2in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; padding-left: 12px"><p style="margin: 0px; font-size: 10pt">Current   portion of notes payable</p></td>
    <td style="width: 0.1in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="vertical-align: bottom; text-align: right; width: 1.2in"><p style="margin: 0px; font-size: 10pt"><ix:nonFraction name="us-gaap:NotesPayableCurrent" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,400,000</ix:nonFraction></p></td>
    <td style="width: 0.2in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.1in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="vertical-align: bottom; text-align: right; width: 1.2in"><p style="margin: 0px; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0089">&#8212;</span></p></td>
    <td style="width: 0.2in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; background-color: rgb(230, 239, 255); padding-left: 12px"><p style="margin: 0px; font-size: 10pt">Current   portion of lease liabilities</p></td>
    <td style="width: 0.1in; background-color: rgb(230, 239, 255)"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="border-bottom: black 1.01px solid; vertical-align: bottom; text-align: right; width: 1.2in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">162,295</ix:nonFraction></p></td>
    <td style="width: 0.2in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.1in; background-color: rgb(230, 239, 255)"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="border-bottom: black 1.01px solid; vertical-align: bottom; text-align: right; width: 1.2in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0092">&#8212;</span></p></td>
    <td style="width: 0.2in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom"><p style="margin: 0px; font-size: 10pt">Total   Current Liabilities</p></td>
    <td style="width: 0.1in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="border-bottom: black 1.01px solid; vertical-align: bottom; text-align: right; width: 1.2in"><p style="margin: 0px; font-size: 10pt"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,337,669</ix:nonFraction></p></td>
    <td style="width: 0.2in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.1in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="border-bottom: black 1.01px solid; vertical-align: bottom; text-align: right; width: 1.2in"><p style="margin: 0px; font-size: 10pt"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">776,782</ix:nonFraction></p></td>
    <td style="width: 0.2in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.1in; background-color: rgb(230, 239, 255)"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 1.2in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.2in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.1in; background-color: rgb(230, 239, 255)"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 1.2in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.2in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom"><p style="margin: 0px; font-size: 10pt">Notes   payable to shareholder, net of current portion</p></td>
    <td style="width: 0.1in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="vertical-align: bottom; text-align: right; width: 1.2in"><p style="margin: 0px; font-size: 10pt"><ix:nonFraction name="RGPX:NotesPayableShareholder" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">275,905</ix:nonFraction></p></td>
    <td style="width: 0.2in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.1in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="vertical-align: bottom; text-align: right; width: 1.2in"><p style="margin: 0px; font-size: 10pt"><ix:nonFraction name="RGPX:NotesPayableShareholder" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">314,704</ix:nonFraction></p></td>
    <td style="width: 0.2in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">Notes   payable to related parties</p></td>
    <td style="width: 0.1in; background-color: rgb(230, 239, 255)"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="vertical-align: bottom; text-align: right; width: 1.2in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt"><ix:nonFraction name="RGPX:NotesPayableRelatedParties" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,000</ix:nonFraction></p></td>
    <td style="width: 0.2in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.1in; background-color: rgb(230, 239, 255)"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="vertical-align: bottom; text-align: right; width: 1.2in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt"><ix:nonFraction name="RGPX:NotesPayableRelatedParties" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">38,000</ix:nonFraction></p></td>
    <td style="width: 0.2in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom"><p style="margin: 0px; font-size: 10pt">Notes   payable, net of current portion</p></td>
    <td style="width: 0.1in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="vertical-align: bottom; text-align: right; width: 1.2in"><p style="margin: 0px; font-size: 10pt"><ix:nonFraction name="us-gaap:NotesPayable" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">184,232</ix:nonFraction></p></td>
    <td style="width: 0.2in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.1in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="vertical-align: bottom; text-align: right; width: 1.2in"><p style="margin: 0px; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0104">&#8212;</span></p></td>
    <td style="width: 0.2in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">Lease   liabilities, net of current portion</p></td>
    <td style="width: 0.1in; background-color: rgb(230, 239, 255)"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="border-bottom: black 1.01px solid; vertical-align: bottom; text-align: right; width: 1.2in; background-color: rgb(230, 239, 255)"><p style="margin: 0px; font-size: 10pt"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">764,171</ix:nonFraction></p></td>
    <td style="width: 0.2in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.1in; background-color: rgb(230, 239, 255)"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="border-bottom: black 1.01px solid; vertical-align: bottom; text-align: right; width: 1.2in; background-color: rgb(230, 239, 255)"><p style="margin: 0px; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0107">&#8212;</span></p></td>
    <td style="width: 0.2in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom"><p style="margin-left: 37.79px; margin-top: 0px; margin-bottom: 0px; font-size: 10pt"><b>Total   Liabilities</b></p></td>
    <td style="width: 0.1in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="border-bottom: black 1.01px solid; vertical-align: bottom; text-align: right; width: 1.2in"><p style="margin: 0px; font-size: 10pt"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,565,977</ix:nonFraction></p></td>
    <td style="width: 0.2in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.1in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="border-bottom: black 1.01px solid; vertical-align: bottom; text-align: right; width: 1.2in"><p style="margin: 0px; font-size: 10pt"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,129,486</ix:nonFraction></p></td>
    <td style="width: 0.2in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.1in; background-color: rgb(230, 239, 255)"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 1.2in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.2in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.1in; background-color: rgb(230, 239, 255)"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 1.2in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.2in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom"><p style="margin: 0px; font-size: 10pt">Commitments   and Contingencies (Note 7)</p></td>
    <td style="width: 0.1in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 1.2in"><p style="margin: 0px; font-size: 10pt; text-align: right">&#160;<span style="-sec-ix-hidden: xdx2ixbrl0112">-</span></p></td>
    <td style="width: 0.2in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.1in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 1.2in"><p style="margin: 0px; font-size: 10pt; text-align: right">&#160;<span style="-sec-ix-hidden: xdx2ixbrl0113">-</span></p></td>
    <td style="width: 0.2in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.1in; background-color: rgb(230, 239, 255)"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 1.2in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.2in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.1in; background-color: rgb(230, 239, 255)"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 1.2in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.2in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom"><p style="margin: 0px; font-size: 10pt"><b>Stockholders&#8217; Deficit</b></p></td>
    <td style="width: 0.1in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 1.2in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.2in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.1in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 1.2in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.2in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; background-color: rgb(230, 239, 255); padding-left: 12px"><p style="margin-top: 0px; margin-bottom: 0px; font-size: 10pt">Common stock: $<ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction></ix:nonFraction> par value: <ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">675,000,000</ix:nonFraction></ix:nonFraction> shares   authorized:</p><p style="margin-top: 0px; margin-bottom: 0px; font-size: 10pt"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">277,915,910</ix:nonFraction></ix:nonFraction> and <ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">277,112,660</ix:nonFraction></ix:nonFraction> issued and outstanding   at September 30, 2023 and March 31, 2023, respectively</p></td>
    <td style="width: 0.1in; background-color: rgb(230, 239, 255)"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="vertical-align: bottom; text-align: right; width: 1.2in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">277,916</ix:nonFraction></p></td>
    <td style="width: 0.2in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.1in; background-color: rgb(230, 239, 255)"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="vertical-align: bottom; text-align: right; width: 1.2in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">277,113</ix:nonFraction></p></td>
    <td style="width: 0.2in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; padding-left: 12px"><p style="margin-top: 0px; margin-bottom: 0px; font-size: 10pt">Additional paid-in capital</p></td>
    <td style="width: 0.1in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="vertical-align: bottom; text-align: right; width: 1.2in"><p style="margin: 0px; font-size: 10pt"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,147,798</ix:nonFraction></p></td>
    <td style="width: 0.2in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.1in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="vertical-align: bottom; text-align: right; width: 1.2in"><p style="margin: 0px; font-size: 10pt"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">671,963</ix:nonFraction></p></td>
    <td style="width: 0.2in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; background-color: rgb(230, 239, 255); padding-left: 12px"><p style="margin-top: 0px; margin-bottom: 0px; font-size: 10pt">Accumulated deficit</p></td>
    <td style="width: 0.1in; background-color: rgb(230, 239, 255)"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="border-bottom: black 1.01px solid; vertical-align: bottom; text-align: right; width: 1.2in; background-color: rgb(230, 239, 255)"><p style="margin: 0px; font-size: 10pt">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">5,059,047</ix:nonFraction></p></td>
    <td style="vertical-align: bottom; width: 0.2in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">)</p></td>
    <td style="width: 0.1in; background-color: rgb(230, 239, 255)"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="border-bottom: black 1.01px solid; vertical-align: bottom; text-align: right; width: 1.2in; background-color: rgb(230, 239, 255)"><p style="margin: 0px; font-size: 10pt">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,072,023</ix:nonFraction></p></td>
    <td style="vertical-align: bottom; width: 0.2in; background-color: #e6efff"><p style="margin: 0px">)</p></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom"><p style="margin: 0px; font-size: 10pt">Total   Stockholders&#8217; Deficit</p></td>
    <td style="width: 0.1in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="border-bottom: black 1.01px solid; vertical-align: bottom; text-align: right; width: 1.2in"><p style="margin: 0px; font-size: 10pt">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,633,333</ix:nonFraction></p></td>
    <td style="vertical-align: bottom; width: 0.2in"><p style="margin: 0px; font-size: 10pt">)</p></td>
    <td style="width: 0.1in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="border-bottom: black 1.01px solid; vertical-align: bottom; text-align: right; width: 1.2in"><p style="margin: 0px; font-size: 10pt">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,122,947</ix:nonFraction></p></td>
    <td style="vertical-align: bottom; width: 0.2in"><p style="margin: 0px">)</p></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; background-color: #e6efff"><p style="margin-left: 37.79px; margin-top: 0px; margin-bottom: 0px; font-size: 10pt"><b>Total   Liabilities and Stockholders&#8217; Deficit</b></p></td>
    <td style="vertical-align: bottom; text-align: right; width: 0.1in; background-color: rgb(230, 239, 255)"><p style="margin: 0px; font-size: 10pt">$</p></td>
    <td style="border-bottom: black 3px double; vertical-align: bottom; text-align: right; width: 1.2in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">932,644</ix:nonFraction></p></td>
    <td style="width: 0.2in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="vertical-align: bottom; text-align: right; width: 0.1in; background-color: rgb(230, 239, 255)"><p style="margin: 0px; font-size: 10pt">$</p></td>
    <td style="border-bottom: black 3px double; vertical-align: bottom; text-align: right; width: 1.2in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,539</ix:nonFraction></p></td>
    <td style="width: 0.2in; background-color: #e6efff"><p style="font-size: 10pt; margin-top: 0px; margin-right: 0px; margin-bottom: 0px">&#160;</p></td>
  </tr>
</tbody>
</table>

<p style="margin: 0px; text-align: justify; font-size: 10pt">&#160;</p>

<p style="margin: 0px; text-align: center; font-size: 10pt">The accompanying notes are
an integral part of these unaudited financial statements.</p>

<table cellpadding="0" class="adv_pagination" cellspacing="0" border="0" style="width: 100%; font-size: 10pt; margin-top: 10px">
  <tbody>
  <tr style="vertical-align: top; text-align: left">
    <td style="width: 33%"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 34%; text-align: center"><p class="pagenumber" style="margin: 0px; font-size: 10pt">1</p></td>
    <td style="width: 33%; text-align: right"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
  </tr>
</tbody>
</table>

<table border="0" cellspacing="0" cellpadding="0" style="width: 100%; page-break-after: always">
  <tbody>
  <tr>
    <td style="border-bottom: black 4px solid"><p style="margin: 0; font-size: 10pt">&#160;</p></td>
  </tr>
</tbody>
</table>

<p style="margin-top: 0pt; margin-bottom: 0pt"><span id="page_2" class="adv_highlightanchor adv_pagination"></span></p>

<p style="margin: 0; font-size: 10pt">&#160;<b style="font-size: 10pt; text-align: center">&#160;</b></p>

<p style="margin: 0px; text-align: center; font-size: 10pt"><b>REGENEREX PHARMA, INC.</b></p>

<p style="margin: 0px; text-align: center; font-size: 10pt"><b>STATEMENTS OF OPERATIONS</b></p>

<p style="margin: 0px; text-align: center; font-size: 10pt"><b>(UNAUDITED)</b><span style="font-size: 10pt">&#160;</span></p>

<p style="margin: 0px; text-align: center; font-size: 10pt">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
  <tbody>
  <tr>
    <td style="vertical-align: bottom"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="vertical-align: bottom"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="vertical-align: bottom"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="vertical-align: bottom"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="vertical-align: bottom"><p style="margin: 0px; font-size: 10pt; text-align: center">&#160;</p></td>
    <td><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="vertical-align: bottom"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="vertical-align: bottom"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="vertical-align: bottom"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="vertical-align: bottom"><p style="margin: 0px; font-size: 10pt; text-align: center">&#160;</p></td>
    <td><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.1in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td colspan="4" style="vertical-align: bottom; width: 1.2in"><p style="margin: 0px; font-size: 10pt; text-align: center"><b style="font-size: 10pt">Three Months Ended</b></p></td>
    <td style="width: 0.2in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.1in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td colspan="4" style="vertical-align: bottom; width: 1.2in"><p style="margin: 0px; font-size: 10pt; text-align: center"><b style="font-size: 10pt">Six Months Ended</b></p></td>
    <td style="width: 0.2in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="border-bottom: black 1.01px solid; width: 0.1in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td colspan="4" style="border-bottom: black 1.01px solid; vertical-align: bottom; width: 1.2in"><p style="margin: 0px; font-size: 10pt; text-align: center"><b style="font-size: 10pt">September 30,</b></p></td>
    <td style="width: 0.2in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="border-bottom: black 1.01px solid; width: 0.1in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td colspan="4" style="border-bottom: black 1.01px solid; vertical-align: bottom; width: 1.2in"><p style="margin: 0px; font-size: 10pt; text-align: center"><b style="font-size: 10pt">September 30,</b></p></td>
    <td style="width: 0.2in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="border-bottom: black 1.01px solid; width: 0.1in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="border-bottom: black 1.01px solid; vertical-align: bottom; width: 1.2in"><p style="margin: 0px; text-align: center; font-size: 10pt"><b>2023</b></p></td>
    <td style="width: 0.2in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="border-bottom: black 1.01px solid; width: 0.1in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="border-bottom: black 1.01px solid; vertical-align: bottom; width: 1.2in"><p style="margin: 0px; text-align: center; font-size: 10pt"><b>2022</b></p></td>
    <td style="width: 0.2in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="border-bottom: black 1.01px solid; width: 0.1in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="border-bottom: black 1.01px solid; vertical-align: bottom; width: 1.2in"><p style="margin: 0px; text-align: center; font-size: 10pt"><b>2023</b></p></td>
    <td style="width: 0.2in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.1in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="border-bottom: black 1.01px solid; vertical-align: bottom; width: 1.2in"><p style="margin: 0px; text-align: center; font-size: 10pt"><b>2022</b></p></td>
    <td style="width: 0.2in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.1in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="vertical-align: bottom"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.2in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.1in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="vertical-align: bottom"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.2in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.1in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="vertical-align: bottom"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.2in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.1in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="vertical-align: bottom"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.2in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom"><p style="margin: 0px; font-size: 10pt"><b>Operating Expenses</b></p></td>
    <td style="width: 0.1in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="vertical-align: bottom"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.2in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.1in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="vertical-align: bottom"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.2in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.1in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="vertical-align: bottom"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.2in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.1in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="vertical-align: bottom"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.2in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; background-color: #e6efff"><p style="margin-left: 12px; margin-top: 0px; margin-bottom: 0px; font-size: 10pt">Selling, general and administration</p></td>
    <td style="vertical-align: bottom; text-align: right; width: 0.1in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">$</p></td>
    <td style="vertical-align: bottom; text-align: right; width: 1.2in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2023-07-012023-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">385,923</ix:nonFraction></p></td>
    <td style="width: 0.2in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="vertical-align: bottom; text-align: right; width: 0.1in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">$</p></td>
    <td style="vertical-align: bottom; text-align: right; width: 1.2in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2022-07-012022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">21,504</ix:nonFraction></p></td>
    <td style="width: 0.2in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="vertical-align: bottom; text-align: right; width: 0.1in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">$</p></td>
    <td style="vertical-align: bottom; text-align: right; width: 1.2in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2023-04-01to2023-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">546,097</ix:nonFraction></p></td>
    <td style="width: 0.2in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="vertical-align: bottom; text-align: right; width: 0.1in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">$</p></td>
    <td style="vertical-align: bottom; text-align: right; width: 1.2in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2022-04-012022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">38,789</ix:nonFraction></p></td>
    <td style="width: 0.2in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom"><p style="margin-left: 12px; margin-top: 0px; margin-bottom: 0px; font-size: 10pt">Research   and development</p></td>
    <td style="width: 0.1in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="border-bottom: black 1.01px solid; vertical-align: bottom; text-align: right; width: 1.2in"><p style="margin: 0px; font-size: 10pt"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-07-012023-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,400,000</ix:nonFraction></p></td>
    <td style="width: 0.2in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.1in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="border-bottom: black 1.01px solid; vertical-align: bottom; text-align: right; width: 1.2in"><p style="margin: 0px; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0152">&#8212;</span></p></td>
    <td style="width: 0.2in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.1in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="border-bottom: black 1.01px solid; vertical-align: bottom; text-align: right; width: 1.2in"><p style="margin: 0px; font-size: 10pt"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-04-01to2023-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,400,000</ix:nonFraction></p></td>
    <td style="width: 0.2in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.1in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="border-bottom: black 1.01px solid; vertical-align: bottom; text-align: right; width: 1.2in"><p style="margin: 0px; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0154">&#8212;</span></p></td>
    <td style="width: 0.2in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; background-color: #e6efff"><p style="margin-left: 24px; margin-top: 0px; margin-bottom: 0px; font-size: 10pt">Total   Operating Expenses</p></td>
    <td style="width: 0.1in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="vertical-align: bottom; text-align: right; width: 1.2in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2023-07-012023-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,785,923</ix:nonFraction></p></td>
    <td style="width: 0.2in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.1in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="vertical-align: bottom; text-align: right; width: 1.2in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2022-07-012022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">21,504</ix:nonFraction></p></td>
    <td style="width: 0.2in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.1in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="vertical-align: bottom; text-align: right; width: 1.2in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2023-04-01to2023-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,946,097</ix:nonFraction></p></td>
    <td style="width: 0.2in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.1in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="vertical-align: bottom; text-align: right; width: 1.2in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2022-04-012022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">38,789</ix:nonFraction></p></td>
    <td style="width: 0.2in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.1in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="border-bottom: black 1.01px solid; width: 1.2in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.2in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.1in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="border-bottom: black 1.01px solid; width: 1.2in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.2in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.1in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="border-bottom: black 1.01px solid; width: 1.2in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.2in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.1in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="border-bottom: black 1.01px solid; width: 1.2in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.2in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt"><b>Operating Loss</b></p></td>
    <td style="width: 0.1in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="vertical-align: bottom; text-align: right; width: 1.2in; background-color: rgb(230, 239, 255)"><p style="margin: 0px; font-size: 10pt">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2023-07-012023-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,785,923</ix:nonFraction></p></td>
    <td style="vertical-align: bottom; width: 0.2in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">)</p></td>
    <td style="width: 0.1in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="vertical-align: bottom; text-align: right; width: 1.2in; background-color: rgb(230, 239, 255)"><p style="margin: 0px; font-size: 10pt">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2022-07-012022-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">21,504</ix:nonFraction></p></td>
    <td style="vertical-align: bottom; width: 0.2in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">)</p></td>
    <td style="width: 0.1in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="vertical-align: bottom; text-align: right; width: 1.2in; background-color: rgb(230, 239, 255)"><p style="margin: 0px; font-size: 10pt">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2023-04-01to2023-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,946,097</ix:nonFraction></p></td>
    <td style="width: 0.2in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">)&#160;</p></td>
    <td style="width: 0.1in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="vertical-align: bottom; text-align: right; width: 1.2in; background-color: rgb(230, 239, 255)"><p style="margin: 0px; font-size: 10pt">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2022-04-012022-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">38,789</ix:nonFraction></p></td>
    <td style="vertical-align: bottom; width: 0.2in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">)</p></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.1in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 1.2in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.2in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.1in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 1.2in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.2in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.1in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 1.2in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.2in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.1in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 1.2in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.2in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt"><b>Other Income (Expense)</b></p></td>
    <td style="width: 0.1in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 1.2in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.2in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.1in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 1.2in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.2in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.1in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 1.2in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.2in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.1in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 1.2in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.2in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom"><p style="margin-left: 12px; margin-top: 0px; margin-bottom: 0px; font-size: 10pt">Interest   expense</p></td>
    <td style="width: 0.1in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="vertical-align: bottom; text-align: right; width: 1.2in"><p style="margin: 0px; font-size: 10pt">(<ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2023-07-012023-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">19,801</ix:nonFraction></p></td>
    <td style="vertical-align: bottom; width: 0.2in"><p style="margin: 0px; font-size: 10pt">)</p></td>
    <td style="width: 0.1in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="vertical-align: bottom; text-align: right; width: 1.2in"><p style="margin: 0px; font-size: 10pt">(<ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2022-07-012022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">16,607</ix:nonFraction></p></td>
    <td style="vertical-align: bottom; width: 0.2in"><p style="margin: 0px; font-size: 10pt">)</p></td>
    <td style="width: 0.1in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="vertical-align: bottom; text-align: right; width: 1.2in"><p style="margin: 0px; font-size: 10pt">(<ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2023-04-01to2023-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">38,307</ix:nonFraction></p></td>
    <td style="width: 0.2in"><p style="margin: 0px; font-size: 10pt">)</p></td>
    <td style="width: 0.1in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="vertical-align: bottom; text-align: right; width: 1.2in"><p style="margin: 0px; font-size: 10pt">(<ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2022-04-012022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">32,125</ix:nonFraction></p></td>
    <td style="vertical-align: bottom; width: 0.2in"><p style="margin: 0px; font-size: 10pt">)</p></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; background-color: #e6efff"><p style="margin-left: 12px; margin-top: 0px; margin-bottom: 0px; font-size: 10pt">Foreign   currency gain (loss)</p></td>
    <td style="width: 0.1in; background-color: rgb(230, 239, 255)"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="border-bottom: black 1.01px solid; vertical-align: bottom; text-align: right; width: 1.2in; background-color: rgb(230, 239, 255)"><p style="margin: 0px; font-size: 10pt"><ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="From2023-07-012023-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,275</ix:nonFraction></p></td>
    <td style="width: 0.2in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.1in; background-color: rgb(230, 239, 255)"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="border-bottom: black 1.01px solid; vertical-align: bottom; text-align: right; width: 1.2in; background-color: rgb(230, 239, 255)"><p style="margin: 0px; font-size: 10pt"><ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="From2022-07-012022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">19,675</ix:nonFraction></p></td>
    <td style="width: 0.2in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.1in; background-color: rgb(230, 239, 255)"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="border-bottom: black 1.01px solid; vertical-align: bottom; text-align: right; width: 1.2in; background-color: rgb(230, 239, 255)"><p style="margin: 0px; font-size: 10pt">(<ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="From2023-04-01to2023-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,620</ix:nonFraction></p></td>
    <td style="width: 0.2in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">)</p></td>
    <td style="width: 0.1in; background-color: rgb(230, 239, 255)"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="border-bottom: black 1.01px solid; vertical-align: bottom; text-align: right; width: 1.2in; background-color: rgb(230, 239, 255)"><p style="margin: 0px; font-size: 10pt"><ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="From2022-04-012022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">29,274</ix:nonFraction></p></td>
    <td style="width: 0.2in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom"><p style="margin-left: 28.4px; margin-top: 0px; margin-bottom: 0px; font-size: 10pt">Total   Other Income (Expense)</p></td>
    <td style="width: 0.1in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="vertical-align: bottom; text-align: right; width: 1.2in"><p style="margin: 0px; font-size: 10pt">(<ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2023-07-012023-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">15,526</ix:nonFraction></p></td>
    <td style="vertical-align: bottom; width: 0.2in"><p style="margin: 0px; font-size: 10pt">)</p></td>
    <td style="width: 0.1in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="vertical-align: bottom; text-align: right; width: 1.2in"><p style="margin: 0px; font-size: 10pt"><ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2022-07-012022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,068</ix:nonFraction></p></td>
    <td style="width: 0.2in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.1in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="vertical-align: bottom; text-align: right; width: 1.2in"><p style="margin: 0px; font-size: 10pt">(<ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2023-04-01to2023-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">40,927</ix:nonFraction></p></td>
    <td style="width: 0.2in"><p style="margin: 0px; font-size: 10pt">)</p></td>
    <td style="width: 0.1in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="vertical-align: bottom; text-align: right; width: 1.2in"><p style="margin: 0px; font-size: 10pt">(<ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2022-04-012022-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,851</ix:nonFraction></p></td>
    <td style="vertical-align: bottom; width: 0.2in"><p style="margin: 0px; font-size: 10pt">)</p></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.1in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="border-bottom: black 1.01px solid; width: 1.2in; background-color: rgb(230, 239, 255)"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.2in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.1in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="border-bottom: black 1.01px solid; width: 1.2in; background-color: rgb(230, 239, 255)"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.2in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.1in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="border-bottom: black 1.01px solid; width: 1.2in; background-color: rgb(230, 239, 255)"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.2in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.1in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="border-bottom: black 1.01px solid; width: 1.2in; background-color: rgb(230, 239, 255)"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.2in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom"><p style="margin: 0px; font-size: 10pt">Net Loss</p></td>
    <td style="vertical-align: bottom; text-align: right; width: 0.1in"><p style="margin: 0px; font-size: 10pt">$</p></td>
    <td style="border-bottom: black 3px double; vertical-align: bottom; text-align: right; width: 1.2in"><p style="margin: 0px; font-size: 10pt">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-07-012023-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,801,449</ix:nonFraction></p></td>
    <td style="vertical-align: bottom; width: 0.2in"><p style="margin: 0px; font-size: 10pt">)</p></td>
    <td style="vertical-align: bottom; text-align: right; width: 0.1in"><p style="margin: 0px; font-size: 10pt">$</p></td>
    <td style="border-bottom: black 3px double; vertical-align: bottom; text-align: right; width: 1.2in"><p style="margin: 0px; font-size: 10pt">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-07-012022-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">18,436</ix:nonFraction></p></td>
    <td style="vertical-align: bottom; width: 0.2in"><p style="margin: 0px; font-size: 10pt">)</p></td>
    <td style="vertical-align: bottom; text-align: right; width: 0.1in"><p style="margin: 0px; font-size: 10pt">$</p></td>
    <td style="border-bottom: black 3px double; vertical-align: bottom; text-align: right; width: 1.2in"><p style="margin: 0px; font-size: 10pt">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-04-01to2023-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,987,024</ix:nonFraction></p></td>
    <td style="width: 0.2in"><p style="margin: 0px; font-size: 10pt">)</p></td>
    <td style="vertical-align: bottom; text-align: right; width: 0.1in"><p style="margin: 0px; font-size: 10pt">$</p></td>
    <td style="border-bottom: black 3px double; vertical-align: bottom; text-align: right; width: 1.2in"><p style="margin: 0px; font-size: 10pt">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-04-012022-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">41,640</ix:nonFraction></p></td>
    <td style="vertical-align: bottom; width: 0.2in"><p style="margin: 0px; font-size: 10pt">)</p></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.1in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 1.2in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.2in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.1in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 1.2in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.2in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.1in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 1.2in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.2in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.1in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 1.2in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.2in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom"><p style="margin: 0px; font-size: 10pt"><b>Basic and Diluted Loss   per Common Share</b></p></td>
    <td style="vertical-align: bottom; text-align: right; width: 0.1in"><p style="margin: 0px; font-size: 10pt">$</p></td>
    <td style="border-bottom: black 3px double; vertical-align: bottom; text-align: right; width: 1.2in"><p style="margin: 0px; font-size: 10pt">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" contextRef="From2023-07-012023-09-30" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.01</ix:nonFraction></p></td>
    <td style="vertical-align: bottom; width: 0.2in"><p style="margin: 0px; font-size: 10pt">)</p></td>
    <td style="vertical-align: bottom; text-align: right; width: 0.1in"><p style="margin: 0px; font-size: 10pt">$</p></td>
    <td style="border-bottom: black 3px double; vertical-align: bottom; text-align: right; width: 1.2in"><p style="margin: 0px; font-size: 10pt">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" contextRef="From2022-07-012022-09-30" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.00</ix:nonFraction></p></td>
    <td style="vertical-align: bottom; width: 0.2in"><p style="margin: 0px; font-size: 10pt">)</p></td>
    <td style="vertical-align: bottom; text-align: right; width: 0.1in"><p style="margin: 0px; font-size: 10pt">$</p></td>
    <td style="border-bottom: black 3px double; vertical-align: bottom; text-align: right; width: 1.2in"><p style="margin: 0px; font-size: 10pt">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" contextRef="From2023-04-01to2023-09-30" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.01</ix:nonFraction></p></td>
    <td style="width: 0.2in"><p style="margin: 0px; font-size: 10pt">)</p></td>
    <td style="vertical-align: bottom; text-align: right; width: 0.1in"><p style="margin: 0px; font-size: 10pt">$</p></td>
    <td style="border-bottom: black 3px double; vertical-align: bottom; text-align: right; width: 1.2in"><p style="margin: 0px; font-size: 10pt">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" contextRef="From2022-04-012022-09-30" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.00</ix:nonFraction></p></td>
    <td style="vertical-align: bottom; width: 0.2in"><p style="margin: 0px; font-size: 10pt">)</p></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt"><b>Weighted Average Number   of Common Shares Outstanding</b></p></td>
    <td style="width: 0.1in; background-color: rgb(230, 239, 255)"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="border-bottom: black 3px double; vertical-align: bottom; text-align: right; width: 1.2in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2023-07-012023-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">277,516,358</ix:nonFraction></p></td>
    <td style="width: 0.2in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.1in; background-color: rgb(230, 239, 255)"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="border-bottom: black 3px double; vertical-align: bottom; text-align: right; width: 1.2in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2022-07-012022-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">277,112,660</ix:nonFraction></p></td>
    <td style="width: 0.2in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.1in; background-color: rgb(230, 239, 255)"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="border-bottom: black 3px double; vertical-align: bottom; text-align: right; width: 1.2in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2023-04-01to2023-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">277,337,306</ix:nonFraction></p></td>
    <td style="width: 0.2in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.1in; background-color: rgb(230, 239, 255)"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="border-bottom: black 3px double; vertical-align: bottom; text-align: right; width: 1.2in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2022-04-012022-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">277,112,660</ix:nonFraction></p></td>
    <td style="width: 0.2in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
  </tr>
</tbody>
</table>

<p style="margin: 0px; text-align: center; font-size: 10pt">&#160;</p>

<p style="margin: 0px; text-align: center; font-size: 10pt">The accompanying notes are
an integral part of these unaudited financial statements.</p>

<p style="margin: 0px; text-align: center; font-size: 10pt"><b>&#160;</b></p>

<table cellpadding="0" class="adv_pagination" cellspacing="0" border="0" style="width: 100%; font-size: 10pt; margin-top: 10px">
  <tbody>
  <tr style="vertical-align: top; text-align: left">
    <td style="width: 33%"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 34%; text-align: center"><p class="pagenumber" style="margin: 0px; font-size: 10pt">2</p></td>
    <td style="width: 33%; text-align: right"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
  </tr>
</tbody>
</table>

<table border="0" cellspacing="0" cellpadding="0" style="width: 100%; page-break-after: always">
  <tbody>
  <tr>
    <td style="border-bottom: black 4px solid"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
  </tr>
</tbody>
</table>

<p style="margin-top: 0pt; margin-bottom: 0pt"><span id="page_3" class="adv_highlightanchor adv_pagination"></span></p>

<p style="margin: 0px; text-align: justify; font-size: 10pt">&#160;</p>

<p style="margin: 0px; text-align: center; font-size: 10pt"><b>REGENEREX PHARMA, INC.</b></p>

<p style="margin: 0px; text-align: center; font-size: 10pt"><b>STATEMENTS OF CASH FLOWS</b></p>

<p style="margin: 0px; text-align: center; font-size: 10pt"><b>(UNAUDITED)</b><span style="font-size: 10pt">&#160;</span></p>

<p style="margin: 0px; text-align: center; font-size: 10pt">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
  <tbody>
  <tr>
    <td style="vertical-align: bottom"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="vertical-align: bottom"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="vertical-align: bottom"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="vertical-align: bottom"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="vertical-align: bottom"><p style="margin: 0px; font-size: 10pt; text-align: center">&#160;</p></td>
    <td><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="border-bottom: black 1.01px solid; width: 0.1in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td colspan="4" style="border-bottom: black 1.01px solid; vertical-align: bottom; width: 1.2in"><p style="margin: 0px; font-size: 10pt; text-align: center"><b style="font-size: 10pt">For the Six Months Ended</b></p></td>
    <td style="width: 0.2in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.1in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td colspan="4" style="vertical-align: bottom; width: 1.2in"><p style="margin: 0px; font-size: 10pt; text-align: center"><b style="font-size: 10pt">September 30,</b></p></td>
    <td style="width: 0.2in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.1in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="border-bottom: black 1.01px solid; vertical-align: bottom; width: 1.2in"><p style="margin: 0px; text-align: center; font-size: 10pt"><b>2023</b></p></td>
    <td style="width: 0.2in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.1in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="border-bottom: black 1.01px solid; vertical-align: bottom; width: 1.2in"><p style="margin: 0px; text-align: center; font-size: 10pt"><b>2022</b></p></td>
    <td style="width: 0.2in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom"><p style="margin: 0px; font-size: 10pt"><b>Cash Flows from Operating   Activities:</b></p></td>
    <td style="width: 0.1in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="vertical-align: bottom"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.2in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.1in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="vertical-align: bottom"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.2in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">Net   loss</p></td>
    <td style="vertical-align: bottom; width: 0.1in; text-align: right; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">$</p></td>
    <td style="vertical-align: bottom; width: 1.2in; text-align: right; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-04-01to2023-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,987,024</ix:nonFraction></p></td>
    <td style="vertical-align: bottom; width: 0.2in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">)</p></td>
    <td style="vertical-align: bottom; width: 0.1in; text-align: right; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">$</p></td>
    <td style="vertical-align: bottom; width: 1.2in; text-align: right; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-04-012022-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">41,640</ix:nonFraction></p></td>
    <td style="vertical-align: bottom; width: 0.2in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">)</p></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom"><p style="margin: 0px; font-size: 10pt">Adjustments   to reconcile net loss to cash flows used in operating activities:</p></td>
    <td style="width: 0.1in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 1.2in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.2in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.1in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 1.2in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.2in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; background-color: #e6efff"><p style="margin-left: 15.46px; margin-top: 0px; margin-bottom: 0px; font-size: 10pt">Depreciation</p></td>
    <td style="width: 0.1in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="vertical-align: bottom; width: 1.2in; text-align: right; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2023-04-01to2023-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,975</ix:nonFraction></p></td>
    <td style="width: 0.2in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.1in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="vertical-align: bottom; width: 1.2in; text-align: right; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2022-04-012022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,794</ix:nonFraction></p></td>
    <td style="width: 0.2in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom"><p style="margin-left: 15.46px; margin-top: 0px; margin-bottom: 0px; font-size: 10pt">Stock-based compensation</p></td>
    <td style="width: 0.1in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="vertical-align: bottom; width: 1.2in; text-align: right"><p style="margin: 0px; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2023-04-01to2023-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">133,388</ix:nonFraction></p></td>
    <td style="width: 0.2in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.1in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="vertical-align: bottom; width: 1.2in; text-align: right"><p style="margin: 0px; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0214">&#8212;</span></p></td>
    <td style="width: 0.2in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; background-color: #e6efff"><p style="margin-left: 15.46px; margin-top: 0px; margin-bottom: 0px; font-size: 10pt">Non-cash
research and development expenses</p></td>
    <td style="width: 0.1in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="vertical-align: bottom; width: 1.2in; text-align: right; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt"><ix:nonFraction name="us-gaap:PaymentsToAcquireIntangibleAssets" contextRef="From2023-04-01to2023-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,400,000</ix:nonFraction></p></td>
    <td style="width: 0.2in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.1in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="vertical-align: bottom; width: 1.2in; text-align: right; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0217">&#8212;</span></p></td>
    <td style="width: 0.2in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom"><p style="margin-left: 15.46px; margin-top: 0px; margin-bottom: 0px; font-size: 10pt">Amortization of ROU assets, net of liabilities</p></td>
    <td style="width: 0.1in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="vertical-align: bottom; width: 1.2in; text-align: right"><p style="margin: 0px; font-size: 10pt"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" contextRef="From2023-04-01to2023-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">22,880</ix:nonFraction></p></td>
    <td style="width: 0.2in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.1in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="vertical-align: bottom; width: 1.2in; text-align: right"><p style="margin: 0px; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0220">&#8212;</span></p></td>
    <td style="width: 0.2in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; background-color: #e6efff"><p style="margin-left: 15.46px; margin-top: 0px; margin-bottom: 0px; font-size: 10pt">Foreign currency adjustments</p></td>
    <td style="width: 0.1in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="vertical-align: bottom; width: 1.2in; text-align: right; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt"><ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="From2023-04-01to2023-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,620</ix:nonFraction></p></td>
    <td style="width: 0.2in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.1in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="vertical-align: bottom; width: 1.2in; text-align: right; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">(<ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="From2022-04-012022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">29,274</ix:nonFraction></p></td>
    <td style="vertical-align: bottom; width: 0.2in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">)</p></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom"><p style="margin: 0px; font-size: 10pt">Changes   in operating assets and liabilities:</p></td>
    <td style="width: 0.1in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 1.2in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.2in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.1in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 1.2in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.2in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; background-color: #e6efff"><p style="margin-left: 34.4px; margin-top: 0px; margin-bottom: 0px; font-size: 10pt">Prepaid expenses</p></td>
    <td style="width: 0.1in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="vertical-align: bottom; width: 1.2in; text-align: right; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidExpense" contextRef="From2023-04-01to2023-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">13,250</ix:nonFraction></p></td>
    <td style="vertical-align: bottom; width: 0.2in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">)</p></td>
    <td style="width: 0.1in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="vertical-align: bottom; width: 1.2in; text-align: right; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt"><ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidExpense" contextRef="From2022-04-012022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,756</ix:nonFraction></p></td>
    <td style="width: 0.2in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom"><p style="margin-left: 34.4px; margin-top: 0px; margin-bottom: 0px; font-size: 10pt">Accounts payable and accrued liabilities</p></td>
    <td style="width: 0.1in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="border-bottom: black 1.01px solid; vertical-align: bottom; width: 1.2in; text-align: right"><p style="margin: 0px; font-size: 10pt"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" contextRef="From2023-04-01to2023-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">146,125</ix:nonFraction></p></td>
    <td style="width: 0.2in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.1in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="border-bottom: black 1.01px solid; vertical-align: bottom; width: 1.2in; text-align: right"><p style="margin: 0px; font-size: 10pt"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" contextRef="From2022-04-012022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">21,852</ix:nonFraction></p></td>
    <td style="width: 0.2in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">Net   cash used in operating activities</p></td>
    <td style="width: 0.1in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="border-bottom: black 1.01px solid; vertical-align: bottom; width: 1.2in; text-align: right; background-color: rgb(230, 239, 255)"><p style="margin: 0px; font-size: 10pt">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2023-04-01to2023-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">293,286</ix:nonFraction></p></td>
    <td style="vertical-align: bottom; width: 0.2in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">)</p></td>
    <td style="width: 0.1in; background-color: rgb(230, 239, 255)"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="border-bottom: black 1.01px solid; vertical-align: bottom; width: 1.2in; text-align: right; background-color: rgb(230, 239, 255)"><p style="margin: 0px; font-size: 10pt">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2022-04-012022-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">44,512</ix:nonFraction></p></td>
    <td style="vertical-align: bottom; width: 0.2in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">)</p></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.1in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 1.2in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.2in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.1in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 1.2in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.2in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt"><b>Cash Flows from Investing   Activities:</b></p></td>
    <td style="width: 0.1in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 1.2in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.2in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.1in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 1.2in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.2in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom"><p style="margin-left: 15.46px; margin-top: 0px; margin-bottom: 0px; font-size: 10pt">Purchase of furniture and computer equipment</p></td>
    <td style="width: 0.1in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="border-bottom: black 1.01px solid; vertical-align: bottom; width: 1.2in; text-align: right"><p style="margin: 0px; font-size: 10pt">(<ix:nonFraction name="us-gaap:PaymentsToAcquireFurnitureAndFixtures" contextRef="From2023-04-01to2023-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,299</ix:nonFraction></p></td>
    <td style="vertical-align: bottom; width: 0.2in"><p style="margin: 0px; font-size: 10pt">)</p></td>
    <td style="width: 0.1in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="border-bottom: black 1.01px solid; vertical-align: bottom; width: 1.2in; text-align: right"><p style="margin: 0px; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0241">&#8212;</span></p></td>
    <td style="width: 0.2in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; background-color: #e6efff"><p style="margin-left: 12px; margin-top: 0px; margin-bottom: 0px; font-size: 10pt">Net cash used in investing activities</p></td>
    <td style="width: 0.1in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="border-bottom: black 1.01px solid; vertical-align: bottom; width: 1.2in; text-align: right; background-color: rgb(230, 239, 255)"><p style="margin: 0px; font-size: 10pt">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2023-04-01to2023-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">6,299</ix:nonFraction></p></td>
    <td style="vertical-align: bottom; width: 0.2in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">)</p></td>
    <td style="width: 0.1in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="border-bottom: black 1.01px solid; vertical-align: bottom; width: 1.2in; text-align: right; background-color: rgb(230, 239, 255)"><p style="margin: 0px; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0244">&#8212;</span></p></td>
    <td style="width: 0.2in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.1in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 1.2in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.2in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.1in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 1.2in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.2in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt"><b>Cash Flows from Financing   Activities:</b></p></td>
    <td style="width: 0.1in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 1.2in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.2in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.1in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 1.2in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.2in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom"><p style="margin-left: 15.46px; margin-top: 0px; margin-bottom: 0px; font-size: 10pt">Related party advances</p></td>
    <td style="width: 0.1in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="vertical-align: bottom; width: 1.2in; text-align: right"><p style="margin: 0px; font-size: 10pt"><ix:nonFraction name="us-gaap:ProceedsFromRelatedPartyDebt" contextRef="From2023-04-01to2023-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,437</ix:nonFraction></p></td>
    <td style="width: 0.2in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.1in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="vertical-align: bottom; width: 1.2in; text-align: right"><p style="margin: 0px; font-size: 10pt"><ix:nonFraction name="us-gaap:ProceedsFromRelatedPartyDebt" contextRef="From2022-04-012022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,600</ix:nonFraction></p></td>
    <td style="width: 0.2in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; background-color: #e6efff"><p style="margin-left: 15.46px; margin-top: 0px; margin-bottom: 0px; font-size: 10pt">Repayment of notes payable to related parties</p></td>
    <td style="width: 0.1in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="vertical-align: bottom; width: 1.2in; text-align: right; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">(<ix:nonFraction name="us-gaap:RepaymentsOfNotesPayable" contextRef="From2023-04-012023-09-30_us-gaap_OtherAffiliatesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">34,000</ix:nonFraction></p></td>
    <td style="vertical-align: bottom; width: 0.2in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">)</p></td>
    <td style="width: 0.1in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="vertical-align: bottom; width: 1.2in; text-align: right; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0253">&#8212;</span></p></td>
    <td style="width: 0.2in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom"><p style="margin-left: 15.46px; margin-top: 0px; margin-bottom: 0px; font-size: 10pt">Repayment of notes payable to shareholder</p></td>
    <td style="width: 0.1in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="vertical-align: bottom; width: 1.2in; text-align: right"><p style="margin: 0px; font-size: 10pt">(<ix:nonFraction name="us-gaap:RepaymentsOfNotesPayable" contextRef="From2023-04-012023-09-30_custom_ShareholderMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,000</ix:nonFraction></p></td>
    <td style="vertical-align: bottom; width: 0.2in"><p style="margin: 0px; font-size: 10pt">)</p></td>
    <td style="width: 0.1in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="vertical-align: bottom; width: 1.2in; text-align: right"><p style="margin: 0px; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0256">&#8212;</span></p></td>
    <td style="width: 0.2in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; background-color: #e6efff"><p style="margin-left: 15.46px; margin-top: 0px; margin-bottom: 0px; font-size: 10pt">Proceeds from notes payable to shareholder</p></td>
    <td style="width: 0.1in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="vertical-align: bottom; width: 1.2in; text-align: right; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt"><ix:nonFraction name="us-gaap:ProceedsFromNotesPayable" contextRef="From2023-04-01to2023-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,843</ix:nonFraction></p></td>
    <td style="width: 0.2in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.1in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="vertical-align: bottom; width: 1.2in; text-align: right; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt"><ix:nonFraction name="us-gaap:ProceedsFromNotesPayable" contextRef="From2022-04-012022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">34,901</ix:nonFraction></p></td>
    <td style="width: 0.2in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom"><p style="margin-left: 15.46px; margin-top: 0px; margin-bottom: 0px; font-size: 10pt">Proceeds from sale of common stock and warrants</p></td>
    <td style="width: 0.1in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="border-bottom: black 1.01px solid; vertical-align: bottom; width: 1.2in; text-align: right"><p style="margin: 0px; font-size: 10pt"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfWarrants" contextRef="From2023-04-01to2023-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">343,250</ix:nonFraction></p></td>
    <td style="width: 0.2in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.1in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="border-bottom: black 1.01px solid; vertical-align: bottom; width: 1.2in; text-align: right"><p style="margin: 0px; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0262">&#8212;</span></p></td>
    <td style="width: 0.2in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; background-color: #e6efff"><p style="margin-left: 12px; margin-top: 0px; margin-bottom: 0px; font-size: 10pt">Net cash provided by financing activities</p></td>
    <td style="width: 0.1in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="border-bottom: black 1.01px solid; vertical-align: bottom; width: 1.2in; text-align: right; background-color: rgb(230, 239, 255)"><p style="margin: 0px; font-size: 10pt"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2023-04-01to2023-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">304,530</ix:nonFraction></p></td>
    <td style="width: 0.2in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.1in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="border-bottom: black 1.01px solid; vertical-align: bottom; width: 1.2in; text-align: right; background-color: rgb(230, 239, 255)"><p style="margin: 0px; font-size: 10pt"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2022-04-012022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">42,501</ix:nonFraction></p></td>
    <td style="width: 0.2in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.1in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 1.2in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.2in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.1in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 1.2in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.2in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt"><span style="font-size: 10pt"><b>Increase (decrease) in cash and equivalents</b></span></p></td>
    <td style="width: 0.1in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="vertical-align: bottom; width: 1.2in; text-align: right; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="From2023-04-01to2023-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,945</ix:nonFraction></p></td>
    <td style="width: 0.2in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.1in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="vertical-align: bottom; width: 1.2in; text-align: right; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="From2022-04-012022-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,011</ix:nonFraction></p></td>
    <td style="vertical-align: bottom; width: 0.2in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">)</p></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom"><p style="margin: 0px; font-size: 10pt">Cash   and cash equivalents, beginning of period</p></td>
    <td style="width: 0.1in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="border-bottom: black 1.01px solid; vertical-align: bottom; width: 1.2in; text-align: right"><p style="margin: 0px; font-size: 10pt"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,135</ix:nonFraction></p></td>
    <td style="width: 0.2in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.1in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="border-bottom: black 1.01px solid; vertical-align: bottom; width: 1.2in; text-align: right"><p style="margin: 0px; font-size: 10pt"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,640</ix:nonFraction></p></td>
    <td style="width: 0.2in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">Cash   and cash equivalents, end of period</p></td>
    <td style="vertical-align: bottom; width: 0.1in; text-align: right; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">$</p></td>
    <td style="border-bottom: black 3px double; vertical-align: bottom; width: 1.2in; text-align: right; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,080</ix:nonFraction></p></td>
    <td style="width: 0.2in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="vertical-align: bottom; width: 0.1in; text-align: right; background-color: rgb(230, 239, 255)"><p style="margin: 0px; font-size: 10pt">$</p></td>
    <td style="border-bottom: black 3px double; vertical-align: bottom; width: 1.2in; text-align: right; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">629</ix:nonFraction></p></td>
    <td style="width: 0.2in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.1in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 1.2in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.2in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.1in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 1.2in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.2in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">Supplemental   Cash Flow Information &#8211; Cash Paid For:</p></td>
    <td style="width: 0.1in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 1.2in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.2in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.1in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 1.2in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.2in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom"><p style="margin-left: 15.46px; margin-top: 0px; margin-bottom: 0px; font-size: 10pt">Income Taxes</p></td>
    <td style="vertical-align: bottom; width: 0.1in; text-align: right"><p style="margin: 0px; font-size: 10pt">$</p></td>
    <td style="border-bottom: black 3px double; vertical-align: bottom; width: 1.2in; text-align: right"><p style="margin: 0px; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0279">&#8212;</span></p></td>
    <td style="width: 0.2in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="vertical-align: bottom; width: 0.1in; text-align: right"><p style="margin: 0px; font-size: 10pt">$</p></td>
    <td style="border-bottom: black 3px double; vertical-align: bottom; width: 1.2in; text-align: right"><p style="margin: 0px; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0280">&#8212;</span></p></td>
    <td style="width: 0.2in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; background-color: #e6efff"><p style="margin-left: 15.46px; margin-top: 0px; margin-bottom: 0px; font-size: 10pt">Interest</p></td>
    <td style="vertical-align: bottom; width: 0.1in; text-align: right; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">$</p></td>
    <td style="border-bottom: black 3px double; vertical-align: bottom; width: 1.2in; text-align: right; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0282">&#8212;</span></p></td>
    <td style="width: 0.2in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="vertical-align: bottom; width: 0.1in; text-align: right; background-color: rgb(230, 239, 255)"><p style="margin: 0px; font-size: 10pt">$</p></td>
    <td style="border-bottom: black 3px double; vertical-align: bottom; width: 1.2in; text-align: right; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0283">&#8212;</span></p></td>
    <td style="width: 0.2in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom"><p style="margin: 0px; font-size: 10pt">Non-Cash   Investing and Financing Activities:</p></td>
    <td style="width: 0.1in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="border-bottom: black 3px double; width: 1.2in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.2in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.1in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="border-bottom: black 3px double; width: 1.2in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.2in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; background-color: #e6efff"><p style="margin-left: 15.46px; margin-top: 0px; margin-bottom: 0px; font-size: 10pt">Accrued interest converted into notes payable</p></td>
    <td style="vertical-align: bottom; width: 0.1in; text-align: right; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">$</p></td>
    <td style="border-bottom: black 3px double; vertical-align: bottom; width: 1.2in; text-align: right; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt"><ix:nonFraction name="RGPX:AccruedInterestConvertedIntoNotePayableToShareholder" contextRef="From2023-04-01to2023-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">78,194</ix:nonFraction></p></td>
    <td style="width: 0.2in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="vertical-align: bottom; width: 0.1in; text-align: right; background-color: rgb(230, 239, 255)"><p style="margin: 0px; font-size: 10pt">$</p></td>
    <td style="border-bottom: black 3px double; vertical-align: bottom; width: 1.2in; text-align: right; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt"><ix:nonFraction name="RGPX:AccruedInterestConvertedIntoNotePayableToShareholder" contextRef="From2022-04-012022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,015</ix:nonFraction></p></td>
    <td style="width: 0.2in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom"><p style="margin-left: 15.46px; margin-top: 0px; margin-bottom: 0px; font-size: 10pt">Operating leases, ROU asset and liabilities</p></td>
    <td style="vertical-align: bottom; width: 0.1in; text-align: right"><p style="margin: 0px; font-size: 10pt">$</p></td>
    <td style="border-bottom: black 3px double; vertical-align: bottom; width: 1.2in; text-align: right"><p style="margin: 0px; font-size: 10pt"><ix:nonFraction name="RGPX:OperatingLeasesRouAssetAndLiabilities" contextRef="From2023-04-01to2023-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">953,535</ix:nonFraction></p></td>
    <td style="width: 0.2in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="vertical-align: bottom; width: 0.1in; text-align: right"><p style="margin: 0px; font-size: 10pt">$</p></td>
    <td style="border-bottom: black 3px double; vertical-align: bottom; width: 1.2in; text-align: right"><p style="margin: 0px; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0292">&#8212;</span></p></td>
    <td style="width: 0.2in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; background-color: #e6efff"><p style="margin-left: 15.46px; margin-top: 0px; margin-bottom: 0px; font-size: 10pt">Shares issued for the acquisition of intellectual   property</p></td>
    <td style="vertical-align: bottom; width: 0.1in; text-align: right; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">$</p></td>
    <td style="border-bottom: black 3px double; vertical-align: bottom; width: 1.2in; text-align: right; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0294">&#8212;</span></p></td>
    <td style="width: 0.2in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="vertical-align: bottom; width: 0.1in; text-align: right; background-color: rgb(230, 239, 255)"><p style="margin: 0px; font-size: 10pt">$</p></td>
    <td style="border-bottom: black 3px double; vertical-align: bottom; width: 1.2in; text-align: right; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt"><ix:nonFraction name="us-gaap:NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1" contextRef="From2022-04-012022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">150,000</ix:nonFraction></p></td>
    <td style="width: 0.2in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom"><p style="margin-left: 15.46px; margin-top: 0px; margin-bottom: 0px; font-size: 10pt">Note payable issued for acquisition of   intellectual property</p></td>
    <td style="vertical-align: bottom; width: 0.1in; text-align: right"><p style="margin: 0px; font-size: 10pt">$</p></td>
    <td style="border-bottom: black 3px double; vertical-align: bottom; width: 1.2in; text-align: right"><p style="margin: 0px; font-size: 10pt"><ix:nonFraction name="RGPX:NoncashOrPartNoncashAcquisitionOfIntangibleAssetsExcludingGoodwill" contextRef="From2023-04-01to2023-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,400,000</ix:nonFraction></p></td>
    <td style="width: 0.2in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="vertical-align: bottom; width: 0.1in; text-align: right"><p style="margin: 0px; font-size: 10pt">$</p></td>
    <td style="border-bottom: black 3px double; vertical-align: bottom; width: 1.2in; text-align: right"><p style="margin: 0px; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0298">&#8212;</span></p></td>
    <td style="width: 0.2in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
  </tr>
</tbody>
</table>

<p style="margin: 0px; text-align: center; font-size: 10pt"><b>&#160;&#160;</b></p>

<p style="margin: 0px; text-align: center; font-size: 10pt">The accompanying notes are
an integral part of these unaudited financial statements.</p>

<table cellpadding="0" class="adv_pagination" cellspacing="0" border="0" style="width: 100%; font-size: 10pt; margin-top: 10px">
  <tbody>
  <tr style="vertical-align: top; text-align: left">
    <td style="width: 33%"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 34%; text-align: center"><p class="pagenumber" style="margin: 0px; font-size: 10pt">3</p></td>
    <td style="width: 33%; text-align: right"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
  </tr>
</tbody>
</table>

<table border="0" cellspacing="0" cellpadding="0" style="width: 100%; page-break-after: always">
  <tbody>
  <tr>
    <td style="border-bottom: black 4px solid"><p style="margin: 0; font-size: 10pt">&#160;</p></td>
  </tr>
</tbody>
</table>

<p style="margin-top: 0pt; margin-bottom: 0pt"><span id="page_4" class="adv_highlightanchor adv_pagination"></span></p>

<p style="margin: 0; font-size: 10pt">&#160;</p>

<p style="margin: 0px; text-align: center; font-size: 10pt"><b>REGENEREX PHARMA, INC.</b><b></b></p>

<p style="margin: 0px; text-align: center; font-size: 10pt"><b>STATEMENTS OF
STOCKHOLDERS&#8217; DEFICIT</b></p>

<p style="margin: 0px; text-align: center; font-size: 10pt"><b>(UNAUDITED)</b><span style="font-size: 10pt">&#160;</span></p>

<p style="margin: 0px; font-size: 10pt">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
  <tbody>
  <tr>
    <td style="vertical-align: bottom"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="vertical-align: bottom"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="vertical-align: bottom"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="vertical-align: bottom"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="vertical-align: bottom"><p style="margin: 0px; text-align: center; font-size: 10pt">&#160;</p></td>
    <td><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="vertical-align: bottom"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="vertical-align: bottom"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="vertical-align: bottom"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="border-bottom: black 1.01px solid; width: 0.1in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td colspan="4" style="border-bottom: black 1.01px solid; vertical-align: bottom; width: 1.2in"><p style="margin: 0px; text-align: center; font-size: 10pt"><b>Common&#160;Stock</b></p></td>
    <td style="width: 0.2in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.1in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="vertical-align: bottom"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.2in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.1in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="vertical-align: bottom"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.2in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.1in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="vertical-align: bottom"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.2in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
  </tr>
  <tr>
    <td style="padding: 0cm 0cm 1.5pt; vertical-align: bottom"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="border-bottom: black 1.01px solid; width: 0.1in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="border-bottom: black 1.01px solid; padding: 0cm 0cm 1.5pt; vertical-align: bottom; width: 1.2in"><p style="margin: 0px; text-align: center; font-size: 10pt"><b>Shares</b></p></td>
    <td style="width: 0.2in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="border-bottom: black 1.01px solid; width: 0.1in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="border-bottom: black 1.01px solid; padding: 0cm 0cm 1.5pt; vertical-align: bottom; width: 1.2in"><p style="margin: 0px; text-align: center; font-size: 10pt"><b>Amount</b></p></td>
    <td style="width: 0.2in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="border-bottom: black 1.01px solid; width: 0.1in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="border-bottom: black 1.01px solid; padding: 0cm 0cm 1.5pt; vertical-align: bottom; width: 1.2in"><p style="margin: 0px; text-align: center; font-size: 10pt"><b>Additional </b></p><p style="margin: 0px; text-align: center; font-size: 10pt"><b>Paid-in&#160;Capital</b></p></td>
    <td style="width: 0.2in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="border-bottom: black 1.01px solid; width: 0.1in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="border-bottom: black 1.01px solid; padding: 0cm 0cm 1.5pt; vertical-align: bottom; width: 1.2in"><p style="margin: 0px; text-align: center; font-size: 10pt"><b>Accumulated</b>   <b>Deficit</b></p></td>
    <td style="width: 0.2in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="border-bottom: black 1.01px solid; width: 0.1in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="border-bottom: black 1.01px solid; padding: 0cm 0cm 1.5pt; vertical-align: bottom; width: 1.2in"><p style="margin: 0px; font-size: 10pt"></p><p style="margin: 0px; text-align: center; font-size: 10pt"><b>Stockholders&#8217; Deficit</b></p><p style="margin: 0px; font-size: 10pt"></p></td>
    <td style="border-bottom: white 1.01px solid; width: 0.2in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt"><b>Balance at </b></p><p style="margin: 0px; font-size: 10pt"><b>March 31, 2022</b></p></td>
    <td style="width: 0.1in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="vertical-align: bottom; width: 1.2in; text-align: right; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;<ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2022-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">277,112,660</ix:nonFraction></p></td>
    <td style="width: 0.2in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="vertical-align: bottom; width: 0.1in; text-align: right; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">$</p></td>
    <td style="vertical-align: bottom; width: 1.2in; text-align: right; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">277,113</ix:nonFraction></p></td>
    <td style="width: 0.2in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="vertical-align: bottom; width: 0.1in; text-align: right; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">$</p></td>
    <td style="vertical-align: bottom; width: 1.2in; text-align: right; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">671,963</ix:nonFraction></p></td>
    <td style="width: 0.2in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="vertical-align: bottom; width: 0.1in; text-align: right; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">$</p></td>
    <td style="vertical-align: bottom; width: 1.2in; text-align: right; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-03-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,934,693</ix:nonFraction></p></td>
    <td style="vertical-align: bottom; width: 0.2in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">)</p></td>
    <td style="vertical-align: bottom; width: 0.1in; text-align: right; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">$</p></td>
    <td style="vertical-align: bottom; width: 1.2in; text-align: right; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">985,617</ix:nonFraction></p></td>
    <td style="vertical-align: bottom; width: 0.2in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">)</p></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom"><p style="margin: 0px; font-size: 10pt">Net   loss</p></td>
    <td style="width: 0.1in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="border-bottom: black 1.01px solid; vertical-align: bottom; width: 1.2in; text-align: right"><p style="margin: 0px; font-size: 10pt">&#8212;</p></td>
    <td style="width: 0.2in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.1in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="border-bottom: black 1.01px solid; vertical-align: bottom; width: 1.2in; text-align: right"><p style="margin: 0px; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0306">&#8212;</span></p></td>
    <td style="width: 0.2in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.1in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="border-bottom: black 1.01px solid; vertical-align: bottom; width: 1.2in; text-align: right"><p style="margin: 0px; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0307">&#8212;</span></p></td>
    <td style="width: 0.2in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.1in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="border-bottom: black 1.01px solid; vertical-align: bottom; width: 1.2in; text-align: right"><p style="margin: 0px; font-size: 10pt">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-04-012022-06-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">23,204</ix:nonFraction></p></td>
    <td style="vertical-align: bottom; width: 0.2in"><p style="margin: 0px; font-size: 10pt">)</p></td>
    <td style="width: 0.1in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="border-bottom: black 1.01px solid; vertical-align: bottom; width: 1.2in; text-align: right"><p style="margin: 0px; font-size: 10pt">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">23,204</ix:nonFraction></p></td>
    <td style="vertical-align: bottom; width: 0.2in"><p style="margin: 0px; font-size: 10pt">)</p></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt"><b>Balance at</b></p><p style="margin: 0px; font-size: 10pt"><b>June 30, 2022</b></p></td>
    <td style="width: 0.1in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="border-bottom: black 1.01px solid; vertical-align: bottom; width: 1.2in; text-align: right; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2022-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">277,112,660</ix:nonFraction></p></td>
    <td style="width: 0.2in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.1in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="border-bottom: black 1.01px solid; vertical-align: bottom; width: 1.2in; text-align: right; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">277,113</ix:nonFraction></p></td>
    <td style="width: 0.2in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.1in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="border-bottom: black 1.01px solid; vertical-align: bottom; width: 1.2in; text-align: right; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">671,963</ix:nonFraction></p></td>
    <td style="width: 0.2in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.1in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="border-bottom: black 1.01px solid; vertical-align: bottom; width: 1.2in; text-align: right; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-06-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,957,897</ix:nonFraction></p></td>
    <td style="vertical-align: bottom; width: 0.2in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">)</p></td>
    <td style="width: 0.1in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="border-bottom: black 1.01px solid; vertical-align: bottom; width: 1.2in; text-align: right; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,008,821</ix:nonFraction></p></td>
    <td style="vertical-align: bottom; width: 0.2in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">)</p></td>
  </tr>
  <tr style="display: none">
    <td style="vertical-align: bottom; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt"><b>Balance at</b></p><p style="margin: 0px; font-size: 10pt"><b>June 30, 2022</b></p></td>
    <td style="width: 0.1in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="border-bottom: black 1.01px solid; vertical-align: bottom; width: 1.2in; text-align: right; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2022-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">277,112,660</ix:nonFraction></p></td>
    <td style="width: 0.2in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.1in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="border-bottom: black 1.01px solid; vertical-align: bottom; width: 1.2in; text-align: right; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">277,113</ix:nonFraction></p></td>
    <td style="width: 0.2in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.1in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="border-bottom: black 1.01px solid; vertical-align: bottom; width: 1.2in; text-align: right; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">671,963</ix:nonFraction></p></td>
    <td style="width: 0.2in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.1in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="border-bottom: black 1.01px solid; vertical-align: bottom; width: 1.2in; text-align: right; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-06-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,957,897</ix:nonFraction></p></td>
    <td style="vertical-align: bottom; width: 0.2in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">)</p></td>
    <td style="width: 0.1in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="border-bottom: black 1.01px solid; vertical-align: bottom; width: 1.2in; text-align: right; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,008,821</ix:nonFraction></p></td>
    <td style="vertical-align: bottom; width: 0.2in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">)</p></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom"><p style="margin: 0px; font-size: 10pt">Net   loss<b></b></p></td>
    <td style="width: 0.1in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="border-bottom: black 1.01px solid; vertical-align: bottom; width: 1.2in; text-align: right"><p style="margin: 0px; font-size: 10pt">&#8212;</p></td>
    <td style="width: 0.2in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.1in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="border-bottom: black 1.01px solid; vertical-align: bottom; width: 1.2in; text-align: right"><p style="margin: 0px; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0323">&#8212;</span></p></td>
    <td style="width: 0.2in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.1in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="border-bottom: black 1.01px solid; vertical-align: bottom; width: 1.2in; text-align: right"><p style="margin: 0px; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0324">&#8212;</span></p></td>
    <td style="width: 0.2in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.1in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="border-bottom: black 1.01px solid; vertical-align: bottom; width: 1.2in; text-align: right"><p style="margin: 0px; font-size: 10pt">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-07-012022-09-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">18,436</ix:nonFraction></p></td>
    <td style="vertical-align: bottom; width: 0.2in"><p style="margin: 0px; font-size: 10pt">)</p></td>
    <td style="width: 0.1in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="border-bottom: black 1.01px solid; vertical-align: bottom; width: 1.2in; text-align: right"><p style="margin: 0px; font-size: 10pt">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-07-012022-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">18,436</ix:nonFraction></p></td>
    <td style="vertical-align: bottom; width: 0.2in"><p style="margin: 0px; font-size: 10pt">)</p></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt"><b>Balance at</b></p><p style="margin: 0px; font-size: 10pt"><b>September 30, 2022</b></p></td>
    <td style="width: 0.1in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="border-bottom: black 3px double; vertical-align: bottom; width: 1.2in; text-align: right; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;<ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2022-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">277,112,660</ix:nonFraction></p></td>
    <td style="width: 0.2in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="vertical-align: bottom; width: 0.1in; text-align: right; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">$</p></td>
    <td style="border-bottom: black 3px double; vertical-align: bottom; width: 1.2in; text-align: right; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">277,113</ix:nonFraction></p></td>
    <td style="width: 0.2in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="vertical-align: bottom; width: 0.1in; text-align: right; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">$</p></td>
    <td style="border-bottom: black 3px double; vertical-align: bottom; width: 1.2in; text-align: right; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">671,963</ix:nonFraction></p></td>
    <td style="width: 0.2in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="vertical-align: bottom; width: 0.1in; text-align: right; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">$</p></td>
    <td style="border-bottom: black 3px double; vertical-align: bottom; width: 1.2in; text-align: right; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-09-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,976,333</ix:nonFraction></p></td>
    <td style="vertical-align: bottom; width: 0.2in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">)</p></td>
    <td style="vertical-align: bottom; width: 0.1in; text-align: right; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">$</p></td>
    <td style="border-bottom: black 3px double; vertical-align: bottom; width: 1.2in; text-align: right; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,027,257</ix:nonFraction></p></td>
    <td style="vertical-align: bottom; width: 0.2in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">)</p></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.1in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="border-bottom: black 1.01px solid; width: 1.2in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.2in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.1in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="border-bottom: black 1.01px solid; width: 1.2in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.2in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.1in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="border-bottom: black 1.01px solid; width: 1.2in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.2in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.1in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="border-bottom: black 1.01px solid; width: 1.2in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.2in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.1in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="border-bottom: black 1.01px solid; width: 1.2in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.2in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt"><b>Balance at </b></p><p style="margin: 0px; font-size: 10pt"><b>March 31, 2023</b></p></td>
    <td style="width: 0.1in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="vertical-align: bottom; width: 1.2in; text-align: right; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2023-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">277,112,660</ix:nonFraction></p></td>
    <td style="width: 0.2in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="vertical-align: bottom; width: 0.1in; text-align: right; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">$</p></td>
    <td style="vertical-align: bottom; width: 1.2in; text-align: right; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">277,113</ix:nonFraction></p></td>
    <td style="width: 0.2in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="vertical-align: bottom; width: 0.1in; text-align: right; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">$</p></td>
    <td style="vertical-align: bottom; width: 1.2in; text-align: right; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">671,963</ix:nonFraction></p></td>
    <td style="width: 0.2in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="vertical-align: bottom; width: 0.1in; text-align: right; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">$</p></td>
    <td style="vertical-align: bottom; width: 1.2in; text-align: right; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-03-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,072,023</ix:nonFraction></p></td>
    <td style="vertical-align: bottom; width: 0.2in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">)</p></td>
    <td style="vertical-align: bottom; width: 0.1in; text-align: right; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">$</p></td>
    <td style="vertical-align: bottom; width: 1.2in; text-align: right; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,122,947</ix:nonFraction></p></td>
    <td style="vertical-align: bottom; width: 0.2in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">)</p></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom"><p style="margin: 0px; font-size: 10pt">Shares   and warrants sold for cash</p></td>
    <td style="width: 0.1in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="vertical-align: bottom; width: 1.2in; text-align: right"><p style="margin: 0px; font-size: 10pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2023-04-012023-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">190,000</ix:nonFraction></p></td>
    <td style="width: 0.2in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.1in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="vertical-align: bottom; width: 1.2in; text-align: right"><p style="margin: 0px; font-size: 10pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2023-04-012023-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">190</ix:nonFraction></p></td>
    <td style="width: 0.2in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.1in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="vertical-align: bottom; width: 1.2in; text-align: right"><p style="margin: 0px; font-size: 10pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2023-04-012023-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">189,810</ix:nonFraction></p></td>
    <td style="width: 0.2in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.1in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="vertical-align: bottom; width: 1.2in; text-align: right"><p style="margin: 0px; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0342">&#8212;</span></p></td>
    <td style="width: 0.2in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.1in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="vertical-align: bottom; width: 1.2in; text-align: right"><p style="margin: 0px; font-size: 10pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2023-04-012023-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">190,000</ix:nonFraction></p></td>
    <td style="width: 0.2in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">Stock-based   compensation</p></td>
    <td style="width: 0.1in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="vertical-align: bottom; width: 1.2in; text-align: right; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="From2023-04-012023-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">30,000</ix:nonFraction></p></td>
    <td style="width: 0.2in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.1in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="vertical-align: bottom; width: 1.2in; text-align: right; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2023-04-012023-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">30</ix:nonFraction></p></td>
    <td style="width: 0.2in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.1in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="vertical-align: bottom; width: 1.2in; text-align: right; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2023-04-012023-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">34,524</ix:nonFraction></p></td>
    <td style="width: 0.2in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.1in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="vertical-align: bottom; width: 1.2in; text-align: right; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0348">&#8212;</span></p></td>
    <td style="width: 0.2in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.1in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="vertical-align: bottom; width: 1.2in; text-align: right; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2023-04-012023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">34,554</ix:nonFraction></p></td>
    <td style="width: 0.2in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom"><p style="margin: 0px; font-size: 10pt">Net   loss<b></b></p></td>
    <td style="width: 0.1in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="border-bottom: black 1.01px solid; vertical-align: bottom; width: 1.2in; text-align: right"><p style="margin: 0px; font-size: 10pt">&#8212;</p></td>
    <td style="width: 0.2in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.1in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="border-bottom: black 1.01px solid; vertical-align: bottom; width: 1.2in; text-align: right"><p style="margin: 0px; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0352">&#8212;</span></p></td>
    <td style="width: 0.2in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.1in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="border-bottom: black 1.01px solid; vertical-align: bottom; width: 1.2in; text-align: right"><p style="margin: 0px; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0353">&#8212;</span></p></td>
    <td style="width: 0.2in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.1in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="border-bottom: black 1.01px solid; vertical-align: bottom; width: 1.2in; text-align: right"><p style="margin: 0px; font-size: 10pt">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-04-012023-06-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">185,575</ix:nonFraction></p></td>
    <td style="vertical-align: bottom; width: 0.2in"><p style="margin: 0px; font-size: 10pt">)</p></td>
    <td style="width: 0.1in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="border-bottom: black 1.01px solid; vertical-align: bottom; width: 1.2in; text-align: right"><p style="margin: 0px; font-size: 10pt">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-04-012023-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">185,575</ix:nonFraction></p></td>
    <td style="vertical-align: bottom; width: 0.2in"><p style="margin: 0px; font-size: 10pt">)</p></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt"><b>Balance at</b></p><p style="margin: 0px; font-size: 10pt"><b>June 30, 2023</b></p></td>
    <td style="width: 0.1in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="vertical-align: bottom; width: 1.2in; text-align: right; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2023-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">277,332,660</ix:nonFraction></p></td>
    <td style="width: 0.2in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="vertical-align: bottom; width: 0.1in; text-align: right; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">$</p></td>
    <td style="vertical-align: bottom; width: 1.2in; text-align: right; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">277,333</ix:nonFraction></p></td>
    <td style="width: 0.2in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="vertical-align: bottom; width: 0.1in; text-align: right; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">$</p></td>
    <td style="vertical-align: bottom; width: 1.2in; text-align: right; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">896,297</ix:nonFraction></p></td>
    <td style="width: 0.2in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="vertical-align: bottom; width: 0.1in; text-align: right; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">$</p></td>
    <td style="vertical-align: bottom; width: 1.2in; text-align: right; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-06-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,257,598</ix:nonFraction></p></td>
    <td style="vertical-align: bottom; width: 0.2in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">)</p></td>
    <td style="vertical-align: bottom; width: 0.1in; text-align: right; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">$</p></td>
    <td style="vertical-align: bottom; width: 1.2in; text-align: right; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,083,968</ix:nonFraction></p></td>
    <td style="vertical-align: bottom; width: 0.2in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">)</p></td>
  </tr>
  <tr style="display: none">
    <td style="vertical-align: bottom; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt"><b>Balance at</b></p><p style="margin: 0px; font-size: 10pt"><b>June 30, 2023</b></p></td>
    <td style="width: 0.1in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="vertical-align: bottom; width: 1.2in; text-align: right; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2023-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">277,332,660</ix:nonFraction></p></td>
    <td style="width: 0.2in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="vertical-align: bottom; width: 0.1in; text-align: right; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">$</p></td>
    <td style="vertical-align: bottom; width: 1.2in; text-align: right; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">277,333</ix:nonFraction></p></td>
    <td style="width: 0.2in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="vertical-align: bottom; width: 0.1in; text-align: right; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">$</p></td>
    <td style="vertical-align: bottom; width: 1.2in; text-align: right; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">896,297</ix:nonFraction></p></td>
    <td style="width: 0.2in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="vertical-align: bottom; width: 0.1in; text-align: right; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">$</p></td>
    <td style="vertical-align: bottom; width: 1.2in; text-align: right; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-06-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,257,598</ix:nonFraction></p></td>
    <td style="vertical-align: bottom; width: 0.2in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">)</p></td>
    <td style="vertical-align: bottom; width: 0.1in; text-align: right; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">$</p></td>
    <td style="vertical-align: bottom; width: 1.2in; text-align: right; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,083,968</ix:nonFraction></p></td>
    <td style="vertical-align: bottom; width: 0.2in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">)</p></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom"><p style="margin: 0px; font-size: 10pt">Shares   and warrants sold for cash</p></td>
    <td style="width: 0.1in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="vertical-align: bottom; width: 1.2in; text-align: right"><p style="margin: 0px; font-size: 10pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2023-07-012023-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">153,250</ix:nonFraction></p></td>
    <td style="width: 0.2in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.1in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="vertical-align: bottom; width: 1.2in; text-align: right"><p style="margin: 0px; font-size: 10pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-07-012023-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">153</ix:nonFraction></p></td>
    <td style="width: 0.2in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.1in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="vertical-align: bottom; width: 1.2in; text-align: right"><p style="margin: 0px; font-size: 10pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-07-012023-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">153,097</ix:nonFraction></p></td>
    <td style="width: 0.2in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.1in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="vertical-align: bottom; width: 1.2in; text-align: right"><p style="margin: 0px; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0371">&#8212;</span></p></td>
    <td style="width: 0.2in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.1in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="vertical-align: bottom; width: 1.2in; text-align: right"><p style="margin: 0px; font-size: 10pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-07-012023-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">153,250</ix:nonFraction></p></td>
    <td style="width: 0.2in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">Stock-based   compensation</p></td>
    <td style="width: 0.1in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="vertical-align: bottom; width: 1.2in; text-align: right; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="From2023-07-012023-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">430,000</ix:nonFraction></p></td>
    <td style="width: 0.2in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.1in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="vertical-align: bottom; width: 1.2in; text-align: right; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2023-07-012023-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">430</ix:nonFraction></p></td>
    <td style="width: 0.2in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.1in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="vertical-align: bottom; width: 1.2in; text-align: right; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2023-07-012023-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">98,404</ix:nonFraction></p></td>
    <td style="width: 0.2in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.1in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="vertical-align: bottom; width: 1.2in; text-align: right; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0377">&#8212;</span></p></td>
    <td style="width: 0.2in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.1in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="vertical-align: bottom; width: 1.2in; text-align: right; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2023-07-012023-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">98,834</ix:nonFraction></p></td>
    <td style="width: 0.2in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom"><p style="margin: 0px; font-size: 10pt">Net   loss</p></td>
    <td style="width: 0.1in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="border-bottom: black 1.01px solid; vertical-align: bottom; width: 1.2in; text-align: right"><p style="margin: 0px; font-size: 10pt">&#8212;</p></td>
    <td style="width: 0.2in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.1in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="border-bottom: black 1.01px solid; vertical-align: bottom; width: 1.2in; text-align: right"><p style="margin: 0px; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0381">&#8212;</span></p></td>
    <td style="width: 0.2in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.1in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="border-bottom: black 1.01px solid; vertical-align: bottom; width: 1.2in; text-align: right"><p style="margin: 0px; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0382">&#8212;</span></p></td>
    <td style="width: 0.2in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.1in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="border-bottom: black 1.01px solid; vertical-align: bottom; width: 1.2in; text-align: right"><p style="margin: 0px; font-size: 10pt">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-07-012023-09-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,801,449</ix:nonFraction></p></td>
    <td style="vertical-align: bottom; width: 0.2in"><p style="margin: 0px; font-size: 10pt">)</p></td>
    <td style="width: 0.1in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="border-bottom: black 1.01px solid; vertical-align: bottom; width: 1.2in; text-align: right"><p style="margin: 0px; font-size: 10pt">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-07-012023-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,801,449</ix:nonFraction></p></td>
    <td style="vertical-align: bottom; width: 0.2in"><p style="margin: 0px; font-size: 10pt">)</p></td>
  </tr>
  <tr>
    <td style="padding: 0cm 0cm 2.5pt; vertical-align: bottom; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt"><b>Balance   at </b></p><p style="margin: 0px; font-size: 10pt"><b>September   30, 2023</b></p></td>
    <td style="width: 0.1in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="border-bottom: black 3px double; padding: 0cm 0cm 2.5pt; vertical-align: bottom; width: 1.2in; text-align: right; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2023-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">277,915,910</ix:nonFraction></p></td>
    <td style="width: 0.2in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="vertical-align: bottom; width: 0.1in; text-align: right; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">$</p></td>
    <td style="border-bottom: black 3px double; padding: 0cm 0cm 2.5pt; vertical-align: bottom; width: 1.2in; text-align: right; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">277,916</ix:nonFraction></p></td>
    <td style="width: 0.2in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="vertical-align: bottom; width: 0.1in; text-align: right; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">$</p></td>
    <td style="border-bottom: black 3px double; padding: 0cm 0cm 2.5pt; vertical-align: bottom; width: 1.2in; text-align: right; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,147,798</ix:nonFraction></p></td>
    <td style="width: 0.2in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="vertical-align: bottom; width: 0.1in; text-align: right; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">$</p></td>
    <td style="border-bottom: black 3px double; padding: 0cm 0cm 2.5pt; vertical-align: bottom; width: 1.2in; text-align: right; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-09-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">5,059,047</ix:nonFraction></p></td>
    <td style="vertical-align: bottom; width: 0.2in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">)</p></td>
    <td style="vertical-align: bottom; width: 0.1in; text-align: right; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">$</p></td>
    <td style="border-bottom: black 3px double; padding: 0cm 0cm 2.5pt; vertical-align: bottom; width: 1.2in; text-align: right; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,633,333</ix:nonFraction></p></td>
    <td style="vertical-align: bottom; width: 0.2in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">)</p></td>
  </tr>
</tbody>
</table>

<p style="margin: 0px; font-size: 10pt">&#160;</p>

<p style="margin: 0px; text-align: center; font-size: 10pt">The accompanying notes are an integral part of these
unaudited financial statements.</p>

<table cellpadding="0" class="adv_pagination" cellspacing="0" border="0" style="width: 100%; font-size: 10pt; margin-top: 10px">
  <tbody>
  <tr style="vertical-align: top; text-align: left">
    <td style="width: 33%"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 34%; text-align: center"><p class="pagenumber" style="margin: 0px; font-size: 10pt">4</p></td>
    <td style="width: 33%; text-align: right"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
  </tr>
</tbody>
</table>

<table border="0" cellspacing="0" cellpadding="0" style="width: 100%; page-break-after: always">
  <tbody>
  <tr>
    <td style="border-bottom: black 4px solid"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
  </tr>
</tbody>
</table>

<p style="margin-top: 0pt; margin-bottom: 0pt"><span id="page_5" class="adv_highlightanchor adv_pagination"></span></p>

<p style="margin: 0px; text-align: justify; font-size: 10pt">&#160;</p>

<p style="margin: 0px; text-align: center; font-size: 10pt"><b>REGENEREX
PHARMA, INC.</b></p>

<p style="margin: 0px; text-align: center; font-size: 10pt"><b>NOTES TO FINANCIAL
STATEMENTS</b></p>

<p style="margin: 0px; text-align: center; font-size: 10pt"><b>(UNAUDITED)</b></p>

<p style="margin: 0px; font-size: 10pt"><b>&#160;</b></p>

<ix:nonNumeric contextRef="From2023-04-01to2023-09-30" escape="true" name="us-gaap:NatureOfOperations"><p style="margin: 0px; font-size: 10pt"><b>NOTE 1 &#8211;
NATURE OF OPERATIONS</b></p>

<p style="margin: 0px; font-size: 10pt">&#160;</p>

<p style="margin: 0px; text-align: justify; font-size: 10pt">Regenerex Pharma, Inc., formerly Peptide Technologies, Inc. (the
&#8220;Company&#8221; or &#8220;Regenerex&#8221;), was incorporated in the State of Nevada, United States
of America, on <ix:nonNumeric contextRef="From2023-04-01to2023-09-30" format="ixt:datemonthdayyearen" name="dei:EntityIncorporationDateOfIncorporation">November 18, 2005</ix:nonNumeric>.</p>

<p style="margin: 0px; font-size: 10pt">&#160;</p>

<p style="margin: 0px; text-align: justify; font-size: 10pt">On November 15, 2021,
the Company entered into an Asset Purchase Agreement in which the Company
purchased certain intellectual property in exchange for <ix:nonFraction name="us-gaap:SharesIssued" contextRef="AsOf2021-11-15_custom_PurchaseIntellectualPropertyMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">150,000,000</ix:nonFraction> shares of
the Company&#8217;s common stock and up to $<ix:nonFraction name="us-gaap:AssetAcquisitionContingentConsiderationLiability" contextRef="AsOf2021-11-15" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,000,000</ix:nonFraction> in contingent consideration to
be paid at the rate of 15% of all gross revenues received from sales or
investment money into the Company, payable on the 15<sup>th</sup> of the
following month, for a period of 60 months.&#160;
The Company received all rights and title to proprietary wound healing
technologies platforms and formulas involving the application of wound
care protocols to treat all wounds, such
as diabetic ulcers, pressure ulcers, burns and surgical wounds.&#160; These unique products strategically position
the Company to enter the wound treatment market in the U.S.</p>

<p style="margin: 0px; text-align: justify; font-size: 10pt">&#160;</p>

<p style="margin: 0px; text-align: justify; font-size: 10pt"><i>Risks and Uncertainties</i><span style="font-size: 10pt">&#160;</span></p>

<p style="margin: 0px; font-size: 10pt">&#160;</p>

<p style="margin: 0px; text-align: justify; font-size: 10pt">Our
business and our forward-looking statements involve substantial known and
unknown risks and uncertainties, including the risks and uncertainties inherent
in our statements regarding the impacts of COVID-19, or other future pandemics
on our business, results of operations, financial position, and cash flows.</p>

<p style="margin: 0px; font-size: 10pt">&#160;</p>

<p style="margin: 0px; text-align: justify; font-size: 10pt">The Company has
a lack of revenue history and has had a limited history of operations.&#160; No
revenue has historically been derived from the assets purchased. &#160;Regenerex can give no assurance of success or
profitability to the Company&#8217;s investors.</p>

<p style="margin: 0px; text-align: justify; font-size: 10pt">&#160;</p>

<p style="margin: 0px; text-align: justify; font-size: 10pt">The wound care
healing space is well suited for Home Care service providers that are funded by
the US Government. Strategic planning and development will be performed
internally by the Company.<span style="font-size: 10pt">&#160;</span></p>

<p style="margin: 0px; font-size: 10pt">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-04-01to2023-09-30" escape="true" name="us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock"><p style="margin: 0px; text-align: justify; font-size: 10pt"><b>NOTE 2 &#8211; BASIS OF PRESENTATION OF INTERIM FINANCIAL STATEMENTS</b></p>

<p style="margin: 0px; font-size: 10pt">&#160;</p>

<p style="margin: 0px; text-align: justify; font-size: 10pt">The
Company prepares its financial statements in accordance with accounting
principles generally accepted in the United States of America. The accompanying
interim unaudited financial statements have been prepared in accordance with
generally accepted accounting principles for interim financial information in
accordance with the instructions to Form 10-Q and Article 8 of Regulation S-X.
In our opinion, all adjustments (consisting of normal recurring adjustments)
considered necessary for a fair presentation have been included.</p>

<p style="margin: 0px; font-size: 10pt">&#160;</p>

<p style="margin: 0px; text-align: justify; font-size: 10pt">Operating
results for the three and six months ended September 30, 2023, are not
necessarily indicative of the results that may be expected for the year ending
March 31, 2024. &#160;Notes to the unaudited
interim financial statements that would substantially duplicate the disclosures
contained in the audited financial statements for the year ended March 31, 2023,
have been omitted. This report should be read in conjunction with the audited
financial statements and the footnotes thereto for the fiscal year ended March
31, 2023, included within the Company&#8217;s Annual Report on Form 10-K as filed
with the Securities and Exchange Commission.</p>

<p style="margin: 0px; font-size: 10pt">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-04-01to2023-09-30" escape="true" name="us-gaap:SubstantialDoubtAboutGoingConcernTextBlock"><p style="margin: 0px; text-align: justify; font-size: 10pt"><b>NOTE 3
&#8211; GOING CONCERN</b></p>

<p style="margin: 0px; font-size: 10pt">&#160;</p>

<p style="margin: 0px; text-align: justify; font-size: 10pt">These financial statements
have been prepared in conformity with accounting principles generally accepted
in the United States of America (&#8220;U.S. GAAP&#8221;), which contemplate the
continuation of the Company as a going concern. The Company has incurred losses
from operations, and as of September 30, 2023, it had excess liabilities over
assets of $<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,633,333</ix:nonFraction>. &#160;These factors
raise substantial doubt about the Company&#8217;s ability to continue as a going
concern.</p>

<ix:exclude><table cellpadding="0" class="adv_pagination" cellspacing="0" border="0" style="width: 100%; font-size: 10pt; margin-top: 10px">
  <tbody>
  <tr style="vertical-align: top; text-align: left">
    <td style="width: 33%"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 34%; text-align: center"><p class="pagenumber" style="margin: 0px; font-size: 10pt">5</p></td>
    <td style="width: 33%; text-align: right"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
  </tr>
</tbody>
</table></ix:exclude>

<ix:exclude><table border="0" cellspacing="0" cellpadding="0" style="width: 100%; page-break-after: always">
  <tbody>
  <tr>
    <td style="border-bottom: black 4px solid"><p style="margin: 0; font-size: 10pt">&#160;</p></td>
  </tr>
</tbody>
</table></ix:exclude>

<p style="margin-top: 0pt; margin-bottom: 0pt"><span id="page_6" class="adv_highlightanchor adv_pagination"></span></p>

<p style="margin: 0; font-size: 10pt">&#160;</p>

<p style="margin: 0; font-size: 10pt"></p>

<p style="margin: 0px; text-align: justify; font-size: 10pt"><span style="font-size: 10pt">The Company requires
significant cash to launch its business and reduce its payable.&#160; Management&#8217;s plans are to actively seek
capital to enable the Company to add new products and/or services to ultimately
achieve profitability. However, management cannot provide assurance that they
can raise sufficient capital and whether the Company will ultimately achieve
profitability, become cash flow positive, or raise additional debt and/or
equity capital. &#160;If the Company is unable
to raise additional capital in the near future or meet financing requirements,
management expects that the Company will need to curtail operations, seek
additional capital on less favorable terms, and/or pursue other remedial
measures.</span></p>

<p style="margin: 0px; text-align: justify; font-size: 10pt">&#160;</p>

<p style="margin: 0px; text-align: justify; font-size: 10pt">These
financial statements do not include any adjustments related to the
recoverability and classification of assets or the amounts and classification
of liabilities that might be necessary should the Company become unable to
continue as a going concern.</p>

<p style="margin: 0px; font-size: 10pt">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-04-01to2023-09-30" escape="true" name="us-gaap:SignificantAccountingPoliciesTextBlock"><p style="margin: 0px; text-align: justify; font-size: 10pt"><b>NOTE 4
&#8211;SIGNIFICANT ACCOUNTING POLICIES</b></p>

<p style="margin: 0px; font-size: 10pt">&#160;</p>

<ix:nonNumeric contextRef="From2023-04-01to2023-09-30" escape="true" name="us-gaap:RevenueRecognitionPolicyTextBlock"><p style="margin: 0px; text-align: justify; font-size: 10pt"><i>Revenue Recognition</i></p>

<p style="margin: 0px; font-size: 10pt">&#160;</p>

<p style="margin: 0px; text-align: justify; font-size: 10pt">The Company will record
revenue under ASC 606 by 1) identifying the contract with the customer 2)
identifying the performance obligations in the contract 3) determining the
transaction price, 4) allocating the transaction price to the required performance
obligations in the contract, and 5) recognizing revenue when or as the
companies satisfies a performance obligation.</p>

<p style="margin: 0px; font-size: 10pt">&#160;</p>

<p style="margin: 0px; text-align: justify; font-size: 10pt">We expect to
generate revenue from home care service providers that are funded by the U.S.
Government, State Medicaid Programs, International Health Care Programs, Veteran&#8217;s
administration, Prison system, Home Health Care Providers, and other applicable
Medicare reimbursement models.&#160; The
Company will defer revenue where the earnings process is not yet complete.&#160; To date, no revenue has been generated from
the asset acquisition disclosed in Note 1.</p>

<p style="margin: 0px; font-size: 10pt">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-04-01to2023-09-30" escape="true" name="us-gaap:EarningsPerSharePolicyTextBlock"><p style="margin: 0px; text-align: justify; font-size: 10pt"><i>Earnings per
Share</i></p>

<p style="margin: 0px; font-size: 10pt">&#160;</p>

<p style="margin: 0px; text-align: justify; font-size: 10pt">Earnings per share is reported in accordance
with FASB ASC Topic 260 &#8220;<i>Earnings per Share</i>&#8221; which requires dual
presentation of basic earnings per share (&#8220;EPS&#8221;) and diluted EPS on the face of all statements of
earnings, for all entities with complex capital structures. Diluted EPS
reflects the potential dilution that could occur from common shares issuable
through the exercise or conversion of stock options, restricted stock awards,
warrants and convertible securities. In certain circumstances, the conversion
of these options, warrants and convertible securities are excluded from diluted
EPS if the effect of such inclusion would be anti-dilutive. Fully diluted EPS is
not provided, when the effect is anti-dilutive. When the effect of dilution on
loss per share is anti-dilutive, diluted loss per share equals the loss per
share.</p>

<p style="margin: 0px; text-align: justify; font-size: 10pt">&#160;</p>

<p style="margin: 0px; text-align: justify; font-size: 10pt">During the six months ended September 30, 2023,
the Company excluded the outstanding stock warrants from its calculation of
earnings per share, as the warrants would be anti-dilutive. As of September 30, 2023
and 2022, the Company had common shares warrants outstanding of <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,306,250</ix:nonFraction> and
<ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">0</ix:nonFraction>, respectively.</p>

<p style="margin: 0; font-size: 10pt">&#160;</p>

<p style="margin: 0; font-size: 10pt"></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-04-01to2023-09-30" escape="true" name="us-gaap:ResearchDevelopmentAndComputerSoftwarePolicyTextBlock"><p style="margin: 0px; font-size: 10pt"><i style="font-size: 10pt; text-align: justify">Website</i></p>

<p style="margin: 0px; font-size: 10pt">&#160;</p>

<p style="margin: 0px; text-align: justify; font-size: 10pt">Expenditures related to the planning and
operation of the Company&#8217;s website are expensed as incurred. Expenditures
related to the website application and
infrastructure development are capitalized and amortized over the website&#8217;s
estimated useful life of three (<ix:nonNumeric contextRef="AsOf2023-09-30" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife">3</ix:nonNumeric>) years. Amortization expense for the three
and six months ended September 30, 2023 and 2022 was $<ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2023-04-012023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">723</ix:nonFraction> and $<ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2023-04-01to2023-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">723</ix:nonFraction> and $<ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,437</ix:nonFraction> and
$<ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2022-04-012022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,794</ix:nonFraction>, respectively.</p>

<p style="margin: 0px; font-size: 10pt">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-04-01to2023-09-30" escape="true" name="us-gaap:PropertyPlantAndEquipmentPreproductionDesignAndDevelopmentCosts"><p style="margin: 0px; text-align: justify; font-size: 10pt"><i>Furniture and Computer Equipment</i></p>

<p style="margin: 0px; font-size: 10pt">&#160;</p>

<p style="margin: 0px; text-align: justify; font-size: 10pt">Furniture and computer equipment are stated
at cost, less accumulated depreciation.&#160;
Depreciation is computed using the straight-line method over the
estimated useful life of three (<ix:nonNumeric contextRef="AsOf2023-09-30_srt_MinimumMember" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">3</ix:nonNumeric>) to five (<ix:nonNumeric contextRef="AsOf2023-09-30_srt_MaximumMember" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">5</ix:nonNumeric>) years.&#160; Depreciation expense for the three and six
months ended September 30, 2023 and 2022 was $<ix:nonFraction name="us-gaap:OtherDepreciationAndAmortization" contextRef="From2023-04-012023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">422</ix:nonFraction> and $<ix:nonFraction name="us-gaap:OtherDepreciationAndAmortization" contextRef="From2023-04-01to2023-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">0</ix:nonFraction> and $<ix:nonFraction name="us-gaap:OtherDepreciationAndAmortization" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">538</ix:nonFraction> and $<ix:nonFraction name="us-gaap:OtherDepreciationAndAmortization" contextRef="From2022-04-012022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">0</ix:nonFraction>, respectively.&#160; Significant betterments are capitalized while
purchases under $500 are expensed as incurred.</p>

<ix:exclude><table cellpadding="0" class="adv_pagination" cellspacing="0" border="0" style="width: 100%; font-size: 10pt; margin-top: 10px">
  <tbody>
  <tr style="vertical-align: top; text-align: left">
    <td style="width: 33%"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 34%; text-align: center"><p class="pagenumber" style="margin: 0px; font-size: 10pt">6</p></td>
    <td style="width: 33%; text-align: right"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
  </tr>
</tbody>
</table></ix:exclude>

<ix:exclude><table border="0" cellspacing="0" cellpadding="0" style="width: 100%; page-break-after: always">
  <tbody>
  <tr>
    <td style="border-bottom: black 4px solid"><p style="margin: 0; font-size: 10pt">&#160;</p></td>
  </tr>
</tbody>
</table></ix:exclude>

<p style="margin-top: 0pt; margin-bottom: 0pt"><span id="page_7" class="adv_highlightanchor adv_pagination"></span></p>

<p style="margin: 0; font-size: 10pt"></p>

<p style="margin: 0px; font-size: 10pt">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-04-01to2023-09-30" escape="true" name="us-gaap:LesseeLeasesPolicyTextBlock"><p style="margin: 0px; font-size: 10pt"><i>Right of Use Assets and Lease Liabilities</i></p>

<p style="margin: 0px; font-size: 10pt">&#160;</p>

<p style="margin: 0px; text-align: justify; font-size: 10pt">The Company has
active operating lease arrangements for office space, production equipment, and
production facilities.&#160; The Company is
required to make fixed minimum rent payments relating to its right to use the
underlying leased asset.&#160; In accordance
with the adoption of ASC 842, the Company recorded right-of-use assets and
related lease liabilities for these leases as of September 2023.</p>

<p style="margin: 0px; font-size: 10pt">&#160;</p>

<p style="margin: 0px; text-align: justify; font-size: 10pt">The Company&#8217;s
lease agreements do not provide an implicit borrowing rate.&#160; Therefore, the Company used a benchmark
approach to derive an incremental borrowing rate of <ix:nonFraction name="us-gaap:LesseeFinanceLeaseDiscountRate" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">10</ix:nonFraction>% to discount each of its
lease liabilities based on the remining lease term.</p>

<p style="margin: 0px; font-size: 10pt">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-04-01to2023-09-30" escape="true" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy"><p style="margin: 0px; font-size: 10pt"><i>Stock-Based Compensation</i></p>

<p style="margin: 0px; font-size: 10pt">&#160;</p>

<p style="margin: 0px; text-align: justify; font-size: 10pt">Stock-based
compensation is measured at the grant date, based on the estimated fair value
of the award.&#160; Stock-based compensation
is recognized as expense over the employee&#8217;s requisite vesting period and over
the nonemployee&#8217;s period of providing goods or services.&#160; The fair value of each stock warrant is
estimated on the date of grant using the Black-Scholes option valuation model.
Restricted shares are measured based on the fair market value of the underlying
stock on the grant date.</p>

<p style="margin: 0px; text-align: justify; font-size: 10pt"><br /></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-04-01to2023-09-30" escape="true" name="us-gaap:ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock"><p style="margin: 0px; font-size: 10pt"><i>Research and Development</i></p>

<p style="margin: 0px; font-size: 10pt">&#160;</p>

<p style="margin: 0px; text-align: justify; font-size: 10pt">We incur research
and development costs during the process of researching and developing additional
technologies purchased and future manufacturing processes.&#160; Our research and development costs consist
primarily of the purchase of additional intellectual property that we will use
in the development of our planned product.&#160;
We expense these costs as incurred until the resulting product has been
completed, tested, and made ready for commercial use.</p>

<p style="margin: 0px; text-align: justify; font-size: 10pt"></p>

<p style="margin: 0px; font-size: 10pt">&#160;</p>

<p style="margin: 0px; font-size: 10pt">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-04-01to2023-09-30" escape="true" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock"><p style="margin: 0px; font-size: 10pt"><i>Recent Accounting Pronouncements</i></p>

<p style="margin: 0px; font-size: 10pt">&#160;</p>

<p style="margin: 0px; text-align: justify; font-size: 10pt">The Financial
Accounting Standards Board issued Accounting Standards Updates (&#8220;ASU&#8221;) to amend
the authoritative literature in the Accounting Standards Codification (&#8220;ASC&#8221;).
There have been a number of ASUs to date that amend the original text of the
ASC. The Company believes those updates issued-to-date either (i) provide
supplemental guidance, (ii) are technical corrections, (iii) are not applicable
to the Company, or (iv) are not expected to have a significant impact on the
Company.</p>

</ix:nonNumeric><p style="margin: 0px; font-size: 10pt">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-04-01to2023-09-30" escape="true" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock"><p style="margin: 0px; text-align: justify; font-size: 10pt"><b>NOTE 5 &#8211; RELATED PARTY TRANSACTIONS </b></p>

<p style="margin: 0px; font-size: 10pt">&#160;</p>

<p style="margin: 0px; text-align: justify; font-size: 10pt">The Company purchased assets from the Company&#8217;s
current Chief Executive Officer (&#8220;CEO&#8221;) and Secretary/Treasurer (see note 6).</p>

<p style="margin: 0px; font-size: 10pt">&#160;</p>

<p style="margin: 0px; text-align: justify; font-size: 10pt">On June 10, 2023, the Company, has entered into an
agreement with Woundcare Labs, LLC., a party related to the CFO and CEO of the Company,
to lease a plant and to lease equipment in Tennessee (see note 8).</p>

<p style="margin: 0; font-size: 10pt">&#160;</p>

<p style="margin: 0; font-size: 10pt"></p>

<p style="margin: 0px; font-size: 10pt"><i style="font-size: 10pt; text-align: justify">Related Party Advances</i></p>

<p style="margin: 0px; font-size: 10pt">&#160;</p>

<p style="margin: 0px; text-align: justify; font-size: 10pt">The Company&#8217;s
former Chief Financial Officer (&#8220;CFO&#8221;) had advanced the Company monies for
operating expenses; no amounts were advanced during the periods presented.&#160; The advances were
due on demand, but no later than June 30, 2023.&#160;
The related party advances began to accrue interest at ten (<ix:nonFraction name="us-gaap:RelatedPartyTransactionRate" contextRef="From2023-04-01to2023-09-30" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">10</ix:nonFraction>) percent
per annum on July 1, 2019.&#160; During the six
months ended September 30, 2023, this note was transferred to a relative of the
former CFO and was renewed upon maturity in the principal amount of $<ix:nonFraction name="us-gaap:NotesAndLoansPayable" contextRef="AsOf2023-09-30_srt_ChiefFinancialOfficerMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">131,687</ix:nonFraction>
plus interest accrued as at June 30, 2023 in the amount of $<ix:nonFraction name="RGPX:RelatedPartyAdvances" contextRef="AsOf2023-09-30_srt_ChiefFinancialOfficerMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">52,545</ix:nonFraction>.&#160; Interest expense was $<ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2023-04-012023-09-30_custom_AffiliatesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,285</ix:nonFraction> and $<ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2022-04-012022-09-30_custom_AffiliatesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,284</ix:nonFraction> during
the six-month periods ended September 30, 2023 and 2022, respectively.&#160; This transaction is no longer considered
related party in nature, and thus is included in notes payable in the
accompanying balance sheet.</p>

<ix:exclude><table cellpadding="0" class="adv_pagination" cellspacing="0" border="0" style="width: 100%; font-size: 10pt; margin-top: 10px">
  <tbody>
  <tr style="vertical-align: top; text-align: left">
    <td style="width: 33%"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 34%; text-align: center"><p class="pagenumber" style="margin: 0px; font-size: 10pt">7</p></td>
    <td style="width: 33%; text-align: right"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
  </tr>
</tbody>
</table></ix:exclude>

<ix:exclude><table border="0" cellspacing="0" cellpadding="0" style="width: 100%; page-break-after: always">
  <tbody>
  <tr>
    <td style="border-bottom: black 4px solid"><p style="margin: 0; font-size: 10pt">&#160;</p></td>
  </tr>
</tbody>
</table></ix:exclude>

<p style="margin-top: 0pt; margin-bottom: 0pt"><span id="page_8" class="adv_highlightanchor adv_pagination"></span></p>

<p style="margin: 0; font-size: 10pt">&#160;</p>

<p style="margin: 0; font-size: 10pt"></p>

<p style="margin: 0px; font-size: 10pt"><span style="font-size: 10pt; text-align: justify">During the
six-month period ended September 30, 2023, the Company&#8217;s Chief Financial
Officer (&#8220;CFO&#8221;) and the Company&#8217;s Chief Executive Officer (&#8220;CEO&#8221;) advanced the
Company monies for operating expenses in the net amount of $</span><ix:nonFraction name="RGPX:RelatedPartyAdvances" contextRef="AsOf2023-09-30_srt_ChiefExecutiveOfficerMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,437</ix:nonFraction><span style="font-size: 10pt; text-align: justify">.</span></p>

<p style="margin: 0px; font-size: 10pt">&#160;</p>

<p style="margin: 0px; text-align: justify; font-size: 10pt">The related party advances totaled $<ix:nonFraction name="RGPX:RelatedPartyAdvances" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,637</ix:nonFraction> and $<ix:nonFraction name="RGPX:RelatedPartyAdvances" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">131,887</ix:nonFraction> as of September
30, 2023 and March 31, 2023, respectively.</p>

<p style="margin: 0px; font-size: 10pt">&#160;</p>

<p style="margin: 0px; text-align: justify; font-size: 10pt"><i>Notes Payable to Related Parties</i></p>

<p style="margin: 0px; font-size: 10pt">&#160;</p>

<p style="margin: 0px; text-align: justify; font-size: 10pt">During the year
ended March 31, 2023, the Company&#8217;s CFO and the Company&#8217;s CEO advanced the
Company monies for operating expenses in the amount of $<ix:nonFraction name="us-gaap:NotesAndLoansPayable" contextRef="AsOf2023-03-31_custom_ChiefExecutiveOfficerAndChiefFinancialOfficerMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">40,500</ix:nonFraction>.&#160; Repayment during the six-month period ended
September 30, 2023 and September 30, 2022 was $<ix:nonFraction name="us-gaap:RepaymentsOfNotesPayable" contextRef="From2023-04-012023-09-30_custom_ChiefExecutiveOfficerAndChiefFinancialOfficerMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">34,000</ix:nonFraction> and $<ix:nonFraction name="us-gaap:RepaymentsOfNotesPayable" contextRef="From2022-04-012022-09-30_custom_ChiefExecutiveOfficerAndChiefFinancialOfficerMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">0</ix:nonFraction>. &#160;The notes are unsecured and accrue interest at
ten (<ix:nonFraction name="us-gaap:DebtInstrumentInterestRateDuringPeriod" contextRef="From2023-04-012023-09-30_custom_ChiefExecutiveOfficerAndChiefFinancialOfficerMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">10</ix:nonFraction>) percent per annum.&#160; Repayment is
due no later than November 4, 2024.</p>

<p style="margin: 0px; font-size: 10pt">&#160;</p>

<p style="margin: 0px; text-align: justify; font-size: 10pt">The related party notes
payable totaled $<ix:nonFraction name="RGPX:NotesPayableRelatedParties" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,000</ix:nonFraction> and $<ix:nonFraction name="RGPX:NotesPayableRelatedParties" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">38,000</ix:nonFraction> as at September 30, 2023 and March 31,
2023.&#160; Interest expenses were $<ix:nonFraction name="us-gaap:InterestExpenseDebt" contextRef="From2023-04-01to2023-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,630</ix:nonFraction> and
$<ix:nonFraction name="us-gaap:InterestExpenseDebt" contextRef="From2022-04-012022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">129</ix:nonFraction> during the six-month periods ended September 30, 2023 and 2022,
respectively, which is included in other accrued liabilities.</p>

<p style="margin: 0px; font-size: 10pt">&#160;</p>

<p style="margin: 0px; font-size: 10pt"><i>Note Payable to Shareholder</i></p>

<p style="margin: 0px; font-size: 10pt">&#160;</p>

<p style="margin: 0px; text-align: justify; font-size: 10pt">As at September 30, 2023 and March 31, 2023, the Company had various
promissory notes with total outstanding principal balances of $<ix:nonFraction name="us-gaap:NotesAndLoansPayable" contextRef="AsOf2023-09-30_us-gaap_MajorityShareholderMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">558,691</ix:nonFraction> and $<ix:nonFraction name="us-gaap:NotesAndLoansPayable" contextRef="AsOf2023-03-31_us-gaap_MajorityShareholderMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">537,475</ix:nonFraction>,
respectively, due to a shareholder of the Company.&#160; These notes are unsecured, bear interest at
10% per annum, and have maturity dates ranging from October 11, 2023 to June 17,
2025.</p>

<p style="margin: 0px; font-size: 10pt">&#160;</p>

<p style="margin: 0px; text-align: justify; font-size: 10pt">During the six-months ended September 30, 2023, notes with principal
amounts totaling approximately $<ix:nonFraction name="us-gaap:NotesPayable" contextRef="AsOf2023-09-30_custom_ReissuedNotesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">128,000</ix:nonFraction> ($167,500 Canadian Funds) that came due
during the period were reissued in the total principal amount of approximately
$<ix:nonFraction name="us-gaap:DebtInstrumentCarryingAmount" contextRef="AsOf2023-09-30_custom_ReissuedNotesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">155,000</ix:nonFraction> ($201,000 Canadian Funds) which included the principal amount plus
accrued interest of approximately $<ix:nonFraction name="us-gaap:InterestPayableCurrent" contextRef="AsOf2023-09-30_custom_ReissuedNotesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">26,000</ix:nonFraction> ($33,500 Canadian Funds.)&#160; These notes are unsecured and bear interest
at ten (<ix:nonFraction name="us-gaap:DebtInstrumentInterestRateDuringPeriod" contextRef="From2023-04-01to2023-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">10</ix:nonFraction>) percent per annum with principal and interest due twelve (12)
months after the date of issue.</p>

<p style="margin: 0px; font-size: 10pt">&#160;</p>

<p style="margin: 0px; text-align: justify; font-size: 10pt">During the six-month period ended September 30, 2023, repayment of ten
thousand dollars ($<ix:nonFraction name="us-gaap:RepaymentsOfNotesPayable" contextRef="From2023-04-012023-09-30_custom_ShareholderMember_custom_PromissoryNotesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,000</ix:nonFraction>) US Funds was made on the principal of a promissory
note due October 11, 2023.</p>

<p style="margin: 0px; font-size: 10pt">&#160;</p>

<p style="margin: 0px; text-align: justify; font-size: 10pt">During the six-month period ended September 30, 2023,
a shareholder was issued additional one (1) promissory note totaling approximately
$<ix:nonFraction name="us-gaap:LongTermNotesPayable" contextRef="AsOf2023-09-30_custom_ShareholderMember_custom_Promissory1NotesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,800</ix:nonFraction> ($3,844 Canadian Funds).&#160; This
note is unsecured and bears interest at ten (<ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="AsOf2023-09-30_custom_ShareholderMember_custom_Promissory1NotesMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">10</ix:nonFraction>) percent per annum with
principal and interest due twelve (12) months after the date of issue.</p>

<p style="margin: 0px; font-size: 10pt">&#160;</p>

<p style="margin: 0px; text-align: justify; font-size: 10pt">Accrued interest was $<ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2023-09-30_custom_AggregateInterestExpenseMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">70,746</ix:nonFraction> and $<ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2022-09-30_custom_AggregateInterestExpenseMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">102,858</ix:nonFraction> as of September 30, 2023 and September
30, 2022, respectively, which is included in other accrued liabilities at
September 30, 2023 and March 31, 2023, respectively.</p>

<p style="margin: 0px; font-size: 10pt">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-04-01to2023-09-30" escape="true" name="us-gaap:IntangibleAssetsDisclosureTextBlock"><p style="margin: 0px; text-align: justify; font-size: 10pt"><b>NOTE 6 &#8211; INTANGIBLE ASSETS AND INTELLECTUAL PROPERTY</b></p>

<p style="margin: 0px; font-size: 10pt">&#160;</p>

<p style="margin: 0px; text-align: justify; font-size: 10pt">On November 15, 2021,
the Company entered into a Related Party



Asset Purchase Agreement in which the Company
purchased certain intellectual property in exchange for 150,000,000 shares of
the Company&#8217;s common stock <ix:nonNumeric contextRef="From2021-11-012021-11-15" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsDescription">and up to $10,000,000 in contingent consideration to be paid at the rate of 15% of all gross revenues received from sales or investment money into the Company, payable on the 15th of the following month, for a period of 60 months</ix:nonNumeric>.&#160;
The Company received all rights and title to proprietary wound healing
technologies platforms and formulas involving the application of wound
care protocols to treat all wounds, such
as diabetic ulcers, pressure ulcers, burns and surgical wounds.&#160; These unique products strategically position
the Company to enter and capture a high proportionate market share in the U.S.</p>

<p style="margin: 0; font-size: 10pt">&#160;</p>

<p style="margin: 0; font-size: 10pt"></p>

<ix:exclude><table cellpadding="0" class="adv_pagination" cellspacing="0" border="0" style="width: 100%; font-size: 10pt; margin-top: 10px">
  <tbody>
  <tr style="vertical-align: top; text-align: left">
    <td style="width: 33%"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 34%; text-align: center"><p class="pagenumber" style="margin: 0px; font-size: 10pt">8</p></td>
    <td style="width: 33%; text-align: right"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
  </tr>
</tbody>
</table></ix:exclude>

<ix:exclude><table border="0" cellspacing="0" cellpadding="0" style="width: 100%; page-break-after: always">
  <tbody>
  <tr>
    <td style="border-bottom: black 4px solid"><p style="margin: 0; font-size: 10pt">&#160;</p></td>
  </tr>
</tbody>
</table></ix:exclude>

<p style="margin-top: 0pt; margin-bottom: 0pt"><span id="page_9" class="adv_highlightanchor adv_pagination"></span></p>

<p style="margin: 0; font-size: 10pt">&#160;</p>

<p style="margin: 0; font-size: 10pt"></p>

<p style="margin: 0px; text-align: justify; font-size: 10pt"><span style="font-size: 10pt">On August 17, 2023, the Company entered into an Agreement to Purchase Technology Platforms



 in which the Company purchased certain intellectual property in
exchange for a two million four hundred thousand dollars ($2,400,000) note
payable.&#160; The intellectual property that
was purchased requires further development prior to the product being finalized
and produced so it has been expensed as research and development.&#160; &#160;The note payable is due within twelve (12)
months of the date of the agreement and is included in current liabilities.&#160; If the Company has not raised a minimum of
ten million dollars ($10,000,000) in sales within twelve (12) months, or a maximum
of ten million dollars ($10,000,000) in investment, the Company has the option
to extend the payment due date for a further twelve (12)&#160;</span><span style="font-size: 10pt">months of the
agreement date, or a maximum of ten million dollars ($10,000,000) in investment,
the seller will extend the payment for a further period of twelve (12) months
for a 10% payment of the outstanding balance.</span></p>

<p style="margin: 0px; text-align: justify; font-size: 10pt"><span style="font-size: 10pt">&#160;</span></p>

<p style="margin: 0px; font-size: 10pt">The Technology Platforms include but are not limited to:</p>

<p style="margin: 0px; font-size: 10pt">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse">
  <tbody>
  <tr>
    <td style="width: 0.5in; vertical-align: top"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.5in; vertical-align: top"><p style="margin: 0px; font-size: 10pt">A.<span style="font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; font-kerning: auto; font-optical-sizing: auto; font-feature-settings: normal; font-variation-settings: normal; font-stretch: normal; font-size: 7pt; line-height: normal"></span></p></td>
    <td style="text-align: justify; vertical-align: top"><p style="margin: 0px; font-size: 10pt">Proteomic research platforms which include proprietary blends.</p></td>
  </tr>
</tbody>
</table>

<table border="0" cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse">
  <tbody>
  <tr>
    <td style="width: 0.5in; vertical-align: top"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.5in; vertical-align: top"><p style="margin: 0px; font-size: 10pt">B.<span style="font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; font-kerning: auto; font-optical-sizing: auto; font-feature-settings: normal; font-variation-settings: normal; font-stretch: normal; font-size: 7pt; line-height: normal"></span></p></td>
    <td style="text-align: justify; vertical-align: top"><p style="margin: 0px; font-size: 10pt">Combination design Techniques</p></td>
  </tr>
</tbody>
</table>

<table border="0" cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse">
  <tbody>
  <tr>
    <td style="width: 0.5in; vertical-align: top"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.5in; vertical-align: top"><p style="margin: 0px; font-size: 10pt">C.<span style="font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; font-kerning: auto; font-optical-sizing: auto; font-feature-settings: normal; font-variation-settings: normal; font-stretch: normal; font-size: 7pt; line-height: normal"></span></p></td>
    <td style="text-align: justify; vertical-align: top"><p style="margin: 0px; font-size: 10pt">Patent Pending Proprietary Blends</p></td>
  </tr>
</tbody>
</table>

<table border="0" cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse">
  <tbody>
  <tr>
    <td style="width: 0.5in; vertical-align: top"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.5in; vertical-align: top"><p style="margin: 0px; font-size: 10pt">D.<span style="font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; font-kerning: auto; font-optical-sizing: auto; font-feature-settings: normal; font-variation-settings: normal; font-stretch: normal; font-size: 7pt; line-height: normal"></span></p></td>
    <td style="text-align: justify; vertical-align: top"><p style="margin: 0px; font-size: 10pt">Patent Pending Formulas</p></td>
  </tr>
</tbody>
</table>

<table border="0" cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse">
  <tbody>
  <tr>
    <td style="width: 0.5in; vertical-align: top"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.5in; vertical-align: top"><p style="margin: 0px; font-size: 10pt">E.<span style="font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; font-kerning: auto; font-optical-sizing: auto; font-feature-settings: normal; font-variation-settings: normal; font-stretch: normal; font-size: 7pt; line-height: normal"></span></p></td>
    <td style="text-align: justify; vertical-align: top"><p style="margin: 0px; font-size: 10pt">Trademarks and all pending Trademarks</p></td>
  </tr>
</tbody>
</table>

<table border="0" cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse">
  <tbody>
  <tr>
    <td style="width: 0.5in; vertical-align: top"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.5in; vertical-align: top"><p style="margin: 0px; font-size: 10pt">F.<span style="font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; font-kerning: auto; font-optical-sizing: auto; font-feature-settings: normal; font-variation-settings: normal; font-stretch: normal; font-size: 7pt; line-height: normal"></span></p></td>
    <td style="text-align: justify; vertical-align: top"><p style="margin: 0px; font-size: 10pt">510K USA FDA, information, and Know-how for application</p></td>
  </tr>
</tbody>
</table>

<table border="0" cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse">
  <tbody>
  <tr>
    <td style="width: 0.5in; vertical-align: top"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.5in; vertical-align: top"><p style="margin: 0px; font-size: 10pt">G.<span style="font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; font-kerning: auto; font-optical-sizing: auto; font-feature-settings: normal; font-variation-settings: normal; font-stretch: normal; font-size: 7pt; line-height: normal"></span></p></td>
    <td style="text-align: justify; vertical-align: top"><p style="margin: 0px; font-size: 10pt">All Clinical trials, (Right to use)</p></td>
  </tr>
</tbody>
</table>

<table border="0" cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse">
  <tbody>
  <tr>
    <td style="width: 0.5in; vertical-align: top"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.5in; vertical-align: top"><p style="margin: 0px; font-size: 10pt">H.<span style="font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; font-kerning: auto; font-optical-sizing: auto; font-feature-settings: normal; font-variation-settings: normal; font-stretch: normal; font-size: 7pt; line-height: normal"></span></p></td>
    <td style="text-align: justify; vertical-align: top"><p style="margin: 0px; font-size: 10pt">CE mark (International)</p></td>
  </tr>
</tbody>
</table>

<table border="0" cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse">
  <tbody>
  <tr>
    <td style="width: 0.5in; vertical-align: top"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.5in; vertical-align: top"><p style="margin: 0px; font-size: 10pt">I.<span style="font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; font-kerning: auto; font-optical-sizing: auto; font-feature-settings: normal; font-variation-settings: normal; font-stretch: normal; font-size: 7pt; line-height: normal"></span></p></td>
    <td style="text-align: justify; vertical-align: top"><p style="margin: 0px; font-size: 10pt">Regenerex Library formula incorporated in the Wound Healing Technology.</p></td>
  </tr>
</tbody>
</table>

<table border="0" cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse">
  <tbody>
  <tr>
    <td style="width: 0.5in; vertical-align: top"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.5in; vertical-align: top"><p style="margin: 0px; font-size: 10pt">J.<span style="font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; font-kerning: auto; font-optical-sizing: auto; font-feature-settings: normal; font-variation-settings: normal; font-stretch: normal; font-size: 7pt; line-height: normal"></span></p></td>
    <td style="text-align: justify; vertical-align: top"><p style="margin: 0px; font-size: 10pt">Wound Healing Technology QBX</p></td>
  </tr>
</tbody>
</table>

<table border="0" cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse">
  <tbody>
  <tr>
    <td style="width: 0.5in; vertical-align: top"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.5in; vertical-align: top"><p style="margin: 0px; font-size: 10pt">K.<span style="font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; font-kerning: auto; font-optical-sizing: auto; font-feature-settings: normal; font-variation-settings: normal; font-stretch: normal; font-size: 7pt; line-height: normal"></span></p></td>
    <td style="text-align: justify; vertical-align: top"><p style="margin: 0px; font-size: 10pt">Synthetic Compositions of Cations derived from botanical material in the ash of Red- Oak Bark.</p></td>
  </tr>
</tbody>
</table>

<p style="margin: 0px; font-size: 10pt">&#160;</p>

<p style="margin: 0px; font-size: 10pt">Products:</p>

<table border="0" cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse">
  <tbody>
  <tr>
    <td style="width: 0.5in; vertical-align: top"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.5in; vertical-align: top"><p style="margin: 0px; font-size: 10pt">1.<span style="font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; font-kerning: auto; font-optical-sizing: auto; font-feature-settings: normal; font-variation-settings: normal; font-stretch: normal; font-size: 7pt; line-height: normal"></span></p></td>
    <td style="text-align: justify; vertical-align: top"><p style="margin: 0px; font-size: 10pt">Xcellderma over the counter product.</p></td>
  </tr>
</tbody>
</table>

<table border="0" cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse">
  <tbody>
  <tr>
    <td style="width: 0.5in; vertical-align: top"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.5in; vertical-align: top"><p style="margin: 0px; font-size: 10pt">2.<span style="font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; font-kerning: auto; font-optical-sizing: auto; font-feature-settings: normal; font-variation-settings: normal; font-stretch: normal; font-size: 7pt; line-height: normal"></span></p></td>
    <td style="text-align: justify; vertical-align: top"><p style="margin: 0px; font-size: 10pt">Accelerex, combination product as a drug device.</p></td>
  </tr>
</tbody>
</table>

<table border="0" cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse">
  <tbody>
  <tr>
    <td style="width: 0.5in; vertical-align: top"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.5in; vertical-align: top"><p style="margin: 0px; font-size: 10pt">3.<span style="font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; font-kerning: auto; font-optical-sizing: auto; font-feature-settings: normal; font-variation-settings: normal; font-stretch: normal; font-size: 7pt; line-height: normal"></span></p></td>
    <td style="text-align: justify; vertical-align: top"><p style="margin: 0px; font-size: 10pt">Accelerex in a tube.</p></td>
  </tr>
</tbody>
</table>

<p style="margin-top: 0px; margin-bottom: 0px; margin-left: 48px; font-size: 10pt"><b>&#160;</b></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-04-01to2023-09-30" escape="true" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock"><p style="margin: 0px; font-size: 10pt"><b>NOTE 7 &#8211; COMMITMENTS AND CONTINGENCIES</b></p>

<p style="margin: 0px; text-align: justify; font-size: 10pt">&#160;</p>

<p style="margin: 0px; text-align: justify; font-size: 10pt">The Company is not currently involved with and does
not have knowledge of any pending or threatened litigation against the Company
or any of its officers.</p>

<p style="margin: 0px; font-size: 10pt">&#160;</p>

<p style="margin: 0px; text-align: justify; font-size: 10pt">See Note 6 for discussion of the $<ix:nonFraction name="us-gaap:AssetAcquisitionContingentConsiderationLiability" contextRef="AsOf2021-11-15" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,000,000</ix:nonFraction> in
contingent consideration to be paid in connection with the November 15, 2021

Related Party



Asset Purchase Agreement. Payments made to the Company&#8217;s CEO and CFO in
connection with the Asset Purchase Agreement are $<ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2023-04-012023-09-30_custom_ChiefExecutiveOfficerAndChiefFinancialOfficerMember397223531" format="ixt:numdotdecimal" decimals="0" unitRef="USD">43,500</ix:nonFraction> and $<ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2022-04-012023-03-31_custom_ChiefExecutiveOfficerAndChiefFinancialOfficerMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">0</ix:nonFraction> as at September
30, 2023 and March 31, 2023 respectively.&#160;
The outstanding liability of $<ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2023-09-30_custom_AssetPurchaseAgreementLiabilityMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,988</ix:nonFraction> and $<ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2023-03-31_custom_AssetPurchaseAgreementLiabilityMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">0</ix:nonFraction> as at September 30, 2023 and
March 31, 2023 respectively is included in other accrued liabilities.</p>

<p style="margin: 0px; font-size: 10pt">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-04-01to2023-09-30" escape="true" name="us-gaap:LesseeOperatingLeasesTextBlock"><p style="margin: 0px; text-align: justify; font-size: 10pt"><b>NOTE 8 &#8211; OPERATING LEASES</b></p>

<p style="margin: 0px; font-size: 10pt">&#160;</p>

<p style="margin: 0px; text-align: justify; font-size: 10pt">On April 1, 2023, the Company
entered into an office lease agreement commencing in May 2023 which expires on
April 30, 2028.&#160; Under this agreement,
the monthly rental payments are $<ix:nonFraction name="us-gaap:OperatingLeasesFutureMinimumPaymentsDue" contextRef="AsOf2023-09-30_custom_OfficeLeaseMember_custom_MonthlyRentalPaymentsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,650</ix:nonFraction> throughout the term of the lease.&#160; The Company is required to pay for all
utilities used on the premises and has paid a security deposit of $<ix:nonFraction name="us-gaap:PrepaidExpenseCurrent" contextRef="AsOf2023-09-30_custom_OfficeLeaseMember_custom_SecurityDepositMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">800</ix:nonFraction> which is
included in prepaid expenses.</p>

<p style="margin: 0px; text-align: justify; font-size: 10pt">&#160;</p>

<p style="margin: 0px; text-align: justify; font-size: 10pt"><ix:nonNumeric contextRef="From2023-04-01to2023-09-30" name="us-gaap:LesseeOperatingLeaseDescription">On June 10, 2023, the Company entered into a plant facility lease agreement with a related party commencing June 9, 2023 which expires on June 30, 2028.&#160; Under this agreement, the monthly rental payments are $<ix:nonFraction name="us-gaap:OperatingLeasesFutureMinimumPaymentsDue" contextRef="AsOf2023-09-30_custom_PlantFacilityMember_custom_MonthlyRentalPaymentsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">18,000</ix:nonFraction> throughout the term of the lease excepting the month of June 2023 the rent is $<ix:nonFraction name="us-gaap:CapitalLeaseObligationsCurrent" contextRef="AsOf2023-06-30_custom_PlantFacilityMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,920</ix:nonFraction>, To commence with production, the plant needs to prepare for FDA inspection which will include inspection of the facility, equipment, and the Company&#8217;s procedures.&#160; We expect to launch production during the Company&#8217;s third or fourth quarter and will notify the FDA to come into the plant for the inspection at that time.&#160; The Company is able to start production while the plant waits for the FDA Inspection.&#160; Until the certification is complete, the monthly rent is reduced by forty (40%) percent to $10,800. Under this agreement, the Company is also leasing the equipment in the plant facility through five (5) annual rent payments of $10,000, which are due on the 15th day of&#160; each June from June 2023 to June 2027.</ix:nonNumeric></p>

<p style="margin: 0; font-size: 10pt">&#160;</p>

<p style="margin: 0; font-size: 10pt"></p>

<ix:exclude><table cellpadding="0" class="adv_pagination" cellspacing="0" border="0" style="width: 100%; font-size: 10pt; margin-top: 10px">
  <tbody>
  <tr style="vertical-align: top; text-align: left">
    <td style="width: 33%"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 34%; text-align: center"><p class="pagenumber" style="margin: 0px; font-size: 10pt">9</p></td>
    <td style="width: 33%; text-align: right"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
  </tr>
</tbody>
</table></ix:exclude>

<ix:exclude><table border="0" cellspacing="0" cellpadding="0" style="width: 100%; page-break-after: always">
  <tbody>
  <tr>
    <td style="border-bottom: black 4px solid"><p style="margin: 0; font-size: 10pt">&#160;</p></td>
  </tr>
</tbody>
</table></ix:exclude>

<p style="margin-top: 0pt; margin-bottom: 0pt"><span id="page_10" class="adv_highlightanchor adv_pagination"></span></p>

<p style="margin: 0; font-size: 10pt">&#160;</p>

<p style="margin: 0; font-size: 10pt"></p>

<p style="margin: 0px; text-align: justify; font-size: 10pt"><span style="font-size: 10pt">During the six-month
periods ended September 30, 2023 and September 30, 2022 the operating lease
cost was $<ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2023-04-012023-09-30_custom_OperatingLeaseCostMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">81,451</ix:nonFraction> and $<ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2022-04-012022-09-30_custom_OperatingLeaseCostMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">0</ix:nonFraction> respectively and is included in general and
administrative expenses in the accompanying financial statements.</span></p>

<p style="margin: 0px; text-align: justify; font-size: 10pt"><b>&#160;</b></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-04-01to2023-09-30" escape="true" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock"><p style="margin: 0px; text-align: justify; font-size: 10pt"><b>NOTE
9 &#8211; STOCKHOLDERS&#8217; DEFICIT</b></p>

<p style="margin: 0px; font-size: 10pt">&#160;</p>

<p style="margin: 0px; text-align: justify; font-size: 10pt">The Company has authorized
the issuance of <ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">675,000,000</ix:nonFraction> shares of common stock with a par value of $<ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction>
per share.</p>

<p style="margin: 0px; text-align: justify; font-size: 10pt"><br /></p>

<p style="margin: 0px; text-align: justify; font-size: 10pt">During the six months ended
September 30, 2023, the Company issued <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="From2023-04-012023-09-30_custom_BoardMembersAndConsultantsMember_custom_ServicesRenderedMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">460,000</ix:nonFraction> shares to board members and
consultants for services rendered.&#160; Total
stock-based compensation expense was $<ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2023-04-012023-09-30_custom_BoardMembersAndConsultantsMember_custom_ServicesRenderedMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">82,800</ix:nonFraction> during the six months ended
September 30, 2023 in connection with these issuances based on the fair value
of the stock on the respective grant dates.</p>

<p style="margin: 0px; text-align: justify; font-size: 10pt"><br /></p>

<p style="margin: 0px; text-align: justify; font-size: 10pt">During the six months ended September 30, 2023,
the Company issued <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2023-09-30_custom_BoardMembersAndConsultantsMember_custom_ServicesRenderedMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">590,000</ix:nonFraction> warrants to board members and consultants for
services rendered with a total grant date fair value of $<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2023-09-30_custom_BoardMembersAndConsultantsMember_custom_ServicesRenderedMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">59,691</ix:nonFraction>&#160; Total stock-based compensation expense of
$<ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2023-04-012023-09-30_custom_BoardMembersAndConsultantsMember_custom_ServicesRenderedMember_custom_WarrantsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">50,588</ix:nonFraction> was recorded in connection with these awards during the six months
ended September 30, 2023.&#160; The remaining
stock-based compensation of $<ix:nonFraction name="RGPX:StockBasedCompensationUnrecognizedCompensationCost" contextRef="AsOf2023-09-30_custom_BoardMembersAndConsultantsMember_custom_ServicesRenderedMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,103</ix:nonFraction> will be recognized over the next nine months.&#160; The warrants contain an exercise price of
$<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" contextRef="AsOf2023-09-30_custom_BoardMembersAndConsultantsMember_custom_ServicesRenderedMember_custom_WarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.33</ix:nonFraction> per share, vesting terms ranging from immediately to June 30, 2024, and
expire on dates ranging from July 1, 2029 to October 1, 2029.</p>

<p style="margin: 0; font-size: 10pt">&#160;</p>

<p style="margin: 0; font-size: 10pt"></p>

<p style="margin: 0px; font-size: 10pt"><span style="font-size: 10pt; text-align: justify">The warrant fair values were estimated using a Black
Scholes model with a 5-year expected term, risk-free interest rate ranging from
<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" contextRef="From2023-04-01to2023-09-30" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">5.19</ix:nonFraction>% to <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" contextRef="From2023-04-01to2023-09-30" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">5.54</ix:nonFraction>%, a dividend yield of <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2023-04-01to2023-09-30" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0</ix:nonFraction>%, and an annualized standard deviation of
stock price volatility of <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2023-04-01to2023-09-30" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">80.0</ix:nonFraction>%.&#160; The
risk-free interest rate assumptions for options granted is based upon observed
interest rates on the United States government securities appropriate for the
expected term of the equity awards.</span></p>

<p style="margin: 0px; font-size: 10pt">&#160;</p>

<p style="margin: 0px; text-align: justify; font-size: 10pt">As of the date of this valuation, the Companies stock
was not trading.&#160; The volatility was calculated
based on comparable public companies.&#160;
The Company will continue to monitor peer companies and other relevant
factors used to measure expected volatility for future equipment award grants,
until such time that the Company&#8217;s Common Stock has enough market history to
use historical volatility.</p>

<p style="margin: 0px; font-size: 10pt">&#160;</p>

<p style="margin: 0px; text-align: justify; font-size: 10pt">The dividend yield assumption for equity awards
granted is based on Company&#8217;s history and expectation of dividend payouts.&#160; The Company has never declared or paid any
cash dividends on its Common Stock, and the Company does not anticipate paying
any cash dividends in the foreseeable future.</p>

<p style="margin: 0px; font-size: 10pt">&#160;</p>

<p style="margin: 0px; text-align: justify; font-size: 10pt">The closing stock price of the Company&#8217;s common stock
is not available as the Company&#8217;s stock is not trading. As a result, the Board
of Directors and management determined the fair value of the common stock to be
$<ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.18</ix:nonFraction> per share based upon an allocation of the recent cash price paid for
common stock and warrants during the six months ended September 30, 2023.</p>

<p style="margin: 0px; text-align: justify; font-size: 10pt"><br /></p>

<p style="margin: 0px; text-align: justify; font-size: 10pt">During the six-month period ended September 30, 2023,
the Company issued <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-04-01to2023-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">343,250</ix:nonFraction> shares of common stock with a par value of $<ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction>
for the price of one ($1) dollar per share for a total of for a total of $<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-04-01to2023-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">343,250</ix:nonFraction>.&#160; <ix:nonNumeric contextRef="From2023-04-01to2023-09-30" name="us-gaap:TemporaryEquityContractTerms">Five warrants were issued for each share
purchased, for a total of 1,716,250 warrants.&#160;
The warrants are exercisable at twenty ($0.20) cents and expire from
April 2025 through September 2025.</ix:nonNumeric></p>

<p style="margin: 0px; text-align: justify; font-size: 10pt"><br /></p>

<p style="margin: 0px; text-align: justify; font-size: 10pt">As of September 30, 2023, <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,306,250</ix:nonFraction> warrants had been issued of which <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" contextRef="From2023-04-01to2023-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,216,238</ix:nonFraction>
are vested. &#160;None of the warrants have been exercised.</p>

<p style="margin: 0px; font-size: 10pt">&#160;</p>

<ix:exclude><table cellpadding="0" class="adv_pagination" cellspacing="0" border="0" style="width: 100%; font-size: 10pt; margin-top: 10px">
  <tbody>
  <tr style="vertical-align: top; text-align: left">
    <td style="width: 33%"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 34%; text-align: center"><p class="pagenumber" style="margin: 0px; font-size: 10pt">10</p></td>
    <td style="width: 33%; text-align: right"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
  </tr>
</tbody>
</table></ix:exclude>

<ix:exclude><table border="0" cellspacing="0" cellpadding="0" style="width: 100%; page-break-after: always">
  <tbody>
  <tr>
    <td style="border-bottom: black 4px solid"><p style="margin: 0; font-size: 10pt">&#160;</p></td>
  </tr>
</tbody>
</table></ix:exclude>

<p style="margin-top: 0pt; margin-bottom: 0pt"><span id="page_11" class="adv_highlightanchor adv_pagination"></span></p>

<p style="margin: 0; font-size: 10pt">&#160;</p>

<p style="margin: 0; font-size: 10pt"></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-04-01to2023-09-30" escape="true" name="us-gaap:SubsequentEventsTextBlock"><p style="margin: 0px; font-size: 10pt"><b>NOTE 10 &#8211; SUBSEQUENT EVENTS</b></p>

<p style="margin: 0px; font-size: 10pt">&#160;</p>

<p style="margin: 0px; text-align: justify; font-size: 10pt">Subsequent to the six-month period ended September 30, 2023, three
additional notes to a shareholder that were originally due in October 2023 with
a principal amount of $<ix:nonFraction name="us-gaap:NotesPayable" contextRef="AsOf2023-10-01_us-gaap_SubsequentEventMember_custom_ReissuedNotesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">67,400</ix:nonFraction> were reissued in the principal amount of $<ix:nonFraction name="us-gaap:DebtInstrumentCarryingAmount" contextRef="AsOf2023-10-01_us-gaap_SubsequentEventMember_custom_ReissuedNotesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">82,735</ix:nonFraction> which
included the original principal amount of $67,400 plus interest accrued in the
amount of $<ix:nonFraction name="us-gaap:InterestPayableCurrent" contextRef="AsOf2023-10-01_us-gaap_SubsequentEventMember_custom_ReissuedNotesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">15,335</ix:nonFraction>. Repayment of the notes are due within six (6) months of the
date of renewal.</p>

<p style="margin: 0px; font-size: 10pt">&#160;</p>

<p style="margin: 0px; text-align: justify; font-size: 10pt">Subsequent to the six-month period ended
September 30, 2023, one additional note to a shareholder that was originally
due November 2, 2023 with a principal amount of approximately $<ix:nonFraction name="us-gaap:NotesPayable" contextRef="AsOf2023-11-01_us-gaap_SubsequentEventMember_custom_ReissuedNotesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,500</ix:nonFraction> US Funds
($12,000 Canadian funds) was reissued in the principal amount of approximately
$<ix:nonFraction name="us-gaap:DebtInstrumentCarryingAmount" contextRef="AsOf2023-11-01_us-gaap_SubsequentEventMember_custom_ReissuedNotesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,500</ix:nonFraction> US Funds ($14,400 Canadian Funds) which included the original principal
amount of approximately $9,500 US Funds ($12,000 Canadian funds) plus interest
accrued in the amount of approximately $<ix:nonFraction name="us-gaap:InterestPayableCurrent" contextRef="AsOf2023-11-01_us-gaap_SubsequentEventMember_custom_ReissuedNotesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,000</ix:nonFraction> US Funds ($2,400 Canadian Funds).&#160; Repayment of the note is due <ix:nonNumeric contextRef="From2023-11-012023-11-30_us-gaap_SubsequentEventMember_custom_ReissuedNotesMember" format="ixt:datemonthdayyearen" name="us-gaap:DebtInstrumentMaturityDate">May 2, 2024</ix:nonNumeric>.</p>

</ix:nonNumeric><p style="margin: 0px; font-size: 10pt">&#160;</p>

<p style="margin: 0px; text-align: justify; font-size: 10pt">&#160;</p>

<table cellpadding="0" class="adv_pagination" cellspacing="0" border="0" style="width: 100%; font-size: 10pt; margin-top: 10px">
  <tbody>
  <tr style="vertical-align: top; text-align: left">
    <td style="width: 33%"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 34%; text-align: center"><p class="pagenumber" style="margin: 0px; font-size: 10pt">11</p></td>
    <td style="width: 33%; text-align: right"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
  </tr>
</tbody>
</table>

<table border="0" cellspacing="0" cellpadding="0" style="width: 100%; page-break-after: always">
  <tbody>
  <tr>
    <td style="border-bottom: black 4px solid"><p style="margin: 0; font-size: 10pt">&#160;</p></td>
  </tr>
</tbody>
</table>

<p style="margin-top: 0pt; margin-bottom: 0pt"><span id="page_12" class="adv_highlightanchor adv_pagination"></span></p>

<p style="margin: 0; font-size: 10pt">&#160;</p>

<p style="margin: 0; font-size: 10pt"></p>

<p style="margin: 0px; font-size: 10pt"><b>ITEM 2. MANAGEMENT&#8217;S
DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</b></p>

<p style="margin: 0px; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0px; text-align: justify; font-size: 10pt">In this Quarterly Report,
&#8220;Company,&#8221; &#8220;our company,&#8221; &#8220;us,&#8221; and &#8220;our&#8221; refer to Regenerex Pharma, Inc.
unless the context requires otherwise.</p>

<p style="margin: 0px; text-align: justify; font-size: 10pt">&#160;</p>

<p style="margin: 0px; text-align: justify; font-size: 10pt"><b>Forward-Looking Statements</b></p>

<p style="margin: 0px; font-size: 10pt">&#160;</p>

<p style="margin: 0px; text-align: justify; font-size: 10pt">The following information
contains certain forward-looking statements. Forward-looking statements are
statements that estimate the happening of future events and are not based on
historical fact. Forward-looking statements may be identified by the use of
forward-looking terminology, such as &#8220;may,&#8221; &#8220;could,&#8221; &#8220;expect,&#8221; &#8220;estimate,&#8221;
&#8220;anticipate,&#8221; &#8220;plan,&#8221; &#8220;predict,&#8221; &#8220;probable,&#8221; &#8220;possible,&#8221; &#8220;should,&#8221; &#8220;continue,&#8221;
or similar terms, variations of those terms or the negative of those terms. The
forward-looking statements specified in the following information have been
compiled by our management on the basis of assumptions made by management and
considered by management to be reasonable. Our future operating results,
however, are impossible to predict and no representation, guaranty, or warranty
is to be inferred from those forward-looking statements.</p>

<p style="margin: 0px; text-align: justify; font-size: 10pt">&#160;</p>

<p style="margin: 0px; text-align: justify; font-size: 10pt"><b><i>Estimated COVID-19 impacts and uncertainties</i></b></p>

<p style="margin: 0px; text-align: justify; font-size: 10pt">COVID-19 has severely impacted, and is expected to continue to
impact, the economies of the U.S. and other countries around the world COVID-19
has created significant public health concerns as well as significant
volatility, uncertainty, and economic disruption in every region in which we
operate, all of which have adversely affected and may continue to adversely
affect our industries and our business operations. Further, financial and
credit markets have experienced and may again experience volatility.</p>

<p style="margin: 0px; text-align: justify; font-size: 10pt">&#160;</p>

<p style="margin: 0px; text-align: justify; font-size: 10pt">Beginning in our first fiscal quarter of 2020, the novel
coronavirus known as &#8220;COVID-19" began to spread throughout the world,
resulting in a global pandemic. The pandemic triggered a significant downturn
in global commerce as early as February 2020 and the challenging market
conditions continued throughout the second half of fiscal 2020; through 2021
and into the first half of fiscal 2022 and may continue for an extended period
of time.</p>

<p style="margin: 0px; text-align: justify; font-size: 10pt">&#160;</p>

<p style="margin: 0px; text-align: justify; font-size: 10pt">COVID-19 continues to affect global economic conditions. &#160;The situation surrounding COVID-19 remains
fluid, and we are actively managing our response in collaboration with team
members and business partners and assessing potential impacts to our financial
position and operating results, as well as developments in our business.</p>

<p style="margin: 0px; text-align: justify; font-size: 10pt">&#160;</p>

<p style="margin: 0px; text-align: justify; font-size: 10pt"><b>Operations and New Developments</b></p>

<p style="margin: 0px; text-align: justify; font-size: 10pt"><br /></p>

<p style="margin: 0px; text-align: justify; font-size: 10pt">On November 15, 2021,
the Company entered into a Related Party Asset Purchase Agreement in which the
Company purchased certain intellectual property in exchange for 150,000,000
shares of the Company&#8217;s common stock and up to $10,000,000 in contingent
consideration to be paid at the rate of 15% of all gross revenues received from
sales or investment money into the Company, payable on the 15<sup>th</sup> of
the following month, for a period of 60 months.</p>

<p style="margin: 0px; text-align: justify; font-size: 10pt">&#160;</p>

<p style="margin: 0px; text-align: justify; font-size: 10pt">

On August 17, 2023, the Company entered into an Agreement to Purchase
Technology Platforms in which the Company purchased certain intellectual
property in exchange for a two million four hundred thousand dollars
($2,400,000) interest-free due August 17, 2024. &#160;The note payable is due within twelve (12)
months of the date of the agreement.&#160; If
the Company has not raised a minimum of ten million dollars ($10,000,000) in
sales within twelve (12) months, or a maximum of ten million dollars
($10,000,000) in investment, the seller will extend the payments for a further
period of twelve (12) months for a 10% payment of the outstanding balance.&#160; &#160; &#160;</p>

<p style="margin: 0px; text-align: justify; font-size: 10pt">&#160;</p>

<p style="margin: 0px; text-align: justify; font-size: 10pt">The Company received
all rights and title to proprietary wound healing technologies platforms and
formulas involving the application of wound care protocols to treat all wounds, such as diabetic ulcers, pressure
ulcers, burns and surgical wounds.&#160; These
unique products strategically position the Company to enter and capture a high
proportionate market share in the U.S.</p>

<p style="margin: 0px; text-align: justify; font-size: 10pt">&#160;</p>

<p style="margin: 0px; text-align: justify; font-size: 10pt">Currently
management is engaged in developing managed care agreements with southeastern
states to manage their Medicaid wound care patients. Regenerex would provide
our wound care products and protocols which would result in a large savings for
the state Medicaid population. The Company is also in the process of
negotiating with several distributors in various Middle Eastern countries to
provide the Company's products.</p>

<p style="margin: 0; font-size: 10pt">&#160;</p>

<p style="margin: 0; font-size: 10pt"></p>

<table cellpadding="0" class="adv_pagination" cellspacing="0" border="0" style="width: 100%; font-size: 10pt; margin-top: 10px">
  <tbody>
  <tr style="vertical-align: top; text-align: left">
    <td style="width: 33%"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 34%; text-align: center"><p class="pagenumber" style="margin: 0px; font-size: 10pt">12</p></td>
    <td style="width: 33%; text-align: right"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
  </tr>
</tbody>
</table>

<table border="0" cellspacing="0" cellpadding="0" style="width: 100%; page-break-after: always">
  <tbody>
  <tr>
    <td style="border-bottom: black 4px solid"><p style="margin: 0; font-size: 10pt">&#160;</p></td>
  </tr>
</tbody>
</table>

<p style="margin-top: 0pt; margin-bottom: 0pt"><span id="page_13" class="adv_highlightanchor adv_pagination"></span></p>

<p style="margin: 0; font-size: 10pt">&#160;</p>

<p style="margin: 0; font-size: 10pt"></p>

<p style="margin: 0px; text-align: justify; font-size: 10pt"><b style="font-size: 10pt">Business of Issuer</b></p>

<p style="margin: 0px; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0px; text-align: justify; font-size: 10pt">The business of Regenerex Pharma, Inc., (the &#8220;Company&#8221; or &#8220;Regenerex
Pharma,&#8221;), is to develop and market Woundcare Healing products.&#160; The Company has three technologies for different types of wound conditions.</p>

<p style="margin: 0px; text-align: justify; font-size: 10pt">&#160;</p>

<table cellpadding="0" cellspacing="0" border="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">
  <tbody>
  <tr>
    <td style="width: 0.5in; vertical-align: top"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.25in; vertical-align: top"><p style="margin: 0px; font-size: 14pt">&#8226;</p></td>
    <td style="text-align: justify; vertical-align: top"><p style="margin: 0px; font-size: 10pt"><span style="text-decoration: underline">The first is for closing chronic wounds,</span></p></td>
  </tr>
</tbody>
</table>

<table cellpadding="0" cellspacing="0" border="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">
  <tbody>
  <tr>
    <td style="width: 0.5in; vertical-align: top"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.25in; vertical-align: top"><p style="margin: 0px; font-size: 14pt">&#8226;</p></td>
    <td style="text-align: justify; vertical-align: top"><p style="margin: 0px; font-size: 10pt"><span style="text-decoration: underline">the second is for accelerating closure of acute or surgical wounds, and</span></p></td>
  </tr>
</tbody>
</table>

<table cellpadding="0" cellspacing="0" border="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">
  <tbody>
  <tr>
    <td style="width: 0.5in; vertical-align: top"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.25in; vertical-align: top"><p style="margin: 0px; font-size: 14pt">&#8226;</p></td>
    <td style="text-align: justify; vertical-align: top"><p style="margin: 0px; font-size: 10pt"><span style="text-decoration: underline">the third solves the issue on contamination of all types of wounds including the destruction of biofilms</span>.</p></td>
  </tr>
</tbody>
</table>

<p style="margin: 0px; text-align: justify; font-size: 10pt"><span style="font-size: 10pt">&#160;</span></p>

<p style="margin: 0px; text-align: justify; font-size: 10pt">The
current product technology provides the Company a number of
complete wound care protocols to treat
all wounds, such as diabetic ulcers, pressure ulcers, burns and surgical
wounds.&#160; These unique products strategically position
the Company to enter and capture a high proportionate market share in the U.S.
and global markets.</p>

<p style="margin: 0px; text-align: justify; font-size: 10pt">&#160;</p>

<p style="margin: 0px; text-align: justify; font-size: 10pt">Products:</p>

<p style="margin: 0px; text-align: justify; font-size: 10pt">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse">
  <tbody>
  <tr>
    <td style="width: 0.5in; vertical-align: top"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.5in; vertical-align: top"><p style="margin: 0px; font-size: 10pt">1.<span style="font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; font-kerning: auto; font-optical-sizing: auto; font-feature-settings: normal; font-variation-settings: normal; font-stretch: normal; font-size: 7pt; line-height: normal"></span></p></td>
    <td style="text-align: justify; vertical-align: top"><p style="margin: 0px; font-size: 10pt">Xcellderma OTC - Liquid Bandage Skin Protectant Xcellderma&#8482; products are sterile wound dressings and are effective for treating diabetic foot ulcers, pressure ulcers, and other chronic wounds. During the last several years, a scientific and medical consensus has emerged that elevated protease levels impede wound healing. QBx&#8482; the active ingredient down regulates the production of certain proteases and matrix metalloproteases, or MMPs, which are protein enzymes that are proven to impede the healing of a majority of chronic wounds. Approximately 80% of chronic wounds display elevated levels of proteases (including MMPs).</p></td>
  </tr>
</tbody>
</table>

<p style="margin: 0px; text-align: justify; text-indent: 4px; font-size: 10pt">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse">
  <tbody>
  <tr>
    <td style="width: 0.5in; vertical-align: top"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.5in; vertical-align: top"><p style="margin: 0px; font-size: 10pt">2.<span style="font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; font-kerning: auto; font-optical-sizing: auto; font-feature-settings: normal; font-variation-settings: normal; font-stretch: normal; font-size: 7pt; line-height: normal"></span></p></td>
    <td style="text-align: justify; vertical-align: top"><p style="margin: 0px; font-size: 10pt">Accelerex Sterile Wound Cream - The first commercially available medical device, Accelerex, is for the treatment of a wide variety of chronic and acute wounds. Accelerex is a custom-designed, FDA and CE approved unit-dose, sterile wound dressing impregnated with an ointment containing QBx. Chronic wounds are generally defined as wounds that have not healed after thirty days of consistent clinical treatment, and include diabetic ulcers, burns, pressure ulcers (bedsores), and venous stasis ulcers. The Company&#8217;s broadly enabling technology was discovered from oak bark extract and referred to as QBx&#8482;.</p></td>
  </tr>
</tbody>
</table>

<p style="text-align: justify; margin-top: 0px; margin-bottom: 0px; margin-left: 48px; font-size: 10pt">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse">
  <tbody>
  <tr>
    <td style="width: 0.5in; vertical-align: top"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.5in; vertical-align: top"><p style="margin: 0px; font-size: 10pt">3.<span style="font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; font-kerning: auto; font-optical-sizing: auto; font-feature-settings: normal; font-variation-settings: normal; font-stretch: normal; font-size: 7pt; line-height: normal"></span></p></td>
    <td style="text-align: justify; vertical-align: top"><p style="margin: 0px; font-size: 10pt">Accelerex Impregnated Sterile Wound Dressing - For use as a wound dressing to manage pressure ulcers (stages I-IV), stasis ulcers, diabetic skin ulcers, skin irritations, cuts, and abrasions. FDA-cleared, prescription-only combination device that blends the benefits of a wound dressing with two drug components. Provides 3 modes of action to help treat acute and chronic wounds: Protective dressing, moisturizing ointment and 2 drug components: rubidium chloride and potassium chloride.</p></td>
  </tr>
</tbody>
</table>

<p style="margin: 0px; text-align: justify; line-height: 107%; font-size: 10pt"><span style="line-height: 107%">&#160;</span></p>

<p style="margin: 0px; text-align: justify; line-height: 107%; font-size: 10pt"><span style="line-height: 107%">Regenerex System
has been shown in many clinical trials to successfully close up to 95% of
non-responding chronic wounds within 90 days. The wounds clinically tested had
already been subject to current protocols of treatment and failed to heal.
Competitive clinical trials indicated there isn&#8217;t another System that has the
ability to close chronic wounds at these levels and speed. Not only does the
System close chronic wounds relatively quickly but it does so at a very
reasonable cost.</span></p>

<p style="margin: 0px; text-align: justify; line-height: 107%; font-size: 10pt"><span style="line-height: 107%">&#160;</span></p>

<p style="margin: 0px; text-align: justify; font-size: 10pt">QBx&#8482; contributes to setting up a suitable
environment to allow wounds to close.&#160;&#160;Other than the products
marketed by the Company, there are no products currently available on the
market that are successful in healing chronic, non-healing wounds through the
down regulation of proteases.&#160; Other modern wound dressings such as hydrocolloids and
collagens absorb wound fluids, but these dressings do not impact the cellular
environment with simple gauze and gauze-like dressings to cover and protect the
wound.</p>

<p style="margin: 0px; font-size: 10pt">&#160;</p>

<p style="margin: 0px; text-align: justify; font-size: 10pt">Our QBx&#8482;
technology is the most efficacious, and clinically proven Chronic wound Care
product in the world. Chronic wounds are those that fail to progress through a normal, orderly,
and timely sequence of repair. They are not only characterized by delayed healing
for weeks, months, or even years, but also by a resistance to treatment with
conventional dressings and therapies. They impart a particularly devastating
financial and quality-of-life burden on individuals suffering from the wounds
and are frustrating for the caregivers and clinicians who attempt to manage,
but fail to heal, these wounds.</p>

<p style="margin: 0; font-size: 10pt">&#160;</p>

<p style="margin: 0; font-size: 10pt"></p>

<table cellpadding="0" class="adv_pagination" cellspacing="0" border="0" style="width: 100%; font-size: 10pt; margin-top: 10px">
  <tbody>
  <tr style="vertical-align: top; text-align: left">
    <td style="width: 33%"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 34%; text-align: center"><p class="pagenumber" style="margin: 0px; font-size: 10pt">13</p></td>
    <td style="width: 33%; text-align: right"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
  </tr>
</tbody>
</table>

<table border="0" cellspacing="0" cellpadding="0" style="width: 100%; page-break-after: always">
  <tbody>
  <tr>
    <td style="border-bottom: black 4px solid"><p style="margin: 0; font-size: 10pt">&#160;</p></td>
  </tr>
</tbody>
</table>

<p style="margin-top: 0pt; margin-bottom: 0pt"><span id="page_14" class="adv_highlightanchor adv_pagination"></span></p>

<p style="margin: 0; font-size: 10pt">&#160;</p>

<p style="margin: 0; font-size: 10pt"></p>

<p style="margin: 0px; font-size: 10pt"><span style="font-size: 10pt; text-align: justify">Non-healing
chronic wounds are thought to be a consequence of factors that affect both the
production of new tissue and the elevated destruction of existing tissue. Biochemically,
these wounds appear to be stuck in a catabolic, inflammatory phase that is
hostile to local growth factors and the activity of fibroblasts and
keratinocytes.&#160; Increases in matrix
metalloproteinases (MMPs) MMP-2 and MMP-9 are of significance in non-healing
chronic wounds.</span></p>

<p style="margin: 0px; font-size: 10pt">&#160;</p>

<p style="margin: 0px; text-align: justify; line-height: 107%; font-size: 10pt"><span style="line-height: 107%">MMPs
are a group of zinc-containing proteolytic enzymes that play an important role
in the remodeling of the extracellular matrix of wounds.&#160; An overproduction of MMPs may result in
degradation of the extracellular matrix and inactivation of vital growth
factors.&#160; A precisely orchestrated
balance of MMP production and their natural inhibitors (TIMPs) is needed.</span></p>

<p style="margin: 0px; font-size: 10pt">&#160;</p>

<p style="margin: 0px; text-align: justify; line-height: 107%; font-size: 10pt"><span style="line-height: 107%">Additionally,
it is theorized that wounds stuck in the inflammatory phase persistently
overproduce free radicals or reactive oxygen species (ROS).&#160; At low concentration and early in the
inflammatory phase of wound healing, ROS such as hydrogen peroxide (H2O2), have
a positive effect on healing through stimulation of fibroblast proliferation.
However, persistent overproduction of ROS is thought to be detrimental to
healing.&#160; A new treatment strategy has
emerged focused upon manipulating the expression of genes which control the
endogenous production of MMPs and TIMPs within the local wound
environment.&#160; Contrary to modalities
designed to sequester MMPs and/or act as a competitive substrate for protease
activity, this technology strategy relies on delivery of metal ions into the
wound to help regulate gene expression for the production of MMPs and TIMPs,
thus bringing them into balance. These metal ions are delivered via a
polyethylene glycol based, QBx&#8482; ointment, which also contains citric acid to
help normalize wound pH and reduce ROS activity. The QBx&#8482; ointment is delivered
via a tube or an acetylated regenerated cellulose carrier which allows for the
passage of wound drainage and is non-fiber shedding. The entire composition is
marketed as our primary wound dressing called Accelerex&#8482;.</span></p>

<p style="margin: 0px; font-size: 10pt">&#160;</p>

<p style="margin: 0px; text-align: justify; line-height: 107%; font-size: 10pt"><span style="line-height: 107%">Approximately 80% of
chronic wounds display elevated levels of MMPs. Traditionally, however, these wounds have been managed with
simple gauze and gauze-like dressings to cover and protect the wound.&#160; Other modern wound dressings such as
hydrocolloids and collagens absorb wound fluids, but these dressings do not
impact the cellular environment. This void in the treatment regimen offers a
unique market advantage. QBx&#8482; contributes to creating a suitable environment to
allow wounds to close.&#160; </span><span style="line-height: 107%">These formularies
are based on Proteases Down Regulating Technology and provide the System for a
comprehensive suite of wound care products
</span><span style="line-height: 107%">focused on the
treatment of chronic wounds.</span></p>

<p style="margin: 0px; font-size: 10pt">&#160;</p>

<p style="margin: 0px; text-align: justify; font-size: 10pt">Chronic wounds impose significant costs to the US economy.&#160; Chronic wounds are a growing issue in the
United States, causing immense patient pain and suffering as well as substantial
economic and social cost.&#160; Although
precise information on the prevalence of chronic wounds in the US is
unavailable, it is estimated that, as of 2021, there were more than 8.3 million
Americans suffering from chronic wounds.&#160;
Chronic wounds are generally defined as wounds that have not healed
after ninety days of consistent clinical treatment, and include diabetic foot
ulcers, pressure ulcers (bedsores), and venous stasis ulcers, however this does
not include acute wounds.</p>

<p style="margin: 0px; text-align: justify; font-size: 10pt">&#160;</p>

<p style="margin: 0px; text-align: justify; font-size: 10pt">The most common chronic wounds are diabetic foot ulcers and
pressure ulcers.&#160; The increasing number
of Americans with diabetes and obesity we well as the aging population will
likely cause the number of individuals with chronic wounds to continue to
rise.&#160; In addition to the immeasurable
human benefits of improving treatment outcomes, there would be substantial
economic effect.&#160; The costs of medical
treatment could be expected to decrease, and, as patients are able to return to
work sooner, productivity would increase.</p>

<p style="margin: 0px; text-align: justify; font-size: 10pt">&#160;</p>

<p style="margin: 0px; text-align: justify; font-size: 10pt">Due to the staggering
costs associated with chronic wounds in the US, the Affordable Healthcare Act
(AHA) is changing how the entire wound care system is reimbursed in the US. Now
all four markets segments: hospital, nursing homes, home health, and general
wound care clinics are all on paid on a &#8220;pay for performance basis.&#8221;&#160; These cost pressures in the healthcare system
are a major issue in the wound care market, with the US government and payors
seeking new approaches that address cost constraints and product performance.&#160; Home health is now paid on a &#8220;diagnostic code&#8221;
for the wound in single payments removing the risk from the Payee to the
Payer.&#160; The Company&#8217;s first markets will
be those segments that are totally &#8220;at risk&#8221; for single payments to close the
wounds.&#160; Today, the fastest growing
segment in the US wound market is Home Health and Nursing Homes due to the
aging population.</p>

<p style="margin: 0; font-size: 10pt">&#160;</p>

<p style="margin: 0; font-size: 10pt"></p>

<table cellpadding="0" class="adv_pagination" cellspacing="0" border="0" style="width: 100%; font-size: 10pt; margin-top: 10px">
  <tbody>
  <tr style="vertical-align: top; text-align: left">
    <td style="width: 33%"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 34%; text-align: center"><p class="pagenumber" style="margin: 0px; font-size: 10pt">14</p></td>
    <td style="width: 33%; text-align: right"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
  </tr>
</tbody>
</table>

<table border="0" cellspacing="0" cellpadding="0" style="width: 100%; page-break-after: always">
  <tbody>
  <tr>
    <td style="border-bottom: black 4px solid"><p style="margin: 0; font-size: 10pt">&#160;</p></td>
  </tr>
</tbody>
</table>

<p style="margin-top: 0pt; margin-bottom: 0pt"><span id="page_15" class="adv_highlightanchor adv_pagination"></span></p>

<p style="margin: 0; font-size: 10pt">&#160;</p>

<p style="margin: 0; font-size: 10pt"></p>

<p style="margin: 0px; font-size: 10pt"><span style="font-size: 10pt; text-align: justify">The Company has purchased proprietary
wound care formulations, and has entered into an agreement, dated June 10,
2023, with Woundcare Labs, LLC to lease a plant and equipment in
Tennessee.&#160; We expect to launch our
sales initiative during the Company&#8217;s third or fourth quarter of our year end
March 31, 2024.</span><span style="font-size: 10pt; text-align: justify">&#160;</span></p>

<p style="margin: 0px; font-size: 10pt">&#160;</p>

<p style="margin: 0px; text-align: justify; font-size: 10pt">Currently management is
engaged in developing managed care agreements with southeastern states to
manage their Medicaid wound care patients. Regenerex would provide our wound
care products and protocols which would result in a large savings for the state
Medicaid population. The Company is also in the process of negotiating with
several distributors in various Middle Eastern countries to provide the
Company's products. The Company has engaged into an agreement as of June 11,
2023, in the amount of $45,000, with First Forte Consultancy in the UAE to
assist in meetings and road shows, introducing potential clients for
distribution of the companies wound care product. $22,500 was paid June 15,
2023, and the balance of $22,500 is to be paid after the road shows and
meetings are completed, in the Company&#8217;s third or fourth quarter.</p>

<p style="margin: 0px; font-size: 10pt">&#160;</p>

<p style="margin: 0px; text-align: justify; font-size: 10pt"><b>Financial Results and
Trends</b><b></b></p>

<p style="margin: 0px; text-align: justify; font-size: 10pt"><i>&#160;</i></p>

<p style="margin: 0px; text-align: justify; font-size: 10pt"><i>Results of Operations for the Six Months Ended September
30, 2023 and 2022</i></p>

<p style="margin: 0px; text-align: justify; font-size: 10pt">&#160;</p>

<p style="margin: 0px; text-align: justify; font-size: 10pt">At present, the
Company has $0 revenue during the six months ended September 30, 2023 and September
30, 2022.&#160; Net loss increased from $41,640
for the six months ended September 30, 2022 to $2,987,024 for the six months
ended September 30, 2023 due to the purchase of intellectual property which was
recorded as research and development expenses due to the nature of the acquired
IP, &#160;higher payroll expense, stock-based
compensation, administration expense, consulting expense, lease expenses,
accounting expense, and travel expenses, offset by decrease in filing fees and
a gain in foreign exchange.</p>

<p style="margin: 0px; text-align: justify; font-size: 10pt">&#160;</p>

<p style="margin: 0px; text-align: justify; font-size: 10pt"><i>Liquidity and Capital Resources</i></p>

<p style="margin: 0px; font-size: 10pt">&#160;</p>

<p style="margin: 0px; text-align: justify; font-size: 10pt">The Company requires
significant cash to launch its business and reduce its payable.&#160; Management&#8217;s plans are to actively seek
capital to enable the Company to add new products and/or services to ultimately
achieve profitability. However, management cannot provide assurance that they
can raise sufficient capital and whether the Company will ultimately achieve
profitability, become cash flow positive, or raise additional debt and/or
equity capital. The Company&#8217;s primary sources of liquidity and capital
resources have been notes payable, which are not sufficient prospectively.&#160; These factors raise substantial doubt about
the Company&#8217;s ability to continue as a going concern.&#160; If the Company is unable to raise additional
capital in the near future or meet financing requirements, the Company may need
to curtail or alter its plan of operations, seek additional capital on less
favorable terms, and/or pursue other remedial measures.</p>

<p style="margin: 0px; text-align: justify; font-size: 10pt"><i>&#160;</i></p>

<p style="margin: 0px; text-align: justify; font-size: 10pt"><i>Cash Flow</i></p>

<p style="margin: 0px; font-size: 10pt">&#160;</p>

<p style="margin: 0px; text-align: justify; font-size: 10pt">The following table
summarizes, for the periods indicated, selected items in our condensed
Statements of Cash Flows:</p>

<p style="margin: 0px; font-size: 10pt">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
  <tbody>
  <tr>
    <td style="vertical-align: bottom"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td colspan="5" style="vertical-align: bottom; width: 1.2in"><p style="margin: 0px; text-align: center; font-size: 10pt"><b>Six Months Ended</b></p></td>
    <td style="width: 0.2in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td colspan="5" style="border-bottom: black 2px solid; vertical-align: bottom; width: 1.2in"><p style="margin: 0px; text-align: center; font-size: 10pt"><b>September 30,</b></p></td>
    <td style="width: 0.2in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td colspan="2" style="border-bottom: black 2px solid; vertical-align: bottom; width: 1.2in"><p style="margin: 0px; text-align: center; font-size: 10pt"><b>2023</b></p></td>
    <td style="width: 0.2in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td colspan="2" style="border-bottom: black 2px solid; vertical-align: bottom; width: 1.2in"><p style="margin: 0px; text-align: center; font-size: 10pt"><b>2022</b></p></td>
    <td style="width: 0.2in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom"><p style="margin: 0px; font-size: 10pt">Net   cash (used in) provided by:</p></td>
    <td style="width: 0.1in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="vertical-align: bottom"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.2in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.1in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="vertical-align: bottom"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.2in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
  </tr>
  <tr>
    <td style="padding: 0cm 0cm 0cm 10pt; vertical-align: bottom; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">Operating   activities</p></td>
    <td style="vertical-align: bottom; width: 0.1in; text-align: right; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">$</p></td>
    <td style="vertical-align: bottom; width: 1.2in; text-align: right; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">(293,286</p></td>
    <td style="vertical-align: bottom; width: 0.2in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">)</p></td>
    <td style="vertical-align: bottom; width: 0.1in; text-align: right; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">$</p></td>
    <td style="vertical-align: bottom; width: 1.2in; text-align: right; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">(44,512</p></td>
    <td style="vertical-align: bottom; width: 0.2in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">)</p></td>
  </tr>
  <tr>
    <td style="padding: 0cm 0cm 0cm 10pt; vertical-align: bottom"><p style="margin: 0px; font-size: 10pt">Investing   activities</p></td>
    <td style="vertical-align: bottom; width: 0.1in; text-align: right"><p style="margin: 0px; font-size: 10pt">$</p></td>
    <td style="vertical-align: bottom; width: 1.2in; text-align: right"><p style="margin: 0px; font-size: 10pt">(6,299</p></td>
    <td style="vertical-align: bottom; width: 0.2in"><p style="margin: 0px; font-size: 10pt">)</p></td>
    <td style="vertical-align: bottom; width: 0.1in; text-align: right"><p style="margin: 0px; font-size: 10pt">$</p></td>
    <td style="vertical-align: bottom; width: 1.2in; text-align: right"><p style="margin: 0px; font-size: 10pt">&#8212;</p></td>
    <td style="width: 0.2in"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
  </tr>
  <tr>
    <td style="padding: 0cm 0cm 0cm 10pt; vertical-align: bottom; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">Financing   activities</p></td>
    <td style="vertical-align: bottom; width: 0.1in; text-align: right; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">$</p></td>
    <td style="vertical-align: bottom; width: 1.2in; text-align: right; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">304,530</p></td>
    <td style="width: 0.2in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="vertical-align: bottom; width: 0.1in; text-align: right; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">$</p></td>
    <td style="vertical-align: bottom; width: 1.2in; text-align: right; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">42,501</p></td>
    <td style="width: 0.2in; background-color: #e6efff"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
  </tr>
</tbody>
</table>

<p style="margin: 0; font-size: 10pt"><span style="font-size: 10pt">&#160;&#160;</span></p>

<table cellpadding="0" class="adv_pagination" cellspacing="0" border="0" style="width: 100%; font-size: 10pt; margin-top: 10px">
  <tbody>
  <tr style="vertical-align: top; text-align: left">
    <td style="width: 33%"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 34%; text-align: center"><p class="pagenumber" style="margin: 0px; font-size: 10pt">15</p></td>
    <td style="width: 33%; text-align: right"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
  </tr>
</tbody>
</table>

<table border="0" cellspacing="0" cellpadding="0" style="width: 100%; page-break-after: always">
  <tbody>
  <tr>
    <td style="border-bottom: black 4px solid"><p style="margin: 0; font-size: 10pt">&#160;</p></td>
  </tr>
</tbody>
</table>

<p style="margin-top: 0pt; margin-bottom: 0pt"><span id="page_16" class="adv_highlightanchor adv_pagination"></span></p>

<p style="margin: 0; font-size: 10pt">&#160;</p>

<p style="margin: 0; font-size: 10pt"></p>

<p style="margin: 0px; text-align: justify; font-size: 10pt"><i>Operating Activities</i></p>

<p style="margin: 0px; text-align: justify; font-size: 10pt">&#160;</p>

<p style="margin: 0px; text-align: justify; font-size: 10pt">Cash
used in operating activities was $293,286 and $44,512 for the six months ended September
30, 2023 and 2022, respectively. The increase in cash used in operating
activities was primarily due to an increase in net loss.</p>

<p style="margin: 0px; text-align: justify; font-size: 10pt">&#160;</p>

<p style="margin: 0px; text-align: justify; font-size: 10pt"><i>Investing Activities</i></p>

<p style="margin: 0px; font-size: 10pt"><i>&#160;</i></p>

<p style="margin: 0px; text-align: justify; font-size: 10pt">Cash
used in investing activities was $6,299 and $0 for the six months ended September
30, 2023 and 2022.&#160; The increase in cash
used was due to the purchase of furniture and computer equipment.</p>

<p style="margin: 0px; text-align: justify; font-size: 10pt"><i>&#160;</i></p>

<p style="margin: 0px; text-align: justify; font-size: 10pt"><i>Financing Activities</i></p>

<p style="margin: 0px; font-size: 10pt"><i>&#160;</i></p>

<p style="margin: 0px; text-align: justify; font-size: 10pt">Cash provided by financing
activities was $304,530 and $42,501 for the six months ended September 30, 2023
and 2022, respectively. The increase in cash provided by financing activities
was primarily due to proceeds from sale of common stocks and warrants and an additional
note payable offset by repayment of notes payable.</p>

<p style="margin: 0px; text-align: justify; font-size: 10pt">&#160;</p>

<p style="margin: 0px; text-align: justify; font-size: 10pt"><i>Off-Balance Sheet Arrangements</i></p>

<p style="margin: 0px; font-size: 10pt">&#160;</p>

<p style="margin: 0px; text-align: justify; font-size: 10pt">None.</p>

<p style="margin: 0px; text-align: justify; font-size: 10pt">&#160;</p>

<table cellpadding="0" class="adv_pagination" cellspacing="0" border="0" style="width: 100%; font-size: 10pt; margin-top: 10px">
  <tbody>
  <tr style="vertical-align: top; text-align: left">
    <td style="width: 33%"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 34%; text-align: center"><p class="pagenumber" style="margin: 0px; font-size: 10pt">16</p></td>
    <td style="width: 33%; text-align: right"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
  </tr>
</tbody>
</table>

<table border="0" cellspacing="0" cellpadding="0" style="width: 100%; page-break-after: always">
  <tbody>
  <tr>
    <td style="border-bottom: black 4px solid"><p style="margin: 0; font-size: 10pt">&#160;</p></td>
  </tr>
</tbody>
</table>

<p style="margin-top: 0pt; margin-bottom: 0pt"><span id="page_17" class="adv_highlightanchor adv_pagination"></span></p>

<p style="margin: 0; font-size: 10pt">&#160;</p>

<p style="margin: 0; font-size: 10pt"></p>

<p style="margin: 0px; text-align: center; font-size: 10pt"><b>WHERE YOU CAN FIND MORE
INFORMATION</b></p>

<p style="margin: 0px; text-align: center; font-size: 10pt">&#160;</p>

<p style="margin: 0px; text-align: justify; font-size: 10pt">You are advised
to read this Quarterly Report on Form 10-Q in conjunction with other reports
and documents that we file from time to time with the SEC. In particular,
please read our Registration Statement on Form 10-12G, Quarterly Reports on
Form 10-Q, Annual Reports on Form 10-K, and Current Reports on Form 8-K that we
file from time to time. You may obtain copies of these reports directly from us
or from the SEC at the SEC&#8217;s Public Reference Room at 100 F. Street, N.E.
Washington, D.C. 20549, and you may obtain information about obtaining access
to the Reference Room by calling the SEC at 1-800-SEC-0330. In addition, the
SEC maintains information for electronic filers at its website <span style="text-decoration: underline">http://www.sec.gov.</span></p>

<p style="margin: 0px; font-size: 10pt">&#160;</p>

<p style="margin: 0px; font-size: 10pt"><b>ITEM 3.
QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</b></p>

<p style="margin: 0px; font-size: 10pt">&#160;</p>

<p style="margin: 0px; text-align: justify; font-size: 10pt">We had no material changes
in market risk from those described in &#8220;Item 2&#8212;Quantitative and Qualitative
Disclosures about Market Risk&#8221; of our Annual Report on Form 10-K.</p>

<p style="margin: 0px; text-align: justify; font-size: 10pt">&#160;</p>

<p style="margin: 0px; text-align: justify; font-size: 10pt"><b>ITEM 4. CONTROLS AND
PROCEDURES</b></p>

<p style="margin: 0px; font-size: 10pt">&#160;</p>

<p style="margin: 0px; text-align: justify; font-size: 10pt">This report includes the
certification of our Chief Executive Officer required by Rule 13a-14 of the
Securities Exchange Act of 1934 (the &#8220;Exchange Act&#8221;). See Exhibits 31.1 and
31.2. This Item 4 includes information concerning the controls and control
evaluations revered to in those certifications.</p>

<p style="margin: 0px; font-size: 10pt">&#160;</p>

<p style="margin: 0px; text-align: justify; font-size: 10pt"><i>Evaluation of Disclosure
Controls and Procedures</i></p>

<p style="margin: 0px; font-size: 10pt"><i>&#160;</i></p>

<p style="margin: 0px; text-align: justify; font-size: 10pt">We maintain disclosure controls and procedures that
are designed to ensure that information required to be disclosed in the reports
we file or submit under the Exchange Act is recorded, processed, summarized and
reported within the time periods specified in the Securities and Exchange
Commission&#8217;s (the &#8220;SEC&#8221;) rules and forms and that such information is
accumulated and communicated to our Chief Executive Officer and Chief Financial
Officer, as appropriate, to allow for timely decisions regarding required
disclosure.</p>

<p style="margin: 0px; text-align: justify; font-size: 10pt">&#160;</p>

<p style="margin: 0px; text-align: justify; font-size: 10pt">Under the supervision and with the
participation of management, including the principal executive officer and
principal financial officer, the Company conducted an evaluation of the
effectiveness of internal control over financial reporting. This assessment was
based on the framework in Internal Control &#8211; Integrated Framework issued by the
Committee of Sponsoring Organizations of the Treadway Commission. Based on this
evaluation under the framework in Internal Control &#8211; Integrated Framework,
management concluded that the Company maintained effective internal control
over financial reporting as of September 30, 2023, as such term is defined in
Exchange Act Rule 13a-15(f).</p>

<p style="margin: 0px; text-align: justify; font-size: 10pt">&#160;</p>

<p style="margin: 0px; text-align: justify; font-size: 10pt">In designing and evaluating the disclosure controls
and procedures, management recognizes that any controls and procedures, no
matter how well designed and operated, can provide only reasonable assurance of
achieving the desired control objectives, and management is required to apply
its judgment in evaluating the cost-benefit relationship of possible controls
and procedures. Our disclosure controls and procedures were designed to provide
reasonable assurance that the controls and procedures would meet their
objectives.</p>

<p style="margin: 0px; text-align: justify; font-size: 10pt">&#160;</p>

<p style="margin: 0px; text-align: justify; font-size: 10pt">As required by SEC Rule 13a-15(b), our Chief Executive
Officer and Chief Financial Officer need to carry out an evaluation of the
effectiveness of the design and operation of our disclosure controls and
procedures as of the end of the period covered by this report. Based on the
foregoing, our Chief Executive Officer concluded that our disclosure controls
and procedures were effective as of September 30, 2023.</p>

<p style="margin: 0px; text-align: justify; font-size: 10pt">&#160;</p>

<p style="margin: 0px; text-align: justify; font-size: 10pt"><i>Management&#8217;s Report on
Internal Control over Financial Reporting</i></p>

<p style="margin: 0px; font-size: 10pt"><i>&#160;</i></p>

<p style="margin: 0px; text-align: justify; font-size: 10pt">Our Chief Executive Officer
and the Chief Financial Officer are responsible for establishing and maintaining
adequate internal control over financial reporting and for the assessment of
the effectiveness of our internal control over financial reporting. Internal
control over financial reporting (as defined in Rules 13a-15(f) and 15d(f)
under the Exchange Act) is a process designed to provide reasonable assurance
regarding the reliability of financial reporting and the preparation of
financial statements for external reporting purposes in accordance with U.S.
GAAP. Internal&#160;</p>

<p style="margin: 0px; text-align: justify; font-size: 10pt"><span style="font-size: 10pt"><br /></span></p>

<table cellpadding="0" class="adv_pagination" cellspacing="0" border="0" style="width: 100%; font-size: 10pt; margin-top: 10px">
  <tbody>
  <tr style="vertical-align: top; text-align: left">
    <td style="width: 33%"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 34%; text-align: center"><p class="pagenumber" style="margin: 0px; font-size: 10pt">17</p></td>
    <td style="width: 33%; text-align: right"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
  </tr>
</tbody>
</table>

<table border="0" cellspacing="0" cellpadding="0" style="width: 100%; page-break-after: always">
  <tbody>
  <tr>
    <td style="border-bottom: black 4px solid"><p style="margin: 0; font-size: 10pt">&#160;</p></td>
  </tr>
</tbody>
</table>

<p style="margin-top: 0pt; margin-bottom: 0pt"><span id="page_18" class="adv_highlightanchor adv_pagination"></span></p>

<p style="margin: 0; font-size: 10pt">&#160;</p>

<p style="margin: 0; font-size: 10pt"></p>

<p style="margin: 0px; text-align: justify; font-size: 10pt"><span style="font-size: 10pt">control over financial reporting includes those policies and
procedures that (a) pertain to the maintenance of records that, in reasonable
detail, accurately and fairly reflect the transactions and dispositions of
assets, (b) provide reasonable assurance that transactions are recorded as necessary
to permit preparation of financial statements in accordance with GAAP, (c)
provide reasonable assurance that receipts and expenditures are being made only
in accordance with appropriate authorization of management and the Board of
Directors, and (d) provide reasonable assurance regarding prevention or timely
detection of unauthorized acquisition, use or disposition of assets that could
have a material effect on the financial statements.</span></p>

<p style="margin: 0px; text-align: justify; font-size: 10pt">&#160;</p>

<p style="margin: 0px; text-align: justify; font-size: 10pt">In connection
with the preparation of this Quarterly Report on Form 10-Q for the quarter
ended September 30, 2023, our Chief Executive Officer and Chief Financial
Officer have concluded that our internal controls and procedures over financial
reporting were effective as of September 30, 2023.</p>

<p style="margin: 0px; text-align: justify; font-size: 10pt">&#160;</p>

<p style="margin: 0px; text-align: justify; font-size: 10pt"><i>Inherent Limitations
on Internal Controls</i></p>

<p style="margin: 0px; font-size: 10pt"><i>&#160;</i></p>

<p style="margin: 0px; text-align: justify; font-size: 10pt">It should be
noted that any system of controls, however well designed and operated, can
provide only reasonable and not absolute assurance that the objectives of the
control system are met. In addition, the design of any control system is based
in part upon certain assumptions about the likelihood of certain events.
Limitations inherent in any control system include the following:</p>

<p style="margin: 0px; text-align: justify; text-indent: -24px; font-size: 10pt">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse">
  <tbody>
  <tr>
    <td style="width: 24px; vertical-align: top"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 24px; vertical-align: top"><p style="margin: 0px; font-size: 10pt">&#9679;</p></td>
    <td style="vertical-align: top"><p style="margin: 0px; text-align: justify; font-size: 10pt">Judgments in decision-making can be faulty, and
  control and process breakdowns can occur because of simple errors or
  mistakes;</p></td>
  </tr>
  <tr>
    <td style="vertical-align: top"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="vertical-align: top"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="vertical-align: top"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
  </tr>
  <tr>
    <td style="vertical-align: top"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="vertical-align: top"><p style="margin: 0px; font-size: 10pt">&#9679;</p></td>
    <td style="vertical-align: top"><p style="margin: 0px; text-align: justify; font-size: 10pt">Controls can be circumvented by individuals,
  acting alone or in collusion with others, or by management override;</p></td>
  </tr>
  <tr>
    <td style="vertical-align: top"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="vertical-align: top"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="vertical-align: top"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
  </tr>
  <tr>
    <td style="vertical-align: top"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="vertical-align: top"><p style="margin: 0px; font-size: 10pt">&#9679;</p></td>
    <td style="vertical-align: top"><p style="margin: 0px; text-align: justify; font-size: 10pt">The design of any system of controls is based in
  part on certain assumptions about the likelihood of future events, and there
  can be no assurance that any design will succeed in achieving its stated
  goals under all potential future conditions;</p></td>
  </tr>
  <tr>
    <td style="vertical-align: top"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="vertical-align: top"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="vertical-align: top"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
  </tr>
  <tr>
    <td style="vertical-align: top"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="vertical-align: top"><p style="margin: 0px; font-size: 10pt">&#9679;</p></td>
    <td style="vertical-align: top"><p style="margin: 0px; text-align: justify; font-size: 10pt">Over time, controls may become inadequate because
  of changes in conditions or deterioration in the degree of compliance with
  associated policies or procedures; and</p></td>
  </tr>
  <tr>
    <td style="vertical-align: top"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="vertical-align: top"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="vertical-align: top"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
  </tr>
  <tr>
    <td style="vertical-align: top"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="vertical-align: top"><p style="margin: 0px; font-size: 10pt">&#9679;</p></td>
    <td style="vertical-align: top"><p style="margin: 0px; text-align: justify; font-size: 10pt">The design of a control system must reflect the
  fact that resources are constrained, and the benefits of controls must be
  considered relative to their costs.</p></td>
  </tr>
</tbody>
</table>

<p style="margin: 0px; text-align: justify; font-size: 10pt">&#160;</p>

<p style="margin: 0px; text-align: justify; font-size: 10pt">Because of the inherent
limitations in all control systems, no evaluation of controls can provide
absolute assurance that all control issues and instances of fraud, if any, have
been detected.</p>

<table cellpadding="0" class="adv_pagination" cellspacing="0" border="0" style="width: 100%; font-size: 10pt; margin-top: 10px">
  <tbody>
  <tr style="vertical-align: top; text-align: left">
    <td style="width: 33%"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 34%; text-align: center"><p class="pagenumber" style="margin: 0px; font-size: 10pt">18</p></td>
    <td style="width: 33%; text-align: right"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
  </tr>
</tbody>
</table>

<table border="0" cellspacing="0" cellpadding="0" style="width: 100%; page-break-after: always">
  <tbody>
  <tr>
    <td style="border-bottom: black 4px solid"><p style="margin: 0; font-size: 10pt">&#160;</p></td>
  </tr>
</tbody>
</table>

<p style="margin-top: 0pt; margin-bottom: 0pt"><span id="page_19" class="adv_highlightanchor adv_pagination"></span></p>

<p style="margin: 0; font-size: 10pt">&#160;</p>

<p style="margin: 0; font-size: 10pt"></p>

<p style="margin: 0px; text-align: center; font-size: 10pt"><b>PART II</b></p>

<p style="margin: 0px; text-align: center; font-size: 10pt"><b>OTHER INFORMATION</b></p>

<p style="margin: 0px; text-align: center; font-size: 10pt">&#160;</p>

<p style="margin: 0px; text-align: justify; font-size: 10pt"><b>ITEM 1. LEGAL PROCEEDINGS</b></p>

<p style="margin: 0px; font-size: 10pt">&#160;</p>

<p style="margin: 0px; text-align: justify; font-size: 10pt">As of September 30, 2023,
the Company is not involved in any material litigation.</p>

<p style="margin: 0px; text-align: justify; font-size: 10pt">&#160;</p>

<p style="margin: 0px; text-align: justify; font-size: 10pt"><b>ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS
SECURITIES</b></p>

<p style="margin: 0px; font-size: 10pt">&#160;</p>

<p style="margin: 0px; text-align: justify; font-size: 10pt">During the six months ended September
30, 2023, the Company issued three hundred forty-three thousand two hundred
fifty (343,250) shares of common stock with a par value of $0.001 for the
prince of one ($1) dollar per share for a total of three hundred forty-three
thousand two hundred fifty ($343,250) dollars.&#160;
Five warrants were issued for each share purchased, for a total of one
million seven hundred sixteen thousand two hundred fifty (1,716,250)
warrants.&#160; The warrants are exercisable
at twenty ($0.20) cents and expire twenty-four (24) months after the date of
the purchase agreement.</p>

<p style="margin: 0px; text-align: justify; font-size: 10pt">&#160;</p>

<p style="margin: 0px; text-align: justify; font-size: 10pt"><b>ITEM 3. DEFAULTS UPON SENIOR SECURITIES</b></p>

<p style="margin: 0px; font-size: 10pt">&#160;</p>

<p style="margin: 0px; text-align: justify; font-size: 10pt">Not applicable.</p>

<p style="margin: 0px; font-size: 10pt">&#160;</p>

<p style="margin: 0px; text-align: justify; font-size: 10pt"><b>ITEM 4. MINING SAFETY DISCLOSURES</b></p>

<p style="margin: 0px; font-size: 10pt">&#160;</p>

<p style="margin: 0px; text-align: justify; font-size: 10pt">Not applicable.</p>

<p style="margin: 0px; font-size: 10pt">&#160;</p>

<p style="margin: 0px; text-align: justify; font-size: 10pt"><b>ITEM 5. OTHER INFORMATION</b></p>

<p style="margin: 0px; font-size: 10pt">&#160;</p>

<p style="margin: 0px; text-align: justify; font-size: 10pt">There is no information with
respect to which information is not otherwise called for by this form.</p>

<p style="margin: 0px; font-size: 10pt">&#160;&#160;</p>

<p style="margin: 0px; text-align: justify; font-size: 10pt"><b>ITEM 6. EXHIBITS</b></p>

<p style="margin: 0px; font-size: 10pt">&#160;</p>

<p style="margin: 0px; text-align: justify; font-size: 10pt"><span style="text-decoration: underline">Exhibits</span></p>

<p style="margin: 0px; font-size: 10pt">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse">
  <tbody>
  <tr>
    <td style="width: 72px; vertical-align: top; background-color: #eeeeee"><p style="margin: 0px; font-size: 10pt">3.0</p></td>
    <td style="vertical-align: top; background-color: #eeeeee"><p style="margin: 0px; text-align: justify; font-size: 10pt">Articles of Incorporation.&#160; Incorporated by reference to the
  Registrant&#8217;s Form 10-12G filed on July 28, 2017.</p></td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 72px"><p style="margin: 0px">&#160;</p></td>
    <td style="vertical-align: top"><p style="margin: 0px">&#160;</p></td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 72px; background-color: #eeeeee"><p style="margin: 0px; font-size: 10pt">3.1</p></td>
    <td style="vertical-align: top; background-color: #eeeeee"><p style="margin: 0px; text-align: justify; font-size: 10pt">Amended Articles of Incorporation.&#160; Incorporated by reference to the
  Registrant&#8217;s Form 10-12G filed on July 28, 2017.</p></td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 72px"><p style="margin: 0px">&#160;</p></td>
    <td style="vertical-align: top"><p style="margin: 0px">&#160;</p></td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 72px; background-color: #eeeeee"><p style="margin: 0px; font-size: 10pt">3.2</p></td>
    <td style="vertical-align: top; background-color: #eeeeee"><p style="margin: 0px; text-align: justify; font-size: 10pt">Amended Articles of Incorporation.&#160; Incorporated by reference to the
  Registrant&#8217;s Form 10-12G filed on July 28, 2017.</p></td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 72px"><p style="margin: 0px">&#160;</p></td>
    <td style="vertical-align: top"><p style="margin: 0px">&#160;</p></td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 72px; background-color: #eeeeee"><p style="margin: 0px; font-size: 10pt">3.3</p></td>
    <td style="vertical-align: top; background-color: #eeeeee"><p style="margin: 0px; text-align: justify; font-size: 10pt">Corporate Bylaws.&#160;
  Incorporated by reference to the Registrant&#8217;s Form 10-12G filed on
  July 28, 2017.</p></td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 72px"><p style="margin: 0px">&#160;</p></td>
    <td style="vertical-align: top"><p style="margin: 0px">&#160;</p></td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 72px; background-color: #eeeeee"><p style="margin: 0px; font-size: 10pt">10.1</p></td>
    <td style="vertical-align: top; background-color: #eeeeee"><p style="margin: 0px; text-align: justify; font-size: 10pt">Advance from Shareholder of Regenerex Pharma, Inc.&#160; Incorporated by reference to the
  Registrant&#8217;s Form 10-12G filed on July 28, 2017.</p></td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 72px"><p style="margin: 0px">&#160;</p></td>
    <td style="vertical-align: top"><p style="margin: 0px">&#160;</p></td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 72px; background-color: #eeeeee"><p style="margin: 0px; font-size: 10pt"><a href="exhibit31-1.htm">31.1</a></p></td>
    <td style="vertical-align: top; background-color: #eeeeee"><p style="margin: 0px; text-align: justify; font-size: 10pt"><a href="exhibit31-1.htm">Certification of Chief Executive Officer Pursuant
  to Section 302 of the Sarbanes-Oxley Act</a></p></td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 72px"><p style="margin: 0px">&#160;</p></td>
    <td style="vertical-align: top"><p style="margin: 0px">&#160;</p></td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 72px; background-color: #eeeeee"><p style="margin: 0px; font-size: 10pt"><a href="exhibit31-2.htm">31.2</a></p></td>
    <td style="vertical-align: top; background-color: #eeeeee"><p style="margin: 0px; text-align: justify; font-size: 10pt"><a href="exhibit31-2.htm">Certification of Chief Financial Officer Pursuant
  to Section 302 of the Sarbanes-Oxley Act</a></p></td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 72px"><p style="margin: 0px">&#160;</p></td>
    <td style="vertical-align: top"><p style="margin: 0px">&#160;</p></td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 72px; background-color: #eeeeee"><p style="margin: 0px; font-size: 10pt"><a href="exhibit32-1.htm">32.1</a></p></td>
    <td style="vertical-align: top; background-color: #eeeeee"><p style="margin: 0px; text-align: justify; font-size: 10pt"><a href="exhibit32-1.htm">Certification of Chief Executive Officer Pursuant
  to Section 906 of the Sarbanes-Oxley Act</a></p></td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 72px"><p style="margin: 0px">&#160;</p></td>
    <td style="vertical-align: top"><p style="margin: 0px">&#160;</p></td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 72px; background-color: #eeeeee"><p style="margin: 0px; font-size: 10pt"><a href="exhibit32-2.htm">32.2</a></p></td>
    <td style="vertical-align: top; background-color: #eeeeee"><p style="margin: 0px; text-align: justify; font-size: 10pt"><a href="exhibit32-2.htm">Certification of Chief Financial Officer Pursuant
  to Section 906 of the Sarbanes-Oxley Act</a></p></td>
  </tr>
</tbody>
</table>

<p style="margin: 0px; font-size: 10pt">&#160;</p>

<table cellpadding="0" class="adv_pagination" cellspacing="0" border="0" style="width: 100%; font-size: 10pt; margin-top: 10px">
  <tbody>
  <tr style="vertical-align: top; text-align: left">
    <td style="width: 33%"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 34%; text-align: center"><p class="pagenumber" style="margin: 0px; font-size: 10pt">19</p></td>
    <td style="width: 33%; text-align: right"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
  </tr>
</tbody>
</table>

<table border="0" cellspacing="0" cellpadding="0" style="width: 100%; page-break-after: always">
  <tbody>
  <tr>
    <td style="border-bottom: black 4px solid"><p style="margin: 0; font-size: 10pt">&#160;</p></td>
  </tr>
</tbody>
</table>

<p style="margin-top: 0pt; margin-bottom: 0pt"><span id="page_20" class="adv_highlightanchor adv_pagination"></span></p>

<p style="margin: 0; font-size: 10pt">&#160;</p>

<p style="margin: 0; font-size: 10pt"></p>

<p style="margin: 0px; text-align: center; font-size: 10pt"><b>SIGNATURES</b></p>

<p style="margin: 0px; font-size: 10pt">&#160;</p>

<p style="margin: 0px; text-align: justify; font-size: 10pt">Pursuant to the requirements
of Section 13 or 15(d) of the Securities Exchange Act of 1934 the registrant
has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized.</p>

<p style="margin: 0px; text-align: justify; font-size: 10pt">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse">
  <tbody>
  <tr>
    <td style="vertical-align: top; width: 50%"><p style="margin: 0px; font-size: 10pt">Registrant</p></td>
    <td colspan="2" style="vertical-align: top"><p style="margin: 0px; font-size: 10pt"><i>Regenerex
  Pharma, Inc.</i></p></td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 50%"><p style="margin: 0px">&#160;</p></td>
    <td colspan="2" style="vertical-align: top"><p style="margin: 0px">&#160;</p></td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 50%"><p style="margin: 0px; font-size: 10pt">Date:
  November 08, 2023</p></td>
    <td style="vertical-align: top; width: 48px"><p style="margin: 0px; font-size: 10pt"><i>By:
  </i></p></td>
    <td style="border-bottom: black 1.5pt solid; vertical-align: top"><p style="margin: 0px; font-size: 10pt"><i>/s/
  Gregory Pilant</i></p></td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 50%"><p style="margin: 0px">&#160;</p></td>
    <td colspan="2" style="vertical-align: top"><p style="margin: 0px; font-size: 10pt">Gregory
  Pilant</p></td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 50%"><p style="margin: 0px">&#160;</p></td>
    <td colspan="2" style="vertical-align: top"><p style="margin: 0px; font-size: 10pt">Chief
  Executive Officer</p></td>
  </tr>
</tbody>
</table>

<p style="margin: 0px; text-align: right; font-size: 10pt"><b>&#160;</b><span style="font-size: 10pt">&#160;</span></p>

<hr style="border-top: black 0 dashed; border-bottom: black 0 solid; border-right-width: 0; border-left-width: 0; border-top-width: 1px; border-bottom-width: 4px; background-color: transparent; height: 3px; margin-top: 20px" />

</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>exhibit31-1.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<html>
<head>
   <title>Filed by Avantafile.com - Regenerex Pharma, Inc. - Exhibit 31.1</title>
</head>

<body>

<hr style="border: 0; border-top: 4px solid black; border-bottom: 1px dashed black; background-color: transparent; height: 3px; margin-bottom: 20px;">

<p style="margin: 0px; text-align: right; font-size: 10pt;"><b>Exhibit 31.1</b></p>

<p style="margin: 0px; text-align: right; font-size: 10pt;"><b>&nbsp;</b></p>

<p style="margin: 0px; text-align: center; font-size: 10pt;"><b>Certification pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 302 of the Sarbanes-Oxley Act<br>of 2002 and pursuant to Rule 13a-14(a) and Rule 15d-14 under the Securities Exchange Act of 1934 for<br>the period ending September 30, 2023</b></p>

<p style="margin: 0px; font-size: 10pt;">I, Gregory Pilant, certify that:</p>

<p style="margin: 0px; font-size: 10pt;">&nbsp;</p>

<table border="0" cellspacing="0" cellpadding="0" style="width:100.0%;border-collapse:collapse;">
  <tr>
    <td style="vertical-align: top; width: 48px;"><p style="text-align: justify; margin: 0px; font-size: 10pt;">1.</p></td>
    <td style="vertical-align: top;"><p style="text-align: justify; margin: 0px; font-size: 10pt;">I have reviewed this Quarterly Report on Form 10-Q of Regenerex Pharma, Inc.;</p></td>
  </tr>
  <tr>
    <td style="vertical-align: top;"><p style="margin: 0px;">&nbsp;</p></td>
    <td style="vertical-align: top;"><p style="margin: 0px;">&nbsp;</p></td>
  </tr>
  <tr>
    <td style="vertical-align: top;"><p style="text-align: justify; margin: 0px; font-size: 10pt;">2.</p></td>
    <td style="vertical-align: top;"><p style="text-align: justify; margin: 0px; font-size: 10pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p></td>
  </tr>
  <tr>
    <td style="vertical-align: top;"><p style="margin: 0px;">&nbsp;</p></td>
    <td style="vertical-align: top;"><p style="margin: 0px;">&nbsp;</p></td>
  </tr>
  <tr>
    <td style="vertical-align: top;"><p style="text-align: justify; margin: 0px; font-size: 10pt;">3.</p></td>
    <td style="vertical-align: top;"><p style="text-align: justify; margin: 0px; font-size: 10pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p></td>
  </tr>
  <tr>
    <td style="vertical-align: top;"><p style="margin: 0px;">&nbsp;</p></td>
    <td style="vertical-align: top;"><p style="margin: 0px;">&nbsp;</p></td>
  </tr>
  <tr>
    <td style="vertical-align: top;"><p style="text-align: justify; margin: 0px; font-size: 10pt;">4.</p></td>
    <td style="vertical-align: top;"><p style="text-align: justify; margin: 0px; font-size: 10pt;">The registrant&rsquo;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</p></td>
  </tr>
</table>

<p style="margin: 0px; text-align: justify; text-indent: -28.8px; font-size: 10pt;">&nbsp;</p>

<table border="0" cellspacing="0" cellpadding="0" style="width:100.0%;border-collapse:collapse;">
  <tr>
    <td style="vertical-align: top; width: 48px;"><p style="margin: 0px;">&nbsp;</p></td>
    <td style="vertical-align: top; width: 48px;"><p style="text-align: justify; margin: 0px; font-size: 10pt;">a.</p></td>
    <td style="vertical-align: top;"><p style="text-align: justify; margin: 0px; font-size: 10pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p></td>
  </tr>
  <tr>
    <td style="vertical-align: top;"><p style="margin: 0px;">&nbsp;</p></td>
    <td style="vertical-align: top;"><p style="margin: 0px;">&nbsp;</p></td>
    <td style="vertical-align: top;"><p style="margin: 0px;">&nbsp;</p></td>
  </tr>
  <tr>
    <td style="vertical-align: top;"><p style="margin: 0px;">&nbsp;</p></td>
    <td style="vertical-align: top;"><p style="text-align: justify; margin: 0px; font-size: 10pt;">b.</p></td>
    <td style="vertical-align: top;"><p style="text-align: justify; margin: 0px; font-size: 10pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p></td>
  </tr>
  <tr>
    <td style="vertical-align: top;"><p style="margin: 0px;">&nbsp;</p></td>
    <td style="vertical-align: top;"><p style="margin: 0px;">&nbsp;</p></td>
    <td style="vertical-align: top;"><p style="margin: 0px;">&nbsp;</p></td>
  </tr>
  <tr>
    <td style="vertical-align: top;"><p style="margin: 0px;">&nbsp;</p></td>
    <td style="vertical-align: top;"><p style="text-align: justify; margin: 0px; font-size: 10pt;">c.</p></td>
    <td style="vertical-align: top;"><p style="text-align: justify; margin: 0px; font-size: 10pt;">Evaluated the effectiveness of the registrant&rsquo;s disclosure and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluations: and</p></td>
  </tr>
  <tr>
    <td style="vertical-align: top;"><p style="margin: 0px;">&nbsp;</p></td>
    <td style="vertical-align: top;"><p style="margin: 0px;">&nbsp;</p></td>
    <td style="vertical-align: top;"><p style="margin: 0px;">&nbsp;</p></td>
  </tr>
  <tr>
    <td style="vertical-align: top;"><p style="margin: 0px;">&nbsp;</p></td>
    <td style="vertical-align: top;"><p style="text-align: justify; margin: 0px; font-size: 10pt;">d.</p></td>
    <td style="vertical-align: top;"><p style="text-align: justify; margin: 0px; font-size: 10pt;">Disclosed in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting; and</p></td>
  </tr>
</table>

<p style="margin: 0px; text-align: justify; text-indent: -28.8px; font-size: 10pt;">&nbsp;</p>

<table border="0" cellspacing="0" cellpadding="0" style="width:100.0%;border-collapse:collapse;">
  <tr>
    <td style="vertical-align: top; width: 48px;"><p style="text-align: justify; margin: 0px; font-size: 10pt;">5.</p></td>
    <td style="vertical-align: top;"><p style="text-align: justify; margin: 0px; font-size: 10pt;">The registrant&rsquo;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors (or persons performing the equivalent functions):</p></td>
  </tr>
</table>

<p style="margin: 0px; text-align: justify; text-indent: -28.8px; font-size: 10pt;">&nbsp;</p>

<table border="0" cellspacing="0" cellpadding="0" style="width:100.0%;border-collapse:collapse;">
  <tr>
    <td style="vertical-align: top; width: 48px;"><p style="margin: 0px;">&nbsp;</p></td>
    <td style="vertical-align: top; width: 48px;"><p style="text-align: justify; margin: 0px; font-size: 10pt;">a.</p></td>
    <td style="vertical-align: top;"><p style="text-align: justify; margin: 0px; font-size: 10pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information; and</p></td>
  </tr>
  <tr>
    <td style="vertical-align: top;"><p style="margin: 0px;">&nbsp;</p></td>
    <td style="vertical-align: top;"><p style="margin: 0px;">&nbsp;</p></td>
    <td style="vertical-align: top;"><p style="margin: 0px;">&nbsp;</p></td>
  </tr>
  <tr>
    <td style="vertical-align: top;"><p style="margin: 0px;">&nbsp;</p></td>
    <td style="vertical-align: top;"><p style="text-align: justify; margin: 0px; font-size: 10pt;">b.</p></td>
    <td style="vertical-align: top;"><p style="text-align: justify; margin: 0px; font-size: 10pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s internal control over financial reporting.</p></td>
  </tr>
</table>

<p style="margin: 0px; text-align: justify; font-size: 10pt;">&nbsp;</p>

<table border="0" cellspacing="0" cellpadding="0" style="width:100.0%;border-collapse:collapse;">
  <tr>
    <td style="vertical-align: top; width: 50%;"><p style="text-align: justify; margin: 0px; font-size: 10pt;">Registrant</p></td>
    <td style="vertical-align: top;" colspan="2"><p style="margin: 0px; font-size: 10pt;"><i>Regenerex Pharma, Inc.</i></p></td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 50%;"><p style="margin: 0px;">&nbsp;</p></td>
    <td style="vertical-align: top;" colspan="2"><p style="margin: 0px;">&nbsp;</p></td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 50%;"><p style="text-align: justify; margin: 0px; font-size: 10pt;">Date: November 08, 2023</p></td>
    <td style="vertical-align: top; width: 48px;"><p style="text-align: justify; margin: 0px; font-size: 10pt;"><i>By:</i></p></td>
    <td style="border-bottom: 1.5pt solid black; vertical-align: top;"><p style="margin: 0px; font-size: 10pt;"><i>/s/ Gregory Pilant</i></p></td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 50%;"><p style="margin: 0px;">&nbsp;</p></td>
    <td style="vertical-align: top;" colspan="2"><p style="margin: 0px; font-size: 10pt;">Gregory Pilant</p></td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 50%;"><p style="margin: 0px;">&nbsp;</p></td>
    <td style="vertical-align: top;" colspan="2"><p style="margin: 0px; font-size: 10pt;">Chief Executive Officer (Principal Executive Officer)</p></td>
  </tr>
</table>

<p style="text-align: justify; margin: 0px; font-size: 10pt;">&nbsp;</p>

<hr style="border: 0; border-top: 1px dashed black; border-bottom: 4px solid black; background-color: transparent; height: 3px; margin-top: 20px;">

</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>exhibit31-2.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<html>
<head>
   <title>Filed by Avantafile.com - Regenerex Pharma, Inc. - Exhibit 31.2</title>
</head>

<body>

<hr style="border: 0; border-top: 4px solid black; border-bottom: 1px dashed black; background-color: transparent; height: 3px; margin-bottom: 20px;">

<p style="margin: 0px; text-align: right; font-size: 10pt;"><b style="font-size: 10pt;">Exhibit 31.2</b></p>

<p style="margin: 0px; text-align: right; font-size: 10pt;"><b>&nbsp;</b></p>

<p style="margin: 0px; text-align: center; font-size: 10pt;"><b>Certification pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 302 of the Sarbanes-Oxley Act<br>of 2002 and pursuant to Rule 13a-14(a) and Rule 15d-14 under the Securities Exchange Act of 1934 for<br>the period ending September 30, 2023</b><font style="font-size: 10pt;">&nbsp;</font></p>

<p style="margin: 0px; font-size: 10pt;">I, Deborah Pilant, certify that:&nbsp;</p>

<p style="margin: 0px; font-size: 10pt;">&nbsp;</p>

<table border="0" cellspacing="0" cellpadding="0" style="width:100.0%;border-collapse:collapse;">
  <tr>
    <td style="vertical-align: top; width: 48px;"><p style="margin: 0px; font-size: 10pt;">1.</p></td>
    <td style="vertical-align: top;"><p style="margin: 0px; font-size: 10pt;">I have reviewed this Quarterly Report on Form 10-Q of Regenerex Pharma, Inc.;</p></td>
  </tr>
  <tr>
    <td style="vertical-align: top;"><p style="margin: 0px;">&nbsp;</p></td>
    <td style="vertical-align: top;"><p style="margin: 0px;">&nbsp;</p></td>
  </tr>
  <tr>
    <td style="vertical-align: top;"><p style="text-align: justify; margin: 0px; font-size: 10pt;">2.</p></td>
    <td style="vertical-align: top;"><p style="text-align: justify; margin: 0px; font-size: 10pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p></td>
  </tr>
  <tr>
    <td style="vertical-align: top;"><p style="margin: 0px;">&nbsp;</p></td>
    <td style="vertical-align: top;"><p style="margin: 0px;">&nbsp;</p></td>
  </tr>
  <tr>
    <td style="vertical-align: top;"><p style="text-align: justify; margin: 0px; font-size: 10pt;">3.</p></td>
    <td style="vertical-align: top;"><p style="text-align: justify; margin: 0px; font-size: 10pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p></td>
  </tr>
  <tr>
    <td style="vertical-align: top;"><p style="margin: 0px;">&nbsp;</p></td>
    <td style="vertical-align: top;"><p style="margin: 0px;">&nbsp;</p></td>
  </tr>
  <tr>
    <td style="vertical-align: top;"><p style="text-align: justify; margin: 0px; font-size: 10pt;">4.</p></td>
    <td style="vertical-align: top;"><p style="text-align: justify; margin: 0px; font-size: 10pt;">The registrant&rsquo;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</p></td>
  </tr>
</table>

<p style="margin: 0px; text-align: justify; font-size: 10pt;">&nbsp;</p>

<table border="0" cellspacing="0" cellpadding="0" style="width:100.0%;border-collapse:collapse;">
  <tr>
    <td style="vertical-align: top; width: 48px;"><p style="margin: 0px;">&nbsp;</p></td>
    <td style="vertical-align: top; width: 48px;"><p style="text-align: justify; margin: 0px; font-size: 10pt;">a.</p></td>
    <td style="vertical-align: top;"><p style="margin: 0px; font-size: 10pt; text-align: justify;"><font style="font-size: 10pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></p></td>
  </tr>
  <tr>
    <td style="vertical-align: top;"><p style="margin: 0px;">&nbsp;</p></td>
    <td style="vertical-align: top;"><p style="margin: 0px;">&nbsp;</p></td>
    <td style="vertical-align: top;"><p style="margin: 0px;">&nbsp;</p></td>
  </tr>
  <tr>
    <td style="vertical-align: top;"><p style="margin: 0px;">&nbsp;</p></td>
    <td style="vertical-align: top;"><p style="text-align: justify; margin: 0px; font-size: 10pt;">b.</p></td>
    <td style="vertical-align: top;"><p style="margin: 0px; font-size: 10pt; text-align: justify;"><font style="font-size: 10pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></p></td>
  </tr>
  <tr>
    <td style="vertical-align: top;"><p style="margin: 0px;">&nbsp;</p></td>
    <td style="vertical-align: top;"><p style="margin: 0px;">&nbsp;</p></td>
    <td style="vertical-align: top;"><p style="margin: 0px;">&nbsp;</p></td>
  </tr>
  <tr>
    <td style="vertical-align: top;"><p style="margin: 0px;">&nbsp;</p></td>
    <td style="vertical-align: top;"><p style="text-align: justify; margin: 0px; font-size: 10pt;">c.</p></td>
    <td style="vertical-align: top;"><p style="text-align: justify; margin: 0px; font-size: 10pt;">Evaluated the effectiveness of the registrant&rsquo;s disclosure and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluations: and</p></td>
  </tr>
  <tr>
    <td style="vertical-align: top;"><p style="margin: 0px;">&nbsp;</p></td>
    <td style="vertical-align: top;"><p style="margin: 0px;">&nbsp;</p></td>
    <td style="vertical-align: top;"><p style="margin: 0px;">&nbsp;</p></td>
  </tr>
  <tr>
    <td style="vertical-align: top;"><p style="margin: 0px;">&nbsp;</p></td>
    <td style="vertical-align: top;"><p style="text-align: justify; margin: 0px; font-size: 10pt;">d.</p></td>
    <td style="vertical-align: top;"><p style="margin: 0px; font-size: 10pt; text-align: justify;"><font style="font-size: 10pt;">Disclosed in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting; and</font></p></td>
  </tr>
</table>

<p style="margin: 0px; text-align: justify; font-size: 10pt;">&nbsp;</p>

<table border="0" cellspacing="0" cellpadding="0" style="width:100.0%;border-collapse:collapse;">
  <tr>
    <td style="vertical-align: top; width: 48px;"><p style="text-align: justify; margin: 0px; font-size: 10pt;">5.</p></td>
    <td style="vertical-align: top;"><p style="margin: 0px; font-size: 10pt; text-align: justify;"><font style="font-size: 10pt;">The registrant&rsquo;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors (or persons performing the equivalent functions):</font></p></td>
  </tr>
</table>

<p style="margin: 0px; text-align: justify; font-size: 10pt;">&nbsp;</p>

<table border="0" cellspacing="0" cellpadding="0" style="width:100.0%;border-collapse:collapse;">
  <tr>
    <td style="padding: 0cm 3.6pt 0cm 0cm; vertical-align: top; width: 48px;"><p style="margin: 0px;">&nbsp;</p></td>
    <td style="padding: 0cm 3.6pt 0cm 0cm; vertical-align: top; width: 48px;"><p style="text-align: justify; margin: 0px; font-size: 10pt;">a.</p></td>
    <td style="vertical-align: top;"><p style="margin: 0px; font-size: 10pt; text-align: justify;"><font style="font-size: 10pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information; and</font></p></td>
  </tr>
  <tr>
    <td style="padding: 0cm 3.6pt 0cm 0cm; vertical-align: top; width: 48px;"><p style="margin: 0px;">&nbsp;</p></td>
    <td style="padding: 0cm 3.6pt 0cm 0cm; vertical-align: top; width: 48px;"><p style="margin: 0px;">&nbsp;</p></td>
    <td style="padding: 0cm 3.6pt 0cm 0cm; vertical-align: top;"><p style="margin: 0px;">&nbsp;</p></td>
  </tr>
  <tr>
    <td style="padding: 0cm 3.6pt 0cm 0cm; vertical-align: top; width: 48px;"><p style="margin: 0px;">&nbsp;</p></td>
    <td style="padding: 0cm 3.6pt 0cm 0cm; vertical-align: top; width: 48px;"><p style="text-align: justify; margin: 0px; font-size: 10pt;">b.</p></td>
    <td style="vertical-align: top;"><p style="margin: 0px; font-size: 10pt; text-align: justify;"><font style="font-size: 10pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s internal control over financial reporting.</font></p></td>
  </tr>
</table>

<p style="margin: 0px; font-size: 10pt;">&nbsp;</p>

<table border="0" cellspacing="0" cellpadding="0" style="width:100.0%;border-collapse:collapse;">
  <tr>
    <td style="padding: 0cm 3.6pt 0cm 0cm; vertical-align: top; width: 50%;"><p style="text-align: justify; margin: 0px; font-size: 10pt;">Registrant</p></td>
    <td style="padding: 0cm 3.6pt 0cm 0cm; vertical-align: top;" colspan="2"><p style="margin: 0px; font-size: 10pt;"><i>Regenerex Pharma, Inc.</i></p></td>
  </tr>
  <tr>
    <td style="padding: 0cm 3.6pt 0cm 0cm; vertical-align: top; width: 50%;"><p style="margin: 0px;">&nbsp;</p></td>
    <td style="padding: 0cm 3.6pt 0cm 0cm; vertical-align: top;" colspan="2"><p style="margin: 0px;">&nbsp;</p></td>
  </tr>
  <tr>
    <td style="padding: 0cm 3.6pt 1.5pt 0cm; vertical-align: top; width: 50%;"><p style="text-align: justify; margin: 0px; font-size: 10pt;">Date: November 08, 2023</p></td>
    <td style="padding: 0cm 3.6pt 1.5pt 0cm; vertical-align: top; width: 48px;"><p style="text-align: justify; margin: 0px; font-size: 10pt;"><i>By:</i></p></td>
    <td style="border-bottom: 1.5pt solid black; vertical-align: top;"><p style="margin: 0px; font-size: 10pt;"><i>/s/ Deborah Pilant</i></p></td>
  </tr>
  <tr>
    <td style="padding: 0cm 3.6pt 0cm 0cm; vertical-align: top; width: 50%;"><p style="margin: 0px;">&nbsp;</p></td>
    <td style="vertical-align: top;" colspan="2"><p style="margin: 0px; font-size: 10pt;">Deborah Pilant</p></td>
  </tr>
  <tr>
    <td style="padding: 0cm 3.6pt 0cm 0cm; vertical-align: top; width: 50%;"><p style="margin: 0px;">&nbsp;</p></td>
    <td style="padding: 0cm 3.6pt 0cm 0cm; vertical-align: top;" colspan="2"><p style="margin: 0px; font-size: 10pt;">Chief Financial Officer (Principal Financial Officer)</p></td>
  </tr>
</table>

<p style="margin: 0px; text-align: justify; text-indent: 26.6667px; font-size: 10pt;">&nbsp;</p>

<hr style="border: 0; border-top: 1px dashed black; border-bottom: 4px solid black; background-color: transparent; height: 3px; margin-top: 20px;">

</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>exhibit32-1.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<html>
<head>
   <title>Filed by Avantafile.com - Regenerex Pharma, Inc. - Exhibit 32.1</title>
</head>

<body>

<hr style="border: 0; border-top: 4px solid black; border-bottom: 1px dashed black; background-color: transparent; height: 3px; margin-bottom: 20px;">

<p style="margin: 0px; text-align: right; font-size: 10pt;"><b>Exhibit 32.1</b></p>

<p style="margin: 0px; text-align: right; font-size: 10pt;"><b>&nbsp;</b></p>

<p style="margin: 0px; text-align: center; font-size: 10pt;"><b>CERTIFICATIONS PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</b></p>

<p style="margin: 0px; text-align: center; font-size: 10pt;"><b>(18 U.S.C. SECTION 1350)</b></p>

<p style="margin: 0px; text-align: justify; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0px; text-align: justify; font-size: 10pt;">In connection with the Quarterly Report of Regenerex Pharma, Inc. (the &lsquo;Company&rsquo;) on Form 10-Q for the period ending September 30, 2023, as filed with the Securities and Exchange Commission on the date hereof (the &lsquo;Report&rsquo;), I, Gregory Pilant, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. &sect; 1350, as adopted pursuant to &sect; 906 of the Sarbanes-Oxley Act of 2002, that:</p>

<p style="margin: 0px; text-align: justify; font-size: 10pt;">&nbsp;</p>

<table border="0" cellspacing="0" cellpadding="0" style="width:100.0%;border-collapse:collapse;">
  <tr>
    <td style="vertical-align: top; width: 48px;"><p style="text-align: justify; margin: 0px; font-size: 10pt;">(1)</p></td>
    <td style="vertical-align: top;"><p style="text-align: justify; margin: 0px; font-size: 10pt;">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and</p></td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 48px;"><p style="margin: 0px;">&nbsp;</p></td>
    <td style="vertical-align: top;"><p style="margin: 0px;">&nbsp;</p></td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 48px;"><p style="text-align: justify; margin: 0px; font-size: 10pt;">(2)</p></td>
    <td style="vertical-align: top;"><p style="text-align: justify; margin: 0px; font-size: 10pt;">The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.</p></td>
  </tr>
</table>

<p style="margin: 0px; text-align: justify; font-size: 10pt;">&nbsp;</p>

<table border="0" cellspacing="0" cellpadding="0" style="width:100.0%;border-collapse:collapse;">
  <tr>
    <td style="vertical-align: top; width: 50%;"><p style="text-align: justify; margin: 0px; font-size: 10pt;">Registrant</p></td>
    <td style="vertical-align: top;" colspan="2"><p style="margin: 0px; font-size: 10pt;"><i>Regenerex Pharma, Inc.</i></p></td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 50%;"><p style="margin: 0px;">&nbsp;</p></td>
    <td style="vertical-align: top;" colspan="2"><p style="margin: 0px;">&nbsp;</p></td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 50%;"><p style="text-align: justify; margin: 0px; font-size: 10pt;">Date: November 08, 2023</p></td>
    <td style="vertical-align: top; width: 48px;"><p style="text-align: justify; margin: 0px; font-size: 10pt;"><i>By:</i></p></td>
    <td style="border-bottom: 1.5pt solid black; vertical-align: top;"><p style="margin: 0px; font-size: 10pt;"><i>/s/ Gregory Pilant</i></p></td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 50%;"><p style="margin: 0px;">&nbsp;</p></td>
    <td style="vertical-align: top;" colspan="2"><p style="margin: 0px; font-size: 10pt;">Gregory Pilant</p></td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 50%;"><p style="margin: 0px;">&nbsp;</p></td>
    <td style="vertical-align: top;" colspan="2"><p style="margin: 0px; font-size: 10pt;">Chief Executive Officer (Principal Executive Officer)</p></td>
  </tr>
</table>

<p style="margin: 0px; font-size: 10pt;">&nbsp;</p>

<hr style="border: 0; border-top: 1px dashed black; border-bottom: 4px solid black; background-color: transparent; height: 3px; margin-top: 20px;">

</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>5
<FILENAME>exhibit32-2.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<html>
<head>
   <title>Filed by Avantafile.com - Regenerex Pharma, Inc. - Exhibit 32.2</title>
</head>

<body>

<hr style="border: 0; border-top: 4px solid black; border-bottom: 1px dashed black; background-color: transparent; height: 3px; margin-bottom: 20px;">

<p style="margin: 0px; text-align: right; font-size: 10pt;"><b>Exhibit 32.2</b></p>

<p style="margin: 0px; text-align: right; font-size: 10pt;"><b>&nbsp;</b></p>

<p style="margin: 0px; text-align: center; font-size: 10pt;"><b>CERTIFICATIONS PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</b></p>

<p style="margin: 0px; text-align: center; font-size: 10pt;"><b>(18 U.S.C. SECTION 1350)</b></p>

<p style="margin: 0px; text-align: justify; font-size: 10pt;"><b>&nbsp;</b></p>

<p style="margin: 0px; text-align: justify; font-size: 10pt;">In connection with the Quarterly Report of Regenerex Pharma, Inc. (the &lsquo;Company&rsquo;) on Form 10-Q for the period ending September 30, 2023, as filed with the Securities and Exchange Commission on the date hereof (the &lsquo;Report&rsquo;), I, Deborah Pilant, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. &sect; 1350, as adopted pursuant to &sect; 906 of the Sarbanes-Oxley Act of 2002, that:</p>

<p style="margin: 0px; text-align: justify; text-indent: 26.6667px; font-size: 10pt;">&nbsp;</p>

<table border="0" cellspacing="0" cellpadding="0" style="width:100.0%;border-collapse:collapse;">
  <tr>
    <td style="vertical-align: top; width: 48px;"><p style="text-align: justify; margin: 0px; font-size: 10pt;">(1)</p></td>
    <td style="vertical-align: top;"><p style="text-align: justify; margin: 0px; font-size: 10pt;">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and</p></td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 48px;"><p style="margin: 0px;">&nbsp;</p></td>
    <td style="vertical-align: top;"><p style="margin: 0px;">&nbsp;</p></td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 48px;"><p style="text-align: justify; margin: 0px; font-size: 10pt;">(2)</p></td>
    <td style="vertical-align: top;"><p style="text-align: justify; margin: 0px; font-size: 10pt;">The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.</p></td>
  </tr>
</table>

<p style="margin: 0px; font-size: 10pt;">&nbsp;</p>

<table border="0" cellspacing="0" cellpadding="0" style="width:100.0%;border-collapse:collapse;">
  <tr>
    <td style="vertical-align: top; width: 50%;"><p style="margin: 0px; font-size: 10pt;">Registrant</p></td>
    <td style="vertical-align: top;" colspan="2"><p style="margin: 0px; font-size: 10pt;"><i>Regenerex Pharma, Inc.</i></p></td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 50%;"><p style="margin: 0px;">&nbsp;</p></td>
    <td style="vertical-align: top;" colspan="2"><p style="margin: 0px;">&nbsp;</p></td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 50%;"><p style="margin: 0px; font-size: 10pt;">Date: November 08, 2023</p></td>
    <td style="vertical-align: top; width: 48px;"><p style="margin: 0px; font-size: 10pt;"><i>By:</i></p></td>
    <td style="border-bottom: 1.5pt solid black; vertical-align: top;"><p style="margin: 0px; font-size: 10pt;"><i>/s/ Deborah Pilant</i></p></td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 50%;"><p style="margin: 0px;">&nbsp;</p></td>
    <td style="vertical-align: top;" colspan="2"><p style="margin: 0px; font-size: 10pt;">Deborah Pilant</p></td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 50%;"><p style="margin: 0px;">&nbsp;</p></td>
    <td style="vertical-align: top;" colspan="2"><p style="margin: 0px; font-size: 10pt;">Chief Financial Officer (Principal Financial Officer)</p></td>
  </tr>
</table>

<p style="text-align: justify; margin: 0px; font-size: 10pt;">&nbsp;</p>

<p style="text-align: justify; margin: 0px; font-size: 10pt;"><b></b><b></b><b></b><b></b><b></b><b></b></p>

<hr style="border: 0; border-top: 1px dashed black; border-bottom: 4px solid black; background-color: transparent; height: 3px; margin-top: 20px;">

</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>regenerexlogo.gif
<TEXT>
begin 644 regenerexlogo.gif
M1TE&.#EA2 $^ /<   !KE !KG !SG !SI0!SK0![I0![K0![M0"$K0"$M0"$
MO0AKE AKG ASE ASG ASI0A[I1!SE!!SG!!SI1![G!![I1ASE!ASG!A[G!A[
MI1B$I1B$K2%SE"%SG"%[E"%[G"%[I2&$I2&$K2ESE"E[E"E[G"E[I2F$G"F$
MI2F$K2F,K3%[E#%[G#&$G#&$I3&,K3&,M3E[G#F$G#F$I3F,I3F,K3F,M3F4
MM4)[E$*$G$*$I4*,I4*,K4*4M4*<O4J$G$J$I4J,G$J,I4J,K4J4K4J4M4J4
MO4J<O5*$G%*,G%*,I5*,K5*4I5*4K5*<M5*<O5*EO5J,G%J,I5J4I5J4K5J<
MK5J<M5JEO5JEQF.,I6.4I6.4K6.<K6.<M6.EO6.EQF.MQFN4G&N4I6N4K6N<
MK6NEM6NMQFNMSFNUSG.4I7.<I7.<K7.<M7.EM7.EO7.MO7.MSG.USGN<I7N<
MK7NEK7NEM7NMM7NMO7NMQGNUSGN]SH2<K82EK82EM82MM82MO82MQH2UQH2]
MSH2]UHREK8REM8RMM8RMO8RUO8RUQHR]UHS&UI2EM92MK92MM92MO92UO92U
MQI2]QI3&UIRMM9RMO9RUM9RUO9RUQIR]QIR]SIS&SIS&WIS.WJ6UM:6UO:6U
MQJ6]O:6]QJ6]SJ7&SJ7.WJVUO:V]O:V]QJV]SJW&SJW&UJW.UJW.WJW6WJW6
MY[6]QK7&QK7&SK7.SK7.UK76Y[W&QKW&SKW.SKW.UKW6UKW6WKW6Y[W>Y\;&
MSL;.SL;.UL;6UL;6WL;>[\;G[\[.SL[.UL[6UL[6WL[>WL[>Y\[G[];6UM;6
MWM;>WM;>Y];GY];G[];G]];O[];O]][>WM[>Y][GY][G[][O]^?GY^?G[^?O
M[^?O]^?W]^_O[^_O]^_W]^_W__?W]_?W__?_________________________
M____________________________________________________________
M_____________________RP     2 $^   (_@#-"1Q(L*#!@P@3*ES(L*'#
MAQ C2IQ(L:+%BQ@S:MS(L:/'CR!#BAQ)LN$X;<U^?2(D1TP."1>0B-GCZ-2O
M:M]*ZMS)LZ?/GQN_'4,U1PD+# X@0'@@0,"#I1(PR)!"*):SG$"S:MW*M:M%
M;;_X_$ Z0," LV6;HCUKUL$'*8Z.8?5*MZ[=NR2__9K#PL':IH #"T8K0$*.
M0L?&X5W,N+'CA..<$6KA-ZW@RYC-EG7PX].UQZ!#B];Z+9:2RIE3ISZ+08PQ
MQ:-CRYZM49NC$F95!W;@0#?@LCE@P:9-O+CQ@];F8&"KN\*+(UBN]$C16_?9
M$I?F'M_.770U-1(L_J=^\"(.KV[APDTKY46$;[,?'&GO3K\^76UK_.IV(.)+
M+7(&=</)$1GX-@ &C\QGWX(,[O3-'.'IEL$3I80C4#G9#+-,-P-AHX@-%5CW
M@2C#-6CBB1Z-4\ERJE5P@R+9#-1-*U_8T$,>O5AH3CG#P/%"=9D-P (N*!9I
M)$:XE"">8 ZH$(<RY0@43B]FA"#!"R^0)\@R )I#3BU7N+=:$LX<:>:9#6FC
M1&Z"!2! "/YU.<XR@OP8P O#]!)"  X4P4DT,@Y8H)N#"<"'@F@F:N8XANAW
M609'<,*AE]%PTH,# 63:@X8I9!I !5>X$J- T2AR0XB7#? !D8JV>B8N_A\L
M&4 &7[0R*8^"]%!!IH Y8,,+ KCI*:231!-E.94^@6I@ _SPF:O0GCB.&&PV
M%4 (@@!*ZB1'[$KH>PZD4*N.Y2ACQJ[,.G!)M.PR"$RL@CT@B([=E')%",$V
MU<,7(E0 A1D !RPPP'!,,BJI5P"IU@_:M.LP=^/,X:BU/8PZC!G4$1H !*5@
M<\4+O7C3S<@DE]Q--MGH.% OG3(K@2PFC?/-S..4^#!D,M-L\SBW./))F?35
M;#-)VLAPF0.3"(3-$YC&.TDO3ZC0RC)45VWUU<LHP^6.5^3[VQJ(#C1.+(3P
M,8<<<O!!R2UAWVP.,HX0LL<<<_#A2"P-"Z0-_AD8K !*T"LY\JQ.MU0@WJ?#
M"#1)TY>EH*L -CPA^>245_[$$4\L(Y B$GQK%@O/*/2-$A%(8#I,'^3 1S5N
M'P1)Z:=+\($,:ARC]Q0)2/ (?=S\( $*M_"TQP.':P!H.6;P>IGGO#7O_//.
MMR)0*1EX/H #M(A.0P$"3"5%#A<,0 $=;3M\1P&J1A'%#[$ZH 7KVN > 22\
MLV! !;;L-$X0RQN_(QB"2<''!/ "+( !#%](H (7R, %)LX<U/.<60PQM(%\
M8WL.P$0UG+$7#!B  \%H74'.)P N.(,9ORA$"0R@.W/$+P'SXUT,#)"!_.ED
M&TIJD__* <# Y*%4_A. $<J&2,0B&C$;78J@8 J@A;9=L  -V,5 M"&$LF2"
M(..HQBUB\8O!$40HL8A%,V36C&9H9QS7^$4L;E&-$FF#&=:H&3-L88LQ'@0L
ML; %,]QXC#:.XQBVR)LY(K/%7PCR&\Q@1ALMR(QC7,4@?^">&RQ8A[-8P87R
MHY\SZ&C'+SKC%K#@HB '68UC-$POOZA9-9C1L&W\PA:_P,HXYLA&@P@%E+:0
MRT.X$8,"U% @WVC&([7A"RXB"HUJ%&5#C)$!6>VPAX QPS $,8%L1>.:V,RF
M-K>I(R4R*P=>+,@3&Y +@E3!+%?4&R6RD(,<_$ ,PB%(,_B0!!GD0 JH_JA$
M%J* # N>0@P_:&<6/B'+1R!A#BI10CNCD!TLVD(- ;VGX 8B"B2HX1>H4 (.
M5"&0:CCB>^Y,@RT4XPPU*"$+P1,(*J* !$*,4B"1%, D!T(* !B ""?!G03X
M@ J01H&@ [$&'[XG QG\0 Z_F"(?D%"(:O A!U.HQC;D$(6XS.$'1EW=-RB1
MA'9J(18$ 491<F!/)1 ": SAI2]M^ LI: $6MW")4>? C()<XQ, +>H/^%#!
M@IS"<#H\WA>4]Z8CI$  *7C"%1;+V,8Z]K$/].9O1@"-A(Q3BAW=G@7*Z<(Y
M=$ "+,C!!QS  E0,A!E:"(_L)""#&#B@ =DS_L<W;N. $N2@!+5U!&RL8( /
M1($%IC-+!_XV$%3(P"VW=0 &Z)"W\Y4@##,HP (D88[O7 "T.4!*#H*''[],
MH6'-$((!+J!;2$J2((D00 &H@,G<D54"E6&!* 9""PY<@ 4R&*T#I%!7<UCC
M!P:0P1PN8  4, ,:+"@ "Z1P7;]@( U\*('IRJ*#I [R$K)K00MB=0&P-42M
MOS2'* ;P "2\!+X#D( 6!/D=W"H7 Q)0@LH20@D(./-X8% 8DZ#'8QV[J133
MJ]Y@+) ,RVZO 9APQC%@(08)"$ ,>3/$!00P!5/8XC8%^$&9QI$?!<^!$G/
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MY8QX F3@B2W>@A KKS2<"U 'V&AC" 98 "E<_BB$!)3 $<ZGQ D4, /;_2$
M!BC_0#"Q@/7N/A:^($.P2"[;.CC: VXA[D'^ /L/?,#)$O #L' [">  ]/<V
M*Y  &' *%O0+E\ '<G :!E #K+-VJK8%<R%W!@ "V#8.=7"! R$,%E!@>>9"
MMT )>Y &.5 63?!AVF9#W#8 *) WXU (9Z$$ L$'-\@-$J%Y-R80W8 -TS"$
M1%B$1GB$0Y@-RW $#L )V/ % J!Z_+8;K6=+-' ]6D (5\4;6O LC=9Q]M1.
MN&4 9# .=V!3U3=%-8!\MD=@4M%..0!<"  $K -G Y (8N,$!@  F@!Q+8
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M7!:5GV ,C91'6)&@_H/4! HI$")7 %+W"XVT17F3<P9 H>807BPT!K'@IL"
M"B%475-0 !*0"=6@!*;&!HAR!ZHFB0:A#5*0.RQ9#:]I#JJP  ;@ H'T"U#9
MBA5(BC$Z$,^0@#.Z:3MJE+R(HXS"/4J@2,9EK+P6 Q+@ OU%$-Q@/_@#G=)Y
MI,P8)<C  F7Q Y=P"[\ "TF%#"\A [5'$#A$C>%P1.I:1">C"!4 (W$ INL9
M&$SD1#1@:JTW#DV@7H>@&+!@-*25! +7 E F$/_:%!_0 AV07WLJ$,9P&@*P
M;$I03S_03^9@!>ACD(.DAY!974VF*C\PL3*  ZP""!59$**@K:R5!$H0_@0E
M4'WC\(651G,),%P'8:HRM9I*D#OT,XH/NB[.@&D.D -:\ .?-:MU]5^YLSN\
MZJN_&:S/P %)"2LIE@3LQ %^D:2YX!=*,#31>C]5&9W3R8P@1PDYE#I8I05C
M\P &\ "19Q#C0*??J2VE8 9?,#!XF[=V"RPU\ 4J(!CS^AL49%E4T $K\&\#
M\0@L\ %JL V#! M94 +7%14ED 8T& M:( /XI06>D' 6@%D0)P9'83H7\ %(
M8+%MP $<D$Z#U 87, )'-ZESD%\P5KHYP%F18%^H]D6?$ 62BSHDT =_A 07
M$ /C1@<EP '"9A"0((P=B1![@P$Q8)K7H 52_F%:XX *V043.2 'UANBVB &
M(! #IC@0UX $'R $!S<.E_ !P6N^HH5G%=<"IO,!2O!4'3 %BO$(GLJ2T)H$
M'S #%L:0;S$<L% "YM8EWW )22!A]:NVQR ##FD*",$'Q#.W.V(&#C"690D]
M3:%C@B$]8LHLL*408T,)M$D0U6 *E! +<^$,IE (?, 'A?"G)5(-MG *L7 -
MS$ #"4 "B,MKL. (?+ 'A7 )OP .DD<)E""DOT )GE""+G1E,TP(E& +/#BI
MGD )FXI%S? )A; '?, (G\"7SK#%L/#"GW )L/!IQP#%^PFW)_@S P$.MD )
MIY!GWV +6E@5V@ ,_I2 "CS(,R@LI-]@:ZC@N +A#"B\G]]P"H'\=Z=@-HY@
M2+8&5M^@!8KZ:8][":>0-W?5PL-1#9]@"4TZ2,:P$C-,";XP2*C !Z80-K=
M 8=3 ;TP/4Y0!$>PR[S<R[Y\!#?@ !4P'9AQ+0_$.=83 ^ZY$3)3,P71S&(C
M9<-7?,\,S18A>,X,$<U<(MNI$];LS<U9$,[@ 14@BR'QS0>I$-M@-$R2-.;@
M#<HP#/(\S_1<SQI2"S8 !;W@KIXS*WE@(>5P!>;H825Q##0,?WS< KFF:2+D
M&,"P AE:%^/ !Q,3+!53$.%@,AH],MX0#?L2#:6 +L$" 3T (P+!,M;S_C([
MH7)O* ,84!COT]".L<(+9Q?OLB3R,F/+, EP8 9P  =Q\--"_=-Q\ 49T!^7
MDBD.\ )PP LZ$@T),Q@,LQ.F@< 7@ &ILP?/*M-<?1#34BW!@BW:8@[94 I/
MH &]X0 /L-8/8):<)P#]82L78BXBK1;JPA/?D,IQ4PB6X OET]5<_0LYQ'FT
M(M<[,DT]  &>DB]8 B1N,B%..!#)4M<+$T[>G,V G=E>[0@5#1B0(BD"00Z5
M4@28DBDIT O1< /#X@6U<##1( BG@AFJ<LJ:7=M=H29@;2UO<@6U !ODL R*
M8"<AP O+\ )\<@0=$RA%,"BI(@#":]O0[16"_KTDNY$"<# ,[!8./1("2PTB
M-: (R\!NX@ FZ1DD2B#%T9W>/\&^+)(:$V #V2(CM6 &/7 CPT N%T,=JB$D
MK*+>_OT3W\ '$:(:GWTKV: UDV(.KPTB(D(B__W@/J$-:M#9F!$"O#TT K+<
M!O(!,@?A'LX3UK & ZX:X6(&M8 -&0W2]_(>JD)Q'_[B)7$-?+ <U'T9%9 "
M/@ %4- #(@#"J2(D0 7C0CX2VD )+)#;J>'C02( /W"@0_[D(5$:X,8<[V$=
M!Z(&KP'E6@X2X] ,A7!<5%[ES'(6$A $*;SE:/X1>L$7U1'F^XT6AA$7W9SF
M=%X18$$(04 6FD$83'N>%M=3 E) ";I4YX3N$8CTRE+0 DCQ%$OQ%&LM.S*0
M!85@"\XPYX5^Z11Q$BEQ"HS0$NST UF0!GM ">"*$YA^ZJB>ZJJ^ZJT2$
!.P$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>rgpx-20230930.xsd
<DESCRIPTION>SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:srt-types="http://fasb.org/srt-types/2023" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:RGPX="http://regenerexpharmainc.com/20230930" elementFormDefault="qualified" targetNamespace="http://regenerexpharmainc.com/20230930">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://regenerexpharmainc.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://regenerexpharmainc.com/role/BalanceSheets" id="BalanceSheets">
          <link:definition>00000002 - Statement - BALANCE SHEETS (UNAUDITED)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://regenerexpharmainc.com/role/BalanceSheetsParenthetical" id="BalanceSheetsParenthetical">
          <link:definition>00000003 - Statement - BALANCE SHEETS (UNAUDITED) (Parenthetical)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://regenerexpharmainc.com/role/StatementsOfOperations" id="StatementsOfOperations">
          <link:definition>00000004 - Statement - STATEMENTS OF OPERATIONS (UNAUDITED)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://regenerexpharmainc.com/role/StatementsOfCashFlows" id="StatementsOfCashFlows">
          <link:definition>00000005 - Statement - STATEMENTS OF CASH FLOWS (UNAUDITED)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://regenerexpharmainc.com/role/StatementsOfStockholdersDeficit" id="StatementsOfStockholdersDeficit">
          <link:definition>00000006 - Statement - STATEMENTS OF STOCKHOLDERS' DEFICIT (UNAUDITED)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://regenerexpharmainc.com/role/NatureOfOperations" id="NatureOfOperations">
          <link:definition>00000007 - Disclosure - NATURE OF OPERATIONS</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://regenerexpharmainc.com/role/BasisOfPresentationOfInterimFinancialStatements" id="BasisOfPresentationOfInterimFinancialStatements">
          <link:definition>00000008 - Disclosure - BASIS OF PRESENTATION OF INTERIM FINANCIAL STATEMENTS</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://regenerexpharmainc.com/role/GoingConcern" id="GoingConcern">
          <link:definition>00000009 - Disclosure - GOING CONCERN</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://regenerexpharmainc.com/role/SignificantAccountingPolicies" id="SignificantAccountingPolicies">
          <link:definition>00000010 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://regenerexpharmainc.com/role/RelatedPartyTransactions" id="RelatedPartyTransactions">
          <link:definition>00000011 - Disclosure - RELATED PARTY TRANSACTIONS</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://regenerexpharmainc.com/role/IntangibleAssetsAndIntellectualProperty" id="IntangibleAssetsAndIntellectualProperty">
          <link:definition>00000012 - Disclosure - INTANGIBLE ASSETS AND INTELLECTUAL PROPERTY</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://regenerexpharmainc.com/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
          <link:definition>00000013 - Disclosure - COMMITMENTS AND CONTINGENCIES</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://regenerexpharmainc.com/role/OperatingLeases" id="OperatingLeases">
          <link:definition>00000014 - Disclosure - OPERATING LEASES</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://regenerexpharmainc.com/role/StockholdersDeficit" id="StockholdersDeficit">
          <link:definition>00000015 - Disclosure - STOCKHOLDERS&#8217; DEFICIT</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://regenerexpharmainc.com/role/SubsequentEvents" id="SubsequentEvents">
          <link:definition>00000016 - Disclosure - SUBSEQUENT EVENTS</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://regenerexpharmainc.com/role/SignificantAccountingPoliciesPolicies" id="SignificantAccountingPoliciesPolicies">
          <link:definition>00000017 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://regenerexpharmainc.com/role/NatureOfOperationsDetailsNarrative" id="NatureOfOperationsDetailsNarrative">
          <link:definition>00000018 - Disclosure - NATURE OF OPERATIONS (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://regenerexpharmainc.com/role/GoingConcernDetailsNarrative" id="GoingConcernDetailsNarrative">
          <link:definition>00000019 - Disclosure - GOING CONCERN (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://regenerexpharmainc.com/role/SignificantAccountingPoliciesDetailsNarrative" id="SignificantAccountingPoliciesDetailsNarrative">
          <link:definition>00000020 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://regenerexpharmainc.com/role/RelatedPartyTransactionsDetailsNarrative" id="RelatedPartyTransactionsDetailsNarrative">
          <link:definition>00000021 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://regenerexpharmainc.com/role/IntangibleAssetsAndIntellectualPropertyDetailsNarrative" id="IntangibleAssetsAndIntellectualPropertyDetailsNarrative">
          <link:definition>00000022 - Disclosure - INTANGIBLE ASSETS AND INTELLECTUAL PROPERTY (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://regenerexpharmainc.com/role/CommitmentsAndContingenciesDetailsNarrative" id="CommitmentsAndContingenciesDetailsNarrative">
          <link:definition>00000023 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://regenerexpharmainc.com/role/OperatingLeasesDetailsNarrative" id="OperatingLeasesDetailsNarrative">
          <link:definition>00000024 - Disclosure - OPERATING LEASES (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://regenerexpharmainc.com/role/StockholdersDeficitDetailsNarrative" id="StockholdersDeficitDetailsNarrative">
          <link:definition>00000025 - Disclosure - STOCKHOLDERS&#8217; DEFICIT (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://regenerexpharmainc.com/role/SubsequentEventsDetailsNarrative" id="SubsequentEventsDetailsNarrative">
          <link:definition>00000026 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="rgpx-20230930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="rgpx-20230930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="rgpx-20230930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="rgpx-20230930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" />
    <import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd" />
    <import namespace="http://fasb.org/us-types/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2023" schemaLocation="https://xbrl.sec.gov/country/2023/country-2023.xsd" />
    <import namespace="http://fasb.org/srt/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd" />
    <import namespace="http://fasb.org/srt-types/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd" />
    <element id="RGPX_ShareholderMember" name="ShareholderMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="RGPX_PurchaseIntellectualPropertyMember" name="PurchaseIntellectualPropertyMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="RGPX_AffiliatesMember" name="AffiliatesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="RGPX_ChiefExecutiveOfficerAndChiefFinancialOfficerMember" name="ChiefExecutiveOfficerAndChiefFinancialOfficerMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="RGPX_ReissuedNotesMember" name="ReissuedNotesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="RGPX_PromissoryNotesMember" name="PromissoryNotesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="RGPX_Promissory1NotesMember" name="Promissory1NotesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="RGPX_AggregateInterestExpenseMember" name="AggregateInterestExpenseMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="RGPX_AssetPurchaseAgreementLiabilityMember" name="AssetPurchaseAgreementLiabilityMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="RGPX_OfficeLeaseMember" name="OfficeLeaseMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="RGPX_MonthlyRentalPaymentsMember" name="MonthlyRentalPaymentsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="RGPX_SecurityDepositMember" name="SecurityDepositMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="RGPX_PlantFacilityMember" name="PlantFacilityMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="RGPX_OperatingLeaseCostMember" name="OperatingLeaseCostMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="RGPX_BoardMembersAndConsultantsMember" name="BoardMembersAndConsultantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="RGPX_ServicesRenderedMember" name="ServicesRenderedMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="RGPX_WarrantsMember" name="WarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="RGPX_RelatedPartyAdvances" name="RelatedPartyAdvances" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RGPX_NotesPayableShareholder" name="NotesPayableShareholder" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RGPX_NotesPayableRelatedParties" name="NotesPayableRelatedParties" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RGPX_AccruedInterestConvertedIntoNotePayableToShareholder" name="AccruedInterestConvertedIntoNotePayableToShareholder" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RGPX_OperatingLeasesRouAssetAndLiabilities" name="OperatingLeasesRouAssetAndLiabilities" nillable="true" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RGPX_NoncashOrPartNoncashAcquisitionOfIntangibleAssetsExcludingGoodwill" name="NoncashOrPartNoncashAcquisitionOfIntangibleAssetsExcludingGoodwill" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RGPX_DisclosureOperatingLeasesAbstract" name="DisclosureOperatingLeasesAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="RGPX_StockBasedCompensationUnrecognizedCompensationCost" name="StockBasedCompensationUnrecognizedCompensationCost" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>8
<FILENAME>rgpx-20230930_cal.xml
<DESCRIPTION>CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://regenerexpharmainc.com/role/Cover" xlink:href="rgpx-20230930.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://regenerexpharmainc.com/role/BalanceSheets" xlink:href="rgpx-20230930.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://regenerexpharmainc.com/role/BalanceSheetsParenthetical" xlink:href="rgpx-20230930.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://regenerexpharmainc.com/role/StatementsOfOperations" xlink:href="rgpx-20230930.xsd#StatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://regenerexpharmainc.com/role/StatementsOfCashFlows" xlink:href="rgpx-20230930.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://regenerexpharmainc.com/role/StatementsOfStockholdersDeficit" xlink:href="rgpx-20230930.xsd#StatementsOfStockholdersDeficit" xlink:type="simple" />
    <link:roleRef roleURI="http://regenerexpharmainc.com/role/NatureOfOperations" xlink:href="rgpx-20230930.xsd#NatureOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://regenerexpharmainc.com/role/BasisOfPresentationOfInterimFinancialStatements" xlink:href="rgpx-20230930.xsd#BasisOfPresentationOfInterimFinancialStatements" xlink:type="simple" />
    <link:roleRef roleURI="http://regenerexpharmainc.com/role/GoingConcern" xlink:href="rgpx-20230930.xsd#GoingConcern" xlink:type="simple" />
    <link:roleRef roleURI="http://regenerexpharmainc.com/role/SignificantAccountingPolicies" xlink:href="rgpx-20230930.xsd#SignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://regenerexpharmainc.com/role/RelatedPartyTransactions" xlink:href="rgpx-20230930.xsd#RelatedPartyTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://regenerexpharmainc.com/role/IntangibleAssetsAndIntellectualProperty" xlink:href="rgpx-20230930.xsd#IntangibleAssetsAndIntellectualProperty" xlink:type="simple" />
    <link:roleRef roleURI="http://regenerexpharmainc.com/role/CommitmentsAndContingencies" xlink:href="rgpx-20230930.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://regenerexpharmainc.com/role/OperatingLeases" xlink:href="rgpx-20230930.xsd#OperatingLeases" xlink:type="simple" />
    <link:roleRef roleURI="http://regenerexpharmainc.com/role/StockholdersDeficit" xlink:href="rgpx-20230930.xsd#StockholdersDeficit" xlink:type="simple" />
    <link:roleRef roleURI="http://regenerexpharmainc.com/role/SubsequentEvents" xlink:href="rgpx-20230930.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://regenerexpharmainc.com/role/SignificantAccountingPoliciesPolicies" xlink:href="rgpx-20230930.xsd#SignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://regenerexpharmainc.com/role/NatureOfOperationsDetailsNarrative" xlink:href="rgpx-20230930.xsd#NatureOfOperationsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://regenerexpharmainc.com/role/GoingConcernDetailsNarrative" xlink:href="rgpx-20230930.xsd#GoingConcernDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://regenerexpharmainc.com/role/SignificantAccountingPoliciesDetailsNarrative" xlink:href="rgpx-20230930.xsd#SignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://regenerexpharmainc.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:href="rgpx-20230930.xsd#RelatedPartyTransactionsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://regenerexpharmainc.com/role/IntangibleAssetsAndIntellectualPropertyDetailsNarrative" xlink:href="rgpx-20230930.xsd#IntangibleAssetsAndIntellectualPropertyDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://regenerexpharmainc.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="rgpx-20230930.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://regenerexpharmainc.com/role/OperatingLeasesDetailsNarrative" xlink:href="rgpx-20230930.xsd#OperatingLeasesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://regenerexpharmainc.com/role/StockholdersDeficitDetailsNarrative" xlink:href="rgpx-20230930.xsd#StockholdersDeficitDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://regenerexpharmainc.com/role/SubsequentEventsDetailsNarrative" xlink:href="rgpx-20230930.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
    <link:calculationLink xlink:type="extended" xlink:role="http://regenerexpharmainc.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:calculationLink xlink:type="extended" xlink:role="http://regenerexpharmainc.com/role/BalanceSheets" xlink:title="00000002 - Statement - BALANCE SHEETS (UNAUDITED)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaapPrepaidExpenseCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapPrepaidExpenseCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MachineryAndEquipmentGross" xlink:label="loc_us-gaapMachineryAndEquipmentGross" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapMachineryAndEquipmentGross" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="rgpx-20230930.xsd#RGPX_RelatedPartyAdvances" xlink:label="loc_RGPXRelatedPartyAdvances" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_RGPXRelatedPartyAdvances" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaapEmployeeRelatedLiabilitiesCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapEmployeeRelatedLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNotesPayableCurrent" xlink:label="loc_us-gaapOtherNotesPayableCurrent" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapOtherNotesPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="rgpx-20230930.xsd#RGPX_NotesPayableShareholder" xlink:label="loc_RGPXNotesPayableShareholder" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_RGPXNotesPayableShareholder" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="rgpx-20230930.xsd#RGPX_NotesPayableRelatedParties" xlink:label="loc_RGPXNotesPayableRelatedParties" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_RGPXNotesPayableRelatedParties" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayable" xlink:label="loc_us-gaapNotesPayable" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapNotesPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://regenerexpharmainc.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - BALANCE SHEETS (UNAUDITED) (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://regenerexpharmainc.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - STATEMENTS OF OPERATIONS (UNAUDITED)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapInterestExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaapForeignCurrencyTransactionGainLossBeforeTax" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapForeignCurrencyTransactionGainLossBeforeTax" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://regenerexpharmainc.com/role/StatementsOfCashFlows" xlink:title="00000005 - Statement - STATEMENTS OF CASH FLOWS (UNAUDITED)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapDepreciation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAssetAmortizationExpense" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAssetAmortizationExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaapForeignCurrencyTransactionGainLossBeforeTax" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapForeignCurrencyTransactionGainLossBeforeTax" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidExpense" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireFurnitureAndFixtures" xlink:label="loc_us-gaapPaymentsToAcquireFurnitureAndFixtures" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquireFurnitureAndFixtures" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="loc_us-gaapProceedsFromRelatedPartyDebt" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromRelatedPartyDebt" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="loc_us-gaapProceedsFromNotesPayable" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromNotesPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaapProceedsFromIssuanceOfWarrants" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceOfWarrants" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://regenerexpharmainc.com/role/StatementsOfStockholdersDeficit" xlink:title="00000006 - Statement - STATEMENTS OF STOCKHOLDERS&apos; DEFICIT (UNAUDITED)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://regenerexpharmainc.com/role/NatureOfOperations" xlink:title="00000007 - Disclosure - NATURE OF OPERATIONS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://regenerexpharmainc.com/role/BasisOfPresentationOfInterimFinancialStatements" xlink:title="00000008 - Disclosure - BASIS OF PRESENTATION OF INTERIM FINANCIAL STATEMENTS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://regenerexpharmainc.com/role/GoingConcern" xlink:title="00000009 - Disclosure - GOING CONCERN" />
    <link:calculationLink xlink:type="extended" xlink:role="http://regenerexpharmainc.com/role/SignificantAccountingPolicies" xlink:title="00000010 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://regenerexpharmainc.com/role/RelatedPartyTransactions" xlink:title="00000011 - Disclosure - RELATED PARTY TRANSACTIONS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://regenerexpharmainc.com/role/IntangibleAssetsAndIntellectualProperty" xlink:title="00000012 - Disclosure - INTANGIBLE ASSETS AND INTELLECTUAL PROPERTY" />
    <link:calculationLink xlink:type="extended" xlink:role="http://regenerexpharmainc.com/role/CommitmentsAndContingencies" xlink:title="00000013 - Disclosure - COMMITMENTS AND CONTINGENCIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://regenerexpharmainc.com/role/OperatingLeases" xlink:title="00000014 - Disclosure - OPERATING LEASES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://regenerexpharmainc.com/role/StockholdersDeficit" xlink:title="00000015 - Disclosure - STOCKHOLDERS&#8217; DEFICIT" />
    <link:calculationLink xlink:type="extended" xlink:role="http://regenerexpharmainc.com/role/SubsequentEvents" xlink:title="00000016 - Disclosure - SUBSEQUENT EVENTS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://regenerexpharmainc.com/role/SignificantAccountingPoliciesPolicies" xlink:title="00000017 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://regenerexpharmainc.com/role/NatureOfOperationsDetailsNarrative" xlink:title="00000018 - Disclosure - NATURE OF OPERATIONS (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://regenerexpharmainc.com/role/GoingConcernDetailsNarrative" xlink:title="00000019 - Disclosure - GOING CONCERN (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://regenerexpharmainc.com/role/SignificantAccountingPoliciesDetailsNarrative" xlink:title="00000020 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://regenerexpharmainc.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:title="00000021 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://regenerexpharmainc.com/role/IntangibleAssetsAndIntellectualPropertyDetailsNarrative" xlink:title="00000022 - Disclosure - INTANGIBLE ASSETS AND INTELLECTUAL PROPERTY (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://regenerexpharmainc.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000023 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://regenerexpharmainc.com/role/OperatingLeasesDetailsNarrative" xlink:title="00000024 - Disclosure - OPERATING LEASES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://regenerexpharmainc.com/role/StockholdersDeficitDetailsNarrative" xlink:title="00000025 - Disclosure - STOCKHOLDERS&#8217; DEFICIT (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://regenerexpharmainc.com/role/SubsequentEventsDetailsNarrative" xlink:title="00000026 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>9
<FILENAME>rgpx-20230930_def.xml
<DESCRIPTION>DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://regenerexpharmainc.com/role/Cover" xlink:href="rgpx-20230930.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://regenerexpharmainc.com/role/BalanceSheets" xlink:href="rgpx-20230930.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://regenerexpharmainc.com/role/BalanceSheetsParenthetical" xlink:href="rgpx-20230930.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://regenerexpharmainc.com/role/StatementsOfOperations" xlink:href="rgpx-20230930.xsd#StatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://regenerexpharmainc.com/role/StatementsOfCashFlows" xlink:href="rgpx-20230930.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://regenerexpharmainc.com/role/StatementsOfStockholdersDeficit" xlink:href="rgpx-20230930.xsd#StatementsOfStockholdersDeficit" xlink:type="simple" />
    <link:roleRef roleURI="http://regenerexpharmainc.com/role/NatureOfOperations" xlink:href="rgpx-20230930.xsd#NatureOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://regenerexpharmainc.com/role/BasisOfPresentationOfInterimFinancialStatements" xlink:href="rgpx-20230930.xsd#BasisOfPresentationOfInterimFinancialStatements" xlink:type="simple" />
    <link:roleRef roleURI="http://regenerexpharmainc.com/role/GoingConcern" xlink:href="rgpx-20230930.xsd#GoingConcern" xlink:type="simple" />
    <link:roleRef roleURI="http://regenerexpharmainc.com/role/SignificantAccountingPolicies" xlink:href="rgpx-20230930.xsd#SignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://regenerexpharmainc.com/role/RelatedPartyTransactions" xlink:href="rgpx-20230930.xsd#RelatedPartyTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://regenerexpharmainc.com/role/IntangibleAssetsAndIntellectualProperty" xlink:href="rgpx-20230930.xsd#IntangibleAssetsAndIntellectualProperty" xlink:type="simple" />
    <link:roleRef roleURI="http://regenerexpharmainc.com/role/CommitmentsAndContingencies" xlink:href="rgpx-20230930.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://regenerexpharmainc.com/role/OperatingLeases" xlink:href="rgpx-20230930.xsd#OperatingLeases" xlink:type="simple" />
    <link:roleRef roleURI="http://regenerexpharmainc.com/role/StockholdersDeficit" xlink:href="rgpx-20230930.xsd#StockholdersDeficit" xlink:type="simple" />
    <link:roleRef roleURI="http://regenerexpharmainc.com/role/SubsequentEvents" xlink:href="rgpx-20230930.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://regenerexpharmainc.com/role/SignificantAccountingPoliciesPolicies" xlink:href="rgpx-20230930.xsd#SignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://regenerexpharmainc.com/role/NatureOfOperationsDetailsNarrative" xlink:href="rgpx-20230930.xsd#NatureOfOperationsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://regenerexpharmainc.com/role/GoingConcernDetailsNarrative" xlink:href="rgpx-20230930.xsd#GoingConcernDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://regenerexpharmainc.com/role/SignificantAccountingPoliciesDetailsNarrative" xlink:href="rgpx-20230930.xsd#SignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://regenerexpharmainc.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:href="rgpx-20230930.xsd#RelatedPartyTransactionsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://regenerexpharmainc.com/role/IntangibleAssetsAndIntellectualPropertyDetailsNarrative" xlink:href="rgpx-20230930.xsd#IntangibleAssetsAndIntellectualPropertyDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://regenerexpharmainc.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="rgpx-20230930.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://regenerexpharmainc.com/role/OperatingLeasesDetailsNarrative" xlink:href="rgpx-20230930.xsd#OperatingLeasesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://regenerexpharmainc.com/role/StockholdersDeficitDetailsNarrative" xlink:href="rgpx-20230930.xsd#StockholdersDeficitDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://regenerexpharmainc.com/role/SubsequentEventsDetailsNarrative" xlink:href="rgpx-20230930.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
    <link:definitionLink xlink:type="extended" xlink:role="http://regenerexpharmainc.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:definitionLink xlink:type="extended" xlink:role="http://regenerexpharmainc.com/role/BalanceSheets" xlink:title="00000002 - Statement - BALANCE SHEETS (UNAUDITED)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://regenerexpharmainc.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - BALANCE SHEETS (UNAUDITED) (Parenthetical)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://regenerexpharmainc.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - STATEMENTS OF OPERATIONS (UNAUDITED)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://regenerexpharmainc.com/role/StatementsOfCashFlows" xlink:title="00000005 - Statement - STATEMENTS OF CASH FLOWS (UNAUDITED)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAffiliatesMember" xlink:label="loc_us-gaapOtherAffiliatesMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapOtherAffiliatesMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="rgpx-20230930.xsd#RGPX_ShareholderMember" xlink:label="loc_RGPXShareholderMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_RGPXShareholderMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalCashFlowElementsOperatingActivitiesAbstract" xlink:label="loc_us-gaapAdditionalCashFlowElementsOperatingActivitiesAbstract_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapAdditionalCashFlowElementsOperatingActivitiesAbstract_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAdditionalCashFlowElementsOperatingActivitiesAbstract_70" xlink:to="loc_us-gaapNetIncomeLoss_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_70" xlink:to="loc_us-gaapDepreciation_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_70" xlink:to="loc_us-gaapShareBasedCompensation_70" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaapPaymentsToAcquireIntangibleAssets_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_70" xlink:to="loc_us-gaapPaymentsToAcquireIntangibleAssets_70" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAssetAmortizationExpense_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_70" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAssetAmortizationExpense_70" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaapForeignCurrencyTransactionGainLossBeforeTax_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_70" xlink:to="loc_us-gaapForeignCurrencyTransactionGainLossBeforeTax_70" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract_70" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidExpense_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract_70" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidExpense_70" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract_70" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities_70" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract_70" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities_70" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract_70" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireFurnitureAndFixtures" xlink:label="loc_us-gaapPaymentsToAcquireFurnitureAndFixtures_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapPaymentsToAcquireFurnitureAndFixtures_70" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities_70" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_70" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="loc_us-gaapProceedsFromRelatedPartyDebt_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapProceedsFromRelatedPartyDebt_70" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="loc_us-gaapRepaymentsOfNotesPayable_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapRepaymentsOfNotesPayable_70" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="loc_us-gaapProceedsFromNotesPayable_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapProceedsFromNotesPayable_70" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaapProceedsFromIssuanceOfWarrants_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfWarrants_70" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities_70" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_70" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_70" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaapSupplementalCashFlowInformationAbstract_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapSupplementalCashFlowInformationAbstract_70" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxesPaid" xlink:label="loc_us-gaapIncomeTaxesPaid_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract_70" xlink:to="loc_us-gaapIncomeTaxesPaid_70" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaid" xlink:label="loc_us-gaapInterestPaid_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract_70" xlink:to="loc_us-gaapInterestPaid_70" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_70" xlink:type="arc" order="27" />
      <link:loc xlink:type="locator" xlink:href="rgpx-20230930.xsd#RGPX_AccruedInterestConvertedIntoNotePayableToShareholder" xlink:label="loc_RGPXAccruedInterestConvertedIntoNotePayableToShareholder_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_RGPXAccruedInterestConvertedIntoNotePayableToShareholder_70" xlink:type="arc" order="28" />
      <link:loc xlink:type="locator" xlink:href="rgpx-20230930.xsd#RGPX_OperatingLeasesRouAssetAndLiabilities" xlink:label="loc_RGPXOperatingLeasesRouAssetAndLiabilities_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_RGPXOperatingLeasesRouAssetAndLiabilities_70" xlink:type="arc" order="29" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1" xlink:label="loc_us-gaapNoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapNoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1_70" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="rgpx-20230930.xsd#RGPX_NoncashOrPartNoncashAcquisitionOfIntangibleAssetsExcludingGoodwill" xlink:label="loc_RGPXNoncashOrPartNoncashAcquisitionOfIntangibleAssetsExcludingGoodwill_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_RGPXNoncashOrPartNoncashAcquisitionOfIntangibleAssetsExcludingGoodwill_70" xlink:type="arc" order="31" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://regenerexpharmainc.com/role/StatementsOfStockholdersDeficit" xlink:title="00000006 - Statement - STATEMENTS OF STOCKHOLDERS&apos; DEFICIT (UNAUDITED)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapRetainedEarningsMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss_50" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_50" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices_50" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices_50" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_50" xlink:type="arc" order="7" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://regenerexpharmainc.com/role/NatureOfOperations" xlink:title="00000007 - Disclosure - NATURE OF OPERATIONS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://regenerexpharmainc.com/role/BasisOfPresentationOfInterimFinancialStatements" xlink:title="00000008 - Disclosure - BASIS OF PRESENTATION OF INTERIM FINANCIAL STATEMENTS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://regenerexpharmainc.com/role/GoingConcern" xlink:title="00000009 - Disclosure - GOING CONCERN" />
    <link:definitionLink xlink:type="extended" xlink:role="http://regenerexpharmainc.com/role/SignificantAccountingPolicies" xlink:title="00000010 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://regenerexpharmainc.com/role/RelatedPartyTransactions" xlink:title="00000011 - Disclosure - RELATED PARTY TRANSACTIONS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://regenerexpharmainc.com/role/IntangibleAssetsAndIntellectualProperty" xlink:title="00000012 - Disclosure - INTANGIBLE ASSETS AND INTELLECTUAL PROPERTY" />
    <link:definitionLink xlink:type="extended" xlink:role="http://regenerexpharmainc.com/role/CommitmentsAndContingencies" xlink:title="00000013 - Disclosure - COMMITMENTS AND CONTINGENCIES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://regenerexpharmainc.com/role/OperatingLeases" xlink:title="00000014 - Disclosure - OPERATING LEASES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://regenerexpharmainc.com/role/StockholdersDeficit" xlink:title="00000015 - Disclosure - STOCKHOLDERS&#8217; DEFICIT" />
    <link:definitionLink xlink:type="extended" xlink:role="http://regenerexpharmainc.com/role/SubsequentEvents" xlink:title="00000016 - Disclosure - SUBSEQUENT EVENTS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://regenerexpharmainc.com/role/SignificantAccountingPoliciesPolicies" xlink:title="00000017 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://regenerexpharmainc.com/role/NatureOfOperationsDetailsNarrative" xlink:title="00000018 - Disclosure - NATURE OF OPERATIONS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="rgpx-20230930.xsd#RGPX_PurchaseIntellectualPropertyMember" xlink:label="loc_RGPXPurchaseIntellectualPropertyMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_RGPXPurchaseIntellectualPropertyMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationDateOfIncorporation" xlink:label="loc_deiEntityIncorporationDateOfIncorporation_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityIncorporationDateOfIncorporation_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaapSharesIssued_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesIssued_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionContingentConsiderationLiability" xlink:label="loc_us-gaapAssetAcquisitionContingentConsiderationLiability_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAssetAcquisitionContingentConsiderationLiability_40" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://regenerexpharmainc.com/role/GoingConcernDetailsNarrative" xlink:title="00000019 - Disclosure - GOING CONCERN (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://regenerexpharmainc.com/role/SignificantAccountingPoliciesDetailsNarrative" xlink:title="00000020 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding_90" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetUsefulLife_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetUsefulLife_90" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaapAmortizationOfIntangibleAssets_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapAmortizationOfIntangibleAssets_90" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaapPropertyPlantAndEquipmentUsefulLife_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentUsefulLife_90" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherDepreciationAndAmortization" xlink:label="loc_us-gaapOtherDepreciationAndAmortization_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapOtherDepreciationAndAmortization_90" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeFinanceLeaseDiscountRate" xlink:label="loc_us-gaapLesseeFinanceLeaseDiscountRate_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapLesseeFinanceLeaseDiscountRate_90" xlink:type="arc" order="5" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://regenerexpharmainc.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:title="00000021 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaapRelatedPartyTransactionLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ChiefFinancialOfficerMember" xlink:label="loc_srtChiefFinancialOfficerMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_srtChiefFinancialOfficerMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="rgpx-20230930.xsd#RGPX_AffiliatesMember" xlink:label="loc_RGPXAffiliatesMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_RGPXAffiliatesMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="loc_srtChiefExecutiveOfficerMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_srtChiefExecutiveOfficerMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="rgpx-20230930.xsd#RGPX_ChiefExecutiveOfficerAndChiefFinancialOfficerMember" xlink:label="loc_RGPXChiefExecutiveOfficerAndChiefFinancialOfficerMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_RGPXChiefExecutiveOfficerAndChiefFinancialOfficerMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MajorityShareholderMember" xlink:label="loc_us-gaapMajorityShareholderMember_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapMajorityShareholderMember_110" xlink:type="arc" order="111" />
      <link:loc xlink:type="locator" xlink:href="rgpx-20230930.xsd#RGPX_ShareholderMember" xlink:label="loc_RGPXShareholderMember_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_RGPXShareholderMember_140" xlink:type="arc" order="141" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaapDebtInstrumentAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapDebtInstrumentAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="rgpx-20230930.xsd#RGPX_ReissuedNotesMember" xlink:label="loc_RGPXReissuedNotesMember_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_RGPXReissuedNotesMember_130" xlink:type="arc" order="131" />
      <link:loc xlink:type="locator" xlink:href="rgpx-20230930.xsd#RGPX_PromissoryNotesMember" xlink:label="loc_RGPXPromissoryNotesMember_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_RGPXPromissoryNotesMember_140" xlink:type="arc" order="142" />
      <link:loc xlink:type="locator" xlink:href="rgpx-20230930.xsd#RGPX_Promissory1NotesMember" xlink:label="loc_RGPXPromissory1NotesMember_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_RGPXPromissory1NotesMember_150" xlink:type="arc" order="152" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaapRelatedPartyTransactionAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaapRelatedPartyTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionAxis" xlink:to="loc_us-gaapRelatedPartyTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaapRelatedPartyTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionAxis" xlink:to="loc_us-gaapRelatedPartyTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="rgpx-20230930.xsd#RGPX_AggregateInterestExpenseMember" xlink:label="loc_RGPXAggregateInterestExpenseMember_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionDomain" xlink:to="loc_RGPXAggregateInterestExpenseMember_160" xlink:type="arc" order="161" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionRate" xlink:label="loc_us-gaapRelatedPartyTransactionRate_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapRelatedPartyTransactionRate_190" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesAndLoansPayable" xlink:label="loc_us-gaapNotesAndLoansPayable_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapNotesAndLoansPayable_190" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="rgpx-20230930.xsd#RGPX_RelatedPartyAdvances" xlink:label="loc_RGPXRelatedPartyAdvances_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_RGPXRelatedPartyAdvances_190" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapInterestExpense_190" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="loc_us-gaapRepaymentsOfNotesPayable_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapRepaymentsOfNotesPayable_190" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:label="loc_us-gaapDebtInstrumentInterestRateDuringPeriod_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateDuringPeriod_190" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="rgpx-20230930.xsd#RGPX_NotesPayableRelatedParties" xlink:label="loc_RGPXNotesPayableRelatedParties_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_RGPXNotesPayableRelatedParties_190" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseDebt" xlink:label="loc_us-gaapInterestExpenseDebt_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapInterestExpenseDebt_190" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayable" xlink:label="loc_us-gaapNotesPayable_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapNotesPayable_190" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaapDebtInstrumentCarryingAmount_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapDebtInstrumentCarryingAmount_190" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPayableCurrent" xlink:label="loc_us-gaapInterestPayableCurrent_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapInterestPayableCurrent_190" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermNotesPayable" xlink:label="loc_us-gaapLongTermNotesPayable_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapLongTermNotesPayable_190" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaapDebtInstrumentInterestRateStatedPercentage_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateStatedPercentage_190" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent_190" xlink:type="arc" order="13" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://regenerexpharmainc.com/role/IntangibleAssetsAndIntellectualPropertyDetailsNarrative" xlink:title="00000022 - Disclosure - INTANGIBLE ASSETS AND INTELLECTUAL PROPERTY (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://regenerexpharmainc.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000023 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsSoldUnderAgreementsToRepurchaseLineItems" xlink:label="loc_us-gaapAssetsSoldUnderAgreementsToRepurchaseLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAssetsSoldUnderAgreementsToRepurchaseTable" xlink:label="loc_us-gaapScheduleOfAssetsSoldUnderAgreementsToRepurchaseTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAssetsSoldUnderAgreementsToRepurchaseLineItems" xlink:to="loc_us-gaapScheduleOfAssetsSoldUnderAgreementsToRepurchaseTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsSoldUnderAgreementsToRepurchaseAxis" xlink:label="loc_us-gaapAssetsSoldUnderAgreementsToRepurchaseAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfAssetsSoldUnderAgreementsToRepurchaseTable" xlink:to="loc_us-gaapAssetsSoldUnderAgreementsToRepurchaseAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsSoldUnderAgreementsToRepurchaseTypeDomain" xlink:label="loc_us-gaapAssetsSoldUnderAgreementsToRepurchaseTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAssetsSoldUnderAgreementsToRepurchaseAxis" xlink:to="loc_us-gaapAssetsSoldUnderAgreementsToRepurchaseTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsSoldUnderAgreementsToRepurchaseTypeDomain" xlink:label="loc_us-gaapAssetsSoldUnderAgreementsToRepurchaseTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAssetsSoldUnderAgreementsToRepurchaseAxis" xlink:to="loc_us-gaapAssetsSoldUnderAgreementsToRepurchaseTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="rgpx-20230930.xsd#RGPX_ChiefExecutiveOfficerAndChiefFinancialOfficerMember" xlink:label="loc_RGPXChiefExecutiveOfficerAndChiefFinancialOfficerMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsSoldUnderAgreementsToRepurchaseTypeDomain" xlink:to="loc_RGPXChiefExecutiveOfficerAndChiefFinancialOfficerMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfAssetsSoldUnderAgreementsToRepurchaseTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="rgpx-20230930.xsd#RGPX_AssetPurchaseAgreementLiabilityMember" xlink:label="loc_RGPXAssetPurchaseAgreementLiabilityMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_RGPXAssetPurchaseAgreementLiabilityMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionContingentConsiderationLiability" xlink:label="loc_us-gaapAssetAcquisitionContingentConsiderationLiability_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsSoldUnderAgreementsToRepurchaseLineItems" xlink:to="loc_us-gaapAssetAcquisitionContingentConsiderationLiability_60" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsSoldUnderAgreementsToRepurchaseLineItems" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsSoldUnderAgreementsToRepurchaseLineItems" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent_60" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://regenerexpharmainc.com/role/OperatingLeasesDetailsNarrative" xlink:title="00000024 - Disclosure - OPERATING LEASES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="loc_us-gaapLesseeLeaseDescriptionLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="loc_us-gaapLesseeLeaseDescriptionTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapLesseeLeaseDescriptionLineItems" xlink:to="loc_us-gaapLesseeLeaseDescriptionTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis" xlink:label="loc_us-gaapPropertySubjectToOrAvailableForOperatingLeaseAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapLesseeLeaseDescriptionTable" xlink:to="loc_us-gaapPropertySubjectToOrAvailableForOperatingLeaseAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain" xlink:label="loc_us-gaapPropertySubjectToOrAvailableForOperatingLeaseDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPropertySubjectToOrAvailableForOperatingLeaseAxis" xlink:to="loc_us-gaapPropertySubjectToOrAvailableForOperatingLeaseDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain" xlink:label="loc_us-gaapPropertySubjectToOrAvailableForOperatingLeaseDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertySubjectToOrAvailableForOperatingLeaseAxis" xlink:to="loc_us-gaapPropertySubjectToOrAvailableForOperatingLeaseDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="rgpx-20230930.xsd#RGPX_OfficeLeaseMember" xlink:label="loc_RGPXOfficeLeaseMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertySubjectToOrAvailableForOperatingLeaseDomain" xlink:to="loc_RGPXOfficeLeaseMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="rgpx-20230930.xsd#RGPX_PlantFacilityMember" xlink:label="loc_RGPXPlantFacilityMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertySubjectToOrAvailableForOperatingLeaseDomain" xlink:to="loc_RGPXPlantFacilityMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="loc_us-gaapLeaseContractualTermAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapLesseeLeaseDescriptionTable" xlink:to="loc_us-gaapLeaseContractualTermAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="loc_us-gaapLeaseContractualTermDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapLeaseContractualTermAxis" xlink:to="loc_us-gaapLeaseContractualTermDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="loc_us-gaapLeaseContractualTermDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapLeaseContractualTermAxis" xlink:to="loc_us-gaapLeaseContractualTermDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="rgpx-20230930.xsd#RGPX_MonthlyRentalPaymentsMember" xlink:label="loc_RGPXMonthlyRentalPaymentsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLeaseContractualTermDomain" xlink:to="loc_RGPXMonthlyRentalPaymentsMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="rgpx-20230930.xsd#RGPX_SecurityDepositMember" xlink:label="loc_RGPXSecurityDepositMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLeaseContractualTermDomain" xlink:to="loc_RGPXSecurityDepositMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="rgpx-20230930.xsd#RGPX_OperatingLeaseCostMember" xlink:label="loc_RGPXOperatingLeaseCostMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLeaseContractualTermDomain" xlink:to="loc_RGPXOperatingLeaseCostMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDue_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLesseeLeaseDescriptionLineItems" xlink:to="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDue_80" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaapPrepaidExpenseCurrent_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLesseeLeaseDescriptionLineItems" xlink:to="loc_us-gaapPrepaidExpenseCurrent_80" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseDescription" xlink:label="loc_us-gaapLesseeOperatingLeaseDescription_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLesseeLeaseDescriptionLineItems" xlink:to="loc_us-gaapLesseeOperatingLeaseDescription_80" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalLeaseObligationsCurrent" xlink:label="loc_us-gaapCapitalLeaseObligationsCurrent_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLesseeLeaseDescriptionLineItems" xlink:to="loc_us-gaapCapitalLeaseObligationsCurrent_80" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLesseeLeaseDescriptionLineItems" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense_80" xlink:type="arc" order="4" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://regenerexpharmainc.com/role/StockholdersDeficitDetailsNarrative" xlink:title="00000025 - Disclosure - STOCKHOLDERS&#8217; DEFICIT (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="rgpx-20230930.xsd#RGPX_BoardMembersAndConsultantsMember" xlink:label="loc_RGPXBoardMembersAndConsultantsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_RGPXBoardMembersAndConsultantsMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaapRelatedPartyTransactionAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_us-gaapRelatedPartyTransactionAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaapRelatedPartyTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionAxis" xlink:to="loc_us-gaapRelatedPartyTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaapRelatedPartyTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionAxis" xlink:to="loc_us-gaapRelatedPartyTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="rgpx-20230930.xsd#RGPX_ServicesRenderedMember" xlink:label="loc_RGPXServicesRenderedMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionDomain" xlink:to="loc_RGPXServicesRenderedMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" xlink:label="loc_us-gaapDeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_us-gaapDeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain" xlink:label="loc_us-gaapEquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" xlink:to="loc_us-gaapEquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain" xlink:label="loc_us-gaapEquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" xlink:to="loc_us-gaapEquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="rgpx-20230930.xsd#RGPX_WarrantsMember" xlink:label="loc_RGPXWarrantsMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain" xlink:to="loc_RGPXWarrantsMember_30" xlink:type="arc" order="33" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapShareBasedCompensation_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding_70" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_70" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="rgpx-20230930.xsd#RGPX_StockBasedCompensationUnrecognizedCompensationCost" xlink:label="loc_RGPXStockBasedCompensationUnrecognizedCompensationCost_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_RGPXStockBasedCompensationUnrecognizedCompensationCost_70" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_70" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_70" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_70" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_70" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_70" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaapSaleOfStockPricePerShare_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapSaleOfStockPricePerShare_70" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_70" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityContractTerms" xlink:label="loc_us-gaapTemporaryEquityContractTerms_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapTemporaryEquityContractTerms_70" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_70" xlink:type="arc" order="15" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://regenerexpharmainc.com/role/SubsequentEventsDetailsNarrative" xlink:title="00000026 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaapSubsequentEventLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaapSubsequentEventTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapSubsequentEventTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaapDebtInstrumentAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapDebtInstrumentAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="rgpx-20230930.xsd#RGPX_ReissuedNotesMember" xlink:label="loc_RGPXReissuedNotesMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_RGPXReissuedNotesMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayable" xlink:label="loc_us-gaapNotesPayable_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapNotesPayable_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaapDebtInstrumentCarryingAmount_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapDebtInstrumentCarryingAmount_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPayableCurrent" xlink:label="loc_us-gaapInterestPayableCurrent_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapInterestPayableCurrent_40" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaapDebtInstrumentMaturityDate_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapDebtInstrumentMaturityDate_40" xlink:type="arc" order="3" />
    </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>10
<FILENAME>rgpx-20230930_lab.xml
<DESCRIPTION>LABELS LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US">Related Party, Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAffiliatesMember" xlink:label="us-gaap_OtherAffiliatesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAffiliatesMember" xlink:to="us-gaap_OtherAffiliatesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAffiliatesMember_lbl" xml:lang="en-US">Other Affiliates [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="rgpx-20230930.xsd#RGPX_ShareholderMember" xlink:label="RGPX_ShareholderMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RGPX_ShareholderMember" xlink:to="RGPX_ShareholderMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RGPX_ShareholderMember_lbl" xml:lang="en-US">Shareholder [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Retained Earnings [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="rgpx-20230930.xsd#RGPX_PurchaseIntellectualPropertyMember" xlink:label="RGPX_PurchaseIntellectualPropertyMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RGPX_PurchaseIntellectualPropertyMember" xlink:to="RGPX_PurchaseIntellectualPropertyMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RGPX_PurchaseIntellectualPropertyMember_lbl" xml:lang="en-US">Purchase Intellectual Property [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ChiefFinancialOfficerMember" xlink:label="srt_ChiefFinancialOfficerMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ChiefFinancialOfficerMember" xlink:to="srt_ChiefFinancialOfficerMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ChiefFinancialOfficerMember_lbl" xml:lang="en-US">Chief Financial Officer [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="rgpx-20230930.xsd#RGPX_AffiliatesMember" xlink:label="RGPX_AffiliatesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RGPX_AffiliatesMember" xlink:to="RGPX_AffiliatesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RGPX_AffiliatesMember_lbl" xml:lang="en-US">Affiliates [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="srt_ChiefExecutiveOfficerMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ChiefExecutiveOfficerMember" xlink:to="srt_ChiefExecutiveOfficerMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ChiefExecutiveOfficerMember_lbl" xml:lang="en-US">Chief Executive Officer [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="rgpx-20230930.xsd#RGPX_ChiefExecutiveOfficerAndChiefFinancialOfficerMember" xlink:label="RGPX_ChiefExecutiveOfficerAndChiefFinancialOfficerMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RGPX_ChiefExecutiveOfficerAndChiefFinancialOfficerMember" xlink:to="RGPX_ChiefExecutiveOfficerAndChiefFinancialOfficerMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RGPX_ChiefExecutiveOfficerAndChiefFinancialOfficerMember_lbl" xml:lang="en-US">Chief Executive Officer And Chief Financial Officer [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MajorityShareholderMember" xlink:label="us-gaap_MajorityShareholderMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MajorityShareholderMember" xlink:to="us-gaap_MajorityShareholderMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MajorityShareholderMember_lbl" xml:lang="en-US">Majority Shareholder [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xml:lang="en-US">Debt Instrument [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="rgpx-20230930.xsd#RGPX_ReissuedNotesMember" xlink:label="RGPX_ReissuedNotesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RGPX_ReissuedNotesMember" xlink:to="RGPX_ReissuedNotesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RGPX_ReissuedNotesMember_lbl" xml:lang="en-US">Reissued Notes [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="rgpx-20230930.xsd#RGPX_PromissoryNotesMember" xlink:label="RGPX_PromissoryNotesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RGPX_PromissoryNotesMember" xlink:to="RGPX_PromissoryNotesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RGPX_PromissoryNotesMember_lbl" xml:lang="en-US">Promissory Notes [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="rgpx-20230930.xsd#RGPX_Promissory1NotesMember" xlink:label="RGPX_Promissory1NotesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RGPX_Promissory1NotesMember" xlink:to="RGPX_Promissory1NotesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RGPX_Promissory1NotesMember_lbl" xml:lang="en-US">Promissory 1 Notes [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionAxis_lbl" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="rgpx-20230930.xsd#RGPX_AggregateInterestExpenseMember" xlink:label="RGPX_AggregateInterestExpenseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RGPX_AggregateInterestExpenseMember" xlink:to="RGPX_AggregateInterestExpenseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RGPX_AggregateInterestExpenseMember_lbl" xml:lang="en-US">Aggregate Interest Expense [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsSoldUnderAgreementsToRepurchaseAxis" xlink:label="us-gaap_AssetsSoldUnderAgreementsToRepurchaseAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsSoldUnderAgreementsToRepurchaseAxis" xlink:to="us-gaap_AssetsSoldUnderAgreementsToRepurchaseAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsSoldUnderAgreementsToRepurchaseAxis_lbl" xml:lang="en-US">Securities or Other Assets Sold under Agreements to Repurchase [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="rgpx-20230930.xsd#RGPX_AssetPurchaseAgreementLiabilityMember" xlink:label="RGPX_AssetPurchaseAgreementLiabilityMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RGPX_AssetPurchaseAgreementLiabilityMember" xlink:to="RGPX_AssetPurchaseAgreementLiabilityMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RGPX_AssetPurchaseAgreementLiabilityMember_lbl" xml:lang="en-US">Asset Purchase Agreement Liability [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis" xlink:label="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis" xlink:to="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis_lbl" xml:lang="en-US">Property Subject to or Available for Operating Lease [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="rgpx-20230930.xsd#RGPX_OfficeLeaseMember" xlink:label="RGPX_OfficeLeaseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RGPX_OfficeLeaseMember" xlink:to="RGPX_OfficeLeaseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RGPX_OfficeLeaseMember_lbl" xml:lang="en-US">Office Lease [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseContractualTermAxis_lbl" xml:lang="en-US">Lease Contractual Term [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="rgpx-20230930.xsd#RGPX_MonthlyRentalPaymentsMember" xlink:label="RGPX_MonthlyRentalPaymentsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RGPX_MonthlyRentalPaymentsMember" xlink:to="RGPX_MonthlyRentalPaymentsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RGPX_MonthlyRentalPaymentsMember_lbl" xml:lang="en-US">Monthly Rental Payments [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="rgpx-20230930.xsd#RGPX_SecurityDepositMember" xlink:label="RGPX_SecurityDepositMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RGPX_SecurityDepositMember" xlink:to="RGPX_SecurityDepositMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RGPX_SecurityDepositMember_lbl" xml:lang="en-US">Security Deposit [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="rgpx-20230930.xsd#RGPX_PlantFacilityMember" xlink:label="RGPX_PlantFacilityMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RGPX_PlantFacilityMember" xlink:to="RGPX_PlantFacilityMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RGPX_PlantFacilityMember_lbl" xml:lang="en-US">Plant Facility [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="rgpx-20230930.xsd#RGPX_OperatingLeaseCostMember" xlink:label="RGPX_OperatingLeaseCostMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RGPX_OperatingLeaseCostMember" xlink:to="RGPX_OperatingLeaseCostMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RGPX_OperatingLeaseCostMember_lbl" xml:lang="en-US">Operating Lease Cost [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="rgpx-20230930.xsd#RGPX_BoardMembersAndConsultantsMember" xlink:label="RGPX_BoardMembersAndConsultantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RGPX_BoardMembersAndConsultantsMember" xlink:to="RGPX_BoardMembersAndConsultantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RGPX_BoardMembersAndConsultantsMember_lbl" xml:lang="en-US">Board Members And Consultants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="rgpx-20230930.xsd#RGPX_ServicesRenderedMember" xlink:label="RGPX_ServicesRenderedMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RGPX_ServicesRenderedMember" xlink:to="RGPX_ServicesRenderedMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RGPX_ServicesRenderedMember_lbl" xml:lang="en-US">Services Rendered [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_lbl" xml:lang="en-US">Equity-Based Arrangements, Individual Contracts, Type of Deferred Compensation [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="rgpx-20230930.xsd#RGPX_WarrantsMember" xlink:label="RGPX_WarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RGPX_WarrantsMember" xlink:to="RGPX_WarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RGPX_WarrantsMember_lbl" xml:lang="en-US">Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent Event [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current Assets-</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xml:lang="en-US">Prepaid expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total Current Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xml:lang="en-US">Website, net of accumulated amortization of $27,834 and $26,397, as of September 30, 2023 and March 31, 2023, respectively</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MachineryAndEquipmentGross" xlink:label="us-gaap_MachineryAndEquipmentGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MachineryAndEquipmentGross" xlink:to="us-gaap_MachineryAndEquipmentGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MachineryAndEquipmentGross_lbl" xml:lang="en-US">Furniture and computer equipment, net of accumulated depreciation of $735 and $197 as of September 30, 2023 and March 31, 2023, respectively</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Right of use asset</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; DEFICIT</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="rgpx-20230930.xsd#RGPX_RelatedPartyAdvances" xlink:label="RGPX_RelatedPartyAdvances" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RGPX_RelatedPartyAdvances" xlink:to="RGPX_RelatedPartyAdvances_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RGPX_RelatedPartyAdvances_lbl" xml:lang="en-US">Related party advances</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Other accrued liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNotesPayableCurrent" xlink:label="us-gaap_OtherNotesPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNotesPayableCurrent" xlink:to="us-gaap_OtherNotesPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNotesPayableCurrent_lbl" xml:lang="en-US">Current portion of notes payable to shareholder</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayableCurrent" xlink:label="us-gaap_NotesPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayableCurrent" xlink:to="us-gaap_NotesPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesPayableCurrent_lbl" xml:lang="en-US">Current portion of notes payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Current portion of lease liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total Current Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="rgpx-20230930.xsd#RGPX_NotesPayableShareholder" xlink:label="RGPX_NotesPayableShareholder" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RGPX_NotesPayableShareholder" xlink:to="RGPX_NotesPayableShareholder_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RGPX_NotesPayableShareholder_lbl" xml:lang="en-US">Notes payable to shareholder, net of current portion</link:label>
      <link:loc xlink:type="locator" xlink:href="rgpx-20230930.xsd#RGPX_NotesPayableRelatedParties" xlink:label="RGPX_NotesPayableRelatedParties" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RGPX_NotesPayableRelatedParties" xlink:to="RGPX_NotesPayableRelatedParties_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RGPX_NotesPayableRelatedParties_lbl" xml:lang="en-US">Notes payable to related parties</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayable" xlink:label="us-gaap_NotesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayable" xlink:to="us-gaap_NotesPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesPayable_lbl" xml:lang="en-US">Notes payable, net of current portion</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Lease liabilities, net of current portion</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments and Contingencies (Note 7)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Stockholders&#8217; Deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common stock: $0.001 par value: 675,000,000 shares authorized: 277,915,910 and 277,112,660 issued and outstanding at September 30, 2023 and March 31, 2023, respectively</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Additional paid-in capital</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total Stockholders&#8217; Deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total Liabilities and Stockholders&#8217; Deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating Expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">Selling, general and administration</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Total Operating Expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Operating Loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US">Other Income (Expense)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestExpense_lbl" xml:lang="en-US">Interest expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xml:lang="en-US">Foreign currency gain (loss)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Total Other Income (Expense)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net Loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:to="us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_lbl" xml:lang="en-US">Basic and Diluted Loss per Common Share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Weighted Average Number of Common Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_lbl" xml:lang="en-US">Schedule of Defined Benefit Plans Disclosures [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="us-gaap_DefinedBenefitPlanDisclosureLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="us-gaap_DefinedBenefitPlanDisclosureLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedBenefitPlanDisclosureLineItems_lbl" xml:lang="en-US">Defined Benefit Plan Disclosure [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalCashFlowElementsOperatingActivitiesAbstract" xlink:label="us-gaap_AdditionalCashFlowElementsOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalCashFlowElementsOperatingActivitiesAbstract" xlink:to="us-gaap_AdditionalCashFlowElementsOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalCashFlowElementsOperatingActivitiesAbstract_lbl" xml:lang="en-US">Cash Flows from Operating Activities:</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_2_lbl" xml:lang="en-US">Net loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to cash flows used in operating activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Depreciation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Stock-based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_lbl" xml:lang="en-US">Non-cash research and development expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" xml:lang="en-US">Amortization of ROU assets, net of liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_2_lbl" xml:lang="en-US">Foreign currency adjustments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xml:lang="en-US">Prepaid expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Accounts payable and accrued liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Cash Flows from Investing Activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireFurnitureAndFixtures" xlink:label="us-gaap_PaymentsToAcquireFurnitureAndFixtures" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireFurnitureAndFixtures" xlink:to="us-gaap_PaymentsToAcquireFurnitureAndFixtures_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireFurnitureAndFixtures_lbl" xml:lang="en-US">Purchase of furniture and computer equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash used in investing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Cash Flows from Financing Activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromRelatedPartyDebt" xlink:to="us-gaap_ProceedsFromRelatedPartyDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt_lbl" xml:lang="en-US">Related party advances</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="us-gaap_RepaymentsOfNotesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfNotesPayable" xlink:to="us-gaap_RepaymentsOfNotesPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfNotesPayable_lbl" xml:lang="en-US">Repayment of notes payable to shareholder</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="us-gaap_ProceedsFromNotesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromNotesPayable" xlink:to="us-gaap_ProceedsFromNotesPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromNotesPayable_lbl" xml:lang="en-US">Proceeds from notes payable to shareholder</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" xml:lang="en-US">Proceeds from sale of common stock and warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by financing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US">Increase (decrease) in cash and equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Cash and cash equivalents, beginning of period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2_lbl" xml:lang="en-US">Cash and cash equivalents, end of period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">Supplemental Cash Flow Information &#8211; Cash Paid For:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxesPaid" xlink:label="us-gaap_IncomeTaxesPaid" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaid" xlink:to="us-gaap_IncomeTaxesPaid_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxesPaid_lbl" xml:lang="en-US">Income Taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaid" xlink:label="us-gaap_InterestPaid" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaid" xlink:to="us-gaap_InterestPaid_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaid_lbl" xml:lang="en-US">Interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xml:lang="en-US">Non-Cash Investing and Financing Activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="rgpx-20230930.xsd#RGPX_AccruedInterestConvertedIntoNotePayableToShareholder" xlink:label="RGPX_AccruedInterestConvertedIntoNotePayableToShareholder" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RGPX_AccruedInterestConvertedIntoNotePayableToShareholder" xlink:to="RGPX_AccruedInterestConvertedIntoNotePayableToShareholder_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RGPX_AccruedInterestConvertedIntoNotePayableToShareholder_lbl" xml:lang="en-US">Accrued interest converted into notes payable</link:label>
      <link:loc xlink:type="locator" xlink:href="rgpx-20230930.xsd#RGPX_OperatingLeasesRouAssetAndLiabilities" xlink:label="RGPX_OperatingLeasesRouAssetAndLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RGPX_OperatingLeasesRouAssetAndLiabilities" xlink:to="RGPX_OperatingLeasesRouAssetAndLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RGPX_OperatingLeasesRouAssetAndLiabilities_lbl" xml:lang="en-US">Operating leases, ROU asset and liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1" xlink:to="us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1_lbl" xml:lang="en-US">Shares issued for the acquisition of intellectual property</link:label>
      <link:loc xlink:type="locator" xlink:href="rgpx-20230930.xsd#RGPX_NoncashOrPartNoncashAcquisitionOfIntangibleAssetsExcludingGoodwill" xlink:label="RGPX_NoncashOrPartNoncashAcquisitionOfIntangibleAssetsExcludingGoodwill" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RGPX_NoncashOrPartNoncashAcquisitionOfIntangibleAssetsExcludingGoodwill" xlink:to="RGPX_NoncashOrPartNoncashAcquisitionOfIntangibleAssetsExcludingGoodwill_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RGPX_NoncashOrPartNoncashAcquisitionOfIntangibleAssetsExcludingGoodwill_lbl" xml:lang="en-US">Note payable issued for acquisition of intellectual property</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_2_lbl" xml:lang="en-US">Beginning balance, value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_2_lbl" xml:lang="en-US">Common Stock, Shares, Outstanding, Beginning Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Shares and warrants sold for cash</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xml:lang="en-US">Stock-based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xml:lang="en-US">Stock Issued During Period, Shares, Issued for Services</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Shares and warrants sold for cash</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_3_lbl" xml:lang="en-US">Ending balance, value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_3_lbl" xml:lang="en-US">Common Stock, Shares, Outstanding, Ending Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NatureOfOperations" xlink:to="us-gaap_NatureOfOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NatureOfOperations_lbl" xml:lang="en-US">NATURE OF OPERATIONS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" xml:lang="en-US">BASIS OF PRESENTATION OF INTERIM FINANCIAL STATEMENTS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:label="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:to="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_lbl" xml:lang="en-US">GOING CONCERN</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">SIGNIFICANT ACCOUNTING POLICIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US">RELATED PARTY TRANSACTIONS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl" xml:lang="en-US">INTANGIBLE ASSETS AND INTELLECTUAL PROPERTY</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</link:label>
      <link:loc xlink:type="locator" xlink:href="rgpx-20230930.xsd#RGPX_DisclosureOperatingLeasesAbstract" xlink:label="RGPX_DisclosureOperatingLeasesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RGPX_DisclosureOperatingLeasesAbstract" xlink:to="RGPX_DisclosureOperatingLeasesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RGPX_DisclosureOperatingLeasesAbstract_lbl" xml:lang="en-US">Operating Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xml:lang="en-US">OPERATING LEASES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US">Equity [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">STOCKHOLDERS&#8217; DEFICIT</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">SUBSEQUENT EVENTS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xml:lang="en-US">Revenue Recognition</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Earnings per Share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock" xlink:label="us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock" xlink:to="us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock_lbl" xml:lang="en-US">Website</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPreproductionDesignAndDevelopmentCosts" xlink:label="us-gaap_PropertyPlantAndEquipmentPreproductionDesignAndDevelopmentCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPreproductionDesignAndDevelopmentCosts" xlink:to="us-gaap_PropertyPlantAndEquipmentPreproductionDesignAndDevelopmentCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPreproductionDesignAndDevelopmentCosts_lbl" xml:lang="en-US">Furniture and Computer Equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xml:lang="en-US">Right of Use Assets and Lease Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US">Stock-Based Compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock" xlink:label="us-gaap_ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock" xlink:to="us-gaap_ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock_lbl" xml:lang="en-US">Research and Development</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationDateOfIncorporation" xlink:label="dei_EntityIncorporationDateOfIncorporation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationDateOfIncorporation" xlink:to="dei_EntityIncorporationDateOfIncorporation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationDateOfIncorporation_lbl" xml:lang="en-US">Entity Incorporation, Date of Incorporation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssued_lbl" xml:lang="en-US">Shares, Issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionContingentConsiderationLiability" xlink:label="us-gaap_AssetAcquisitionContingentConsiderationLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionContingentConsiderationLiability" xlink:to="us-gaap_AssetAcquisitionContingentConsiderationLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetAcquisitionContingentConsiderationLiability_lbl" xml:lang="en-US">Asset Acquisition, Contingent Consideration, Liability</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockholdersEquity_4_lbl" xml:lang="en-US">Equity, Attributable to Parent</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US">Class of Warrant or Right, Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xml:lang="en-US">Amortization of Intangible Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherDepreciationAndAmortization" xlink:label="us-gaap_OtherDepreciationAndAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherDepreciationAndAmortization" xlink:to="us-gaap_OtherDepreciationAndAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherDepreciationAndAmortization_lbl" xml:lang="en-US">Other Depreciation and Amortization</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeFinanceLeaseDiscountRate" xlink:label="us-gaap_LesseeFinanceLeaseDiscountRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeFinanceLeaseDiscountRate" xlink:to="us-gaap_LesseeFinanceLeaseDiscountRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeFinanceLeaseDiscountRate_lbl" xml:lang="en-US">Lessee, Finance Lease, Discount Rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionRate" xlink:label="us-gaap_RelatedPartyTransactionRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionRate" xlink:to="us-gaap_RelatedPartyTransactionRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionRate_lbl" xml:lang="en-US">Related Party Transaction, Rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesAndLoansPayable" xlink:label="us-gaap_NotesAndLoansPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesAndLoansPayable" xlink:to="us-gaap_NotesAndLoansPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesAndLoansPayable_lbl" xml:lang="en-US">Notes and Loans Payable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RGPX_RelatedPartyAdvances" xlink:to="RGPX_RelatedPartyAdvances_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="RGPX_RelatedPartyAdvances_2_lbl" xml:lang="en-US">[custom:RelatedPartyAdvances-0]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpense_2_lbl" xml:lang="en-US">Interest Expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfNotesPayable" xlink:to="us-gaap_RepaymentsOfNotesPayable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfNotesPayable_2_lbl" xml:lang="en-US">Repayments of Notes Payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:label="us-gaap_DebtInstrumentInterestRateDuringPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:to="us-gaap_DebtInstrumentInterestRateDuringPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateDuringPeriod_lbl" xml:lang="en-US">Debt Instrument, Interest Rate During Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RGPX_NotesPayableRelatedParties" xlink:to="RGPX_NotesPayableRelatedParties_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="RGPX_NotesPayableRelatedParties_2_lbl" xml:lang="en-US">[custom:NotesPayableRelatedParties-0]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseDebt" xlink:to="us-gaap_InterestExpenseDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpenseDebt_lbl" xml:lang="en-US">Interest Expense, Debt</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayable" xlink:to="us-gaap_NotesPayable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NotesPayable_2_lbl" xml:lang="en-US">Notes Payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentCarryingAmount" xlink:to="us-gaap_DebtInstrumentCarryingAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentCarryingAmount_lbl" xml:lang="en-US">Long-Term Debt, Gross</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPayableCurrent" xlink:label="us-gaap_InterestPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPayableCurrent" xlink:to="us-gaap_InterestPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPayableCurrent_lbl" xml:lang="en-US">Interest Payable, Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermNotesPayable" xlink:label="us-gaap_LongTermNotesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermNotesPayable" xlink:to="us-gaap_LongTermNotesPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermNotesPayable_lbl" xml:lang="en-US">Notes Payable, Noncurrent</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_2_lbl" xml:lang="en-US">Accrued Liabilities, Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsDescription" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationContingentConsiderationArrangementsDescription" xlink:to="us-gaap_BusinessCombinationContingentConsiderationArrangementsDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsDescription_lbl" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAssetsSoldUnderAgreementsToRepurchaseTable" xlink:label="us-gaap_ScheduleOfAssetsSoldUnderAgreementsToRepurchaseTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAssetsSoldUnderAgreementsToRepurchaseTable" xlink:to="us-gaap_ScheduleOfAssetsSoldUnderAgreementsToRepurchaseTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAssetsSoldUnderAgreementsToRepurchaseTable_lbl" xml:lang="en-US">Schedule of Assets Sold under Agreements to Repurchase [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsSoldUnderAgreementsToRepurchaseLineItems" xlink:label="us-gaap_AssetsSoldUnderAgreementsToRepurchaseLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsSoldUnderAgreementsToRepurchaseLineItems" xlink:to="us-gaap_AssetsSoldUnderAgreementsToRepurchaseLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsSoldUnderAgreementsToRepurchaseLineItems_lbl" xml:lang="en-US">Assets Sold under Agreements to Repurchase [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_2_lbl" xml:lang="en-US">General and Administrative Expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeaseDescriptionTable_lbl" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl" xml:lang="en-US">Operating Leases, Future Minimum Payments Due</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PrepaidExpenseCurrent_2_lbl" xml:lang="en-US">Prepaid Expense, Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseDescription" xlink:label="us-gaap_LesseeOperatingLeaseDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseDescription" xlink:to="us-gaap_LesseeOperatingLeaseDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseDescription_lbl" xml:lang="en-US">Lessee, Operating Lease, Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalLeaseObligationsCurrent" xlink:label="us-gaap_CapitalLeaseObligationsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeaseObligationsCurrent" xlink:to="us-gaap_CapitalLeaseObligationsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalLeaseObligationsCurrent_lbl" xml:lang="en-US">Capital Lease Obligations, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensation_2_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
      <link:loc xlink:type="locator" xlink:href="rgpx-20230930.xsd#RGPX_StockBasedCompensationUnrecognizedCompensationCost" xlink:label="RGPX_StockBasedCompensationUnrecognizedCompensationCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RGPX_StockBasedCompensationUnrecognizedCompensationCost" xlink:to="RGPX_StockBasedCompensationUnrecognizedCompensationCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RGPX_StockBasedCompensationUnrecognizedCompensationCost_lbl" xml:lang="en-US">[custom:StockBasedCompensationUnrecognizedCompensationCost-0]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Exercise Price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_2_lbl" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityContractTerms" xlink:label="us-gaap_TemporaryEquityContractTerms" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityContractTerms" xlink:to="us-gaap_TemporaryEquityContractTerms_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityContractTerms_lbl" xml:lang="en-US">Temporary Equity, Contract Terms</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTable_lbl" xml:lang="en-US">Subsequent Event [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMaturityDate" xlink:to="us-gaap_DebtInstrumentMaturityDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl" xml:lang="en-US">Debt Instrument, Maturity Date</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_2_lbl" xml:lang="en-US">Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_2_lbl" xml:lang="en-US">Operating Expenses [Default Label]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_2_lbl" xml:lang="en-US">Operating Income (Loss)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_2_lbl" xml:lang="en-US">Increase (Decrease) in Prepaid Expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireFurnitureAndFixtures" xlink:to="us-gaap_PaymentsToAcquireFurnitureAndFixtures_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireFurnitureAndFixtures_2_lbl" xml:lang="en-US">Payments to Acquire Furniture and Fixtures</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromRelatedPartyDebt" xlink:to="us-gaap_ProceedsFromRelatedPartyDebt_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt_2_lbl" xml:lang="en-US">Proceeds from Related Party Debt</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_2_lbl" xml:lang="en-US">Stock Issued During Period, Value, Issued for Services</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>11
<FILENAME>rgpx-20230930_pre.xml
<DESCRIPTION>PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://regenerexpharmainc.com/role/Cover" xlink:href="rgpx-20230930.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://regenerexpharmainc.com/role/BalanceSheets" xlink:href="rgpx-20230930.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://regenerexpharmainc.com/role/BalanceSheetsParenthetical" xlink:href="rgpx-20230930.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://regenerexpharmainc.com/role/StatementsOfOperations" xlink:href="rgpx-20230930.xsd#StatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://regenerexpharmainc.com/role/StatementsOfCashFlows" xlink:href="rgpx-20230930.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://regenerexpharmainc.com/role/StatementsOfStockholdersDeficit" xlink:href="rgpx-20230930.xsd#StatementsOfStockholdersDeficit" xlink:type="simple" />
    <link:roleRef roleURI="http://regenerexpharmainc.com/role/NatureOfOperations" xlink:href="rgpx-20230930.xsd#NatureOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://regenerexpharmainc.com/role/BasisOfPresentationOfInterimFinancialStatements" xlink:href="rgpx-20230930.xsd#BasisOfPresentationOfInterimFinancialStatements" xlink:type="simple" />
    <link:roleRef roleURI="http://regenerexpharmainc.com/role/GoingConcern" xlink:href="rgpx-20230930.xsd#GoingConcern" xlink:type="simple" />
    <link:roleRef roleURI="http://regenerexpharmainc.com/role/SignificantAccountingPolicies" xlink:href="rgpx-20230930.xsd#SignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://regenerexpharmainc.com/role/RelatedPartyTransactions" xlink:href="rgpx-20230930.xsd#RelatedPartyTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://regenerexpharmainc.com/role/IntangibleAssetsAndIntellectualProperty" xlink:href="rgpx-20230930.xsd#IntangibleAssetsAndIntellectualProperty" xlink:type="simple" />
    <link:roleRef roleURI="http://regenerexpharmainc.com/role/CommitmentsAndContingencies" xlink:href="rgpx-20230930.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://regenerexpharmainc.com/role/OperatingLeases" xlink:href="rgpx-20230930.xsd#OperatingLeases" xlink:type="simple" />
    <link:roleRef roleURI="http://regenerexpharmainc.com/role/StockholdersDeficit" xlink:href="rgpx-20230930.xsd#StockholdersDeficit" xlink:type="simple" />
    <link:roleRef roleURI="http://regenerexpharmainc.com/role/SubsequentEvents" xlink:href="rgpx-20230930.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://regenerexpharmainc.com/role/SignificantAccountingPoliciesPolicies" xlink:href="rgpx-20230930.xsd#SignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://regenerexpharmainc.com/role/NatureOfOperationsDetailsNarrative" xlink:href="rgpx-20230930.xsd#NatureOfOperationsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://regenerexpharmainc.com/role/GoingConcernDetailsNarrative" xlink:href="rgpx-20230930.xsd#GoingConcernDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://regenerexpharmainc.com/role/SignificantAccountingPoliciesDetailsNarrative" xlink:href="rgpx-20230930.xsd#SignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://regenerexpharmainc.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:href="rgpx-20230930.xsd#RelatedPartyTransactionsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://regenerexpharmainc.com/role/IntangibleAssetsAndIntellectualPropertyDetailsNarrative" xlink:href="rgpx-20230930.xsd#IntangibleAssetsAndIntellectualPropertyDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://regenerexpharmainc.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="rgpx-20230930.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://regenerexpharmainc.com/role/OperatingLeasesDetailsNarrative" xlink:href="rgpx-20230930.xsd#OperatingLeasesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://regenerexpharmainc.com/role/StockholdersDeficitDetailsNarrative" xlink:href="rgpx-20230930.xsd#StockholdersDeficitDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://regenerexpharmainc.com/role/SubsequentEventsDetailsNarrative" xlink:href="rgpx-20230930.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://regenerexpharmainc.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://regenerexpharmainc.com/role/BalanceSheets" xlink:title="00000002 - Statement - BALANCE SHEETS (UNAUDITED)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssetsCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaapPrepaidExpenseCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapPrepaidExpenseCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MachineryAndEquipmentGross" xlink:label="loc_us-gaapMachineryAndEquipmentGross" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapMachineryAndEquipmentGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="rgpx-20230930.xsd#RGPX_RelatedPartyAdvances" xlink:label="loc_RGPXRelatedPartyAdvances" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_RGPXRelatedPartyAdvances" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaapEmployeeRelatedLiabilitiesCurrent" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapEmployeeRelatedLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNotesPayableCurrent" xlink:label="loc_us-gaapOtherNotesPayableCurrent" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapOtherNotesPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayableCurrent" xlink:label="loc_us-gaapNotesPayableCurrent" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapNotesPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="rgpx-20230930.xsd#RGPX_NotesPayableShareholder" xlink:label="loc_RGPXNotesPayableShareholder" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_RGPXNotesPayableShareholder" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="rgpx-20230930.xsd#RGPX_NotesPayableRelatedParties" xlink:label="loc_RGPXNotesPayableRelatedParties" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_RGPXNotesPayableRelatedParties" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayable" xlink:label="loc_us-gaapNotesPayable" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapNotesPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommitmentsAndContingencies" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://regenerexpharmainc.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - BALANCE SHEETS (UNAUDITED) (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://regenerexpharmainc.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - STATEMENTS OF OPERATIONS (UNAUDITED)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaapOperatingExpensesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingExpensesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaapNonoperatingIncomeExpenseAbstract" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapInterestExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaapForeignCurrencyTransactionGainLossBeforeTax" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapForeignCurrencyTransactionGainLossBeforeTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsPerBasicShare" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsPerBasicShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://regenerexpharmainc.com/role/StatementsOfCashFlows" xlink:title="00000005 - Statement - STATEMENTS OF CASH FLOWS (UNAUDITED)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaapStatementOfCashFlowsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAffiliatesMember" xlink:label="loc_us-gaapOtherAffiliatesMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapOtherAffiliatesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="rgpx-20230930.xsd#RGPX_ShareholderMember" xlink:label="loc_RGPXShareholderMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_RGPXShareholderMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalCashFlowElementsOperatingActivitiesAbstract" xlink:label="loc_us-gaapAdditionalCashFlowElementsOperatingActivitiesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapAdditionalCashFlowElementsOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdditionalCashFlowElementsOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapDepreciation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaapPaymentsToAcquireIntangibleAssets" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsToAcquireIntangibleAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAssetAmortizationExpense" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAssetAmortizationExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaapForeignCurrencyTransactionGainLossBeforeTax" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapForeignCurrencyTransactionGainLossBeforeTax" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidExpense" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireFurnitureAndFixtures" xlink:label="loc_us-gaapPaymentsToAcquireFurnitureAndFixtures" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapPaymentsToAcquireFurnitureAndFixtures" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="loc_us-gaapProceedsFromRelatedPartyDebt" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapProceedsFromRelatedPartyDebt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="loc_us-gaapRepaymentsOfNotesPayable" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapRepaymentsOfNotesPayable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="loc_us-gaapProceedsFromNotesPayable" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapProceedsFromNotesPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaapProceedsFromIssuanceOfWarrants" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaapSupplementalCashFlowInformationAbstract" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxesPaid" xlink:label="loc_us-gaapIncomeTaxesPaid" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_us-gaapIncomeTaxesPaid" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaid" xlink:label="loc_us-gaapInterestPaid" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_us-gaapInterestPaid" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="rgpx-20230930.xsd#RGPX_AccruedInterestConvertedIntoNotePayableToShareholder" xlink:label="loc_RGPXAccruedInterestConvertedIntoNotePayableToShareholder" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_RGPXAccruedInterestConvertedIntoNotePayableToShareholder" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="rgpx-20230930.xsd#RGPX_OperatingLeasesRouAssetAndLiabilities" xlink:label="loc_RGPXOperatingLeasesRouAssetAndLiabilities" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_RGPXOperatingLeasesRouAssetAndLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1" xlink:label="loc_us-gaapNoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapNoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="rgpx-20230930.xsd#RGPX_NoncashOrPartNoncashAcquisitionOfIntangibleAssetsExcludingGoodwill" xlink:label="loc_RGPXNoncashOrPartNoncashAcquisitionOfIntangibleAssetsExcludingGoodwill" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_RGPXNoncashOrPartNoncashAcquisitionOfIntangibleAssetsExcludingGoodwill" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://regenerexpharmainc.com/role/StatementsOfStockholdersDeficit" xlink:title="00000006 - Statement - STATEMENTS OF STOCKHOLDERS&apos; DEFICIT (UNAUDITED)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaapStatementOfStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfStockholdersEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapRetainedEarningsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_2" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding_2" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://regenerexpharmainc.com/role/NatureOfOperations" xlink:title="00000007 - Disclosure - NATURE OF OPERATIONS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NatureOfOperations" xlink:label="loc_us-gaapNatureOfOperations" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapNatureOfOperations" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://regenerexpharmainc.com/role/BasisOfPresentationOfInterimFinancialStatements" xlink:title="00000008 - Disclosure - BASIS OF PRESENTATION OF INTERIM FINANCIAL STATEMENTS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="loc_us-gaapBusinessDescriptionAndBasisOfPresentationTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapBusinessDescriptionAndBasisOfPresentationTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://regenerexpharmainc.com/role/GoingConcern" xlink:title="00000009 - Disclosure - GOING CONCERN">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:label="loc_us-gaapSubstantialDoubtAboutGoingConcernTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapSubstantialDoubtAboutGoingConcernTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://regenerexpharmainc.com/role/SignificantAccountingPolicies" xlink:title="00000010 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaapSignificantAccountingPoliciesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapSignificantAccountingPoliciesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://regenerexpharmainc.com/role/RelatedPartyTransactions" xlink:title="00000011 - Disclosure - RELATED PARTY TRANSACTIONS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://regenerexpharmainc.com/role/IntangibleAssetsAndIntellectualProperty" xlink:title="00000012 - Disclosure - INTANGIBLE ASSETS AND INTELLECTUAL PROPERTY">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="loc_us-gaapIntangibleAssetsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapIntangibleAssetsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://regenerexpharmainc.com/role/CommitmentsAndContingencies" xlink:title="00000013 - Disclosure - COMMITMENTS AND CONTINGENCIES">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://regenerexpharmainc.com/role/OperatingLeases" xlink:title="00000014 - Disclosure - OPERATING LEASES">
      <link:loc xlink:type="locator" xlink:href="rgpx-20230930.xsd#RGPX_DisclosureOperatingLeasesAbstract" xlink:label="loc_RGPXDisclosureOperatingLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="loc_us-gaapLesseeOperatingLeasesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_RGPXDisclosureOperatingLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeasesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://regenerexpharmainc.com/role/StockholdersDeficit" xlink:title="00000015 - Disclosure - STOCKHOLDERS&#8217; DEFICIT">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://regenerexpharmainc.com/role/SubsequentEvents" xlink:title="00000016 - Disclosure - SUBSEQUENT EVENTS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaapSubsequentEventsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapSubsequentEventsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://regenerexpharmainc.com/role/SignificantAccountingPoliciesPolicies" xlink:title="00000017 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="loc_us-gaapRevenueRecognitionPolicyTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapRevenueRecognitionPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaapEarningsPerSharePolicyTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapEarningsPerSharePolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock" xlink:label="loc_us-gaapResearchDevelopmentAndComputerSoftwarePolicyTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapResearchDevelopmentAndComputerSoftwarePolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPreproductionDesignAndDevelopmentCosts" xlink:label="loc_us-gaapPropertyPlantAndEquipmentPreproductionDesignAndDevelopmentCosts" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentPreproductionDesignAndDevelopmentCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="loc_us-gaapLesseeLeasesPolicyTextBlock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapLesseeLeasesPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaapShareBasedCompensationOptionAndIncentivePlansPolicy" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock" xlink:label="loc_us-gaapScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://regenerexpharmainc.com/role/NatureOfOperationsDetailsNarrative" xlink:title="00000018 - Disclosure - NATURE OF OPERATIONS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="rgpx-20230930.xsd#RGPX_PurchaseIntellectualPropertyMember" xlink:label="loc_RGPXPurchaseIntellectualPropertyMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_RGPXPurchaseIntellectualPropertyMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationDateOfIncorporation" xlink:label="loc_deiEntityIncorporationDateOfIncorporation" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityIncorporationDateOfIncorporation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaapSharesIssued" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionContingentConsiderationLiability" xlink:label="loc_us-gaapAssetAcquisitionContingentConsiderationLiability" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAssetAcquisitionContingentConsiderationLiability" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://regenerexpharmainc.com/role/GoingConcernDetailsNarrative" xlink:title="00000019 - Disclosure - GOING CONCERN (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://regenerexpharmainc.com/role/SignificantAccountingPoliciesDetailsNarrative" xlink:title="00000020 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_srtRangeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetUsefulLife" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetUsefulLife" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaapAmortizationOfIntangibleAssets" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapAmortizationOfIntangibleAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaapPropertyPlantAndEquipmentUsefulLife" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentUsefulLife" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherDepreciationAndAmortization" xlink:label="loc_us-gaapOtherDepreciationAndAmortization" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapOtherDepreciationAndAmortization" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeFinanceLeaseDiscountRate" xlink:label="loc_us-gaapLesseeFinanceLeaseDiscountRate" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapLesseeFinanceLeaseDiscountRate" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://regenerexpharmainc.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:title="00000021 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaapRelatedPartyTransactionLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ChiefFinancialOfficerMember" xlink:label="loc_srtChiefFinancialOfficerMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_srtChiefFinancialOfficerMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="rgpx-20230930.xsd#RGPX_AffiliatesMember" xlink:label="loc_RGPXAffiliatesMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_RGPXAffiliatesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="loc_srtChiefExecutiveOfficerMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_srtChiefExecutiveOfficerMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="rgpx-20230930.xsd#RGPX_ChiefExecutiveOfficerAndChiefFinancialOfficerMember" xlink:label="loc_RGPXChiefExecutiveOfficerAndChiefFinancialOfficerMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_RGPXChiefExecutiveOfficerAndChiefFinancialOfficerMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MajorityShareholderMember" xlink:label="loc_us-gaapMajorityShareholderMember" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapMajorityShareholderMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="rgpx-20230930.xsd#RGPX_ShareholderMember" xlink:label="loc_RGPXShareholderMember" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_RGPXShareholderMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaapDebtInstrumentAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapDebtInstrumentAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="rgpx-20230930.xsd#RGPX_ReissuedNotesMember" xlink:label="loc_RGPXReissuedNotesMember" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_RGPXReissuedNotesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="rgpx-20230930.xsd#RGPX_PromissoryNotesMember" xlink:label="loc_RGPXPromissoryNotesMember" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_RGPXPromissoryNotesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="rgpx-20230930.xsd#RGPX_Promissory1NotesMember" xlink:label="loc_RGPXPromissory1NotesMember" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_RGPXPromissory1NotesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaapRelatedPartyTransactionAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaapRelatedPartyTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionAxis" xlink:to="loc_us-gaapRelatedPartyTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="rgpx-20230930.xsd#RGPX_AggregateInterestExpenseMember" xlink:label="loc_RGPXAggregateInterestExpenseMember" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionDomain" xlink:to="loc_RGPXAggregateInterestExpenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionRate" xlink:label="loc_us-gaapRelatedPartyTransactionRate" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapRelatedPartyTransactionRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesAndLoansPayable" xlink:label="loc_us-gaapNotesAndLoansPayable" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapNotesAndLoansPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="rgpx-20230930.xsd#RGPX_RelatedPartyAdvances" xlink:label="loc_RGPXRelatedPartyAdvances" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_RGPXRelatedPartyAdvances" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapInterestExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="loc_us-gaapRepaymentsOfNotesPayable" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapRepaymentsOfNotesPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:label="loc_us-gaapDebtInstrumentInterestRateDuringPeriod" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateDuringPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="rgpx-20230930.xsd#RGPX_NotesPayableRelatedParties" xlink:label="loc_RGPXNotesPayableRelatedParties" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_RGPXNotesPayableRelatedParties" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseDebt" xlink:label="loc_us-gaapInterestExpenseDebt" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapInterestExpenseDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayable" xlink:label="loc_us-gaapNotesPayable" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapNotesPayable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaapDebtInstrumentCarryingAmount" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapDebtInstrumentCarryingAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPayableCurrent" xlink:label="loc_us-gaapInterestPayableCurrent" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapInterestPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermNotesPayable" xlink:label="loc_us-gaapLongTermNotesPayable" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapLongTermNotesPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaapDebtInstrumentInterestRateStatedPercentage" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateStatedPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://regenerexpharmainc.com/role/IntangibleAssetsAndIntellectualPropertyDetailsNarrative" xlink:title="00000022 - Disclosure - INTANGIBLE ASSETS AND INTELLECTUAL PROPERTY (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsDescription" xlink:label="loc_us-gaapBusinessCombinationContingentConsiderationArrangementsDescription" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapBusinessCombinationContingentConsiderationArrangementsDescription" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://regenerexpharmainc.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000023 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAssetsSoldUnderAgreementsToRepurchaseTable" xlink:label="loc_us-gaapScheduleOfAssetsSoldUnderAgreementsToRepurchaseTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfAssetsSoldUnderAgreementsToRepurchaseTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsSoldUnderAgreementsToRepurchaseLineItems" xlink:label="loc_us-gaapAssetsSoldUnderAgreementsToRepurchaseLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfAssetsSoldUnderAgreementsToRepurchaseTable" xlink:to="loc_us-gaapAssetsSoldUnderAgreementsToRepurchaseLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsSoldUnderAgreementsToRepurchaseAxis" xlink:label="loc_us-gaapAssetsSoldUnderAgreementsToRepurchaseAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfAssetsSoldUnderAgreementsToRepurchaseTable" xlink:to="loc_us-gaapAssetsSoldUnderAgreementsToRepurchaseAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsSoldUnderAgreementsToRepurchaseTypeDomain" xlink:label="loc_us-gaapAssetsSoldUnderAgreementsToRepurchaseTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsSoldUnderAgreementsToRepurchaseAxis" xlink:to="loc_us-gaapAssetsSoldUnderAgreementsToRepurchaseTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="rgpx-20230930.xsd#RGPX_ChiefExecutiveOfficerAndChiefFinancialOfficerMember" xlink:label="loc_RGPXChiefExecutiveOfficerAndChiefFinancialOfficerMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsSoldUnderAgreementsToRepurchaseTypeDomain" xlink:to="loc_RGPXChiefExecutiveOfficerAndChiefFinancialOfficerMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfAssetsSoldUnderAgreementsToRepurchaseTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="rgpx-20230930.xsd#RGPX_AssetPurchaseAgreementLiabilityMember" xlink:label="loc_RGPXAssetPurchaseAgreementLiabilityMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_RGPXAssetPurchaseAgreementLiabilityMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionContingentConsiderationLiability" xlink:label="loc_us-gaapAssetAcquisitionContingentConsiderationLiability" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsSoldUnderAgreementsToRepurchaseLineItems" xlink:to="loc_us-gaapAssetAcquisitionContingentConsiderationLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsSoldUnderAgreementsToRepurchaseLineItems" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsSoldUnderAgreementsToRepurchaseLineItems" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://regenerexpharmainc.com/role/OperatingLeasesDetailsNarrative" xlink:title="00000024 - Disclosure - OPERATING LEASES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="rgpx-20230930.xsd#RGPX_DisclosureOperatingLeasesAbstract" xlink:label="loc_RGPXDisclosureOperatingLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="loc_us-gaapLesseeLeaseDescriptionTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_RGPXDisclosureOperatingLeasesAbstract" xlink:to="loc_us-gaapLesseeLeaseDescriptionTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="loc_us-gaapLesseeLeaseDescriptionLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLesseeLeaseDescriptionTable" xlink:to="loc_us-gaapLesseeLeaseDescriptionLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis" xlink:label="loc_us-gaapPropertySubjectToOrAvailableForOperatingLeaseAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLesseeLeaseDescriptionTable" xlink:to="loc_us-gaapPropertySubjectToOrAvailableForOperatingLeaseAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain" xlink:label="loc_us-gaapPropertySubjectToOrAvailableForOperatingLeaseDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertySubjectToOrAvailableForOperatingLeaseAxis" xlink:to="loc_us-gaapPropertySubjectToOrAvailableForOperatingLeaseDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="rgpx-20230930.xsd#RGPX_OfficeLeaseMember" xlink:label="loc_RGPXOfficeLeaseMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertySubjectToOrAvailableForOperatingLeaseDomain" xlink:to="loc_RGPXOfficeLeaseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="rgpx-20230930.xsd#RGPX_PlantFacilityMember" xlink:label="loc_RGPXPlantFacilityMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertySubjectToOrAvailableForOperatingLeaseDomain" xlink:to="loc_RGPXPlantFacilityMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="loc_us-gaapLeaseContractualTermAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLesseeLeaseDescriptionTable" xlink:to="loc_us-gaapLeaseContractualTermAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="loc_us-gaapLeaseContractualTermDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeaseContractualTermAxis" xlink:to="loc_us-gaapLeaseContractualTermDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="rgpx-20230930.xsd#RGPX_MonthlyRentalPaymentsMember" xlink:label="loc_RGPXMonthlyRentalPaymentsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeaseContractualTermDomain" xlink:to="loc_RGPXMonthlyRentalPaymentsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="rgpx-20230930.xsd#RGPX_SecurityDepositMember" xlink:label="loc_RGPXSecurityDepositMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeaseContractualTermDomain" xlink:to="loc_RGPXSecurityDepositMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="rgpx-20230930.xsd#RGPX_OperatingLeaseCostMember" xlink:label="loc_RGPXOperatingLeaseCostMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeaseContractualTermDomain" xlink:to="loc_RGPXOperatingLeaseCostMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDue" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLesseeLeaseDescriptionLineItems" xlink:to="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaapPrepaidExpenseCurrent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLesseeLeaseDescriptionLineItems" xlink:to="loc_us-gaapPrepaidExpenseCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseDescription" xlink:label="loc_us-gaapLesseeOperatingLeaseDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLesseeLeaseDescriptionLineItems" xlink:to="loc_us-gaapLesseeOperatingLeaseDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalLeaseObligationsCurrent" xlink:label="loc_us-gaapCapitalLeaseObligationsCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLesseeLeaseDescriptionLineItems" xlink:to="loc_us-gaapCapitalLeaseObligationsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLesseeLeaseDescriptionLineItems" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://regenerexpharmainc.com/role/StockholdersDeficitDetailsNarrative" xlink:title="00000025 - Disclosure - STOCKHOLDERS&#8217; DEFICIT (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="rgpx-20230930.xsd#RGPX_BoardMembersAndConsultantsMember" xlink:label="loc_RGPXBoardMembersAndConsultantsMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_RGPXBoardMembersAndConsultantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaapRelatedPartyTransactionAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_us-gaapRelatedPartyTransactionAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaapRelatedPartyTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionAxis" xlink:to="loc_us-gaapRelatedPartyTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="rgpx-20230930.xsd#RGPX_ServicesRenderedMember" xlink:label="loc_RGPXServicesRenderedMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionDomain" xlink:to="loc_RGPXServicesRenderedMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" xlink:label="loc_us-gaapDeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_us-gaapDeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain" xlink:label="loc_us-gaapEquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" xlink:to="loc_us-gaapEquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="rgpx-20230930.xsd#RGPX_WarrantsMember" xlink:label="loc_RGPXWarrantsMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain" xlink:to="loc_RGPXWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="rgpx-20230930.xsd#RGPX_StockBasedCompensationUnrecognizedCompensationCost" xlink:label="loc_RGPXStockBasedCompensationUnrecognizedCompensationCost" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_RGPXStockBasedCompensationUnrecognizedCompensationCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaapSaleOfStockPricePerShare" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapSaleOfStockPricePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityContractTerms" xlink:label="loc_us-gaapTemporaryEquityContractTerms" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapTemporaryEquityContractTerms" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://regenerexpharmainc.com/role/SubsequentEventsDetailsNarrative" xlink:title="00000026 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaapSubsequentEventTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapSubsequentEventTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaapSubsequentEventLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaapDebtInstrumentAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapDebtInstrumentAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="rgpx-20230930.xsd#RGPX_ReissuedNotesMember" xlink:label="loc_RGPXReissuedNotesMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_RGPXReissuedNotesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayable" xlink:label="loc_us-gaapNotesPayable" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapNotesPayable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaapDebtInstrumentCarryingAmount" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapDebtInstrumentCarryingAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPayableCurrent" xlink:label="loc_us-gaapInterestPayableCurrent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapInterestPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaapDebtInstrumentMaturityDate" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapDebtInstrumentMaturityDate" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139934377318784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Nov. 08, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--03-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-53230<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">REGENEREX PHARMA, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001357878<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">98-0479983<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">NV<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">5348 Vegas Drive #177<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Las Vegas<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NV<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">89108<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(877)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">761-7479<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Elected Not To Use the Extended Transition Period</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">277,915,910<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139934379753808">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>BALANCE SHEETS (UNAUDITED) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current Assets-</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and equivalents</a></td>
<td class="nump">$ 6,080<span></span>
</td>
<td class="nump">$ 1,135<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="nump">13,250<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total Current Assets</a></td>
<td class="nump">19,330<span></span>
</td>
<td class="nump">1,135<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Website, net of accumulated amortization of $27,834 and $26,397, as of September 30, 2023 and March 31, 2023, respectively</a></td>
<td class="nump">2,766<span></span>
</td>
<td class="nump">4,203<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MachineryAndEquipmentGross', window );">Furniture and computer equipment, net of accumulated depreciation of $735 and $197 as of September 30, 2023 and March 31, 2023, respectively</a></td>
<td class="nump">6,962<span></span>
</td>
<td class="nump">1,201<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right of use asset</a></td>
<td class="nump">903,586<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
<td class="nump">932,644<span></span>
</td>
<td class="nump">6,539<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">89,840<span></span>
</td>
<td class="nump">75,145<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RGPX_RelatedPartyAdvances', window );">Related party advances</a></td>
<td class="nump">2,637<span></span>
</td>
<td class="nump">131,887<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation</a></td>
<td class="nump">318,077<span></span>
</td>
<td class="nump">221,192<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Other accrued liabilities</a></td>
<td class="nump">82,034<span></span>
</td>
<td class="nump">125,787<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNotesPayableCurrent', window );">Current portion of notes payable to shareholder</a></td>
<td class="nump">282,786<span></span>
</td>
<td class="nump">222,771<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Current portion of notes payable</a></td>
<td class="nump">2,400,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of lease liabilities</a></td>
<td class="nump">162,295<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total Current Liabilities</a></td>
<td class="nump">3,337,669<span></span>
</td>
<td class="nump">776,782<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RGPX_NotesPayableShareholder', window );">Notes payable to shareholder, net of current portion</a></td>
<td class="nump">275,905<span></span>
</td>
<td class="nump">314,704<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RGPX_NotesPayableRelatedParties', window );">Notes payable to related parties</a></td>
<td class="nump">4,000<span></span>
</td>
<td class="nump">38,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Notes payable, net of current portion</a></td>
<td class="nump">184,232<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Lease liabilities, net of current portion</a></td>
<td class="nump">764,171<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total Liabilities</a></td>
<td class="nump">4,565,977<span></span>
</td>
<td class="nump">1,129,486<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and Contingencies (Note 7)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; Deficit</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock: $0.001 par value: 675,000,000 shares authorized: 277,915,910 and 277,112,660 issued and outstanding at September 30, 2023 and March 31, 2023, respectively</a></td>
<td class="nump">277,916<span></span>
</td>
<td class="nump">277,113<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">1,147,798<span></span>
</td>
<td class="nump">671,963<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(5,059,047)<span></span>
</td>
<td class="num">(2,072,023)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Stockholders&#8217; Deficit</a></td>
<td class="num">(3,633,333)<span></span>
</td>
<td class="num">(1,122,947)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total Liabilities and Stockholders&#8217; Deficit</a></td>
<td class="nump">$ 932,644<span></span>
</td>
<td class="nump">$ 6,539<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RGPX_NotesPayableRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RGPX_NotesPayableRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RGPX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RGPX_NotesPayableShareholder">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RGPX_NotesPayableShareholder</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RGPX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RGPX_RelatedPartyAdvances">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RGPX_RelatedPartyAdvances</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RGPX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-5<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MachineryAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation of tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MachineryAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term notes classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482955/340-10-05-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483032/340-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139934375463696">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>BALANCE SHEETS (UNAUDITED) (Parenthetical) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Finite-Lived Intangible Assets, Accumulated Amortization</a></td>
<td class="nump">$ 27,834<span></span>
</td>
<td class="nump">$ 26,397<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</a></td>
<td class="nump">$ 735<span></span>
</td>
<td class="nump">$ 197<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Par or Stated Value Per Share</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common Stock, Shares Authorized</a></td>
<td class="nump">675,000,000<span></span>
</td>
<td class="nump">675,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common Stock, Shares, Issued</a></td>
<td class="nump">277,915,910<span></span>
</td>
<td class="nump">277,112,660<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common Stock, Shares, Outstanding</a></td>
<td class="nump">277,915,910<span></span>
</td>
<td class="nump">277,112,660<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139934379671888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STATEMENTS OF OPERATIONS (UNAUDITED) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">Selling, general and administration</a></td>
<td class="nump">$ 385,923<span></span>
</td>
<td class="nump">$ 21,504<span></span>
</td>
<td class="nump">$ 546,097<span></span>
</td>
<td class="nump">$ 38,789<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">2,400,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,400,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total Operating Expenses</a></td>
<td class="nump">2,785,923<span></span>
</td>
<td class="nump">21,504<span></span>
</td>
<td class="nump">2,946,097<span></span>
</td>
<td class="nump">38,789<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating Loss</a></td>
<td class="num">(2,785,923)<span></span>
</td>
<td class="num">(21,504)<span></span>
</td>
<td class="num">(2,946,097)<span></span>
</td>
<td class="num">(38,789)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other Income (Expense)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(19,801)<span></span>
</td>
<td class="num">(16,607)<span></span>
</td>
<td class="num">(38,307)<span></span>
</td>
<td class="num">(32,125)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Foreign currency gain (loss)</a></td>
<td class="nump">4,275<span></span>
</td>
<td class="nump">19,675<span></span>
</td>
<td class="num">(2,620)<span></span>
</td>
<td class="nump">29,274<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total Other Income (Expense)</a></td>
<td class="num">(15,526)<span></span>
</td>
<td class="nump">3,068<span></span>
</td>
<td class="num">(40,927)<span></span>
</td>
<td class="num">(2,851)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss</a></td>
<td class="num">$ (2,801,449)<span></span>
</td>
<td class="num">$ (18,436)<span></span>
</td>
<td class="num">$ (2,987,024)<span></span>
</td>
<td class="num">$ (41,640)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare', window );">Basic and Diluted Loss per Common Share</a></td>
<td class="num">$ (0.01)<span></span>
</td>
<td class="nump">$ (0.00)<span></span>
</td>
<td class="num">$ (0.01)<span></span>
</td>
<td class="nump">$ (0.00)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted Average Number of Common Shares Outstanding</a></td>
<td class="nump">277,516,358<span></span>
</td>
<td class="nump">277,112,660<span></span>
</td>
<td class="nump">277,337,306<span></span>
</td>
<td class="nump">277,112,660<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482014/830-20-35-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481956/830-20-45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481926/830-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481839/830-10-45-17<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483013/835-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139934376313232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalCashFlowElementsOperatingActivitiesAbstract', window );"><strong>Cash Flows from Operating Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (2,987,024)<span></span>
</td>
<td class="num">$ (41,640)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to cash flows used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">1,975<span></span>
</td>
<td class="nump">1,794<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">133,388<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Non-cash research and development expenses</a></td>
<td class="nump">2,400,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Amortization of ROU assets, net of liabilities</a></td>
<td class="nump">22,880<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Foreign currency adjustments</a></td>
<td class="nump">2,620<span></span>
</td>
<td class="num">(29,274)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpense', window );">Prepaid expenses</a></td>
<td class="num">(13,250)<span></span>
</td>
<td class="nump">2,756<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued liabilities</a></td>
<td class="nump">146,125<span></span>
</td>
<td class="nump">21,852<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(293,286)<span></span>
</td>
<td class="num">(44,512)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash Flows from Investing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireFurnitureAndFixtures', window );">Purchase of furniture and computer equipment</a></td>
<td class="num">(6,299)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(6,299)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash Flows from Financing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromRelatedPartyDebt', window );">Related party advances</a></td>
<td class="nump">2,437<span></span>
</td>
<td class="nump">7,600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromNotesPayable', window );">Proceeds from notes payable to shareholder</a></td>
<td class="nump">2,843<span></span>
</td>
<td class="nump">34,901<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Proceeds from sale of common stock and warrants</a></td>
<td class="nump">343,250<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">304,530<span></span>
</td>
<td class="nump">42,501<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Increase (decrease) in cash and equivalents</a></td>
<td class="nump">4,945<span></span>
</td>
<td class="num">(2,011)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, beginning of period</a></td>
<td class="nump">1,135<span></span>
</td>
<td class="nump">2,640<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, end of period</a></td>
<td class="nump">6,080<span></span>
</td>
<td class="nump">629<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental Cash Flow Information &#8211; Cash Paid For:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Income Taxes</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaid', window );">Interest</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Non-Cash Investing and Financing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RGPX_AccruedInterestConvertedIntoNotePayableToShareholder', window );">Accrued interest converted into notes payable</a></td>
<td class="nump">78,194<span></span>
</td>
<td class="nump">4,015<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RGPX_OperatingLeasesRouAssetAndLiabilities', window );">Operating leases, ROU asset and liabilities</a></td>
<td class="nump">953,535<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1', window );">Shares issued for the acquisition of intellectual property</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">150,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RGPX_NoncashOrPartNoncashAcquisitionOfIntangibleAssetsExcludingGoodwill', window );">Note payable issued for acquisition of intellectual property</a></td>
<td class="nump">2,400,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_OtherAffiliatesMember', window );">Other Affiliates [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash Flows from Financing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Repayment of notes payable to shareholder</a></td>
<td class="num">(34,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=RGPX_ShareholderMember', window );">Shareholder [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash Flows from Financing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Repayment of notes payable to shareholder</a></td>
<td class="num">$ (10,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RGPX_AccruedInterestConvertedIntoNotePayableToShareholder">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RGPX_AccruedInterestConvertedIntoNotePayableToShareholder</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RGPX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RGPX_NoncashOrPartNoncashAcquisitionOfIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RGPX_NoncashOrPartNoncashAcquisitionOfIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RGPX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RGPX_OperatingLeasesRouAssetAndLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RGPX_OperatingLeasesRouAssetAndLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RGPX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalCashFlowElementsOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalCashFlowElementsOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482014/830-20-35-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481956/830-20-45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481926/830-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481839/830-10-45-17<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, including, but not limited to, capitalized interest and payment to settle zero-coupon bond attributable to accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount; classified as operating and investing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of intangibles that an Entity acquires in a noncash (or part noncash) acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireFurnitureAndFixtures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for acquisition of furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireFurnitureAndFixtures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRelatedPartyDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRelatedPartyDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_OtherAffiliatesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_OtherAffiliatesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=RGPX_ShareholderMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=RGPX_ShareholderMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139934370823952">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>STATEMENTS OF STOCKHOLDERS' DEFICIT (UNAUDITED) - USD ($)<br></strong></div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Retained Earnings [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance, value at Mar. 31, 2022</a></td>
<td class="nump">$ 277,113<span></span>
</td>
<td class="nump">$ 671,963<span></span>
</td>
<td class="num">$ (1,934,693)<span></span>
</td>
<td class="num">$ (985,617)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common Stock, Shares, Outstanding, Beginning Balance at Mar. 31, 2022</a></td>
<td class="nump">277,112,660<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(23,204)<span></span>
</td>
<td class="num">(23,204)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Jun. 30, 2022</a></td>
<td class="nump">$ 277,113<span></span>
</td>
<td class="nump">671,963<span></span>
</td>
<td class="num">(1,957,897)<span></span>
</td>
<td class="num">(1,008,821)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common Stock, Shares, Outstanding, Ending Balance at Jun. 30, 2022</a></td>
<td class="nump">277,112,660<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance, value at Mar. 31, 2022</a></td>
<td class="nump">$ 277,113<span></span>
</td>
<td class="nump">671,963<span></span>
</td>
<td class="num">(1,934,693)<span></span>
</td>
<td class="num">(985,617)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common Stock, Shares, Outstanding, Beginning Balance at Mar. 31, 2022</a></td>
<td class="nump">277,112,660<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(41,640)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Sep. 30, 2022</a></td>
<td class="nump">$ 277,113<span></span>
</td>
<td class="nump">671,963<span></span>
</td>
<td class="num">(1,976,333)<span></span>
</td>
<td class="num">(1,027,257)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common Stock, Shares, Outstanding, Ending Balance at Sep. 30, 2022</a></td>
<td class="nump">277,112,660<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance, value at Jun. 30, 2022</a></td>
<td class="nump">$ 277,113<span></span>
</td>
<td class="nump">671,963<span></span>
</td>
<td class="num">(1,957,897)<span></span>
</td>
<td class="num">(1,008,821)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common Stock, Shares, Outstanding, Beginning Balance at Jun. 30, 2022</a></td>
<td class="nump">277,112,660<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(18,436)<span></span>
</td>
<td class="num">(18,436)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Sep. 30, 2022</a></td>
<td class="nump">$ 277,113<span></span>
</td>
<td class="nump">671,963<span></span>
</td>
<td class="num">(1,976,333)<span></span>
</td>
<td class="num">(1,027,257)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common Stock, Shares, Outstanding, Ending Balance at Sep. 30, 2022</a></td>
<td class="nump">277,112,660<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance, value at Mar. 31, 2023</a></td>
<td class="nump">$ 277,113<span></span>
</td>
<td class="nump">671,963<span></span>
</td>
<td class="num">(2,072,023)<span></span>
</td>
<td class="num">$ (1,122,947)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common Stock, Shares, Outstanding, Beginning Balance at Mar. 31, 2023</a></td>
<td class="nump">277,112,660<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">277,112,660<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">$ (185,575)<span></span>
</td>
<td class="num">$ (185,575)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares and warrants sold for cash</a></td>
<td class="nump">190<span></span>
</td>
<td class="nump">189,810<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">190,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Stock-based compensation</a></td>
<td class="nump">$ 30<span></span>
</td>
<td class="nump">$ 34,524<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 34,554<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Stock Issued During Period, Shares, Issued for Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Jun. 30, 2023</a></td>
<td class="nump">$ 277,333<span></span>
</td>
<td class="nump">896,297<span></span>
</td>
<td class="num">(2,257,598)<span></span>
</td>
<td class="num">$ (1,083,968)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common Stock, Shares, Outstanding, Ending Balance at Jun. 30, 2023</a></td>
<td class="nump">277,332,660<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance, value at Mar. 31, 2023</a></td>
<td class="nump">$ 277,113<span></span>
</td>
<td class="nump">671,963<span></span>
</td>
<td class="num">(2,072,023)<span></span>
</td>
<td class="num">$ (1,122,947)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common Stock, Shares, Outstanding, Beginning Balance at Mar. 31, 2023</a></td>
<td class="nump">277,112,660<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">277,112,660<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2,987,024)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Shares and warrants sold for cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">343,250<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Sep. 30, 2023</a></td>
<td class="nump">$ 277,916<span></span>
</td>
<td class="nump">1,147,798<span></span>
</td>
<td class="num">(5,059,047)<span></span>
</td>
<td class="num">$ (3,633,333)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common Stock, Shares, Outstanding, Ending Balance at Sep. 30, 2023</a></td>
<td class="nump">277,915,910<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">277,915,910<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance, value at Jun. 30, 2023</a></td>
<td class="nump">$ 277,333<span></span>
</td>
<td class="nump">896,297<span></span>
</td>
<td class="num">(2,257,598)<span></span>
</td>
<td class="num">$ (1,083,968)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common Stock, Shares, Outstanding, Beginning Balance at Jun. 30, 2023</a></td>
<td class="nump">277,332,660<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(2,801,449)<span></span>
</td>
<td class="num">$ (2,801,449)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares and warrants sold for cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">153,250<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Stock-based compensation</a></td>
<td class="nump">430<span></span>
</td>
<td class="nump">98,404<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 98,834<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Stock Issued During Period, Shares, Issued for Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">430,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Shares and warrants sold for cash</a></td>
<td class="nump">153<span></span>
</td>
<td class="nump">153,097<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 153,250<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Sep. 30, 2023</a></td>
<td class="nump">$ 277,916<span></span>
</td>
<td class="nump">$ 1,147,798<span></span>
</td>
<td class="num">$ (5,059,047)<span></span>
</td>
<td class="num">$ (3,633,333)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common Stock, Shares, Outstanding, Ending Balance at Sep. 30, 2023</a></td>
<td class="nump">277,915,910<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">277,915,910<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139934376996672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NATURE OF OPERATIONS<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">NATURE OF OPERATIONS</a></td>
<td class="text"><p style="margin: 0px; font-size: 10pt"><b>NOTE 1 &#8211;
NATURE OF OPERATIONS</b></p>

<p style="margin: 0px; font-size: 10pt">&#160;</p>

<p style="margin: 0px; text-align: justify; font-size: 10pt">Regenerex Pharma, Inc., formerly Peptide Technologies, Inc. (the
&#8220;Company&#8221; or &#8220;Regenerex&#8221;), was incorporated in the State of Nevada, United States
of America, on November 18, 2005.</p>

<p style="margin: 0px; font-size: 10pt">&#160;</p>

<p style="margin: 0px; text-align: justify; font-size: 10pt">On November 15, 2021,
the Company entered into an Asset Purchase Agreement in which the Company
purchased certain intellectual property in exchange for 150,000,000 shares of
the Company&#8217;s common stock and up to $10,000,000 in contingent consideration to
be paid at the rate of 15% of all gross revenues received from sales or
investment money into the Company, payable on the 15<sup>th</sup> of the
following month, for a period of 60 months.&#160;
The Company received all rights and title to proprietary wound healing
technologies platforms and formulas involving the application of wound
care protocols to treat all wounds, such
as diabetic ulcers, pressure ulcers, burns and surgical wounds.&#160; These unique products strategically position
the Company to enter the wound treatment market in the U.S.</p>

<p style="margin: 0px; text-align: justify; font-size: 10pt">&#160;</p>

<p style="margin: 0px; text-align: justify; font-size: 10pt"><i>Risks and Uncertainties</i><span style="font-size: 10pt">&#160;</span></p>

<p style="margin: 0px; font-size: 10pt">&#160;</p>

<p style="margin: 0px; text-align: justify; font-size: 10pt">Our
business and our forward-looking statements involve substantial known and
unknown risks and uncertainties, including the risks and uncertainties inherent
in our statements regarding the impacts of COVID-19, or other future pandemics
on our business, results of operations, financial position, and cash flows.</p>

<p style="margin: 0px; font-size: 10pt">&#160;</p>

<p style="margin: 0px; text-align: justify; font-size: 10pt">The Company has
a lack of revenue history and has had a limited history of operations.&#160; No
revenue has historically been derived from the assets purchased. &#160;Regenerex can give no assurance of success or
profitability to the Company&#8217;s investors.</p>

<p style="margin: 0px; text-align: justify; font-size: 10pt">&#160;</p>

<p style="margin: 0px; text-align: justify; font-size: 10pt">The wound care
healing space is well suited for Home Care service providers that are funded by
the US Government. Strategic planning and development will be performed
internally by the Company.<span style="font-size: 10pt">&#160;</span></p>

<p style="margin: 0px; font-size: 10pt">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//275/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139934377747552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BASIS OF PRESENTATION OF INTERIM FINANCIAL STATEMENTS<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">BASIS OF PRESENTATION OF INTERIM FINANCIAL STATEMENTS</a></td>
<td class="text"><p style="margin: 0px; text-align: justify; font-size: 10pt"><b>NOTE 2 &#8211; BASIS OF PRESENTATION OF INTERIM FINANCIAL STATEMENTS</b></p>

<p style="margin: 0px; font-size: 10pt">&#160;</p>

<p style="margin: 0px; text-align: justify; font-size: 10pt">The
Company prepares its financial statements in accordance with accounting
principles generally accepted in the United States of America. The accompanying
interim unaudited financial statements have been prepared in accordance with
generally accepted accounting principles for interim financial information in
accordance with the instructions to Form 10-Q and Article 8 of Regulation S-X.
In our opinion, all adjustments (consisting of normal recurring adjustments)
considered necessary for a fair presentation have been included.</p>

<p style="margin: 0px; font-size: 10pt">&#160;</p>

<p style="margin: 0px; text-align: justify; font-size: 10pt">Operating
results for the three and six months ended September 30, 2023, are not
necessarily indicative of the results that may be expected for the year ending
March 31, 2024. &#160;Notes to the unaudited
interim financial statements that would substantially duplicate the disclosures
contained in the audited financial statements for the year ended March 31, 2023,
have been omitted. This report should be read in conjunction with the audited
financial statements and the footnotes thereto for the fiscal year ended March
31, 2023, included within the Company&#8217;s Annual Report on Form 10-K as filed
with the Securities and Exchange Commission.</p>

<p style="margin: 0px; font-size: 10pt">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//235/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 275<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//275/tableOfContent<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139934380859024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GOING CONCERN<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock', window );">GOING CONCERN</a></td>
<td class="text"><p style="margin: 0px; text-align: justify; font-size: 10pt"><b>NOTE 3
&#8211; GOING CONCERN</b></p>

<p style="margin: 0px; font-size: 10pt">&#160;</p>

<p style="margin: 0px; text-align: justify; font-size: 10pt">These financial statements
have been prepared in conformity with accounting principles generally accepted
in the United States of America (&#8220;U.S. GAAP&#8221;), which contemplate the
continuation of the Company as a going concern. The Company has incurred losses
from operations, and as of September 30, 2023, it had excess liabilities over
assets of $3,633,333. &#160;These factors
raise substantial doubt about the Company&#8217;s ability to continue as a going
concern.</p>





<p style="margin-top: 0pt; margin-bottom: 0pt"><span class="adv_highlightanchor adv_pagination" id="page_6"></span></p>

<p style="margin: 0; font-size: 10pt">&#160;</p>

<p style="margin: 0; font-size: 10pt"></p>

<p style="margin: 0px; text-align: justify; font-size: 10pt"><span style="font-size: 10pt">The Company requires
significant cash to launch its business and reduce its payable.&#160; Management&#8217;s plans are to actively seek
capital to enable the Company to add new products and/or services to ultimately
achieve profitability. However, management cannot provide assurance that they
can raise sufficient capital and whether the Company will ultimately achieve
profitability, become cash flow positive, or raise additional debt and/or
equity capital. &#160;If the Company is unable
to raise additional capital in the near future or meet financing requirements,
management expects that the Company will need to curtail operations, seek
additional capital on less favorable terms, and/or pursue other remedial
measures.</span></p>

<p style="margin: 0px; text-align: justify; font-size: 10pt">&#160;</p>

<p style="margin: 0px; text-align: justify; font-size: 10pt">These
financial statements do not include any adjustments related to the
recoverability and classification of assets or the amounts and classification
of liabilities that might be necessary should the Company become unable to
continue as a going concern.</p>

<p style="margin: 0px; font-size: 10pt">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//205-40/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubstantialDoubtAboutGoingConcernTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139934378986480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><p style="margin: 0px; text-align: justify; font-size: 10pt"><b>NOTE 4
&#8211;SIGNIFICANT ACCOUNTING POLICIES</b></p>

<p style="margin: 0px; font-size: 10pt">&#160;</p>

<p style="margin: 0px; text-align: justify; font-size: 10pt"><i>Revenue Recognition</i></p>

<p style="margin: 0px; font-size: 10pt">&#160;</p>

<p style="margin: 0px; text-align: justify; font-size: 10pt">The Company will record
revenue under ASC 606 by 1) identifying the contract with the customer 2)
identifying the performance obligations in the contract 3) determining the
transaction price, 4) allocating the transaction price to the required performance
obligations in the contract, and 5) recognizing revenue when or as the
companies satisfies a performance obligation.</p>

<p style="margin: 0px; font-size: 10pt">&#160;</p>

<p style="margin: 0px; text-align: justify; font-size: 10pt">We expect to
generate revenue from home care service providers that are funded by the U.S.
Government, State Medicaid Programs, International Health Care Programs, Veteran&#8217;s
administration, Prison system, Home Health Care Providers, and other applicable
Medicare reimbursement models.&#160; The
Company will defer revenue where the earnings process is not yet complete.&#160; To date, no revenue has been generated from
the asset acquisition disclosed in Note 1.</p>

<p style="margin: 0px; font-size: 10pt">&#160;</p>

<p style="margin: 0px; text-align: justify; font-size: 10pt"><i>Earnings per
Share</i></p>

<p style="margin: 0px; font-size: 10pt">&#160;</p>

<p style="margin: 0px; text-align: justify; font-size: 10pt">Earnings per share is reported in accordance
with FASB ASC Topic 260 &#8220;<i>Earnings per Share</i>&#8221; which requires dual
presentation of basic earnings per share (&#8220;EPS&#8221;) and diluted EPS on the face of all statements of
earnings, for all entities with complex capital structures. Diluted EPS
reflects the potential dilution that could occur from common shares issuable
through the exercise or conversion of stock options, restricted stock awards,
warrants and convertible securities. In certain circumstances, the conversion
of these options, warrants and convertible securities are excluded from diluted
EPS if the effect of such inclusion would be anti-dilutive. Fully diluted EPS is
not provided, when the effect is anti-dilutive. When the effect of dilution on
loss per share is anti-dilutive, diluted loss per share equals the loss per
share.</p>

<p style="margin: 0px; text-align: justify; font-size: 10pt">&#160;</p>

<p style="margin: 0px; text-align: justify; font-size: 10pt">During the six months ended September 30, 2023,
the Company excluded the outstanding stock warrants from its calculation of
earnings per share, as the warrants would be anti-dilutive. As of September 30, 2023
and 2022, the Company had common shares warrants outstanding of 2,306,250 and
0, respectively.</p>

<p style="margin: 0; font-size: 10pt">&#160;</p>

<p style="margin: 0; font-size: 10pt"></p>

<p style="margin: 0px; font-size: 10pt"><i style="font-size: 10pt; text-align: justify">Website</i></p>

<p style="margin: 0px; font-size: 10pt">&#160;</p>

<p style="margin: 0px; text-align: justify; font-size: 10pt">Expenditures related to the planning and
operation of the Company&#8217;s website are expensed as incurred. Expenditures
related to the website application and
infrastructure development are capitalized and amortized over the website&#8217;s
estimated useful life of three (3) years. Amortization expense for the three
and six months ended September 30, 2023 and 2022 was $723 and $723 and $1,437 and
$1,794, respectively.</p>

<p style="margin: 0px; font-size: 10pt">&#160;</p>

<p style="margin: 0px; text-align: justify; font-size: 10pt"><i>Furniture and Computer Equipment</i></p>

<p style="margin: 0px; font-size: 10pt">&#160;</p>

<p style="margin: 0px; text-align: justify; font-size: 10pt">Furniture and computer equipment are stated
at cost, less accumulated depreciation.&#160;
Depreciation is computed using the straight-line method over the
estimated useful life of three (3) to five (5) years.&#160; Depreciation expense for the three and six
months ended September 30, 2023 and 2022 was $422 and $0 and $538 and $0, respectively.&#160; Significant betterments are capitalized while
purchases under $500 are expensed as incurred.</p>





<p style="margin-top: 0pt; margin-bottom: 0pt"><span class="adv_highlightanchor adv_pagination" id="page_7"></span></p>

<p style="margin: 0; font-size: 10pt"></p>

<p style="margin: 0px; font-size: 10pt">&#160;</p>

<p style="margin: 0px; font-size: 10pt"><i>Right of Use Assets and Lease Liabilities</i></p>

<p style="margin: 0px; font-size: 10pt">&#160;</p>

<p style="margin: 0px; text-align: justify; font-size: 10pt">The Company has
active operating lease arrangements for office space, production equipment, and
production facilities.&#160; The Company is
required to make fixed minimum rent payments relating to its right to use the
underlying leased asset.&#160; In accordance
with the adoption of ASC 842, the Company recorded right-of-use assets and
related lease liabilities for these leases as of September 2023.</p>

<p style="margin: 0px; font-size: 10pt">&#160;</p>

<p style="margin: 0px; text-align: justify; font-size: 10pt">The Company&#8217;s
lease agreements do not provide an implicit borrowing rate.&#160; Therefore, the Company used a benchmark
approach to derive an incremental borrowing rate of 10% to discount each of its
lease liabilities based on the remining lease term.</p>

<p style="margin: 0px; font-size: 10pt">&#160;</p>

<p style="margin: 0px; font-size: 10pt"><i>Stock-Based Compensation</i></p>

<p style="margin: 0px; font-size: 10pt">&#160;</p>

<p style="margin: 0px; text-align: justify; font-size: 10pt">Stock-based
compensation is measured at the grant date, based on the estimated fair value
of the award.&#160; Stock-based compensation
is recognized as expense over the employee&#8217;s requisite vesting period and over
the nonemployee&#8217;s period of providing goods or services.&#160; The fair value of each stock warrant is
estimated on the date of grant using the Black-Scholes option valuation model.
Restricted shares are measured based on the fair market value of the underlying
stock on the grant date.</p>

<p style="margin: 0px; text-align: justify; font-size: 10pt"><br/></p>

<p style="margin: 0px; font-size: 10pt"><i>Research and Development</i></p>

<p style="margin: 0px; font-size: 10pt">&#160;</p>

<p style="margin: 0px; text-align: justify; font-size: 10pt">We incur research
and development costs during the process of researching and developing additional
technologies purchased and future manufacturing processes.&#160; Our research and development costs consist
primarily of the purchase of additional intellectual property that we will use
in the development of our planned product.&#160;
We expense these costs as incurred until the resulting product has been
completed, tested, and made ready for commercial use.</p>

<p style="margin: 0px; text-align: justify; font-size: 10pt"></p>

<p style="margin: 0px; font-size: 10pt">&#160;</p>

<p style="margin: 0px; font-size: 10pt">&#160;</p>

<p style="margin: 0px; font-size: 10pt"><i>Recent Accounting Pronouncements</i></p>

<p style="margin: 0px; font-size: 10pt">&#160;</p>

<p style="margin: 0px; text-align: justify; font-size: 10pt">The Financial
Accounting Standards Board issued Accounting Standards Updates (&#8220;ASU&#8221;) to amend
the authoritative literature in the Accounting Standards Codification (&#8220;ASC&#8221;).
There have been a number of ASUs to date that amend the original text of the
ASC. The Company believes those updates issued-to-date either (i) provide
supplemental guidance, (ii) are technical corrections, (iii) are not applicable
to the Company, or (iv) are not expected to have a significant impact on the
Company.</p>

<p style="margin: 0px; font-size: 10pt">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139934377580272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">RELATED PARTY TRANSACTIONS</a></td>
<td class="text"><p style="margin: 0px; text-align: justify; font-size: 10pt"><b>NOTE 5 &#8211; RELATED PARTY TRANSACTIONS </b></p>

<p style="margin: 0px; font-size: 10pt">&#160;</p>

<p style="margin: 0px; text-align: justify; font-size: 10pt">The Company purchased assets from the Company&#8217;s
current Chief Executive Officer (&#8220;CEO&#8221;) and Secretary/Treasurer (see note 6).</p>

<p style="margin: 0px; font-size: 10pt">&#160;</p>

<p style="margin: 0px; text-align: justify; font-size: 10pt">On June 10, 2023, the Company, has entered into an
agreement with Woundcare Labs, LLC., a party related to the CFO and CEO of the Company,
to lease a plant and to lease equipment in Tennessee (see note 8).</p>

<p style="margin: 0; font-size: 10pt">&#160;</p>

<p style="margin: 0; font-size: 10pt"></p>

<p style="margin: 0px; font-size: 10pt"><i style="font-size: 10pt; text-align: justify">Related Party Advances</i></p>

<p style="margin: 0px; font-size: 10pt">&#160;</p>

<p style="margin: 0px; text-align: justify; font-size: 10pt">The Company&#8217;s
former Chief Financial Officer (&#8220;CFO&#8221;) had advanced the Company monies for
operating expenses; no amounts were advanced during the periods presented.&#160; The advances were
due on demand, but no later than June 30, 2023.&#160;
The related party advances began to accrue interest at ten (10) percent
per annum on July 1, 2019.&#160; During the six
months ended September 30, 2023, this note was transferred to a relative of the
former CFO and was renewed upon maturity in the principal amount of $131,687
plus interest accrued as at June 30, 2023 in the amount of $52,545.&#160; Interest expense was $3,285 and $3,284 during
the six-month periods ended September 30, 2023 and 2022, respectively.&#160; This transaction is no longer considered
related party in nature, and thus is included in notes payable in the
accompanying balance sheet.</p>





<p style="margin-top: 0pt; margin-bottom: 0pt"><span class="adv_highlightanchor adv_pagination" id="page_8"></span></p>

<p style="margin: 0; font-size: 10pt">&#160;</p>

<p style="margin: 0; font-size: 10pt"></p>

<p style="margin: 0px; font-size: 10pt"><span style="font-size: 10pt; text-align: justify">During the
six-month period ended September 30, 2023, the Company&#8217;s Chief Financial
Officer (&#8220;CFO&#8221;) and the Company&#8217;s Chief Executive Officer (&#8220;CEO&#8221;) advanced the
Company monies for operating expenses in the net amount of $</span>2,437<span style="font-size: 10pt; text-align: justify">.</span></p>

<p style="margin: 0px; font-size: 10pt">&#160;</p>

<p style="margin: 0px; text-align: justify; font-size: 10pt">The related party advances totaled $2,637 and $131,887 as of September
30, 2023 and March 31, 2023, respectively.</p>

<p style="margin: 0px; font-size: 10pt">&#160;</p>

<p style="margin: 0px; text-align: justify; font-size: 10pt"><i>Notes Payable to Related Parties</i></p>

<p style="margin: 0px; font-size: 10pt">&#160;</p>

<p style="margin: 0px; text-align: justify; font-size: 10pt">During the year
ended March 31, 2023, the Company&#8217;s CFO and the Company&#8217;s CEO advanced the
Company monies for operating expenses in the amount of $40,500.&#160; Repayment during the six-month period ended
September 30, 2023 and September 30, 2022 was $34,000 and $0. &#160;The notes are unsecured and accrue interest at
ten (10) percent per annum.&#160; Repayment is
due no later than November 4, 2024.</p>

<p style="margin: 0px; font-size: 10pt">&#160;</p>

<p style="margin: 0px; text-align: justify; font-size: 10pt">The related party notes
payable totaled $4,000 and $38,000 as at September 30, 2023 and March 31,
2023.&#160; Interest expenses were $1,630 and
$129 during the six-month periods ended September 30, 2023 and 2022,
respectively, which is included in other accrued liabilities.</p>

<p style="margin: 0px; font-size: 10pt">&#160;</p>

<p style="margin: 0px; font-size: 10pt"><i>Note Payable to Shareholder</i></p>

<p style="margin: 0px; font-size: 10pt">&#160;</p>

<p style="margin: 0px; text-align: justify; font-size: 10pt">As at September 30, 2023 and March 31, 2023, the Company had various
promissory notes with total outstanding principal balances of $558,691 and $537,475,
respectively, due to a shareholder of the Company.&#160; These notes are unsecured, bear interest at
10% per annum, and have maturity dates ranging from October 11, 2023 to June 17,
2025.</p>

<p style="margin: 0px; font-size: 10pt">&#160;</p>

<p style="margin: 0px; text-align: justify; font-size: 10pt">During the six-months ended September 30, 2023, notes with principal
amounts totaling approximately $128,000 ($167,500 Canadian Funds) that came due
during the period were reissued in the total principal amount of approximately
$155,000 ($201,000 Canadian Funds) which included the principal amount plus
accrued interest of approximately $26,000 ($33,500 Canadian Funds.)&#160; These notes are unsecured and bear interest
at ten (10) percent per annum with principal and interest due twelve (12)
months after the date of issue.</p>

<p style="margin: 0px; font-size: 10pt">&#160;</p>

<p style="margin: 0px; text-align: justify; font-size: 10pt">During the six-month period ended September 30, 2023, repayment of ten
thousand dollars ($10,000) US Funds was made on the principal of a promissory
note due October 11, 2023.</p>

<p style="margin: 0px; font-size: 10pt">&#160;</p>

<p style="margin: 0px; text-align: justify; font-size: 10pt">During the six-month period ended September 30, 2023,
a shareholder was issued additional one (1) promissory note totaling approximately
$2,800 ($3,844 Canadian Funds).&#160; This
note is unsecured and bears interest at ten (10) percent per annum with
principal and interest due twelve (12) months after the date of issue.</p>

<p style="margin: 0px; font-size: 10pt">&#160;</p>

<p style="margin: 0px; text-align: justify; font-size: 10pt">Accrued interest was $70,746 and $102,858 as of September 30, 2023 and September
30, 2022, respectively, which is included in other accrued liabilities at
September 30, 2023 and March 31, 2023, respectively.</p>

<p style="margin: 0px; font-size: 10pt">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//850/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139934377544128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTANGIBLE ASSETS AND INTELLECTUAL PROPERTY<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsDisclosureTextBlock', window );">INTANGIBLE ASSETS AND INTELLECTUAL PROPERTY</a></td>
<td class="text"><p style="margin: 0px; text-align: justify; font-size: 10pt"><b>NOTE 6 &#8211; INTANGIBLE ASSETS AND INTELLECTUAL PROPERTY</b></p>

<p style="margin: 0px; font-size: 10pt">&#160;</p>

<p style="margin: 0px; text-align: justify; font-size: 10pt">On November 15, 2021,
the Company entered into a Related Party



Asset Purchase Agreement in which the Company
purchased certain intellectual property in exchange for 150,000,000 shares of
the Company&#8217;s common stock and up to $10,000,000 in contingent consideration to be paid at the rate of 15% of all gross revenues received from sales or investment money into the Company, payable on the 15th of the following month, for a period of 60 months.&#160;
The Company received all rights and title to proprietary wound healing
technologies platforms and formulas involving the application of wound
care protocols to treat all wounds, such
as diabetic ulcers, pressure ulcers, burns and surgical wounds.&#160; These unique products strategically position
the Company to enter and capture a high proportionate market share in the U.S.</p>

<p style="margin: 0; font-size: 10pt">&#160;</p>

<p style="margin: 0; font-size: 10pt"></p>





<p style="margin-top: 0pt; margin-bottom: 0pt"><span class="adv_highlightanchor adv_pagination" id="page_9"></span></p>

<p style="margin: 0; font-size: 10pt">&#160;</p>

<p style="margin: 0; font-size: 10pt"></p>

<p style="margin: 0px; text-align: justify; font-size: 10pt"><span style="font-size: 10pt">On August 17, 2023, the Company entered into an Agreement to Purchase Technology Platforms



 in which the Company purchased certain intellectual property in
exchange for a two million four hundred thousand dollars ($2,400,000) note
payable.&#160; The intellectual property that
was purchased requires further development prior to the product being finalized
and produced so it has been expensed as research and development.&#160; &#160;The note payable is due within twelve (12)
months of the date of the agreement and is included in current liabilities.&#160; If the Company has not raised a minimum of
ten million dollars ($10,000,000) in sales within twelve (12) months, or a maximum
of ten million dollars ($10,000,000) in investment, the Company has the option
to extend the payment due date for a further twelve (12)&#160;</span><span style="font-size: 10pt">months of the
agreement date, or a maximum of ten million dollars ($10,000,000) in investment,
the seller will extend the payment for a further period of twelve (12) months
for a 10% payment of the outstanding balance.</span></p>

<p style="margin: 0px; text-align: justify; font-size: 10pt"><span style="font-size: 10pt">&#160;</span></p>

<p style="margin: 0px; font-size: 10pt">The Technology Platforms include but are not limited to:</p>

<p style="margin: 0px; font-size: 10pt">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse">
  <tbody>
  <tr>
    <td style="width: 0.5in; vertical-align: top"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.5in; vertical-align: top"><p style="margin: 0px; font-size: 10pt">A.<span style="font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; font-kerning: auto; font-optical-sizing: auto; font-feature-settings: normal; font-variation-settings: normal; font-stretch: normal; font-size: 7pt; line-height: normal"></span></p></td>
    <td style="text-align: justify; vertical-align: top"><p style="margin: 0px; font-size: 10pt">Proteomic research platforms which include proprietary blends.</p></td>
  </tr>
</tbody>
</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse">
  <tbody>
  <tr>
    <td style="width: 0.5in; vertical-align: top"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.5in; vertical-align: top"><p style="margin: 0px; font-size: 10pt">B.<span style="font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; font-kerning: auto; font-optical-sizing: auto; font-feature-settings: normal; font-variation-settings: normal; font-stretch: normal; font-size: 7pt; line-height: normal"></span></p></td>
    <td style="text-align: justify; vertical-align: top"><p style="margin: 0px; font-size: 10pt">Combination design Techniques</p></td>
  </tr>
</tbody>
</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse">
  <tbody>
  <tr>
    <td style="width: 0.5in; vertical-align: top"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.5in; vertical-align: top"><p style="margin: 0px; font-size: 10pt">C.<span style="font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; font-kerning: auto; font-optical-sizing: auto; font-feature-settings: normal; font-variation-settings: normal; font-stretch: normal; font-size: 7pt; line-height: normal"></span></p></td>
    <td style="text-align: justify; vertical-align: top"><p style="margin: 0px; font-size: 10pt">Patent Pending Proprietary Blends</p></td>
  </tr>
</tbody>
</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse">
  <tbody>
  <tr>
    <td style="width: 0.5in; vertical-align: top"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.5in; vertical-align: top"><p style="margin: 0px; font-size: 10pt">D.<span style="font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; font-kerning: auto; font-optical-sizing: auto; font-feature-settings: normal; font-variation-settings: normal; font-stretch: normal; font-size: 7pt; line-height: normal"></span></p></td>
    <td style="text-align: justify; vertical-align: top"><p style="margin: 0px; font-size: 10pt">Patent Pending Formulas</p></td>
  </tr>
</tbody>
</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse">
  <tbody>
  <tr>
    <td style="width: 0.5in; vertical-align: top"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.5in; vertical-align: top"><p style="margin: 0px; font-size: 10pt">E.<span style="font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; font-kerning: auto; font-optical-sizing: auto; font-feature-settings: normal; font-variation-settings: normal; font-stretch: normal; font-size: 7pt; line-height: normal"></span></p></td>
    <td style="text-align: justify; vertical-align: top"><p style="margin: 0px; font-size: 10pt">Trademarks and all pending Trademarks</p></td>
  </tr>
</tbody>
</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse">
  <tbody>
  <tr>
    <td style="width: 0.5in; vertical-align: top"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.5in; vertical-align: top"><p style="margin: 0px; font-size: 10pt">F.<span style="font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; font-kerning: auto; font-optical-sizing: auto; font-feature-settings: normal; font-variation-settings: normal; font-stretch: normal; font-size: 7pt; line-height: normal"></span></p></td>
    <td style="text-align: justify; vertical-align: top"><p style="margin: 0px; font-size: 10pt">510K USA FDA, information, and Know-how for application</p></td>
  </tr>
</tbody>
</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse">
  <tbody>
  <tr>
    <td style="width: 0.5in; vertical-align: top"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.5in; vertical-align: top"><p style="margin: 0px; font-size: 10pt">G.<span style="font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; font-kerning: auto; font-optical-sizing: auto; font-feature-settings: normal; font-variation-settings: normal; font-stretch: normal; font-size: 7pt; line-height: normal"></span></p></td>
    <td style="text-align: justify; vertical-align: top"><p style="margin: 0px; font-size: 10pt">All Clinical trials, (Right to use)</p></td>
  </tr>
</tbody>
</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse">
  <tbody>
  <tr>
    <td style="width: 0.5in; vertical-align: top"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.5in; vertical-align: top"><p style="margin: 0px; font-size: 10pt">H.<span style="font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; font-kerning: auto; font-optical-sizing: auto; font-feature-settings: normal; font-variation-settings: normal; font-stretch: normal; font-size: 7pt; line-height: normal"></span></p></td>
    <td style="text-align: justify; vertical-align: top"><p style="margin: 0px; font-size: 10pt">CE mark (International)</p></td>
  </tr>
</tbody>
</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse">
  <tbody>
  <tr>
    <td style="width: 0.5in; vertical-align: top"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.5in; vertical-align: top"><p style="margin: 0px; font-size: 10pt">I.<span style="font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; font-kerning: auto; font-optical-sizing: auto; font-feature-settings: normal; font-variation-settings: normal; font-stretch: normal; font-size: 7pt; line-height: normal"></span></p></td>
    <td style="text-align: justify; vertical-align: top"><p style="margin: 0px; font-size: 10pt">Regenerex Library formula incorporated in the Wound Healing Technology.</p></td>
  </tr>
</tbody>
</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse">
  <tbody>
  <tr>
    <td style="width: 0.5in; vertical-align: top"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.5in; vertical-align: top"><p style="margin: 0px; font-size: 10pt">J.<span style="font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; font-kerning: auto; font-optical-sizing: auto; font-feature-settings: normal; font-variation-settings: normal; font-stretch: normal; font-size: 7pt; line-height: normal"></span></p></td>
    <td style="text-align: justify; vertical-align: top"><p style="margin: 0px; font-size: 10pt">Wound Healing Technology QBX</p></td>
  </tr>
</tbody>
</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse">
  <tbody>
  <tr>
    <td style="width: 0.5in; vertical-align: top"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.5in; vertical-align: top"><p style="margin: 0px; font-size: 10pt">K.<span style="font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; font-kerning: auto; font-optical-sizing: auto; font-feature-settings: normal; font-variation-settings: normal; font-stretch: normal; font-size: 7pt; line-height: normal"></span></p></td>
    <td style="text-align: justify; vertical-align: top"><p style="margin: 0px; font-size: 10pt">Synthetic Compositions of Cations derived from botanical material in the ash of Red- Oak Bark.</p></td>
  </tr>
</tbody>
</table>

<p style="margin: 0px; font-size: 10pt">&#160;</p>

<p style="margin: 0px; font-size: 10pt">Products:</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse">
  <tbody>
  <tr>
    <td style="width: 0.5in; vertical-align: top"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.5in; vertical-align: top"><p style="margin: 0px; font-size: 10pt">1.<span style="font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; font-kerning: auto; font-optical-sizing: auto; font-feature-settings: normal; font-variation-settings: normal; font-stretch: normal; font-size: 7pt; line-height: normal"></span></p></td>
    <td style="text-align: justify; vertical-align: top"><p style="margin: 0px; font-size: 10pt">Xcellderma over the counter product.</p></td>
  </tr>
</tbody>
</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse">
  <tbody>
  <tr>
    <td style="width: 0.5in; vertical-align: top"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.5in; vertical-align: top"><p style="margin: 0px; font-size: 10pt">2.<span style="font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; font-kerning: auto; font-optical-sizing: auto; font-feature-settings: normal; font-variation-settings: normal; font-stretch: normal; font-size: 7pt; line-height: normal"></span></p></td>
    <td style="text-align: justify; vertical-align: top"><p style="margin: 0px; font-size: 10pt">Accelerex, combination product as a drug device.</p></td>
  </tr>
</tbody>
</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse">
  <tbody>
  <tr>
    <td style="width: 0.5in; vertical-align: top"><p style="margin: 0px; font-size: 10pt">&#160;</p></td>
    <td style="width: 0.5in; vertical-align: top"><p style="margin: 0px; font-size: 10pt">3.<span style="font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; font-kerning: auto; font-optical-sizing: auto; font-feature-settings: normal; font-variation-settings: normal; font-stretch: normal; font-size: 7pt; line-height: normal"></span></p></td>
    <td style="text-align: justify; vertical-align: top"><p style="margin: 0px; font-size: 10pt">Accelerex in a tube.</p></td>
  </tr>
</tbody>
</table>

<p style="margin-top: 0px; margin-bottom: 0px; margin-left: 48px; font-size: 10pt"><b>&#160;</b></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all or part of the information related to intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//350-30/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139934378033088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text"><p style="margin: 0px; font-size: 10pt"><b>NOTE 7 &#8211; COMMITMENTS AND CONTINGENCIES</b></p>

<p style="margin: 0px; text-align: justify; font-size: 10pt">&#160;</p>

<p style="margin: 0px; text-align: justify; font-size: 10pt">The Company is not currently involved with and does
not have knowledge of any pending or threatened litigation against the Company
or any of its officers.</p>

<p style="margin: 0px; font-size: 10pt">&#160;</p>

<p style="margin: 0px; text-align: justify; font-size: 10pt">See Note 6 for discussion of the $10,000,000 in
contingent consideration to be paid in connection with the November 15, 2021

Related Party



Asset Purchase Agreement. Payments made to the Company&#8217;s CEO and CFO in
connection with the Asset Purchase Agreement are $43,500 and $0 as at September
30, 2023 and March 31, 2023 respectively.&#160;
The outstanding liability of $7,988 and $0 as at September 30, 2023 and
March 31, 2023 respectively is included in other accrued liabilities.</p>

<p style="margin: 0px; font-size: 10pt">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//450/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480327/954-440-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139934376956496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OPERATING LEASES<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RGPX_DisclosureOperatingLeasesAbstract', window );"><strong>Operating Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">OPERATING LEASES</a></td>
<td class="text"><p style="margin: 0px; text-align: justify; font-size: 10pt"><b>NOTE 8 &#8211; OPERATING LEASES</b></p>

<p style="margin: 0px; font-size: 10pt">&#160;</p>

<p style="margin: 0px; text-align: justify; font-size: 10pt">On April 1, 2023, the Company
entered into an office lease agreement commencing in May 2023 which expires on
April 30, 2028.&#160; Under this agreement,
the monthly rental payments are $1,650 throughout the term of the lease.&#160; The Company is required to pay for all
utilities used on the premises and has paid a security deposit of $800 which is
included in prepaid expenses.</p>

<p style="margin: 0px; text-align: justify; font-size: 10pt">&#160;</p>

<p style="margin: 0px; text-align: justify; font-size: 10pt">On June 10, 2023, the Company entered into a plant facility lease agreement with a related party commencing June 9, 2023 which expires on June 30, 2028.&#160; Under this agreement, the monthly rental payments are $18,000 throughout the term of the lease excepting the month of June 2023 the rent is $7,920, To commence with production, the plant needs to prepare for FDA inspection which will include inspection of the facility, equipment, and the Company&#8217;s procedures.&#160; We expect to launch production during the Company&#8217;s third or fourth quarter and will notify the FDA to come into the plant for the inspection at that time.&#160; The Company is able to start production while the plant waits for the FDA Inspection.&#160; Until the certification is complete, the monthly rent is reduced by forty (40%) percent to $10,800. Under this agreement, the Company is also leasing the equipment in the plant facility through five (5) annual rent payments of $10,000, which are due on the 15th day of&#160; each June from June 2023 to June 2027.</p>

<p style="margin: 0; font-size: 10pt">&#160;</p>

<p style="margin: 0; font-size: 10pt"></p>





<p style="margin-top: 0pt; margin-bottom: 0pt"><span class="adv_highlightanchor adv_pagination" id="page_10"></span></p>

<p style="margin: 0; font-size: 10pt">&#160;</p>

<p style="margin: 0; font-size: 10pt"></p>

<p style="margin: 0px; text-align: justify; font-size: 10pt"><span style="font-size: 10pt">During the six-month
periods ended September 30, 2023 and September 30, 2022 the operating lease
cost was $81,451 and $0 respectively and is included in general and
administrative expenses in the accompanying financial statements.</span></p>

<p style="margin: 0px; text-align: justify; font-size: 10pt"><b>&#160;</b></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RGPX_DisclosureOperatingLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RGPX_DisclosureOperatingLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RGPX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//842-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139934377544128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS&#8217; DEFICIT<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">STOCKHOLDERS&#8217; DEFICIT</a></td>
<td class="text"><p style="margin: 0px; text-align: justify; font-size: 10pt"><b>NOTE
9 &#8211; STOCKHOLDERS&#8217; DEFICIT</b></p>

<p style="margin: 0px; font-size: 10pt">&#160;</p>

<p style="margin: 0px; text-align: justify; font-size: 10pt">The Company has authorized
the issuance of 675,000,000 shares of common stock with a par value of $0.001
per share.</p>

<p style="margin: 0px; text-align: justify; font-size: 10pt"><br/></p>

<p style="margin: 0px; text-align: justify; font-size: 10pt">During the six months ended
September 30, 2023, the Company issued 460,000 shares to board members and
consultants for services rendered.&#160; Total
stock-based compensation expense was $82,800 during the six months ended
September 30, 2023 in connection with these issuances based on the fair value
of the stock on the respective grant dates.</p>

<p style="margin: 0px; text-align: justify; font-size: 10pt"><br/></p>

<p style="margin: 0px; text-align: justify; font-size: 10pt">During the six months ended September 30, 2023,
the Company issued 590,000 warrants to board members and consultants for
services rendered with a total grant date fair value of $59,691&#160; Total stock-based compensation expense of
$50,588 was recorded in connection with these awards during the six months
ended September 30, 2023.&#160; The remaining
stock-based compensation of $9,103 will be recognized over the next nine months.&#160; The warrants contain an exercise price of
$0.33 per share, vesting terms ranging from immediately to June 30, 2024, and
expire on dates ranging from July 1, 2029 to October 1, 2029.</p>

<p style="margin: 0; font-size: 10pt">&#160;</p>

<p style="margin: 0; font-size: 10pt"></p>

<p style="margin: 0px; font-size: 10pt"><span style="font-size: 10pt; text-align: justify">The warrant fair values were estimated using a Black
Scholes model with a 5-year expected term, risk-free interest rate ranging from
5.19% to 5.54%, a dividend yield of 0%, and an annualized standard deviation of
stock price volatility of 80.0%.&#160; The
risk-free interest rate assumptions for options granted is based upon observed
interest rates on the United States government securities appropriate for the
expected term of the equity awards.</span></p>

<p style="margin: 0px; font-size: 10pt">&#160;</p>

<p style="margin: 0px; text-align: justify; font-size: 10pt">As of the date of this valuation, the Companies stock
was not trading.&#160; The volatility was calculated
based on comparable public companies.&#160;
The Company will continue to monitor peer companies and other relevant
factors used to measure expected volatility for future equipment award grants,
until such time that the Company&#8217;s Common Stock has enough market history to
use historical volatility.</p>

<p style="margin: 0px; font-size: 10pt">&#160;</p>

<p style="margin: 0px; text-align: justify; font-size: 10pt">The dividend yield assumption for equity awards
granted is based on Company&#8217;s history and expectation of dividend payouts.&#160; The Company has never declared or paid any
cash dividends on its Common Stock, and the Company does not anticipate paying
any cash dividends in the foreseeable future.</p>

<p style="margin: 0px; font-size: 10pt">&#160;</p>

<p style="margin: 0px; text-align: justify; font-size: 10pt">The closing stock price of the Company&#8217;s common stock
is not available as the Company&#8217;s stock is not trading. As a result, the Board
of Directors and management determined the fair value of the common stock to be
$0.18 per share based upon an allocation of the recent cash price paid for
common stock and warrants during the six months ended September 30, 2023.</p>

<p style="margin: 0px; text-align: justify; font-size: 10pt"><br/></p>

<p style="margin: 0px; text-align: justify; font-size: 10pt">During the six-month period ended September 30, 2023,
the Company issued 343,250 shares of common stock with a par value of $0.001
for the price of one ($1) dollar per share for a total of for a total of $343,250.&#160; Five warrants were issued for each share
purchased, for a total of 1,716,250 warrants.&#160;
The warrants are exercisable at twenty ($0.20) cents and expire from
April 2025 through September 2025.</p>

<p style="margin: 0px; text-align: justify; font-size: 10pt"><br/></p>

<p style="margin: 0px; text-align: justify; font-size: 10pt">As of September 30, 2023, 2,306,250 warrants had been issued of which 2,216,238
are vested. &#160;None of the warrants have been exercised.</p>

<p style="margin: 0px; font-size: 10pt">&#160;</p>





<p style="margin-top: 0pt; margin-bottom: 0pt"><span class="adv_highlightanchor adv_pagination" id="page_11"></span></p>

<p style="margin: 0; font-size: 10pt">&#160;</p>

<p style="margin: 0; font-size: 10pt"></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139934377638352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENTS</a></td>
<td class="text"><p style="margin: 0px; font-size: 10pt"><b>NOTE 10 &#8211; SUBSEQUENT EVENTS</b></p>

<p style="margin: 0px; font-size: 10pt">&#160;</p>

<p style="margin: 0px; text-align: justify; font-size: 10pt">Subsequent to the six-month period ended September 30, 2023, three
additional notes to a shareholder that were originally due in October 2023 with
a principal amount of $67,400 were reissued in the principal amount of $82,735 which
included the original principal amount of $67,400 plus interest accrued in the
amount of $15,335. Repayment of the notes are due within six (6) months of the
date of renewal.</p>

<p style="margin: 0px; font-size: 10pt">&#160;</p>

<p style="margin: 0px; text-align: justify; font-size: 10pt">Subsequent to the six-month period ended
September 30, 2023, one additional note to a shareholder that was originally
due November 2, 2023 with a principal amount of approximately $9,500 US Funds
($12,000 Canadian funds) was reissued in the principal amount of approximately
$10,500 US Funds ($14,400 Canadian Funds) which included the original principal
amount of approximately $9,500 US Funds ($12,000 Canadian funds) plus interest
accrued in the amount of approximately $2,000 US Funds ($2,400 Canadian Funds).&#160; Repayment of the note is due May 2, 2024.</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139934375704800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><p style="margin: 0px; text-align: justify; font-size: 10pt"><i>Revenue Recognition</i></p>

<p style="margin: 0px; font-size: 10pt">&#160;</p>

<p style="margin: 0px; text-align: justify; font-size: 10pt">The Company will record
revenue under ASC 606 by 1) identifying the contract with the customer 2)
identifying the performance obligations in the contract 3) determining the
transaction price, 4) allocating the transaction price to the required performance
obligations in the contract, and 5) recognizing revenue when or as the
companies satisfies a performance obligation.</p>

<p style="margin: 0px; font-size: 10pt">&#160;</p>

<p style="margin: 0px; text-align: justify; font-size: 10pt">We expect to
generate revenue from home care service providers that are funded by the U.S.
Government, State Medicaid Programs, International Health Care Programs, Veteran&#8217;s
administration, Prison system, Home Health Care Providers, and other applicable
Medicare reimbursement models.&#160; The
Company will defer revenue where the earnings process is not yet complete.&#160; To date, no revenue has been generated from
the asset acquisition disclosed in Note 1.</p>

<p style="margin: 0px; font-size: 10pt">&#160;</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Earnings per Share</a></td>
<td class="text"><p style="margin: 0px; text-align: justify; font-size: 10pt"><i>Earnings per
Share</i></p>

<p style="margin: 0px; font-size: 10pt">&#160;</p>

<p style="margin: 0px; text-align: justify; font-size: 10pt">Earnings per share is reported in accordance
with FASB ASC Topic 260 &#8220;<i>Earnings per Share</i>&#8221; which requires dual
presentation of basic earnings per share (&#8220;EPS&#8221;) and diluted EPS on the face of all statements of
earnings, for all entities with complex capital structures. Diluted EPS
reflects the potential dilution that could occur from common shares issuable
through the exercise or conversion of stock options, restricted stock awards,
warrants and convertible securities. In certain circumstances, the conversion
of these options, warrants and convertible securities are excluded from diluted
EPS if the effect of such inclusion would be anti-dilutive. Fully diluted EPS is
not provided, when the effect is anti-dilutive. When the effect of dilution on
loss per share is anti-dilutive, diluted loss per share equals the loss per
share.</p>

<p style="margin: 0px; text-align: justify; font-size: 10pt">&#160;</p>

<p style="margin: 0px; text-align: justify; font-size: 10pt">During the six months ended September 30, 2023,
the Company excluded the outstanding stock warrants from its calculation of
earnings per share, as the warrants would be anti-dilutive. As of September 30, 2023
and 2022, the Company had common shares warrants outstanding of 2,306,250 and
0, respectively.</p>

<p style="margin: 0; font-size: 10pt">&#160;</p>

<p style="margin: 0; font-size: 10pt"></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock', window );">Website</a></td>
<td class="text"><p style="margin: 0px; font-size: 10pt"><i style="font-size: 10pt; text-align: justify">Website</i></p>

<p style="margin: 0px; font-size: 10pt">&#160;</p>

<p style="margin: 0px; text-align: justify; font-size: 10pt">Expenditures related to the planning and
operation of the Company&#8217;s website are expensed as incurred. Expenditures
related to the website application and
infrastructure development are capitalized and amortized over the website&#8217;s
estimated useful life of three (3) years. Amortization expense for the three
and six months ended September 30, 2023 and 2022 was $723 and $723 and $1,437 and
$1,794, respectively.</p>

<p style="margin: 0px; font-size: 10pt">&#160;</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPreproductionDesignAndDevelopmentCosts', window );">Furniture and Computer Equipment</a></td>
<td class="text"><p style="margin: 0px; text-align: justify; font-size: 10pt"><i>Furniture and Computer Equipment</i></p>

<p style="margin: 0px; font-size: 10pt">&#160;</p>

<p style="margin: 0px; text-align: justify; font-size: 10pt">Furniture and computer equipment are stated
at cost, less accumulated depreciation.&#160;
Depreciation is computed using the straight-line method over the
estimated useful life of three (3) to five (5) years.&#160; Depreciation expense for the three and six
months ended September 30, 2023 and 2022 was $422 and $0 and $538 and $0, respectively.&#160; Significant betterments are capitalized while
purchases under $500 are expensed as incurred.</p>





<p style="margin-top: 0pt; margin-bottom: 0pt"><span class="adv_highlightanchor adv_pagination" id="page_7"></span></p>

<p style="margin: 0; font-size: 10pt"></p>

<p style="margin: 0px; font-size: 10pt">&#160;</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Right of Use Assets and Lease Liabilities</a></td>
<td class="text"><p style="margin: 0px; font-size: 10pt"><i>Right of Use Assets and Lease Liabilities</i></p>

<p style="margin: 0px; font-size: 10pt">&#160;</p>

<p style="margin: 0px; text-align: justify; font-size: 10pt">The Company has
active operating lease arrangements for office space, production equipment, and
production facilities.&#160; The Company is
required to make fixed minimum rent payments relating to its right to use the
underlying leased asset.&#160; In accordance
with the adoption of ASC 842, the Company recorded right-of-use assets and
related lease liabilities for these leases as of September 2023.</p>

<p style="margin: 0px; font-size: 10pt">&#160;</p>

<p style="margin: 0px; text-align: justify; font-size: 10pt">The Company&#8217;s
lease agreements do not provide an implicit borrowing rate.&#160; Therefore, the Company used a benchmark
approach to derive an incremental borrowing rate of 10% to discount each of its
lease liabilities based on the remining lease term.</p>

<p style="margin: 0px; font-size: 10pt">&#160;</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text"><p style="margin: 0px; font-size: 10pt"><i>Stock-Based Compensation</i></p>

<p style="margin: 0px; font-size: 10pt">&#160;</p>

<p style="margin: 0px; text-align: justify; font-size: 10pt">Stock-based
compensation is measured at the grant date, based on the estimated fair value
of the award.&#160; Stock-based compensation
is recognized as expense over the employee&#8217;s requisite vesting period and over
the nonemployee&#8217;s period of providing goods or services.&#160; The fair value of each stock warrant is
estimated on the date of grant using the Black-Scholes option valuation model.
Restricted shares are measured based on the fair market value of the underlying
stock on the grant date.</p>

<p style="margin: 0px; text-align: justify; font-size: 10pt"><br/></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock', window );">Research and Development</a></td>
<td class="text"><p style="margin: 0px; font-size: 10pt"><i>Research and Development</i></p>

<p style="margin: 0px; font-size: 10pt">&#160;</p>

<p style="margin: 0px; text-align: justify; font-size: 10pt">We incur research
and development costs during the process of researching and developing additional
technologies purchased and future manufacturing processes.&#160; Our research and development costs consist
primarily of the purchase of additional intellectual property that we will use
in the development of our planned product.&#160;
We expense these costs as incurred until the resulting product has been
completed, tested, and made ready for commercial use.</p>

<p style="margin: 0px; text-align: justify; font-size: 10pt"></p>

<p style="margin: 0px; font-size: 10pt">&#160;</p>

<p style="margin: 0px; font-size: 10pt">&#160;</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><p style="margin: 0px; font-size: 10pt"><i>Recent Accounting Pronouncements</i></p>

<p style="margin: 0px; font-size: 10pt">&#160;</p>

<p style="margin: 0px; text-align: justify; font-size: 10pt">The Financial
Accounting Standards Board issued Accounting Standards Updates (&#8220;ASU&#8221;) to amend
the authoritative literature in the Accounting Standards Codification (&#8220;ASC&#8221;).
There have been a number of ASUs to date that amend the original text of the
ASC. The Company believes those updates issued-to-date either (i) provide
supplemental guidance, (ii) are technical corrections, (iii) are not applicable
to the Company, or (iv) are not expected to have a significant impact on the
Company.</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPreproductionDesignAndDevelopmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the preproduction design and development costs it incurs related to long-term supply arrangements, including whether such costs are capitalized or expensed as incurred. The entity also may disclose the aggregate amount of (1) assets recognized for agreements that contractually reimburse the entity for its pre-production design and development costs (2) assets recognized for molds, dies and other tools that the entity owns and (3) assets recognized for molds, dies and other tools that the entity does not own.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480341/340-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPreproductionDesignAndDevelopmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its research and development and computer software activities including the accounting treatment for costs incurred for (1) research and development activities, (2) development of computer software for internal use, (3) computer software to be sold, leased or otherwise marketed as a separate product or as part of a product or process and (4) in-process research and development acquired in a purchase business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 4<br> -SubTopic 50<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482610/350-50-25-4<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 1<br> -SubTopic 40<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482633/350-40-30-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the nature and amounts of capitalized costs of a research and development nature that were acquired in a transaction other than a business combination, the amount of such assets charged to expense during the period, and identification of the income statement caption in which the charges are included.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139934372412960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NATURE OF OPERATIONS (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Nov. 15, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationDateOfIncorporation', window );">Entity Incorporation, Date of Incorporation</a></td>
<td class="text">Nov. 18,  2005<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionContingentConsiderationLiability', window );">Asset Acquisition, Contingent Consideration, Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=RGPX_PurchaseIntellectualPropertyMember', window );">Purchase Intellectual Property [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Shares, Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationDateOfIncorporation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date when an entity was incorporated</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationDateOfIncorporation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized from contingent consideration in asset acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 15<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480123/805-50-15-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=RGPX_PurchaseIntellectualPropertyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=RGPX_PurchaseIntellectualPropertyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139934372420592">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>GOING CONCERN (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Equity, Attributable to Parent</a></td>
<td class="nump">$ 3,633,333<span></span>
</td>
<td class="nump">$ 1,083,968<span></span>
</td>
<td class="nump">$ 1,122,947<span></span>
</td>
<td class="nump">$ 1,027,257<span></span>
</td>
<td class="nump">$ 1,008,821<span></span>
</td>
<td class="nump">$ 985,617<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139934372373040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Class of Warrant or Right, Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,306,250<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite-Lived Intangible Asset, Useful Life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of Intangible Assets</a></td>
<td class="nump">$ 723<span></span>
</td>
<td class="nump">$ 1,437<span></span>
</td>
<td class="nump">$ 723<span></span>
</td>
<td class="nump">$ 1,794<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherDepreciationAndAmortization', window );">Other Depreciation and Amortization</a></td>
<td class="nump">$ 422<span></span>
</td>
<td class="nump">$ 538<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeFinanceLeaseDiscountRate', window );">Lessee, Finance Lease, Discount Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, Useful Life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, Useful Life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482686/350-30-45-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeFinanceLeaseDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Discount rate used by lessee to determine present value of finance lease payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeFinanceLeaseDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense charged against earnings to allocate the cost of tangible and intangible assets over their remaining economic lives, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139934376242384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionRate', window );">Related Party Transaction, Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RGPX_RelatedPartyAdvances', window );">[custom:RelatedPartyAdvances-0]</a></td>
<td class="nump">$ 2,637<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,637<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 131,887<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest Expense</a></td>
<td class="nump">19,801<span></span>
</td>
<td class="nump">$ 16,607<span></span>
</td>
<td class="nump">$ 38,307<span></span>
</td>
<td class="nump">$ 32,125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateDuringPeriod', window );">Debt Instrument, Interest Rate During Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1000.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RGPX_NotesPayableRelatedParties', window );">[custom:NotesPayableRelatedParties-0]</a></td>
<td class="nump">4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest Expense, Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,630<span></span>
</td>
<td class="nump">129<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Notes Payable</a></td>
<td class="nump">184,232<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">184,232<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued Liabilities, Current</a></td>
<td class="nump">82,034<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">82,034<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125,787<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=RGPX_AggregateInterestExpenseMember', window );">Aggregate Interest Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued Liabilities, Current</a></td>
<td class="nump">70,746<span></span>
</td>
<td class="nump">$ 102,858<span></span>
</td>
<td class="nump">70,746<span></span>
</td>
<td class="nump">102,858<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=RGPX_ReissuedNotesMember', window );">Reissued Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Notes Payable</a></td>
<td class="nump">128,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">128,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-Term Debt, Gross</a></td>
<td class="nump">155,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">155,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Interest Payable, Current</a></td>
<td class="nump">26,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_ChiefFinancialOfficerMember', window );">Chief Financial Officer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesAndLoansPayable', window );">Notes and Loans Payable</a></td>
<td class="nump">131,687<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">131,687<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RGPX_RelatedPartyAdvances', window );">[custom:RelatedPartyAdvances-0]</a></td>
<td class="nump">52,545<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52,545<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=RGPX_AffiliatesMember', window );">Affiliates [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,285<span></span>
</td>
<td class="nump">3,284<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_ChiefExecutiveOfficerMember', window );">Chief Executive Officer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RGPX_RelatedPartyAdvances', window );">[custom:RelatedPartyAdvances-0]</a></td>
<td class="nump">2,437<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,437<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=RGPX_ChiefExecutiveOfficerAndChiefFinancialOfficerMember', window );">Chief Executive Officer And Chief Financial Officer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesAndLoansPayable', window );">Notes and Loans Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Repayments of Notes Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateDuringPeriod', window );">Debt Instrument, Interest Rate During Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_MajorityShareholderMember', window );">Majority Shareholder [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesAndLoansPayable', window );">Notes and Loans Payable</a></td>
<td class="nump">558,691<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 558,691<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 537,475<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=RGPX_ShareholderMember', window );">Shareholder [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Repayments of Notes Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=RGPX_ShareholderMember', window );">Shareholder [Member] | Promissory Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Repayments of Notes Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=RGPX_ShareholderMember', window );">Shareholder [Member] | Promissory 1 Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermNotesPayable', window );">Notes Payable, Noncurrent</a></td>
<td class="nump">$ 2,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt Instrument, Interest Rate, Stated Percentage</a></td>
<td class="nump">1000.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1000.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RGPX_NotesPayableRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RGPX_NotesPayableRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RGPX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RGPX_RelatedPartyAdvances">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RGPX_RelatedPartyAdvances</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RGPX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average effective interest rate during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483013/835-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesAndLoansPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying value as of the balance sheet date of all notes and loans payable (with maturities initially due after one year or beyond the operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesAndLoansPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Identify the stated interest rate per the agreement, for example, leasing and debt arrangements between related parties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=RGPX_AggregateInterestExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=RGPX_AggregateInterestExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=RGPX_ReissuedNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=RGPX_ReissuedNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_ChiefFinancialOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_ChiefFinancialOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=RGPX_AffiliatesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=RGPX_AffiliatesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_ChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_ChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=RGPX_ChiefExecutiveOfficerAndChiefFinancialOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=RGPX_ChiefExecutiveOfficerAndChiefFinancialOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_MajorityShareholderMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_MajorityShareholderMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=RGPX_ShareholderMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=RGPX_ShareholderMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=RGPX_PromissoryNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=RGPX_PromissoryNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=RGPX_Promissory1NotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=RGPX_Promissory1NotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139934377611392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTANGIBLE ASSETS AND INTELLECTUAL PROPERTY (Details Narrative)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
</tr>
<tr><th class="th"><div>Nov. 15, 2021</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsDescription', window );">Business Combination, Contingent Consideration Arrangements, Description</a></td>
<td class="text">and up to $10,000,000 in contingent consideration to be paid at the rate of 15% of all gross revenues received from sales or investment money into the Company, payable on the 15th of the following month, for a period of 60 months<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For contingent consideration arrangements recognized in connection with a business combination, this element represents a description of such arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479581/805-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139934375724192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Nov. 15, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsSoldUnderAgreementsToRepurchaseLineItems', window );"><strong>Assets Sold under Agreements to Repurchase [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionContingentConsiderationLiability', window );">Asset Acquisition, Contingent Consideration, Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and Administrative Expense</a></td>
<td class="nump">$ 385,923<span></span>
</td>
<td class="nump">$ 21,504<span></span>
</td>
<td class="nump">$ 546,097<span></span>
</td>
<td class="nump">$ 38,789<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued Liabilities, Current</a></td>
<td class="nump">82,034<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">82,034<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 125,787<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=RGPX_AssetPurchaseAgreementLiabilityMember', window );">Asset Purchase Agreement Liability [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsSoldUnderAgreementsToRepurchaseLineItems', window );"><strong>Assets Sold under Agreements to Repurchase [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued Liabilities, Current</a></td>
<td class="nump">$ 7,988<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,988<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsSoldUnderAgreementsToRepurchaseAxis=RGPX_ChiefExecutiveOfficerAndChiefFinancialOfficerMember', window );">Chief Executive Officer And Chief Financial Officer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsSoldUnderAgreementsToRepurchaseLineItems', window );"><strong>Assets Sold under Agreements to Repurchase [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and Administrative Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 43,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized from contingent consideration in asset acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 15<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480123/805-50-15-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsSoldUnderAgreementsToRepurchaseLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(m)(1)(ii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsSoldUnderAgreementsToRepurchaseLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=RGPX_AssetPurchaseAgreementLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=RGPX_AssetPurchaseAgreementLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsSoldUnderAgreementsToRepurchaseAxis=RGPX_ChiefExecutiveOfficerAndChiefFinancialOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsSoldUnderAgreementsToRepurchaseAxis=RGPX_ChiefExecutiveOfficerAndChiefFinancialOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139934376190192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OPERATING LEASES (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid Expense, Current</a></td>
<td class="nump">$ 13,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDescription', window );">Lessee, Operating Lease, Description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">On June 10, 2023, the Company entered into a plant facility lease agreement with a related party commencing June 9, 2023 which expires on June 30, 2028.&#160; Under this agreement, the monthly rental payments are $18,000 throughout the term of the lease excepting the month of June 2023 the rent is $7,920, To commence with production, the plant needs to prepare for FDA inspection which will include inspection of the facility, equipment, and the Company&#8217;s procedures.&#160; We expect to launch production during the Company&#8217;s third or fourth quarter and will notify the FDA to come into the plant for the inspection at that time.&#160; The Company is able to start production while the plant waits for the FDA Inspection.&#160; Until the certification is complete, the monthly rent is reduced by forty (40%) percent to $10,800. Under this agreement, the Company is also leasing the equipment in the plant facility through five (5) annual rent payments of $10,000, which are due on the 15th day of&#160; each June from June 2023 to June 2027.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and Administrative Expense</a></td>
<td class="nump">385,923<span></span>
</td>
<td class="nump">$ 21,504<span></span>
</td>
<td class="nump">$ 546,097<span></span>
</td>
<td class="nump">$ 38,789<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=RGPX_OperatingLeaseCostMember', window );">Operating Lease Cost [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and Administrative Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">81,451<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis=RGPX_OfficeLeaseMember', window );">Office Lease [Member] | Monthly Rental Payments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue', window );">Operating Leases, Future Minimum Payments Due</a></td>
<td class="nump">1,650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis=RGPX_OfficeLeaseMember', window );">Office Lease [Member] | Security Deposit [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid Expense, Current</a></td>
<td class="nump">800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis=RGPX_PlantFacilityMember', window );">Plant Facility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalLeaseObligationsCurrent', window );">Capital Lease Obligations, Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,920<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis=RGPX_PlantFacilityMember', window );">Plant Facility [Member] | Monthly Rental Payments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue', window );">Operating Leases, Future Minimum Payments Due</a></td>
<td class="nump">$ 18,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeaseObligationsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of capital lease obligation due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 840<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481161/840-30-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 840<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481192/840-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeaseObligationsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of lessee's operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 840<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481418/840-10-55-40<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 840<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481501/840-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482955/340-10-05-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483032/340-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=RGPX_OperatingLeaseCostMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=RGPX_OperatingLeaseCostMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis=RGPX_OfficeLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis=RGPX_OfficeLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=RGPX_MonthlyRentalPaymentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=RGPX_MonthlyRentalPaymentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=RGPX_SecurityDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=RGPX_SecurityDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis=RGPX_PlantFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis=RGPX_PlantFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139934375695440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS&#8217; DEFICIT (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common Stock, Shares Authorized</a></td>
<td class="nump">675,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">675,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">675,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Par or Stated Value Per Share</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Stock Issued During Period, Shares, Issued for Services</a></td>
<td class="nump">430,000<span></span>
</td>
<td class="nump">30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-Based Payment Arrangement, Noncash Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 133,388<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Class of Warrant or Right, Outstanding</a></td>
<td class="nump">2,306,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,306,250<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.19%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.54%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of Stock, Price Per Share</a></td>
<td class="nump">$ 0.18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock Issued During Period, Value, New Issues</a></td>
<td class="nump">$ 153,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 343,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityContractTerms', window );">Temporary Equity, Contract Terms</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Five warrants were issued for each share
purchased, for a total of 1,716,250 warrants.&#160;
The warrants are exercisable at twenty ($0.20) cents and expire from
April 2025 through September 2025.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,216,238<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=RGPX_BoardMembersAndConsultantsMember', window );">Board Members And Consultants [Member] | Services Rendered [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Stock Issued During Period, Shares, Issued for Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">460,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-Based Payment Arrangement, Noncash Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 82,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Class of Warrant or Right, Outstanding</a></td>
<td class="nump">590,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">590,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</a></td>
<td class="nump">$ 59,691<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 59,691<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RGPX_StockBasedCompensationUnrecognizedCompensationCost', window );">[custom:StockBasedCompensationUnrecognizedCompensationCost-0]</a></td>
<td class="nump">$ 9,103<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,103<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=RGPX_BoardMembersAndConsultantsMember', window );">Board Members And Consultants [Member] | Services Rendered [Member] | Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-Based Payment Arrangement, Noncash Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,588<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Exercise Price</a></td>
<td class="nump">$ 0.33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RGPX_StockBasedCompensationUnrecognizedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RGPX_StockBasedCompensationUnrecognizedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RGPX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityContractTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Significant terms of equity contract classified as temporary equity to issue additional shares. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityContractTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=RGPX_BoardMembersAndConsultantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=RGPX_BoardMembersAndConsultantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=RGPX_ServicesRenderedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=RGPX_ServicesRenderedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis=RGPX_WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis=RGPX_WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139934376150288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Nov. 30, 2023</div></th>
<th class="th"><div>Nov. 01, 2023</div></th>
<th class="th"><div>Oct. 01, 2023</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Notes Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 184,232<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=RGPX_ReissuedNotesMember', window );">Reissued Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Notes Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">128,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-Term Debt, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">155,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Interest Payable, Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Reissued Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Notes Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,500<span></span>
</td>
<td class="nump">$ 67,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-Term Debt, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,500<span></span>
</td>
<td class="nump">82,735<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Interest Payable, Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="nump">$ 15,335<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Debt Instrument, Maturity Date</a></td>
<td class="text">May  02,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(2))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=RGPX_ReissuedNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=RGPX_ReissuedNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>ixform10q_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:RGPX="http://regenerexpharmainc.com/20230930"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2023"
  xmlns:us-gaap="http://fasb.org/us-gaap/2023"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="rgpx-20230930.xsd" xlink:type="simple"/>
    <context id="From2023-04-01to2023-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357878</identifier>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2023-11-08">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357878</identifier>
        </entity>
        <period>
            <instant>2023-11-08</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357878</identifier>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357878</identifier>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="From2023-07-012023-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357878</identifier>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2022-07-012022-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357878</identifier>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2022-04-012022-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357878</identifier>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2023-04-012023-09-30_us-gaap_OtherAffiliatesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357878</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:OtherAffiliatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2022-04-012022-09-30_us-gaap_OtherAffiliatesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357878</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:OtherAffiliatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2023-04-012023-09-30_custom_ShareholderMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357878</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">RGPX:ShareholderMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2022-04-012022-09-30_custom_ShareholderMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357878</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">RGPX:ShareholderMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2022-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357878</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357878</identifier>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357878</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357878</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357878</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357878</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="AsOf2022-06-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357878</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="AsOf2022-06-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357878</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="AsOf2022-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357878</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357878</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="AsOf2023-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357878</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="AsOf2023-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357878</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357878</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357878</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357878</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357878</identifier>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="From2022-04-012022-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357878</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="From2022-04-012022-06-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357878</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="From2022-04-012022-06-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357878</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="From2022-04-012022-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357878</identifier>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="From2022-07-012022-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357878</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2022-07-012022-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357878</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2022-07-012022-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357878</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2023-04-012023-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357878</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2023-04-012023-06-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357878</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2023-04-012023-06-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357878</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2023-04-012023-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357878</identifier>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012023-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357878</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012023-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357878</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012023-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357878</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2022-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357878</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="AsOf2022-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357878</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="AsOf2022-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357878</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357878</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357878</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357878</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2021-11-15_custom_PurchaseIntellectualPropertyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357878</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">RGPX:PurchaseIntellectualPropertyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-15</instant>
        </period>
    </context>
    <context id="AsOf2021-11-15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357878</identifier>
        </entity>
        <period>
            <instant>2021-11-15</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357878</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357878</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_srt_ChiefFinancialOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357878</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefFinancialOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="From2023-04-012023-09-30_custom_AffiliatesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357878</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">RGPX:AffiliatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2022-04-012022-09-30_custom_AffiliatesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357878</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">RGPX:AffiliatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2023-09-30_srt_ChiefExecutiveOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357878</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-03-31_custom_ChiefExecutiveOfficerAndChiefFinancialOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357878</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">RGPX:ChiefExecutiveOfficerAndChiefFinancialOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="From2023-04-012023-09-30_custom_ChiefExecutiveOfficerAndChiefFinancialOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357878</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">RGPX:ChiefExecutiveOfficerAndChiefFinancialOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2022-04-012022-09-30_custom_ChiefExecutiveOfficerAndChiefFinancialOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357878</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">RGPX:ChiefExecutiveOfficerAndChiefFinancialOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2023-09-30_us-gaap_MajorityShareholderMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357878</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:MajorityShareholderMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-03-31_us-gaap_MajorityShareholderMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357878</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:MajorityShareholderMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_custom_ReissuedNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357878</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">RGPX:ReissuedNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="From2023-04-012023-09-30_custom_ShareholderMember_custom_PromissoryNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357878</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">RGPX:PromissoryNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">RGPX:ShareholderMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2023-09-30_custom_ShareholderMember_custom_Promissory1NotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357878</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">RGPX:Promissory1NotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">RGPX:ShareholderMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_custom_AggregateInterestExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357878</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">RGPX:AggregateInterestExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2022-09-30_custom_AggregateInterestExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357878</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">RGPX:AggregateInterestExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="From2021-11-012021-11-15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357878</identifier>
        </entity>
        <period>
            <startDate>2021-11-01</startDate>
            <endDate>2021-11-15</endDate>
        </period>
    </context>
    <context id="From2023-04-012023-09-30_custom_ChiefExecutiveOfficerAndChiefFinancialOfficerMember397223531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357878</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetsSoldUnderAgreementsToRepurchaseAxis">RGPX:ChiefExecutiveOfficerAndChiefFinancialOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2022-04-012023-03-31_custom_ChiefExecutiveOfficerAndChiefFinancialOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357878</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetsSoldUnderAgreementsToRepurchaseAxis">RGPX:ChiefExecutiveOfficerAndChiefFinancialOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-09-30_custom_AssetPurchaseAgreementLiabilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357878</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">RGPX:AssetPurchaseAgreementLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-03-31_custom_AssetPurchaseAgreementLiabilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357878</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">RGPX:AssetPurchaseAgreementLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_custom_OfficeLeaseMember_custom_MonthlyRentalPaymentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357878</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">RGPX:MonthlyRentalPaymentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertySubjectToOrAvailableForOperatingLeaseAxis">RGPX:OfficeLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_custom_OfficeLeaseMember_custom_SecurityDepositMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357878</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">RGPX:SecurityDepositMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertySubjectToOrAvailableForOperatingLeaseAxis">RGPX:OfficeLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_custom_PlantFacilityMember_custom_MonthlyRentalPaymentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357878</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">RGPX:MonthlyRentalPaymentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertySubjectToOrAvailableForOperatingLeaseAxis">RGPX:PlantFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_custom_PlantFacilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357878</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertySubjectToOrAvailableForOperatingLeaseAxis">RGPX:PlantFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="From2023-04-012023-09-30_custom_OperatingLeaseCostMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357878</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">RGPX:OperatingLeaseCostMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2022-04-012022-09-30_custom_OperatingLeaseCostMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357878</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">RGPX:OperatingLeaseCostMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2023-04-012023-09-30_custom_BoardMembersAndConsultantsMember_custom_ServicesRenderedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357878</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">RGPX:ServicesRenderedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">RGPX:BoardMembersAndConsultantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2023-09-30_custom_BoardMembersAndConsultantsMember_custom_ServicesRenderedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357878</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">RGPX:ServicesRenderedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">RGPX:BoardMembersAndConsultantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="From2023-04-012023-09-30_custom_BoardMembersAndConsultantsMember_custom_ServicesRenderedMember_custom_WarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357878</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">RGPX:WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">RGPX:ServicesRenderedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">RGPX:BoardMembersAndConsultantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2023-09-30_custom_BoardMembersAndConsultantsMember_custom_ServicesRenderedMember_custom_WarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357878</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">RGPX:WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">RGPX:ServicesRenderedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">RGPX:BoardMembersAndConsultantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-10-01_us-gaap_SubsequentEventMember_custom_ReissuedNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357878</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">RGPX:ReissuedNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-10-01</instant>
        </period>
    </context>
    <context id="AsOf2023-11-01_us-gaap_SubsequentEventMember_custom_ReissuedNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357878</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">RGPX:ReissuedNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-01</instant>
        </period>
    </context>
    <context id="From2023-11-012023-11-30_us-gaap_SubsequentEventMember_custom_ReissuedNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357878</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">RGPX:ReissuedNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-01</startDate>
            <endDate>2023-11-30</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <dei:AmendmentFlag contextRef="From2023-04-01to2023-09-30">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus contextRef="From2023-04-01to2023-09-30">2023</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus contextRef="From2023-04-01to2023-09-30">Q2</dei:DocumentFiscalPeriodFocus>
    <dei:CurrentFiscalYearEndDate contextRef="From2023-04-01to2023-09-30">--03-31</dei:CurrentFiscalYearEndDate>
    <dei:EntityCentralIndexKey contextRef="From2023-04-01to2023-09-30">0001357878</dei:EntityCentralIndexKey>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="AsOf2023-03-31"
      id="xdx2ixbrl0046"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2023-03-31"
      id="xdx2ixbrl0062"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NotesPayableCurrent
      contextRef="AsOf2023-03-31"
      id="xdx2ixbrl0089"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2023-03-31"
      id="xdx2ixbrl0092"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NotesPayable
      contextRef="AsOf2023-03-31"
      id="xdx2ixbrl0104"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2023-03-31"
      id="xdx2ixbrl0107"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="AsOf2023-09-30"
      id="xdx2ixbrl0112"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="AsOf2023-03-31"
      id="xdx2ixbrl0113"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2022-07-012022-09-30"
      id="xdx2ixbrl0152"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2022-04-012022-09-30"
      id="xdx2ixbrl0154"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensation
      contextRef="From2022-04-012022-09-30"
      id="xdx2ixbrl0214"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="From2022-04-012022-09-30"
      id="xdx2ixbrl0217"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="From2022-04-012022-09-30"
      id="xdx2ixbrl0220"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PaymentsToAcquireFurnitureAndFixtures
      contextRef="From2022-04-012022-09-30"
      id="xdx2ixbrl0241"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2022-04-012022-09-30"
      id="xdx2ixbrl0244"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="From2022-04-012022-09-30_us-gaap_OtherAffiliatesMember"
      id="xdx2ixbrl0253"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="From2022-04-012022-09-30_custom_ShareholderMember"
      id="xdx2ixbrl0256"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="From2022-04-012022-09-30"
      id="xdx2ixbrl0262"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxesPaid
      contextRef="From2023-04-01to2023-09-30"
      id="xdx2ixbrl0279"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxesPaid
      contextRef="From2022-04-012022-09-30"
      id="xdx2ixbrl0280"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:InterestPaid
      contextRef="From2023-04-01to2023-09-30"
      id="xdx2ixbrl0282"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:InterestPaid
      contextRef="From2022-04-012022-09-30"
      id="xdx2ixbrl0283"
      unitRef="USD"
      xsi:nil="true"/>
    <RGPX:OperatingLeasesRouAssetAndLiabilities
      contextRef="From2022-04-012022-09-30"
      id="xdx2ixbrl0292"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1
      contextRef="From2023-04-01to2023-09-30"
      id="xdx2ixbrl0294"
      unitRef="USD"
      xsi:nil="true"/>
    <RGPX:NoncashOrPartNoncashAcquisitionOfIntangibleAssetsExcludingGoodwill
      contextRef="From2022-04-012022-09-30"
      id="xdx2ixbrl0298"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-04-012022-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0306"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-04-012022-06-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0307"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-07-012022-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0323"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-07-012022-09-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0324"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2023-04-012023-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0342"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2023-04-012023-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0348"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-04-012023-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0352"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-04-012023-06-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0353"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-07-012023-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0371"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2023-07-012023-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0377"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-07-012023-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0381"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-07-012023-09-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0382"
      unitRef="USD"
      xsi:nil="true"/>
    <dei:DocumentType contextRef="From2023-04-01to2023-09-30">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport contextRef="From2023-04-01to2023-09-30">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate contextRef="From2023-04-01to2023-09-30">2023-09-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport contextRef="From2023-04-01to2023-09-30">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="From2023-04-01to2023-09-30">000-53230</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="From2023-04-01to2023-09-30">REGENEREX PHARMA, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2023-04-01to2023-09-30">NV</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="From2023-04-01to2023-09-30">98-0479983</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2023-04-01to2023-09-30">5348 Vegas Drive #177</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="From2023-04-01to2023-09-30">Las Vegas</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2023-04-01to2023-09-30">NV</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2023-04-01to2023-09-30">89108</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2023-04-01to2023-09-30">(877)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2023-04-01to2023-09-30">761-7479</dei:LocalPhoneNumber>
    <dei:EntityCurrentReportingStatus contextRef="From2023-04-01to2023-09-30">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="From2023-04-01to2023-09-30">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="From2023-04-01to2023-09-30">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="From2023-04-01to2023-09-30">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="From2023-04-01to2023-09-30">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="From2023-04-01to2023-09-30">false</dei:EntityExTransitionPeriod>
    <dei:EntityShellCompany contextRef="From2023-04-01to2023-09-30">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding contextRef="AsOf2023-11-08" decimals="INF" unitRef="Shares">277915910</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2023-09-30" decimals="0" unitRef="USD">6080</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">1135</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:PrepaidExpenseCurrent contextRef="AsOf2023-09-30" decimals="0" unitRef="USD">13250</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:AssetsCurrent contextRef="AsOf2023-09-30" decimals="0" unitRef="USD">19330</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">1135</us-gaap:AssetsCurrent>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="AsOf2023-09-30" decimals="0" unitRef="USD">27834</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">26397</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="AsOf2023-09-30" decimals="0" unitRef="USD">2766</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">4203</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="AsOf2023-09-30" decimals="0" unitRef="USD">735</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">197</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:MachineryAndEquipmentGross contextRef="AsOf2023-09-30" decimals="0" unitRef="USD">6962</us-gaap:MachineryAndEquipmentGross>
    <us-gaap:MachineryAndEquipmentGross contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">1201</us-gaap:MachineryAndEquipmentGross>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="AsOf2023-09-30" decimals="0" unitRef="USD">903586</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:Assets contextRef="AsOf2023-09-30" decimals="0" unitRef="USD">932644</us-gaap:Assets>
    <us-gaap:Assets contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">6539</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent contextRef="AsOf2023-09-30" decimals="0" unitRef="USD">89840</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">75145</us-gaap:AccountsPayableCurrent>
    <RGPX:RelatedPartyAdvances contextRef="AsOf2023-09-30" decimals="0" unitRef="USD">2637</RGPX:RelatedPartyAdvances>
    <RGPX:RelatedPartyAdvances contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">131887</RGPX:RelatedPartyAdvances>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="AsOf2023-09-30" decimals="0" unitRef="USD">318077</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">221192</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="AsOf2023-09-30" decimals="0" unitRef="USD">82034</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">125787</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:OtherNotesPayableCurrent contextRef="AsOf2023-09-30" decimals="0" unitRef="USD">282786</us-gaap:OtherNotesPayableCurrent>
    <us-gaap:OtherNotesPayableCurrent contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">222771</us-gaap:OtherNotesPayableCurrent>
    <us-gaap:NotesPayableCurrent contextRef="AsOf2023-09-30" decimals="0" unitRef="USD">2400000</us-gaap:NotesPayableCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="AsOf2023-09-30" decimals="0" unitRef="USD">162295</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2023-09-30" decimals="0" unitRef="USD">3337669</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">776782</us-gaap:LiabilitiesCurrent>
    <RGPX:NotesPayableShareholder contextRef="AsOf2023-09-30" decimals="0" unitRef="USD">275905</RGPX:NotesPayableShareholder>
    <RGPX:NotesPayableShareholder contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">314704</RGPX:NotesPayableShareholder>
    <RGPX:NotesPayableRelatedParties contextRef="AsOf2023-09-30" decimals="0" unitRef="USD">4000</RGPX:NotesPayableRelatedParties>
    <RGPX:NotesPayableRelatedParties contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">38000</RGPX:NotesPayableRelatedParties>
    <us-gaap:NotesPayable contextRef="AsOf2023-09-30" decimals="0" unitRef="USD">184232</us-gaap:NotesPayable>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="AsOf2023-09-30" decimals="0" unitRef="USD">764171</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities contextRef="AsOf2023-09-30" decimals="0" unitRef="USD">4565977</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">1129486</us-gaap:Liabilities>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2023-09-30"
      decimals="INF"
      unitRef="USDPShares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2023-03-31"
      decimals="INF"
      unitRef="USDPShares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2023-09-30" decimals="INF" unitRef="Shares">675000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2023-03-31" decimals="INF" unitRef="Shares">675000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2023-09-30" decimals="INF" unitRef="Shares">277915910</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2023-09-30" decimals="INF" unitRef="Shares">277915910</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2023-03-31" decimals="INF" unitRef="Shares">277112660</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2023-03-31" decimals="INF" unitRef="Shares">277112660</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue contextRef="AsOf2023-09-30" decimals="0" unitRef="USD">277916</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">277113</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital contextRef="AsOf2023-09-30" decimals="0" unitRef="USD">1147798</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">671963</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2023-09-30" decimals="0" unitRef="USD">-5059047</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">-2072023</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity contextRef="AsOf2023-09-30" decimals="0" unitRef="USD">-3633333</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">-1122947</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2023-09-30" decimals="0" unitRef="USD">932644</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">6539</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2023-07-012023-09-30"
      decimals="0"
      unitRef="USD">385923</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2022-07-012022-09-30"
      decimals="0"
      unitRef="USD">21504</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2023-04-01to2023-09-30"
      decimals="0"
      unitRef="USD">546097</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2022-04-012022-09-30"
      decimals="0"
      unitRef="USD">38789</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-07-012023-09-30"
      decimals="0"
      unitRef="USD">2400000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-04-01to2023-09-30"
      decimals="0"
      unitRef="USD">2400000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:OperatingExpenses
      contextRef="From2023-07-012023-09-30"
      decimals="0"
      unitRef="USD">2785923</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2022-07-012022-09-30"
      decimals="0"
      unitRef="USD">21504</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2023-04-01to2023-09-30"
      decimals="0"
      unitRef="USD">2946097</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2022-04-012022-09-30"
      decimals="0"
      unitRef="USD">38789</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2023-07-012023-09-30"
      decimals="0"
      unitRef="USD">-2785923</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2022-07-012022-09-30"
      decimals="0"
      unitRef="USD">-21504</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2023-04-01to2023-09-30"
      decimals="0"
      unitRef="USD">-2946097</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2022-04-012022-09-30"
      decimals="0"
      unitRef="USD">-38789</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestExpense
      contextRef="From2023-07-012023-09-30"
      decimals="0"
      unitRef="USD">19801</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="From2022-07-012022-09-30"
      decimals="0"
      unitRef="USD">16607</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="From2023-04-01to2023-09-30"
      decimals="0"
      unitRef="USD">38307</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="From2022-04-012022-09-30"
      decimals="0"
      unitRef="USD">32125</us-gaap:InterestExpense>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="From2023-07-012023-09-30"
      decimals="0"
      unitRef="USD">4275</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="From2022-07-012022-09-30"
      decimals="0"
      unitRef="USD">19675</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="From2023-04-01to2023-09-30"
      decimals="0"
      unitRef="USD">-2620</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="From2022-04-012022-09-30"
      decimals="0"
      unitRef="USD">29274</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2023-07-012023-09-30"
      decimals="0"
      unitRef="USD">-15526</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2022-07-012022-09-30"
      decimals="0"
      unitRef="USD">3068</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2023-04-01to2023-09-30"
      decimals="0"
      unitRef="USD">-40927</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2022-04-012022-09-30"
      decimals="0"
      unitRef="USD">-2851</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-07-012023-09-30"
      decimals="0"
      unitRef="USD">-2801449</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-07-012022-09-30"
      decimals="0"
      unitRef="USD">-18436</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-04-01to2023-09-30"
      decimals="0"
      unitRef="USD">-2987024</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-04-012022-09-30"
      decimals="0"
      unitRef="USD">-41640</us-gaap:NetIncomeLoss>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="From2023-07-012023-09-30"
      decimals="INF"
      unitRef="USDPShares">-0.01</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="From2022-07-012022-09-30"
      decimals="INF"
      unitRef="USDPShares">-0.00</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="From2023-04-01to2023-09-30"
      decimals="INF"
      unitRef="USDPShares">-0.01</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="From2022-04-012022-09-30"
      decimals="INF"
      unitRef="USDPShares">-0.00</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2023-07-012023-09-30"
      decimals="INF"
      unitRef="Shares">277516358</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2022-07-012022-09-30"
      decimals="INF"
      unitRef="Shares">277112660</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2023-04-01to2023-09-30"
      decimals="INF"
      unitRef="Shares">277337306</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2022-04-012022-09-30"
      decimals="INF"
      unitRef="Shares">277112660</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-04-01to2023-09-30"
      decimals="0"
      unitRef="USD">-2987024</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-04-012022-09-30"
      decimals="0"
      unitRef="USD">-41640</us-gaap:NetIncomeLoss>
    <us-gaap:Depreciation
      contextRef="From2023-04-01to2023-09-30"
      decimals="0"
      unitRef="USD">1975</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="From2022-04-012022-09-30"
      decimals="0"
      unitRef="USD">1794</us-gaap:Depreciation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-04-01to2023-09-30"
      decimals="0"
      unitRef="USD">133388</us-gaap:ShareBasedCompensation>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="From2023-04-01to2023-09-30"
      decimals="0"
      unitRef="USD">2400000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="From2023-04-01to2023-09-30"
      decimals="0"
      unitRef="USD">22880</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="From2023-04-01to2023-09-30"
      decimals="0"
      unitRef="USD">-2620</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="From2022-04-012022-09-30"
      decimals="0"
      unitRef="USD">29274</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="From2023-04-01to2023-09-30"
      decimals="0"
      unitRef="USD">-13250</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="From2022-04-012022-09-30"
      decimals="0"
      unitRef="USD">2756</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="From2023-04-01to2023-09-30"
      decimals="0"
      unitRef="USD">146125</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="From2022-04-012022-09-30"
      decimals="0"
      unitRef="USD">21852</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2023-04-01to2023-09-30"
      decimals="0"
      unitRef="USD">-293286</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2022-04-012022-09-30"
      decimals="0"
      unitRef="USD">-44512</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireFurnitureAndFixtures
      contextRef="From2023-04-01to2023-09-30"
      decimals="0"
      unitRef="USD">6299</us-gaap:PaymentsToAcquireFurnitureAndFixtures>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2023-04-01to2023-09-30"
      decimals="0"
      unitRef="USD">-6299</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromRelatedPartyDebt
      contextRef="From2023-04-01to2023-09-30"
      decimals="0"
      unitRef="USD">2437</us-gaap:ProceedsFromRelatedPartyDebt>
    <us-gaap:ProceedsFromRelatedPartyDebt
      contextRef="From2022-04-012022-09-30"
      decimals="0"
      unitRef="USD">7600</us-gaap:ProceedsFromRelatedPartyDebt>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="From2023-04-012023-09-30_us-gaap_OtherAffiliatesMember"
      decimals="0"
      unitRef="USD">34000</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="From2023-04-012023-09-30_custom_ShareholderMember"
      decimals="0"
      unitRef="USD">10000</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:ProceedsFromNotesPayable
      contextRef="From2023-04-01to2023-09-30"
      decimals="0"
      unitRef="USD">2843</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:ProceedsFromNotesPayable
      contextRef="From2022-04-012022-09-30"
      decimals="0"
      unitRef="USD">34901</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="From2023-04-01to2023-09-30"
      decimals="0"
      unitRef="USD">343250</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2023-04-01to2023-09-30"
      decimals="0"
      unitRef="USD">304530</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2022-04-012022-09-30"
      decimals="0"
      unitRef="USD">42501</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2023-04-01to2023-09-30"
      decimals="0"
      unitRef="USD">4945</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2022-04-012022-09-30"
      decimals="0"
      unitRef="USD">-2011</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">1135</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">2640</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="AsOf2023-09-30" decimals="0" unitRef="USD">6080</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="AsOf2022-09-30" decimals="0" unitRef="USD">629</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <RGPX:AccruedInterestConvertedIntoNotePayableToShareholder
      contextRef="From2023-04-01to2023-09-30"
      decimals="0"
      unitRef="USD">78194</RGPX:AccruedInterestConvertedIntoNotePayableToShareholder>
    <RGPX:AccruedInterestConvertedIntoNotePayableToShareholder
      contextRef="From2022-04-012022-09-30"
      decimals="0"
      unitRef="USD">4015</RGPX:AccruedInterestConvertedIntoNotePayableToShareholder>
    <RGPX:OperatingLeasesRouAssetAndLiabilities
      contextRef="From2023-04-01to2023-09-30"
      decimals="0"
      unitRef="USD">953535</RGPX:OperatingLeasesRouAssetAndLiabilities>
    <us-gaap:NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1
      contextRef="From2022-04-012022-09-30"
      decimals="0"
      unitRef="USD">150000</us-gaap:NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1>
    <RGPX:NoncashOrPartNoncashAcquisitionOfIntangibleAssetsExcludingGoodwill
      contextRef="From2023-04-01to2023-09-30"
      decimals="0"
      unitRef="USD">2400000</RGPX:NoncashOrPartNoncashAcquisitionOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2022-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">277112660</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-03-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">277113</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">671963</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-1934693</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">-985617</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-04-012022-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-23204</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-04-012022-06-30"
      decimals="0"
      unitRef="USD">-23204</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2022-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">277112660</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-06-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">277113</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">671963</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-1957897</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2022-06-30" decimals="0" unitRef="USD">-1008821</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2022-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">277112660</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-06-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">277113</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">671963</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-1957897</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2022-06-30" decimals="0" unitRef="USD">-1008821</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-07-012022-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-18436</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-07-012022-09-30"
      decimals="0"
      unitRef="USD">-18436</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2022-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">277112660</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-09-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">277113</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">671963</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-1976333</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2022-09-30" decimals="0" unitRef="USD">-1027257</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2023-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">277112660</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-03-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">277113</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">671963</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-2072023</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">-1122947</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2023-04-012023-06-30"
      decimals="INF"
      unitRef="Shares">190000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2023-04-012023-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">190</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2023-04-012023-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="INF"
      unitRef="Shares">189810</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2023-04-012023-06-30"
      decimals="INF"
      unitRef="Shares">190000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2023-04-012023-06-30"
      decimals="INF"
      unitRef="Shares">30000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2023-04-012023-06-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">30</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2023-04-012023-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">34524</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2023-04-012023-06-30"
      decimals="0"
      unitRef="USD">34554</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-04-012023-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-185575</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-04-012023-06-30"
      decimals="0"
      unitRef="USD">-185575</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2023-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">277332660</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-06-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">277333</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">896297</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-2257598</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2023-06-30" decimals="0" unitRef="USD">-1083968</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2023-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">277332660</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-06-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">277333</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">896297</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-2257598</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2023-06-30" decimals="0" unitRef="USD">-1083968</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2023-07-012023-09-30"
      decimals="INF"
      unitRef="Shares">153250</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-07-012023-09-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">153</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-07-012023-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">153097</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-07-012023-09-30"
      decimals="0"
      unitRef="USD">153250</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2023-07-012023-09-30"
      decimals="INF"
      unitRef="Shares">430000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2023-07-012023-09-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">430</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2023-07-012023-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">98404</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2023-07-012023-09-30"
      decimals="0"
      unitRef="USD">98834</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-07-012023-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-2801449</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-07-012023-09-30"
      decimals="0"
      unitRef="USD">-2801449</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2023-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">277915910</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-09-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">277916</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">1147798</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-5059047</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2023-09-30" decimals="0" unitRef="USD">-3633333</us-gaap:StockholdersEquity>
    <us-gaap:NatureOfOperations contextRef="From2023-04-01to2023-09-30">&lt;p style="margin: 0px; font-size: 10pt"&gt;&lt;b&gt;NOTE 1 &#x2013;
NATURE OF OPERATIONS&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0px; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0px; text-align: justify; font-size: 10pt"&gt;Regenerex Pharma, Inc., formerly Peptide Technologies, Inc. (the
&#x201c;Company&#x201d; or &#x201c;Regenerex&#x201d;), was incorporated in the State of Nevada, United States
of America, on November 18, 2005.&lt;/p&gt;

&lt;p style="margin: 0px; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0px; text-align: justify; font-size: 10pt"&gt;On November 15, 2021,
the Company entered into an Asset Purchase Agreement in which the Company
purchased certain intellectual property in exchange for 150,000,000 shares of
the Company&#x2019;s common stock and up to $10,000,000 in contingent consideration to
be paid at the rate of 15% of all gross revenues received from sales or
investment money into the Company, payable on the 15&lt;sup&gt;th&lt;/sup&gt; of the
following month, for a period of 60 months.&#160;
The Company received all rights and title to proprietary wound healing
technologies platforms and formulas involving the application of wound
care protocols to treat all wounds, such
as diabetic ulcers, pressure ulcers, burns and surgical wounds.&#160; These unique products strategically position
the Company to enter the wound treatment market in the U.S.&lt;/p&gt;

&lt;p style="margin: 0px; text-align: justify; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0px; text-align: justify; font-size: 10pt"&gt;&lt;i&gt;Risks and Uncertainties&lt;/i&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0px; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0px; text-align: justify; font-size: 10pt"&gt;Our
business and our forward-looking statements involve substantial known and
unknown risks and uncertainties, including the risks and uncertainties inherent
in our statements regarding the impacts of COVID-19, or other future pandemics
on our business, results of operations, financial position, and cash flows.&lt;/p&gt;

&lt;p style="margin: 0px; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0px; text-align: justify; font-size: 10pt"&gt;The Company has
a lack of revenue history and has had a limited history of operations.&#160; No
revenue has historically been derived from the assets purchased. &#160;Regenerex can give no assurance of success or
profitability to the Company&#x2019;s investors.&lt;/p&gt;

&lt;p style="margin: 0px; text-align: justify; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0px; text-align: justify; font-size: 10pt"&gt;The wound care
healing space is well suited for Home Care service providers that are funded by
the US Government. Strategic planning and development will be performed
internally by the Company.&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0px; font-size: 10pt"&gt;&#160;&lt;/p&gt;

</us-gaap:NatureOfOperations>
    <dei:EntityIncorporationDateOfIncorporation contextRef="From2023-04-01to2023-09-30">2005-11-18</dei:EntityIncorporationDateOfIncorporation>
    <us-gaap:SharesIssued
      contextRef="AsOf2021-11-15_custom_PurchaseIntellectualPropertyMember"
      decimals="INF"
      unitRef="Shares">150000000</us-gaap:SharesIssued>
    <us-gaap:AssetAcquisitionContingentConsiderationLiability contextRef="AsOf2021-11-15" decimals="0" unitRef="USD">10000000</us-gaap:AssetAcquisitionContingentConsiderationLiability>
    <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock contextRef="From2023-04-01to2023-09-30">&lt;p style="margin: 0px; text-align: justify; font-size: 10pt"&gt;&lt;b&gt;NOTE 2 &#x2013; BASIS OF PRESENTATION OF INTERIM FINANCIAL STATEMENTS&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0px; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0px; text-align: justify; font-size: 10pt"&gt;The
Company prepares its financial statements in accordance with accounting
principles generally accepted in the United States of America. The accompanying
interim unaudited financial statements have been prepared in accordance with
generally accepted accounting principles for interim financial information in
accordance with the instructions to Form 10-Q and Article 8 of Regulation S-X.
In our opinion, all adjustments (consisting of normal recurring adjustments)
considered necessary for a fair presentation have been included.&lt;/p&gt;

&lt;p style="margin: 0px; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0px; text-align: justify; font-size: 10pt"&gt;Operating
results for the three and six months ended September 30, 2023, are not
necessarily indicative of the results that may be expected for the year ending
March 31, 2024. &#160;Notes to the unaudited
interim financial statements that would substantially duplicate the disclosures
contained in the audited financial statements for the year ended March 31, 2023,
have been omitted. This report should be read in conjunction with the audited
financial statements and the footnotes thereto for the fiscal year ended March
31, 2023, included within the Company&#x2019;s Annual Report on Form 10-K as filed
with the Securities and Exchange Commission.&lt;/p&gt;

&lt;p style="margin: 0px; font-size: 10pt"&gt;&#160;&lt;/p&gt;

</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
    <us-gaap:SubstantialDoubtAboutGoingConcernTextBlock contextRef="From2023-04-01to2023-09-30">&lt;p style="margin: 0px; text-align: justify; font-size: 10pt"&gt;&lt;b&gt;NOTE 3
&#x2013; GOING CONCERN&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0px; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0px; text-align: justify; font-size: 10pt"&gt;These financial statements
have been prepared in conformity with accounting principles generally accepted
in the United States of America (&#x201c;U.S. GAAP&#x201d;), which contemplate the
continuation of the Company as a going concern. The Company has incurred losses
from operations, and as of September 30, 2023, it had excess liabilities over
assets of $3,633,333. &#160;These factors
raise substantial doubt about the Company&#x2019;s ability to continue as a going
concern.&lt;/p&gt;





&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span class="adv_highlightanchor adv_pagination" id="page_6"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt"&gt;&lt;/p&gt;

&lt;p style="margin: 0px; text-align: justify; font-size: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;The Company requires
significant cash to launch its business and reduce its payable.&#160; Management&#x2019;s plans are to actively seek
capital to enable the Company to add new products and/or services to ultimately
achieve profitability. However, management cannot provide assurance that they
can raise sufficient capital and whether the Company will ultimately achieve
profitability, become cash flow positive, or raise additional debt and/or
equity capital. &#160;If the Company is unable
to raise additional capital in the near future or meet financing requirements,
management expects that the Company will need to curtail operations, seek
additional capital on less favorable terms, and/or pursue other remedial
measures.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0px; text-align: justify; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0px; text-align: justify; font-size: 10pt"&gt;These
financial statements do not include any adjustments related to the
recoverability and classification of assets or the amounts and classification
of liabilities that might be necessary should the Company become unable to
continue as a going concern.&lt;/p&gt;

&lt;p style="margin: 0px; font-size: 10pt"&gt;&#160;&lt;/p&gt;

</us-gaap:SubstantialDoubtAboutGoingConcernTextBlock>
    <us-gaap:StockholdersEquity contextRef="AsOf2023-09-30" decimals="0" unitRef="USD">-3633333</us-gaap:StockholdersEquity>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="From2023-04-01to2023-09-30">&lt;p style="margin: 0px; text-align: justify; font-size: 10pt"&gt;&lt;b&gt;NOTE 4
&#x2013;SIGNIFICANT ACCOUNTING POLICIES&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0px; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0px; text-align: justify; font-size: 10pt"&gt;&lt;i&gt;Revenue Recognition&lt;/i&gt;&lt;/p&gt;

&lt;p style="margin: 0px; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0px; text-align: justify; font-size: 10pt"&gt;The Company will record
revenue under ASC 606 by 1) identifying the contract with the customer 2)
identifying the performance obligations in the contract 3) determining the
transaction price, 4) allocating the transaction price to the required performance
obligations in the contract, and 5) recognizing revenue when or as the
companies satisfies a performance obligation.&lt;/p&gt;

&lt;p style="margin: 0px; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0px; text-align: justify; font-size: 10pt"&gt;We expect to
generate revenue from home care service providers that are funded by the U.S.
Government, State Medicaid Programs, International Health Care Programs, Veteran&#x2019;s
administration, Prison system, Home Health Care Providers, and other applicable
Medicare reimbursement models.&#160; The
Company will defer revenue where the earnings process is not yet complete.&#160; To date, no revenue has been generated from
the asset acquisition disclosed in Note 1.&lt;/p&gt;

&lt;p style="margin: 0px; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0px; text-align: justify; font-size: 10pt"&gt;&lt;i&gt;Earnings per
Share&lt;/i&gt;&lt;/p&gt;

&lt;p style="margin: 0px; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0px; text-align: justify; font-size: 10pt"&gt;Earnings per share is reported in accordance
with FASB ASC Topic 260 &#x201c;&lt;i&gt;Earnings per Share&lt;/i&gt;&#x201d; which requires dual
presentation of basic earnings per share (&#x201c;EPS&#x201d;) and diluted EPS on the face of all statements of
earnings, for all entities with complex capital structures. Diluted EPS
reflects the potential dilution that could occur from common shares issuable
through the exercise or conversion of stock options, restricted stock awards,
warrants and convertible securities. In certain circumstances, the conversion
of these options, warrants and convertible securities are excluded from diluted
EPS if the effect of such inclusion would be anti-dilutive. Fully diluted EPS is
not provided, when the effect is anti-dilutive. When the effect of dilution on
loss per share is anti-dilutive, diluted loss per share equals the loss per
share.&lt;/p&gt;

&lt;p style="margin: 0px; text-align: justify; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0px; text-align: justify; font-size: 10pt"&gt;During the six months ended September 30, 2023,
the Company excluded the outstanding stock warrants from its calculation of
earnings per share, as the warrants would be anti-dilutive. As of September 30, 2023
and 2022, the Company had common shares warrants outstanding of 2,306,250 and
0, respectively.&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt"&gt;&lt;/p&gt;

&lt;p style="margin: 0px; font-size: 10pt"&gt;&lt;i style="font-size: 10pt; text-align: justify"&gt;Website&lt;/i&gt;&lt;/p&gt;

&lt;p style="margin: 0px; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0px; text-align: justify; font-size: 10pt"&gt;Expenditures related to the planning and
operation of the Company&#x2019;s website are expensed as incurred. Expenditures
related to the website application and
infrastructure development are capitalized and amortized over the website&#x2019;s
estimated useful life of three (3) years. Amortization expense for the three
and six months ended September 30, 2023 and 2022 was $723 and $723 and $1,437 and
$1,794, respectively.&lt;/p&gt;

&lt;p style="margin: 0px; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0px; text-align: justify; font-size: 10pt"&gt;&lt;i&gt;Furniture and Computer Equipment&lt;/i&gt;&lt;/p&gt;

&lt;p style="margin: 0px; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0px; text-align: justify; font-size: 10pt"&gt;Furniture and computer equipment are stated
at cost, less accumulated depreciation.&#160;
Depreciation is computed using the straight-line method over the
estimated useful life of three (3) to five (5) years.&#160; Depreciation expense for the three and six
months ended September 30, 2023 and 2022 was $422 and $0 and $538 and $0, respectively.&#160; Significant betterments are capitalized while
purchases under $500 are expensed as incurred.&lt;/p&gt;





&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span class="adv_highlightanchor adv_pagination" id="page_7"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt"&gt;&lt;/p&gt;

&lt;p style="margin: 0px; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0px; font-size: 10pt"&gt;&lt;i&gt;Right of Use Assets and Lease Liabilities&lt;/i&gt;&lt;/p&gt;

&lt;p style="margin: 0px; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0px; text-align: justify; font-size: 10pt"&gt;The Company has
active operating lease arrangements for office space, production equipment, and
production facilities.&#160; The Company is
required to make fixed minimum rent payments relating to its right to use the
underlying leased asset.&#160; In accordance
with the adoption of ASC 842, the Company recorded right-of-use assets and
related lease liabilities for these leases as of September 2023.&lt;/p&gt;

&lt;p style="margin: 0px; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0px; text-align: justify; font-size: 10pt"&gt;The Company&#x2019;s
lease agreements do not provide an implicit borrowing rate.&#160; Therefore, the Company used a benchmark
approach to derive an incremental borrowing rate of 10% to discount each of its
lease liabilities based on the remining lease term.&lt;/p&gt;

&lt;p style="margin: 0px; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0px; font-size: 10pt"&gt;&lt;i&gt;Stock-Based Compensation&lt;/i&gt;&lt;/p&gt;

&lt;p style="margin: 0px; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0px; text-align: justify; font-size: 10pt"&gt;Stock-based
compensation is measured at the grant date, based on the estimated fair value
of the award.&#160; Stock-based compensation
is recognized as expense over the employee&#x2019;s requisite vesting period and over
the nonemployee&#x2019;s period of providing goods or services.&#160; The fair value of each stock warrant is
estimated on the date of grant using the Black-Scholes option valuation model.
Restricted shares are measured based on the fair market value of the underlying
stock on the grant date.&lt;/p&gt;

&lt;p style="margin: 0px; text-align: justify; font-size: 10pt"&gt;&lt;br/&gt;&lt;/p&gt;

&lt;p style="margin: 0px; font-size: 10pt"&gt;&lt;i&gt;Research and Development&lt;/i&gt;&lt;/p&gt;

&lt;p style="margin: 0px; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0px; text-align: justify; font-size: 10pt"&gt;We incur research
and development costs during the process of researching and developing additional
technologies purchased and future manufacturing processes.&#160; Our research and development costs consist
primarily of the purchase of additional intellectual property that we will use
in the development of our planned product.&#160;
We expense these costs as incurred until the resulting product has been
completed, tested, and made ready for commercial use.&lt;/p&gt;

&lt;p style="margin: 0px; text-align: justify; font-size: 10pt"&gt;&lt;/p&gt;

&lt;p style="margin: 0px; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0px; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0px; font-size: 10pt"&gt;&lt;i&gt;Recent Accounting Pronouncements&lt;/i&gt;&lt;/p&gt;

&lt;p style="margin: 0px; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0px; text-align: justify; font-size: 10pt"&gt;The Financial
Accounting Standards Board issued Accounting Standards Updates (&#x201c;ASU&#x201d;) to amend
the authoritative literature in the Accounting Standards Codification (&#x201c;ASC&#x201d;).
There have been a number of ASUs to date that amend the original text of the
ASC. The Company believes those updates issued-to-date either (i) provide
supplemental guidance, (ii) are technical corrections, (iii) are not applicable
to the Company, or (iv) are not expected to have a significant impact on the
Company.&lt;/p&gt;

&lt;p style="margin: 0px; font-size: 10pt"&gt;&#160;&lt;/p&gt;

</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="From2023-04-01to2023-09-30">&lt;p style="margin: 0px; text-align: justify; font-size: 10pt"&gt;&lt;i&gt;Revenue Recognition&lt;/i&gt;&lt;/p&gt;

&lt;p style="margin: 0px; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0px; text-align: justify; font-size: 10pt"&gt;The Company will record
revenue under ASC 606 by 1) identifying the contract with the customer 2)
identifying the performance obligations in the contract 3) determining the
transaction price, 4) allocating the transaction price to the required performance
obligations in the contract, and 5) recognizing revenue when or as the
companies satisfies a performance obligation.&lt;/p&gt;

&lt;p style="margin: 0px; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0px; text-align: justify; font-size: 10pt"&gt;We expect to
generate revenue from home care service providers that are funded by the U.S.
Government, State Medicaid Programs, International Health Care Programs, Veteran&#x2019;s
administration, Prison system, Home Health Care Providers, and other applicable
Medicare reimbursement models.&#160; The
Company will defer revenue where the earnings process is not yet complete.&#160; To date, no revenue has been generated from
the asset acquisition disclosed in Note 1.&lt;/p&gt;

&lt;p style="margin: 0px; font-size: 10pt"&gt;&#160;&lt;/p&gt;

</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="From2023-04-01to2023-09-30">&lt;p style="margin: 0px; text-align: justify; font-size: 10pt"&gt;&lt;i&gt;Earnings per
Share&lt;/i&gt;&lt;/p&gt;

&lt;p style="margin: 0px; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0px; text-align: justify; font-size: 10pt"&gt;Earnings per share is reported in accordance
with FASB ASC Topic 260 &#x201c;&lt;i&gt;Earnings per Share&lt;/i&gt;&#x201d; which requires dual
presentation of basic earnings per share (&#x201c;EPS&#x201d;) and diluted EPS on the face of all statements of
earnings, for all entities with complex capital structures. Diluted EPS
reflects the potential dilution that could occur from common shares issuable
through the exercise or conversion of stock options, restricted stock awards,
warrants and convertible securities. In certain circumstances, the conversion
of these options, warrants and convertible securities are excluded from diluted
EPS if the effect of such inclusion would be anti-dilutive. Fully diluted EPS is
not provided, when the effect is anti-dilutive. When the effect of dilution on
loss per share is anti-dilutive, diluted loss per share equals the loss per
share.&lt;/p&gt;

&lt;p style="margin: 0px; text-align: justify; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0px; text-align: justify; font-size: 10pt"&gt;During the six months ended September 30, 2023,
the Company excluded the outstanding stock warrants from its calculation of
earnings per share, as the warrants would be anti-dilutive. As of September 30, 2023
and 2022, the Company had common shares warrants outstanding of 2,306,250 and
0, respectively.&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt"&gt;&lt;/p&gt;

</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="AsOf2023-09-30" decimals="INF" unitRef="Shares">2306250</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="AsOf2022-09-30" decimals="INF" unitRef="Shares">0</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ResearchDevelopmentAndComputerSoftwarePolicyTextBlock contextRef="From2023-04-01to2023-09-30">&lt;p style="margin: 0px; font-size: 10pt"&gt;&lt;i style="font-size: 10pt; text-align: justify"&gt;Website&lt;/i&gt;&lt;/p&gt;

&lt;p style="margin: 0px; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0px; text-align: justify; font-size: 10pt"&gt;Expenditures related to the planning and
operation of the Company&#x2019;s website are expensed as incurred. Expenditures
related to the website application and
infrastructure development are capitalized and amortized over the website&#x2019;s
estimated useful life of three (3) years. Amortization expense for the three
and six months ended September 30, 2023 and 2022 was $723 and $723 and $1,437 and
$1,794, respectively.&lt;/p&gt;

&lt;p style="margin: 0px; font-size: 10pt"&gt;&#160;&lt;/p&gt;

</us-gaap:ResearchDevelopmentAndComputerSoftwarePolicyTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="AsOf2023-09-30">P3Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2023-04-012023-06-30"
      decimals="0"
      unitRef="USD">723</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2023-04-01to2023-09-30"
      decimals="0"
      unitRef="USD">723</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2022-04-012022-06-30"
      decimals="0"
      unitRef="USD">1437</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2022-04-012022-09-30"
      decimals="0"
      unitRef="USD">1794</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:PropertyPlantAndEquipmentPreproductionDesignAndDevelopmentCosts contextRef="From2023-04-01to2023-09-30">&lt;p style="margin: 0px; text-align: justify; font-size: 10pt"&gt;&lt;i&gt;Furniture and Computer Equipment&lt;/i&gt;&lt;/p&gt;

&lt;p style="margin: 0px; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0px; text-align: justify; font-size: 10pt"&gt;Furniture and computer equipment are stated
at cost, less accumulated depreciation.&#160;
Depreciation is computed using the straight-line method over the
estimated useful life of three (3) to five (5) years.&#160; Depreciation expense for the three and six
months ended September 30, 2023 and 2022 was $422 and $0 and $538 and $0, respectively.&#160; Significant betterments are capitalized while
purchases under $500 are expensed as incurred.&lt;/p&gt;





&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span class="adv_highlightanchor adv_pagination" id="page_7"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt"&gt;&lt;/p&gt;

&lt;p style="margin: 0px; font-size: 10pt"&gt;&#160;&lt;/p&gt;

</us-gaap:PropertyPlantAndEquipmentPreproductionDesignAndDevelopmentCosts>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="AsOf2023-09-30_srt_MinimumMember">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="AsOf2023-09-30_srt_MaximumMember">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:OtherDepreciationAndAmortization
      contextRef="From2023-04-012023-06-30"
      decimals="0"
      unitRef="USD">422</us-gaap:OtherDepreciationAndAmortization>
    <us-gaap:OtherDepreciationAndAmortization
      contextRef="From2023-04-01to2023-09-30"
      decimals="0"
      unitRef="USD">0</us-gaap:OtherDepreciationAndAmortization>
    <us-gaap:OtherDepreciationAndAmortization
      contextRef="From2022-04-012022-06-30"
      decimals="0"
      unitRef="USD">538</us-gaap:OtherDepreciationAndAmortization>
    <us-gaap:OtherDepreciationAndAmortization
      contextRef="From2022-04-012022-09-30"
      decimals="0"
      unitRef="USD">0</us-gaap:OtherDepreciationAndAmortization>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="From2023-04-01to2023-09-30">&lt;p style="margin: 0px; font-size: 10pt"&gt;&lt;i&gt;Right of Use Assets and Lease Liabilities&lt;/i&gt;&lt;/p&gt;

&lt;p style="margin: 0px; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0px; text-align: justify; font-size: 10pt"&gt;The Company has
active operating lease arrangements for office space, production equipment, and
production facilities.&#160; The Company is
required to make fixed minimum rent payments relating to its right to use the
underlying leased asset.&#160; In accordance
with the adoption of ASC 842, the Company recorded right-of-use assets and
related lease liabilities for these leases as of September 2023.&lt;/p&gt;

&lt;p style="margin: 0px; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0px; text-align: justify; font-size: 10pt"&gt;The Company&#x2019;s
lease agreements do not provide an implicit borrowing rate.&#160; Therefore, the Company used a benchmark
approach to derive an incremental borrowing rate of 10% to discount each of its
lease liabilities based on the remining lease term.&lt;/p&gt;

&lt;p style="margin: 0px; font-size: 10pt"&gt;&#160;&lt;/p&gt;

</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:LesseeFinanceLeaseDiscountRate contextRef="AsOf2023-09-30" decimals="INF" unitRef="Pure">0.10</us-gaap:LesseeFinanceLeaseDiscountRate>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="From2023-04-01to2023-09-30">&lt;p style="margin: 0px; font-size: 10pt"&gt;&lt;i&gt;Stock-Based Compensation&lt;/i&gt;&lt;/p&gt;

&lt;p style="margin: 0px; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0px; text-align: justify; font-size: 10pt"&gt;Stock-based
compensation is measured at the grant date, based on the estimated fair value
of the award.&#160; Stock-based compensation
is recognized as expense over the employee&#x2019;s requisite vesting period and over
the nonemployee&#x2019;s period of providing goods or services.&#160; The fair value of each stock warrant is
estimated on the date of grant using the Black-Scholes option valuation model.
Restricted shares are measured based on the fair market value of the underlying
stock on the grant date.&lt;/p&gt;

&lt;p style="margin: 0px; text-align: justify; font-size: 10pt"&gt;&lt;br/&gt;&lt;/p&gt;

</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock contextRef="From2023-04-01to2023-09-30">&lt;p style="margin: 0px; font-size: 10pt"&gt;&lt;i&gt;Research and Development&lt;/i&gt;&lt;/p&gt;

&lt;p style="margin: 0px; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0px; text-align: justify; font-size: 10pt"&gt;We incur research
and development costs during the process of researching and developing additional
technologies purchased and future manufacturing processes.&#160; Our research and development costs consist
primarily of the purchase of additional intellectual property that we will use
in the development of our planned product.&#160;
We expense these costs as incurred until the resulting product has been
completed, tested, and made ready for commercial use.&lt;/p&gt;

&lt;p style="margin: 0px; text-align: justify; font-size: 10pt"&gt;&lt;/p&gt;

&lt;p style="margin: 0px; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0px; font-size: 10pt"&gt;&#160;&lt;/p&gt;

</us-gaap:ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="From2023-04-01to2023-09-30">&lt;p style="margin: 0px; font-size: 10pt"&gt;&lt;i&gt;Recent Accounting Pronouncements&lt;/i&gt;&lt;/p&gt;

&lt;p style="margin: 0px; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0px; text-align: justify; font-size: 10pt"&gt;The Financial
Accounting Standards Board issued Accounting Standards Updates (&#x201c;ASU&#x201d;) to amend
the authoritative literature in the Accounting Standards Codification (&#x201c;ASC&#x201d;).
There have been a number of ASUs to date that amend the original text of the
ASC. The Company believes those updates issued-to-date either (i) provide
supplemental guidance, (ii) are technical corrections, (iii) are not applicable
to the Company, or (iv) are not expected to have a significant impact on the
Company.&lt;/p&gt;

</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="From2023-04-01to2023-09-30">&lt;p style="margin: 0px; text-align: justify; font-size: 10pt"&gt;&lt;b&gt;NOTE 5 &#x2013; RELATED PARTY TRANSACTIONS &lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0px; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0px; text-align: justify; font-size: 10pt"&gt;The Company purchased assets from the Company&#x2019;s
current Chief Executive Officer (&#x201c;CEO&#x201d;) and Secretary/Treasurer (see note 6).&lt;/p&gt;

&lt;p style="margin: 0px; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0px; text-align: justify; font-size: 10pt"&gt;On June 10, 2023, the Company, has entered into an
agreement with Woundcare Labs, LLC., a party related to the CFO and CEO of the Company,
to lease a plant and to lease equipment in Tennessee (see note 8).&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt"&gt;&lt;/p&gt;

&lt;p style="margin: 0px; font-size: 10pt"&gt;&lt;i style="font-size: 10pt; text-align: justify"&gt;Related Party Advances&lt;/i&gt;&lt;/p&gt;

&lt;p style="margin: 0px; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0px; text-align: justify; font-size: 10pt"&gt;The Company&#x2019;s
former Chief Financial Officer (&#x201c;CFO&#x201d;) had advanced the Company monies for
operating expenses; no amounts were advanced during the periods presented.&#160; The advances were
due on demand, but no later than June 30, 2023.&#160;
The related party advances began to accrue interest at ten (10) percent
per annum on July 1, 2019.&#160; During the six
months ended September 30, 2023, this note was transferred to a relative of the
former CFO and was renewed upon maturity in the principal amount of $131,687
plus interest accrued as at June 30, 2023 in the amount of $52,545.&#160; Interest expense was $3,285 and $3,284 during
the six-month periods ended September 30, 2023 and 2022, respectively.&#160; This transaction is no longer considered
related party in nature, and thus is included in notes payable in the
accompanying balance sheet.&lt;/p&gt;





&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span class="adv_highlightanchor adv_pagination" id="page_8"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt"&gt;&lt;/p&gt;

&lt;p style="margin: 0px; font-size: 10pt"&gt;&lt;span style="font-size: 10pt; text-align: justify"&gt;During the
six-month period ended September 30, 2023, the Company&#x2019;s Chief Financial
Officer (&#x201c;CFO&#x201d;) and the Company&#x2019;s Chief Executive Officer (&#x201c;CEO&#x201d;) advanced the
Company monies for operating expenses in the net amount of $&lt;/span&gt;2,437&lt;span style="font-size: 10pt; text-align: justify"&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0px; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0px; text-align: justify; font-size: 10pt"&gt;The related party advances totaled $2,637 and $131,887 as of September
30, 2023 and March 31, 2023, respectively.&lt;/p&gt;

&lt;p style="margin: 0px; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0px; text-align: justify; font-size: 10pt"&gt;&lt;i&gt;Notes Payable to Related Parties&lt;/i&gt;&lt;/p&gt;

&lt;p style="margin: 0px; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0px; text-align: justify; font-size: 10pt"&gt;During the year
ended March 31, 2023, the Company&#x2019;s CFO and the Company&#x2019;s CEO advanced the
Company monies for operating expenses in the amount of $40,500.&#160; Repayment during the six-month period ended
September 30, 2023 and September 30, 2022 was $34,000 and $0. &#160;The notes are unsecured and accrue interest at
ten (10) percent per annum.&#160; Repayment is
due no later than November 4, 2024.&lt;/p&gt;

&lt;p style="margin: 0px; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0px; text-align: justify; font-size: 10pt"&gt;The related party notes
payable totaled $4,000 and $38,000 as at September 30, 2023 and March 31,
2023.&#160; Interest expenses were $1,630 and
$129 during the six-month periods ended September 30, 2023 and 2022,
respectively, which is included in other accrued liabilities.&lt;/p&gt;

&lt;p style="margin: 0px; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0px; font-size: 10pt"&gt;&lt;i&gt;Note Payable to Shareholder&lt;/i&gt;&lt;/p&gt;

&lt;p style="margin: 0px; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0px; text-align: justify; font-size: 10pt"&gt;As at September 30, 2023 and March 31, 2023, the Company had various
promissory notes with total outstanding principal balances of $558,691 and $537,475,
respectively, due to a shareholder of the Company.&#160; These notes are unsecured, bear interest at
10% per annum, and have maturity dates ranging from October 11, 2023 to June 17,
2025.&lt;/p&gt;

&lt;p style="margin: 0px; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0px; text-align: justify; font-size: 10pt"&gt;During the six-months ended September 30, 2023, notes with principal
amounts totaling approximately $128,000 ($167,500 Canadian Funds) that came due
during the period were reissued in the total principal amount of approximately
$155,000 ($201,000 Canadian Funds) which included the principal amount plus
accrued interest of approximately $26,000 ($33,500 Canadian Funds.)&#160; These notes are unsecured and bear interest
at ten (10) percent per annum with principal and interest due twelve (12)
months after the date of issue.&lt;/p&gt;

&lt;p style="margin: 0px; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0px; text-align: justify; font-size: 10pt"&gt;During the six-month period ended September 30, 2023, repayment of ten
thousand dollars ($10,000) US Funds was made on the principal of a promissory
note due October 11, 2023.&lt;/p&gt;

&lt;p style="margin: 0px; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0px; text-align: justify; font-size: 10pt"&gt;During the six-month period ended September 30, 2023,
a shareholder was issued additional one (1) promissory note totaling approximately
$2,800 ($3,844 Canadian Funds).&#160; This
note is unsecured and bears interest at ten (10) percent per annum with
principal and interest due twelve (12) months after the date of issue.&lt;/p&gt;

&lt;p style="margin: 0px; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0px; text-align: justify; font-size: 10pt"&gt;Accrued interest was $70,746 and $102,858 as of September 30, 2023 and September
30, 2022, respectively, which is included in other accrued liabilities at
September 30, 2023 and March 31, 2023, respectively.&lt;/p&gt;

&lt;p style="margin: 0px; font-size: 10pt"&gt;&#160;&lt;/p&gt;

</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:RelatedPartyTransactionRate
      contextRef="From2023-04-01to2023-09-30"
      decimals="INF"
      unitRef="Pure">0.10</us-gaap:RelatedPartyTransactionRate>
    <us-gaap:NotesAndLoansPayable
      contextRef="AsOf2023-09-30_srt_ChiefFinancialOfficerMember"
      decimals="0"
      unitRef="USD">131687</us-gaap:NotesAndLoansPayable>
    <RGPX:RelatedPartyAdvances
      contextRef="AsOf2023-09-30_srt_ChiefFinancialOfficerMember"
      decimals="0"
      unitRef="USD">52545</RGPX:RelatedPartyAdvances>
    <us-gaap:InterestExpense
      contextRef="From2023-04-012023-09-30_custom_AffiliatesMember"
      decimals="0"
      unitRef="USD">3285</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="From2022-04-012022-09-30_custom_AffiliatesMember"
      decimals="0"
      unitRef="USD">3284</us-gaap:InterestExpense>
    <RGPX:RelatedPartyAdvances
      contextRef="AsOf2023-09-30_srt_ChiefExecutiveOfficerMember"
      decimals="0"
      unitRef="USD">2437</RGPX:RelatedPartyAdvances>
    <RGPX:RelatedPartyAdvances contextRef="AsOf2023-09-30" decimals="0" unitRef="USD">2637</RGPX:RelatedPartyAdvances>
    <RGPX:RelatedPartyAdvances contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">131887</RGPX:RelatedPartyAdvances>
    <us-gaap:NotesAndLoansPayable
      contextRef="AsOf2023-03-31_custom_ChiefExecutiveOfficerAndChiefFinancialOfficerMember"
      decimals="0"
      unitRef="USD">40500</us-gaap:NotesAndLoansPayable>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="From2023-04-012023-09-30_custom_ChiefExecutiveOfficerAndChiefFinancialOfficerMember"
      decimals="0"
      unitRef="USD">34000</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="From2022-04-012022-09-30_custom_ChiefExecutiveOfficerAndChiefFinancialOfficerMember"
      decimals="0"
      unitRef="USD">0</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="From2023-04-012023-09-30_custom_ChiefExecutiveOfficerAndChiefFinancialOfficerMember"
      decimals="INF"
      unitRef="Pure">0.10</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <RGPX:NotesPayableRelatedParties contextRef="AsOf2023-09-30" decimals="0" unitRef="USD">4000</RGPX:NotesPayableRelatedParties>
    <RGPX:NotesPayableRelatedParties contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">38000</RGPX:NotesPayableRelatedParties>
    <us-gaap:InterestExpenseDebt
      contextRef="From2023-04-01to2023-09-30"
      decimals="0"
      unitRef="USD">1630</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="From2022-04-012022-09-30"
      decimals="0"
      unitRef="USD">129</us-gaap:InterestExpenseDebt>
    <us-gaap:NotesAndLoansPayable
      contextRef="AsOf2023-09-30_us-gaap_MajorityShareholderMember"
      decimals="0"
      unitRef="USD">558691</us-gaap:NotesAndLoansPayable>
    <us-gaap:NotesAndLoansPayable
      contextRef="AsOf2023-03-31_us-gaap_MajorityShareholderMember"
      decimals="0"
      unitRef="USD">537475</us-gaap:NotesAndLoansPayable>
    <us-gaap:NotesPayable
      contextRef="AsOf2023-09-30_custom_ReissuedNotesMember"
      decimals="0"
      unitRef="USD">128000</us-gaap:NotesPayable>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="AsOf2023-09-30_custom_ReissuedNotesMember"
      decimals="0"
      unitRef="USD">155000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:InterestPayableCurrent
      contextRef="AsOf2023-09-30_custom_ReissuedNotesMember"
      decimals="0"
      unitRef="USD">26000</us-gaap:InterestPayableCurrent>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="From2023-04-01to2023-09-30"
      decimals="INF"
      unitRef="Pure">10</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="From2023-04-012023-09-30_custom_ShareholderMember_custom_PromissoryNotesMember"
      decimals="0"
      unitRef="USD">10000</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:LongTermNotesPayable
      contextRef="AsOf2023-09-30_custom_ShareholderMember_custom_Promissory1NotesMember"
      decimals="0"
      unitRef="USD">2800</us-gaap:LongTermNotesPayable>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="AsOf2023-09-30_custom_ShareholderMember_custom_Promissory1NotesMember"
      decimals="INF"
      unitRef="Pure">10</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="AsOf2023-09-30_custom_AggregateInterestExpenseMember"
      decimals="0"
      unitRef="USD">70746</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="AsOf2022-09-30_custom_AggregateInterestExpenseMember"
      decimals="0"
      unitRef="USD">102858</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:IntangibleAssetsDisclosureTextBlock contextRef="From2023-04-01to2023-09-30">&lt;p style="margin: 0px; text-align: justify; font-size: 10pt"&gt;&lt;b&gt;NOTE 6 &#x2013; INTANGIBLE ASSETS AND INTELLECTUAL PROPERTY&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0px; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0px; text-align: justify; font-size: 10pt"&gt;On November 15, 2021,
the Company entered into a Related Party



Asset Purchase Agreement in which the Company
purchased certain intellectual property in exchange for 150,000,000 shares of
the Company&#x2019;s common stock and up to $10,000,000 in contingent consideration to be paid at the rate of 15% of all gross revenues received from sales or investment money into the Company, payable on the 15th of the following month, for a period of 60 months.&#160;
The Company received all rights and title to proprietary wound healing
technologies platforms and formulas involving the application of wound
care protocols to treat all wounds, such
as diabetic ulcers, pressure ulcers, burns and surgical wounds.&#160; These unique products strategically position
the Company to enter and capture a high proportionate market share in the U.S.&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt"&gt;&lt;/p&gt;





&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span class="adv_highlightanchor adv_pagination" id="page_9"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt"&gt;&lt;/p&gt;

&lt;p style="margin: 0px; text-align: justify; font-size: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;On August 17, 2023, the Company entered into an Agreement to Purchase Technology Platforms



 in which the Company purchased certain intellectual property in
exchange for a two million four hundred thousand dollars ($2,400,000) note
payable.&#160; The intellectual property that
was purchased requires further development prior to the product being finalized
and produced so it has been expensed as research and development.&#160; &#160;The note payable is due within twelve (12)
months of the date of the agreement and is included in current liabilities.&#160; If the Company has not raised a minimum of
ten million dollars ($10,000,000) in sales within twelve (12) months, or a maximum
of ten million dollars ($10,000,000) in investment, the Company has the option
to extend the payment due date for a further twelve (12)&#160;&lt;/span&gt;&lt;span style="font-size: 10pt"&gt;months of the
agreement date, or a maximum of ten million dollars ($10,000,000) in investment,
the seller will extend the payment for a further period of twelve (12) months
for a 10% payment of the outstanding balance.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0px; text-align: justify; font-size: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0px; font-size: 10pt"&gt;The Technology Platforms include but are not limited to:&lt;/p&gt;

&lt;p style="margin: 0px; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse"&gt;
  &lt;tbody&gt;
  &lt;tr&gt;
    &lt;td style="width: 0.5in; vertical-align: top"&gt;&lt;p style="margin: 0px; font-size: 10pt"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
    &lt;td style="width: 0.5in; vertical-align: top"&gt;&lt;p style="margin: 0px; font-size: 10pt"&gt;A.&lt;span style="font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; font-kerning: auto; font-optical-sizing: auto; font-feature-settings: normal; font-variation-settings: normal; font-stretch: normal; font-size: 7pt; line-height: normal"&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
    &lt;td style="text-align: justify; vertical-align: top"&gt;&lt;p style="margin: 0px; font-size: 10pt"&gt;Proteomic research platforms which include proprietary blends.&lt;/p&gt;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/tbody&gt;
&lt;/table&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse"&gt;
  &lt;tbody&gt;
  &lt;tr&gt;
    &lt;td style="width: 0.5in; vertical-align: top"&gt;&lt;p style="margin: 0px; font-size: 10pt"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
    &lt;td style="width: 0.5in; vertical-align: top"&gt;&lt;p style="margin: 0px; font-size: 10pt"&gt;B.&lt;span style="font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; font-kerning: auto; font-optical-sizing: auto; font-feature-settings: normal; font-variation-settings: normal; font-stretch: normal; font-size: 7pt; line-height: normal"&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
    &lt;td style="text-align: justify; vertical-align: top"&gt;&lt;p style="margin: 0px; font-size: 10pt"&gt;Combination design Techniques&lt;/p&gt;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/tbody&gt;
&lt;/table&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse"&gt;
  &lt;tbody&gt;
  &lt;tr&gt;
    &lt;td style="width: 0.5in; vertical-align: top"&gt;&lt;p style="margin: 0px; font-size: 10pt"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
    &lt;td style="width: 0.5in; vertical-align: top"&gt;&lt;p style="margin: 0px; font-size: 10pt"&gt;C.&lt;span style="font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; font-kerning: auto; font-optical-sizing: auto; font-feature-settings: normal; font-variation-settings: normal; font-stretch: normal; font-size: 7pt; line-height: normal"&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
    &lt;td style="text-align: justify; vertical-align: top"&gt;&lt;p style="margin: 0px; font-size: 10pt"&gt;Patent Pending Proprietary Blends&lt;/p&gt;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/tbody&gt;
&lt;/table&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse"&gt;
  &lt;tbody&gt;
  &lt;tr&gt;
    &lt;td style="width: 0.5in; vertical-align: top"&gt;&lt;p style="margin: 0px; font-size: 10pt"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
    &lt;td style="width: 0.5in; vertical-align: top"&gt;&lt;p style="margin: 0px; font-size: 10pt"&gt;D.&lt;span style="font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; font-kerning: auto; font-optical-sizing: auto; font-feature-settings: normal; font-variation-settings: normal; font-stretch: normal; font-size: 7pt; line-height: normal"&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
    &lt;td style="text-align: justify; vertical-align: top"&gt;&lt;p style="margin: 0px; font-size: 10pt"&gt;Patent Pending Formulas&lt;/p&gt;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/tbody&gt;
&lt;/table&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse"&gt;
  &lt;tbody&gt;
  &lt;tr&gt;
    &lt;td style="width: 0.5in; vertical-align: top"&gt;&lt;p style="margin: 0px; font-size: 10pt"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
    &lt;td style="width: 0.5in; vertical-align: top"&gt;&lt;p style="margin: 0px; font-size: 10pt"&gt;E.&lt;span style="font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; font-kerning: auto; font-optical-sizing: auto; font-feature-settings: normal; font-variation-settings: normal; font-stretch: normal; font-size: 7pt; line-height: normal"&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
    &lt;td style="text-align: justify; vertical-align: top"&gt;&lt;p style="margin: 0px; font-size: 10pt"&gt;Trademarks and all pending Trademarks&lt;/p&gt;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/tbody&gt;
&lt;/table&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse"&gt;
  &lt;tbody&gt;
  &lt;tr&gt;
    &lt;td style="width: 0.5in; vertical-align: top"&gt;&lt;p style="margin: 0px; font-size: 10pt"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
    &lt;td style="width: 0.5in; vertical-align: top"&gt;&lt;p style="margin: 0px; font-size: 10pt"&gt;F.&lt;span style="font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; font-kerning: auto; font-optical-sizing: auto; font-feature-settings: normal; font-variation-settings: normal; font-stretch: normal; font-size: 7pt; line-height: normal"&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
    &lt;td style="text-align: justify; vertical-align: top"&gt;&lt;p style="margin: 0px; font-size: 10pt"&gt;510K USA FDA, information, and Know-how for application&lt;/p&gt;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/tbody&gt;
&lt;/table&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse"&gt;
  &lt;tbody&gt;
  &lt;tr&gt;
    &lt;td style="width: 0.5in; vertical-align: top"&gt;&lt;p style="margin: 0px; font-size: 10pt"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
    &lt;td style="width: 0.5in; vertical-align: top"&gt;&lt;p style="margin: 0px; font-size: 10pt"&gt;G.&lt;span style="font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; font-kerning: auto; font-optical-sizing: auto; font-feature-settings: normal; font-variation-settings: normal; font-stretch: normal; font-size: 7pt; line-height: normal"&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
    &lt;td style="text-align: justify; vertical-align: top"&gt;&lt;p style="margin: 0px; font-size: 10pt"&gt;All Clinical trials, (Right to use)&lt;/p&gt;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/tbody&gt;
&lt;/table&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse"&gt;
  &lt;tbody&gt;
  &lt;tr&gt;
    &lt;td style="width: 0.5in; vertical-align: top"&gt;&lt;p style="margin: 0px; font-size: 10pt"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
    &lt;td style="width: 0.5in; vertical-align: top"&gt;&lt;p style="margin: 0px; font-size: 10pt"&gt;H.&lt;span style="font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; font-kerning: auto; font-optical-sizing: auto; font-feature-settings: normal; font-variation-settings: normal; font-stretch: normal; font-size: 7pt; line-height: normal"&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
    &lt;td style="text-align: justify; vertical-align: top"&gt;&lt;p style="margin: 0px; font-size: 10pt"&gt;CE mark (International)&lt;/p&gt;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/tbody&gt;
&lt;/table&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse"&gt;
  &lt;tbody&gt;
  &lt;tr&gt;
    &lt;td style="width: 0.5in; vertical-align: top"&gt;&lt;p style="margin: 0px; font-size: 10pt"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
    &lt;td style="width: 0.5in; vertical-align: top"&gt;&lt;p style="margin: 0px; font-size: 10pt"&gt;I.&lt;span style="font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; font-kerning: auto; font-optical-sizing: auto; font-feature-settings: normal; font-variation-settings: normal; font-stretch: normal; font-size: 7pt; line-height: normal"&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
    &lt;td style="text-align: justify; vertical-align: top"&gt;&lt;p style="margin: 0px; font-size: 10pt"&gt;Regenerex Library formula incorporated in the Wound Healing Technology.&lt;/p&gt;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/tbody&gt;
&lt;/table&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse"&gt;
  &lt;tbody&gt;
  &lt;tr&gt;
    &lt;td style="width: 0.5in; vertical-align: top"&gt;&lt;p style="margin: 0px; font-size: 10pt"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
    &lt;td style="width: 0.5in; vertical-align: top"&gt;&lt;p style="margin: 0px; font-size: 10pt"&gt;J.&lt;span style="font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; font-kerning: auto; font-optical-sizing: auto; font-feature-settings: normal; font-variation-settings: normal; font-stretch: normal; font-size: 7pt; line-height: normal"&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
    &lt;td style="text-align: justify; vertical-align: top"&gt;&lt;p style="margin: 0px; font-size: 10pt"&gt;Wound Healing Technology QBX&lt;/p&gt;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/tbody&gt;
&lt;/table&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse"&gt;
  &lt;tbody&gt;
  &lt;tr&gt;
    &lt;td style="width: 0.5in; vertical-align: top"&gt;&lt;p style="margin: 0px; font-size: 10pt"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
    &lt;td style="width: 0.5in; vertical-align: top"&gt;&lt;p style="margin: 0px; font-size: 10pt"&gt;K.&lt;span style="font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; font-kerning: auto; font-optical-sizing: auto; font-feature-settings: normal; font-variation-settings: normal; font-stretch: normal; font-size: 7pt; line-height: normal"&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
    &lt;td style="text-align: justify; vertical-align: top"&gt;&lt;p style="margin: 0px; font-size: 10pt"&gt;Synthetic Compositions of Cations derived from botanical material in the ash of Red- Oak Bark.&lt;/p&gt;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/tbody&gt;
&lt;/table&gt;

&lt;p style="margin: 0px; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0px; font-size: 10pt"&gt;Products:&lt;/p&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse"&gt;
  &lt;tbody&gt;
  &lt;tr&gt;
    &lt;td style="width: 0.5in; vertical-align: top"&gt;&lt;p style="margin: 0px; font-size: 10pt"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
    &lt;td style="width: 0.5in; vertical-align: top"&gt;&lt;p style="margin: 0px; font-size: 10pt"&gt;1.&lt;span style="font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; font-kerning: auto; font-optical-sizing: auto; font-feature-settings: normal; font-variation-settings: normal; font-stretch: normal; font-size: 7pt; line-height: normal"&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
    &lt;td style="text-align: justify; vertical-align: top"&gt;&lt;p style="margin: 0px; font-size: 10pt"&gt;Xcellderma over the counter product.&lt;/p&gt;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/tbody&gt;
&lt;/table&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse"&gt;
  &lt;tbody&gt;
  &lt;tr&gt;
    &lt;td style="width: 0.5in; vertical-align: top"&gt;&lt;p style="margin: 0px; font-size: 10pt"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
    &lt;td style="width: 0.5in; vertical-align: top"&gt;&lt;p style="margin: 0px; font-size: 10pt"&gt;2.&lt;span style="font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; font-kerning: auto; font-optical-sizing: auto; font-feature-settings: normal; font-variation-settings: normal; font-stretch: normal; font-size: 7pt; line-height: normal"&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
    &lt;td style="text-align: justify; vertical-align: top"&gt;&lt;p style="margin: 0px; font-size: 10pt"&gt;Accelerex, combination product as a drug device.&lt;/p&gt;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/tbody&gt;
&lt;/table&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse"&gt;
  &lt;tbody&gt;
  &lt;tr&gt;
    &lt;td style="width: 0.5in; vertical-align: top"&gt;&lt;p style="margin: 0px; font-size: 10pt"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
    &lt;td style="width: 0.5in; vertical-align: top"&gt;&lt;p style="margin: 0px; font-size: 10pt"&gt;3.&lt;span style="font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; font-kerning: auto; font-optical-sizing: auto; font-feature-settings: normal; font-variation-settings: normal; font-stretch: normal; font-size: 7pt; line-height: normal"&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
    &lt;td style="text-align: justify; vertical-align: top"&gt;&lt;p style="margin: 0px; font-size: 10pt"&gt;Accelerex in a tube.&lt;/p&gt;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/tbody&gt;
&lt;/table&gt;

&lt;p style="margin-top: 0px; margin-bottom: 0px; margin-left: 48px; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

</us-gaap:IntangibleAssetsDisclosureTextBlock>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsDescription contextRef="From2021-11-012021-11-15">and up to $10,000,000 in contingent consideration to be paid at the rate of 15% of all gross revenues received from sales or investment money into the Company, payable on the 15th of the following month, for a period of 60 months</us-gaap:BusinessCombinationContingentConsiderationArrangementsDescription>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="From2023-04-01to2023-09-30">&lt;p style="margin: 0px; font-size: 10pt"&gt;&lt;b&gt;NOTE 7 &#x2013; COMMITMENTS AND CONTINGENCIES&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0px; text-align: justify; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0px; text-align: justify; font-size: 10pt"&gt;The Company is not currently involved with and does
not have knowledge of any pending or threatened litigation against the Company
or any of its officers.&lt;/p&gt;

&lt;p style="margin: 0px; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0px; text-align: justify; font-size: 10pt"&gt;See Note 6 for discussion of the $10,000,000 in
contingent consideration to be paid in connection with the November 15, 2021

Related Party



Asset Purchase Agreement. Payments made to the Company&#x2019;s CEO and CFO in
connection with the Asset Purchase Agreement are $43,500 and $0 as at September
30, 2023 and March 31, 2023 respectively.&#160;
The outstanding liability of $7,988 and $0 as at September 30, 2023 and
March 31, 2023 respectively is included in other accrued liabilities.&lt;/p&gt;

&lt;p style="margin: 0px; font-size: 10pt"&gt;&#160;&lt;/p&gt;

</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:AssetAcquisitionContingentConsiderationLiability contextRef="AsOf2021-11-15" decimals="0" unitRef="USD">10000000</us-gaap:AssetAcquisitionContingentConsiderationLiability>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2023-04-012023-09-30_custom_ChiefExecutiveOfficerAndChiefFinancialOfficerMember397223531"
      decimals="0"
      unitRef="USD">43500</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2022-04-012023-03-31_custom_ChiefExecutiveOfficerAndChiefFinancialOfficerMember"
      decimals="0"
      unitRef="USD">0</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="AsOf2023-09-30_custom_AssetPurchaseAgreementLiabilityMember"
      decimals="0"
      unitRef="USD">7988</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="AsOf2023-03-31_custom_AssetPurchaseAgreementLiabilityMember"
      decimals="0"
      unitRef="USD">0</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:LesseeOperatingLeasesTextBlock contextRef="From2023-04-01to2023-09-30">&lt;p style="margin: 0px; text-align: justify; font-size: 10pt"&gt;&lt;b&gt;NOTE 8 &#x2013; OPERATING LEASES&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0px; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0px; text-align: justify; font-size: 10pt"&gt;On April 1, 2023, the Company
entered into an office lease agreement commencing in May 2023 which expires on
April 30, 2028.&#160; Under this agreement,
the monthly rental payments are $1,650 throughout the term of the lease.&#160; The Company is required to pay for all
utilities used on the premises and has paid a security deposit of $800 which is
included in prepaid expenses.&lt;/p&gt;

&lt;p style="margin: 0px; text-align: justify; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0px; text-align: justify; font-size: 10pt"&gt;On June 10, 2023, the Company entered into a plant facility lease agreement with a related party commencing June 9, 2023 which expires on June 30, 2028.&#160; Under this agreement, the monthly rental payments are $18,000 throughout the term of the lease excepting the month of June 2023 the rent is $7,920, To commence with production, the plant needs to prepare for FDA inspection which will include inspection of the facility, equipment, and the Company&#x2019;s procedures.&#160; We expect to launch production during the Company&#x2019;s third or fourth quarter and will notify the FDA to come into the plant for the inspection at that time.&#160; The Company is able to start production while the plant waits for the FDA Inspection.&#160; Until the certification is complete, the monthly rent is reduced by forty (40%) percent to $10,800. Under this agreement, the Company is also leasing the equipment in the plant facility through five (5) annual rent payments of $10,000, which are due on the 15th day of&#160; each June from June 2023 to June 2027.&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt"&gt;&lt;/p&gt;





&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span class="adv_highlightanchor adv_pagination" id="page_10"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt"&gt;&lt;/p&gt;

&lt;p style="margin: 0px; text-align: justify; font-size: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;During the six-month
periods ended September 30, 2023 and September 30, 2022 the operating lease
cost was $81,451 and $0 respectively and is included in general and
administrative expenses in the accompanying financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0px; text-align: justify; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDue
      contextRef="AsOf2023-09-30_custom_OfficeLeaseMember_custom_MonthlyRentalPaymentsMember"
      decimals="0"
      unitRef="USD">1650</us-gaap:OperatingLeasesFutureMinimumPaymentsDue>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="AsOf2023-09-30_custom_OfficeLeaseMember_custom_SecurityDepositMember"
      decimals="0"
      unitRef="USD">800</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:LesseeOperatingLeaseDescription contextRef="From2023-04-01to2023-09-30">On June 10, 2023, the Company entered into a plant facility lease agreement with a related party commencing June 9, 2023 which expires on June 30, 2028.&#160; Under this agreement, the monthly rental payments are $18,000 throughout the term of the lease excepting the month of June 2023 the rent is $7,920, To commence with production, the plant needs to prepare for FDA inspection which will include inspection of the facility, equipment, and the Company&#x2019;s procedures.&#160; We expect to launch production during the Company&#x2019;s third or fourth quarter and will notify the FDA to come into the plant for the inspection at that time.&#160; The Company is able to start production while the plant waits for the FDA Inspection.&#160; Until the certification is complete, the monthly rent is reduced by forty (40%) percent to $10,800. Under this agreement, the Company is also leasing the equipment in the plant facility through five (5) annual rent payments of $10,000, which are due on the 15th day of&#160; each June from June 2023 to June 2027.</us-gaap:LesseeOperatingLeaseDescription>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDue
      contextRef="AsOf2023-09-30_custom_PlantFacilityMember_custom_MonthlyRentalPaymentsMember"
      decimals="0"
      unitRef="USD">18000</us-gaap:OperatingLeasesFutureMinimumPaymentsDue>
    <us-gaap:CapitalLeaseObligationsCurrent
      contextRef="AsOf2023-06-30_custom_PlantFacilityMember"
      decimals="0"
      unitRef="USD">7920</us-gaap:CapitalLeaseObligationsCurrent>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2023-04-012023-09-30_custom_OperatingLeaseCostMember"
      decimals="0"
      unitRef="USD">81451</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2022-04-012022-09-30_custom_OperatingLeaseCostMember"
      decimals="0"
      unitRef="USD">0</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="From2023-04-01to2023-09-30">&lt;p style="margin: 0px; text-align: justify; font-size: 10pt"&gt;&lt;b&gt;NOTE
9 &#x2013; STOCKHOLDERS&#x2019; DEFICIT&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0px; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0px; text-align: justify; font-size: 10pt"&gt;The Company has authorized
the issuance of 675,000,000 shares of common stock with a par value of $0.001
per share.&lt;/p&gt;

&lt;p style="margin: 0px; text-align: justify; font-size: 10pt"&gt;&lt;br/&gt;&lt;/p&gt;

&lt;p style="margin: 0px; text-align: justify; font-size: 10pt"&gt;During the six months ended
September 30, 2023, the Company issued 460,000 shares to board members and
consultants for services rendered.&#160; Total
stock-based compensation expense was $82,800 during the six months ended
September 30, 2023 in connection with these issuances based on the fair value
of the stock on the respective grant dates.&lt;/p&gt;

&lt;p style="margin: 0px; text-align: justify; font-size: 10pt"&gt;&lt;br/&gt;&lt;/p&gt;

&lt;p style="margin: 0px; text-align: justify; font-size: 10pt"&gt;During the six months ended September 30, 2023,
the Company issued 590,000 warrants to board members and consultants for
services rendered with a total grant date fair value of $59,691&#160; Total stock-based compensation expense of
$50,588 was recorded in connection with these awards during the six months
ended September 30, 2023.&#160; The remaining
stock-based compensation of $9,103 will be recognized over the next nine months.&#160; The warrants contain an exercise price of
$0.33 per share, vesting terms ranging from immediately to June 30, 2024, and
expire on dates ranging from July 1, 2029 to October 1, 2029.&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt"&gt;&lt;/p&gt;

&lt;p style="margin: 0px; font-size: 10pt"&gt;&lt;span style="font-size: 10pt; text-align: justify"&gt;The warrant fair values were estimated using a Black
Scholes model with a 5-year expected term, risk-free interest rate ranging from
5.19% to 5.54%, a dividend yield of 0%, and an annualized standard deviation of
stock price volatility of 80.0%.&#160; The
risk-free interest rate assumptions for options granted is based upon observed
interest rates on the United States government securities appropriate for the
expected term of the equity awards.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0px; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0px; text-align: justify; font-size: 10pt"&gt;As of the date of this valuation, the Companies stock
was not trading.&#160; The volatility was calculated
based on comparable public companies.&#160;
The Company will continue to monitor peer companies and other relevant
factors used to measure expected volatility for future equipment award grants,
until such time that the Company&#x2019;s Common Stock has enough market history to
use historical volatility.&lt;/p&gt;

&lt;p style="margin: 0px; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0px; text-align: justify; font-size: 10pt"&gt;The dividend yield assumption for equity awards
granted is based on Company&#x2019;s history and expectation of dividend payouts.&#160; The Company has never declared or paid any
cash dividends on its Common Stock, and the Company does not anticipate paying
any cash dividends in the foreseeable future.&lt;/p&gt;

&lt;p style="margin: 0px; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0px; text-align: justify; font-size: 10pt"&gt;The closing stock price of the Company&#x2019;s common stock
is not available as the Company&#x2019;s stock is not trading. As a result, the Board
of Directors and management determined the fair value of the common stock to be
$0.18 per share based upon an allocation of the recent cash price paid for
common stock and warrants during the six months ended September 30, 2023.&lt;/p&gt;

&lt;p style="margin: 0px; text-align: justify; font-size: 10pt"&gt;&lt;br/&gt;&lt;/p&gt;

&lt;p style="margin: 0px; text-align: justify; font-size: 10pt"&gt;During the six-month period ended September 30, 2023,
the Company issued 343,250 shares of common stock with a par value of $0.001
for the price of one ($1) dollar per share for a total of for a total of $343,250.&#160; Five warrants were issued for each share
purchased, for a total of 1,716,250 warrants.&#160;
The warrants are exercisable at twenty ($0.20) cents and expire from
April 2025 through September 2025.&lt;/p&gt;

&lt;p style="margin: 0px; text-align: justify; font-size: 10pt"&gt;&lt;br/&gt;&lt;/p&gt;

&lt;p style="margin: 0px; text-align: justify; font-size: 10pt"&gt;As of September 30, 2023, 2,306,250 warrants had been issued of which 2,216,238
are vested. &#160;None of the warrants have been exercised.&lt;/p&gt;

&lt;p style="margin: 0px; font-size: 10pt"&gt;&#160;&lt;/p&gt;





&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span class="adv_highlightanchor adv_pagination" id="page_11"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt"&gt;&lt;/p&gt;

</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2023-09-30" decimals="INF" unitRef="Shares">675000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2023-09-30"
      decimals="INF"
      unitRef="USDPShares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2023-04-012023-09-30_custom_BoardMembersAndConsultantsMember_custom_ServicesRenderedMember"
      decimals="INF"
      unitRef="Shares">460000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-04-012023-09-30_custom_BoardMembersAndConsultantsMember_custom_ServicesRenderedMember"
      decimals="0"
      unitRef="USD">82800</us-gaap:ShareBasedCompensation>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2023-09-30_custom_BoardMembersAndConsultantsMember_custom_ServicesRenderedMember"
      decimals="INF"
      unitRef="Shares">590000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2023-09-30_custom_BoardMembersAndConsultantsMember_custom_ServicesRenderedMember"
      decimals="0"
      unitRef="USD">59691</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-04-012023-09-30_custom_BoardMembersAndConsultantsMember_custom_ServicesRenderedMember_custom_WarrantsMember"
      decimals="0"
      unitRef="USD">50588</us-gaap:ShareBasedCompensation>
    <RGPX:StockBasedCompensationUnrecognizedCompensationCost
      contextRef="AsOf2023-09-30_custom_BoardMembersAndConsultantsMember_custom_ServicesRenderedMember"
      decimals="0"
      unitRef="USD">9103</RGPX:StockBasedCompensationUnrecognizedCompensationCost>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="AsOf2023-09-30_custom_BoardMembersAndConsultantsMember_custom_ServicesRenderedMember_custom_WarrantsMember"
      decimals="INF"
      unitRef="USDPShares">0.33</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="From2023-04-01to2023-09-30"
      decimals="INF"
      unitRef="Pure">0.0519</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="From2023-04-01to2023-09-30"
      decimals="INF"
      unitRef="Pure">0.0554</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2023-04-01to2023-09-30"
      decimals="INF"
      unitRef="Pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2023-04-01to2023-09-30"
      decimals="INF"
      unitRef="Pure">0.800</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2023-09-30"
      decimals="INF"
      unitRef="USDPShares">0.18</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-04-01to2023-09-30"
      decimals="0"
      unitRef="USD">343250</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2023-09-30"
      decimals="INF"
      unitRef="USDPShares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-04-01to2023-09-30"
      decimals="0"
      unitRef="USD">343250</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:TemporaryEquityContractTerms contextRef="From2023-04-01to2023-09-30">Five warrants were issued for each share
purchased, for a total of 1,716,250 warrants.&#160;
The warrants are exercisable at twenty ($0.20) cents and expire from
April 2025 through September 2025.</us-gaap:TemporaryEquityContractTerms>
    <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="AsOf2023-09-30" decimals="INF" unitRef="Shares">2306250</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="From2023-04-01to2023-09-30"
      decimals="INF"
      unitRef="Shares">2216238</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:SubsequentEventsTextBlock contextRef="From2023-04-01to2023-09-30">&lt;p style="margin: 0px; font-size: 10pt"&gt;&lt;b&gt;NOTE 10 &#x2013; SUBSEQUENT EVENTS&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0px; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0px; text-align: justify; font-size: 10pt"&gt;Subsequent to the six-month period ended September 30, 2023, three
additional notes to a shareholder that were originally due in October 2023 with
a principal amount of $67,400 were reissued in the principal amount of $82,735 which
included the original principal amount of $67,400 plus interest accrued in the
amount of $15,335. Repayment of the notes are due within six (6) months of the
date of renewal.&lt;/p&gt;

&lt;p style="margin: 0px; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0px; text-align: justify; font-size: 10pt"&gt;Subsequent to the six-month period ended
September 30, 2023, one additional note to a shareholder that was originally
due November 2, 2023 with a principal amount of approximately $9,500 US Funds
($12,000 Canadian funds) was reissued in the principal amount of approximately
$10,500 US Funds ($14,400 Canadian Funds) which included the original principal
amount of approximately $9,500 US Funds ($12,000 Canadian funds) plus interest
accrued in the amount of approximately $2,000 US Funds ($2,400 Canadian Funds).&#160; Repayment of the note is due May 2, 2024.&lt;/p&gt;

</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:NotesPayable
      contextRef="AsOf2023-10-01_us-gaap_SubsequentEventMember_custom_ReissuedNotesMember"
      decimals="0"
      unitRef="USD">67400</us-gaap:NotesPayable>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="AsOf2023-10-01_us-gaap_SubsequentEventMember_custom_ReissuedNotesMember"
      decimals="0"
      unitRef="USD">82735</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:InterestPayableCurrent
      contextRef="AsOf2023-10-01_us-gaap_SubsequentEventMember_custom_ReissuedNotesMember"
      decimals="0"
      unitRef="USD">15335</us-gaap:InterestPayableCurrent>
    <us-gaap:NotesPayable
      contextRef="AsOf2023-11-01_us-gaap_SubsequentEventMember_custom_ReissuedNotesMember"
      decimals="0"
      unitRef="USD">9500</us-gaap:NotesPayable>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="AsOf2023-11-01_us-gaap_SubsequentEventMember_custom_ReissuedNotesMember"
      decimals="0"
      unitRef="USD">10500</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:InterestPayableCurrent
      contextRef="AsOf2023-11-01_us-gaap_SubsequentEventMember_custom_ReissuedNotesMember"
      decimals="0"
      unitRef="USD">2000</us-gaap:InterestPayableCurrent>
    <us-gaap:DebtInstrumentMaturityDate contextRef="From2023-11-012023-11-30_us-gaap_SubsequentEventMember_custom_ReissuedNotesMember">2024-05-02</us-gaap:DebtInstrumentMaturityDate>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>39
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M!7!^P;DZ[.@;%*N?@_\ 4$L#!!0    (  -?:%=-XUJ4,08  &@:   8
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MER0#^VO*1B(P2208#TE8K$9#''8(0R?"[_16,$FGH% ZP.]4K4SKO,Z(I"M
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M^H]V-=8V-11OA&1Y8ZQZD*=%_1M]-($X,% \L %I#$C?P#IA8#8&YKD>K,;
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M^GJC?I%L79W?WYF4+*\>5S1**"\!ZON",?GY4CIH+YDF_P%02P,$%     @
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MJH1<+,$?;.O4;.?S0;MFN&I.PD>"TN'UM2<IX9ZH)+'KVHJDL 1M134MX3?
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M6_KB;"P"7=J<\^_U1_"H<VOZY-;Y]$7 6ZZ&=# >T'0\/7@![Z +\R#A'?P
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MN,A>!'!>.A>W"[E@&$"7_P!02P,$%     @  U]H5X&YN;-C"0  %A8  !D
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MQA[C9P'6\>CER2#.]/8FV)J__,UM"+;DRQ7J63DBP/N%Q?DSW9""[E/P^7\
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MUQJE9:A^++A23B',H25E.W'4+%6RH3V8"'R-Z\L"P6!/00#H&(K"AA'1Q*)
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MX8H6X/M%COQ7-W1 _0'P^O]02P,$%     @  U]H5Z>OI>&Z!@  (P\  !D
M  !X;"]W;W)K<VAE971S+W-H965T,3(N>&ULI5=K;^.V$OVN7S%P']@ KE]Y
M["*;!+ 3[VZZ:=:-L[>]*/J!EL86$4G4DE0<]]?W#"4_@CS0WOLAL222,V=F
MSAR2)TMC[US*[.DASPIWVDJ]+X^[71>GG"O7,247&)D;FRN/5[OHNM*R2L*B
M/.L.>KVC;JYTT3H["=\F]NS$5#[3!4\LN2K/E5V-.#/+TU:_M?YPHQ>IEP_=
MLY-2+7C*_FLYL7CK;JPD.N?":5.0Y?EI:]@_'AW(_##A/YJ7;N>9))*9,7?R
M<IF<MGH"B#..O5A0^+GG<\XR,008WQJ;K8U+6;C[O+;^(<2.6&;*\;G)?M.)
M3T];[UJ4\%Q5F;\QRT_<Q',H]F*3N?"?EO7<P_T6Q97S)F\6 T&NB_I7/31Y
MV%GPKO?"@D&S8!!PUXX"R@OEU=F)-4NR,AO6Y"&$&E8#G"ZD*%-O,:JQSI]=
M7M\.KS]>CJ[&-)Q.Q[=3&EY?$+Z.KZ[&Y[=?AU<TN?DR&=_<_O>DZ^%0EG7C
MQOBH-CYXP?@1_6(*GSH:%PDGC]=W 72#=K!&.QJ\:G#*98?V>VT:] ;[K]C;
MWT2_'^SMOV#OHS')4F<9J2*AR\*K8J%G&=/0.?:.+K2+,^,JR_3'<.:\!8?^
M?"X-M9>#Y[U(7QV[4L5\VD+C.+;WW#K[\;O^4>_]*S$<;&(X>,WZ_UO!5XT_
M#_WZR^V8CNC'[]X-^OWW]"\ T)>"KLT]YS.VU#\,=>RW(Y\RG9N\5,6*N/!L
M.2%=>$.*;CA3'J\39?TJ"G6A267C%)U(PX5EAD)XS*9EJN.4=DQ%93,OH9BM
MAT")4?0_!*%2&946T@:KLI@?,+-8,$'F *S7[O7"'[E4(6XR\UV0(?*W[QW%
M)L\A+>C2^"YPJ"H)L+_O;PW >(PFT# .G'AT.F&K@B1AZHRI5#HAY0-T##"<
M <(/\J- S84USD'_[KFH6!YBAHXE-+<F)Z<R06?AYIZ=#[D (E[5^=O!W(:?
ME1)RBV-\[Q_Z5'S(\]QD4&=@E,4^;8<T*$)ZM$EDTE&O'G&=Z':G6!LP M2*
M +J0!J\]' & Y-AJ]M![R'.%H9052+:(/,=I83*ST B@1)%E@ZE7RU.5*2=!
MF>Q>8 E(59:9CNO, 5(P%\4HCWA!!:"$XM)C;_(!4)CAVMAPXC2"N42K&7L=
M4Y6!$!@02H?N7G^85;:H,>#S L[61CJ$L,&XJM#?JN PJ6($*YK@.<S,5E0:
MIP7>(T(#4N!T,!NKTHM#12FR%=)CK"R1NF-7O .] ^6$-V+E:V?:D:X95@ML
M!M1_6VM?FU[NF6*G+_"^Z9;;=<97-%GG.WJN<>B?-T[TJ'$4^:7!+I5E4J.Y
MJ2RER)Y \ZFIG&0@ =64=?3F^T'[H.Z1/2J,YZCA9TCU"PY]JGRT1"FW""U_
MJ[2TZ+RRB,%B2[['4:,,X8-[@-4T0E,TM)PP:JX+$/$O3B)!58_!G#.D/<$T
MIK'H DX_XD9)YSE6<!L*N>.E!BPA;%I,@VR@R5+[5.JXY.R>Z4U_L!?57;3N
MNZ1I]T#O3='$OA;VQUF5A++B)&"M#&6@L,Y ,@8E+^>/JB:@@0(:H@-B.2[H
MO,J#>"&6=5VV%=C*U)XXJ<7D*>BF]=L42HS#AUB-!/8_L;I5IO83N/)NRKIE
MT"8/,)C4M5*KD K)8DA23:]UC9^":[(8;;,HRQY#IO\!<FAE)U2T%$X*SX!\
MC&TKFD]11O74?N^'S>*F^C@O.QP_$J'F3&6JB)M&>*YKU]2 7H$M-I /U,BU
M[)3>'$?##DV@B6QRJ-V&MUN5K5M^;657I,%>D;MHU)%"S= D06\3=GI1U&!$
M 5UT#A?(,"*8< U[LF-F%,Q$%T\F?6BT/1HC/*L2%M&K)5<DNVRF;8>B#QTZ
M[/<^T]?ID#Y<#-N 7=]%@*L=%GXNS/*G%*>FD-WM+A%][- 01L^QX00M]U:K
M##Q^$^X>H@N5X[WH$V(=!_6E-Y<BI770*MN++CLX@6#GAKP^T)6>60FNV9\D
M?\9"O\,!I='KW\(F]ZG>Y':*UXE^[KPX2+^.?H\^=VBZ DG"#B5-TFPF@=KG
MJG[$T6&[^<\,&!,"0S988ENC4"YL[3><_$1?U!V-$%N@1-BUCJ-^AWZ/06J8
MRQ7A0&;#LACX9*=JE+(3#9# &!,E_+:<=C:$6(LIFEA18JN%**(&::/]G36"
M!YM"-0.9GSOJ=G<N+CG;1;B>N1I'?8?9?-W< (?UQ6<[O;X^_J*P82-#&<^Q
MM-=Y>]BJ3R3K%V_*< U"UG"I"H\XBR #,@'C<X.&:5[$P>9>?/8W4$L#!!0
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M<+U?J!!5VELSGQ-)8\U]XB))&2AH@V#F05'KRUS&E=;!EEI-9;"BJH!7)G\
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M)HDJ\YS*ERO(Q';@=)S]PIRM4VT6W*A?T#4L0#\4,XDSMV9)6 Y<,<&)A-7
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M;B"FF[;E6J\-#V2Q%*K![K16> %C$(^K$9-O=D&9D0123FB*&,S;5M>]CMQ
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M%K0'+"J7FY9Z[G(S"0MSV-6^1!?N@8R&.BPI?E4H?J55_$Z6N62=H.]WD$R
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M;*V976_;-A2&_PJA#4,+I-&7Y3B9;:")I"Y G69QTUT4NZ#M$UNH)+HD93?
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M!+HOJ6)!%_LO&ONO,;=_ %!+ P04    "  #7VA7_^2]XT(!  !%$   &@
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M/^M^D,P^ 5!+ 0(4 Q0    (  -?:%<'04UB@0   +$    0
M  "  0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @  U]H5RP$V#+N
M    *P(  !$              ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L!
M A0#%     @  U]H5YE<G",0!@  G"<  !,              ( !S $  'AL
M+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    "  #7VA7_[6S48(%   )'0
M&               @($-"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L!
M A0#%     @  U]H5TWC6I0Q!@  :!H  !@              ("!Q0T  'AL
M+W=O<FMS:&5E=',O<VAE970R+GAM;%!+ 0(4 Q0    (  -?:%>L8D)I*@,
M .D(   8              " @2P4  !X;"]W;W)K<VAE971S+W-H965T,RYX
M;6Q02P$"% ,4    "  #7VA7FWJE1($$  !P$@  &               @(&,
M%P  >&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L! A0#%     @  U]H5UQ_
M)MQ/!P  X2,  !@              ("!0QP  'AL+W=O<FMS:&5E=',O<VAE
M970U+GAM;%!+ 0(4 Q0    (  -?:%?G]\#F:P<  -PU   8
M  " @<@C  !X;"]W;W)K<VAE971S+W-H965T-BYX;6Q02P$"% ,4    "  #
M7VA7%86"!/ $  !;"@  &               @(%I*P  >&PO=V]R:W-H965T
M<R]S:&5E=#<N>&UL4$L! A0#%     @  U]H5_'0^.9"!   R D  !@
M         ("!CS   'AL+W=O<FMS:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0
M   (  -?:%>5*7$>U@0  (P*   8              " @0<U  !X;"]W;W)K
M<VAE971S+W-H965T.2YX;6Q02P$"% ,4    "  #7VA7@;FYLV,)   6%@
M&0              @($3.@  >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+
M 0(4 Q0    (  -?:%>VM)ZH/ <   P4   9              " @:U#  !X
M;"]W;W)K<VAE971S+W-H965T,3$N>&UL4$L! A0#%     @  U]H5Z>OI>&Z
M!@  (P\  !D              ("!($L  'AL+W=O<FMS:&5E=',O<VAE970Q
M,BYX;6Q02P$"% ,4    "  #7VA7&8!A?W #  !Y!P  &0
M@($14@  >&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    (  -?
M:%<C*9YXR00   T+   9              " @;A5  !X;"]W;W)K<VAE971S
M+W-H965T,30N>&UL4$L! A0#%     @  U]H5VX$9H'N!@  _1   !D
M         ("!N%H  'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"% ,4
M    "  #7VA7K 3&A6<#  !P"   &0              @('=80  >&PO=V]R
M:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4 Q0    (  -?:%<'$S@/\0D  #H:
M   9              " @7ME  !X;"]W;W)K<VAE971S+W-H965T,3<N>&UL
M4$L! A0#%     @  U]H5X$-1.;$ @  H0<  !D              ("!HV\
M 'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6Q02P$"% ,4    "  #7VA74M=*
MVKL"  #("   &0              @(&><@  >&PO=V]R:W-H965T<R]S:&5E
M=#$Y+GAM;%!+ 0(4 Q0    (  -?:%>(58VX/P0  *06   9
M  " @9!U  !X;"]W;W)K<VAE971S+W-H965T,C N>&UL4$L! A0#%     @
M U]H5X,;#[VL"   !E0  !D              ("!!GH  'AL+W=O<FMS:&5E
M=',O<VAE970R,2YX;6Q02P$"% ,4    "  #7VA7#5S6E^ "  #N!0  &0
M            @('I@@  >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4
M Q0    (  -?:%=U1.%F@ 0  .<:   9              " @0"&  !X;"]W
M;W)K<VAE971S+W-H965T,C,N>&UL4$L! A0#%     @  U]H5_$%D>]T!P
M/3(  !D              ("!MXH  'AL+W=O<FMS:&5E=',O<VAE970R-"YX
M;6Q02P$"% ,4    "  #7VA7%P*UZK0'  "E-   &0              @(%B
MD@  >&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    (  -?:%<>
M)QV^-P0   (<   9              " @4V:  !X;"]W;W)K<VAE971S+W-H
M965T,C8N>&UL4$L! A0#%     @  U]H5]NGU?LI P  2A(   T
M     ( !NYX  'AL+W-T>6QE<RYX;6Q02P$"% ,4    "  #7VA7EXJ[',
M   3 @  "P              @ $/H@  7W)E;',O+G)E;'-02P$"% ,4
M"  #7VA7XC07I @#   1$@  #P              @ 'XH@  >&PO=V]R:V)O
M;VLN>&UL4$L! A0#%     @  U]H5__DO>-" 0  11   !H
M ( !+:8  'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#%     @
M U]H5ZH=$+!V 0  *!$  !,              ( !IZ<  %M#;VYT96YT7U1Y
><&5S72YX;6Q02P4&     "( (@ E"0  3JD

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>83</ContextCount>
  <ElementCount>145</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>28</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>4</UnitCount>
  <MyReports>
    <Report instance="ixform10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://regenerexpharmainc.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="ixform10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00000002 - Statement - BALANCE SHEETS (UNAUDITED)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://regenerexpharmainc.com/role/BalanceSheets</Role>
      <ShortName>BALANCE SHEETS (UNAUDITED)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="ixform10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00000003 - Statement - BALANCE SHEETS (UNAUDITED) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://regenerexpharmainc.com/role/BalanceSheetsParenthetical</Role>
      <ShortName>BALANCE SHEETS (UNAUDITED) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="ixform10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00000004 - Statement - STATEMENTS OF OPERATIONS (UNAUDITED)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://regenerexpharmainc.com/role/StatementsOfOperations</Role>
      <ShortName>STATEMENTS OF OPERATIONS (UNAUDITED)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="ixform10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00000005 - Statement - STATEMENTS OF CASH FLOWS (UNAUDITED)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://regenerexpharmainc.com/role/StatementsOfCashFlows</Role>
      <ShortName>STATEMENTS OF CASH FLOWS (UNAUDITED)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="ixform10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00000006 - Statement - STATEMENTS OF STOCKHOLDERS' DEFICIT (UNAUDITED)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://regenerexpharmainc.com/role/StatementsOfStockholdersDeficit</Role>
      <ShortName>STATEMENTS OF STOCKHOLDERS' DEFICIT (UNAUDITED)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="ixform10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>00000007 - Disclosure - NATURE OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://regenerexpharmainc.com/role/NatureOfOperations</Role>
      <ShortName>NATURE OF OPERATIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="ixform10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>00000008 - Disclosure - BASIS OF PRESENTATION OF INTERIM FINANCIAL STATEMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://regenerexpharmainc.com/role/BasisOfPresentationOfInterimFinancialStatements</Role>
      <ShortName>BASIS OF PRESENTATION OF INTERIM FINANCIAL STATEMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="ixform10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>00000009 - Disclosure - GOING CONCERN</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://regenerexpharmainc.com/role/GoingConcern</Role>
      <ShortName>GOING CONCERN</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="ixform10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>00000010 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://regenerexpharmainc.com/role/SignificantAccountingPolicies</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="ixform10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>00000011 - Disclosure - RELATED PARTY TRANSACTIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://regenerexpharmainc.com/role/RelatedPartyTransactions</Role>
      <ShortName>RELATED PARTY TRANSACTIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="ixform10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>00000012 - Disclosure - INTANGIBLE ASSETS AND INTELLECTUAL PROPERTY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://regenerexpharmainc.com/role/IntangibleAssetsAndIntellectualProperty</Role>
      <ShortName>INTANGIBLE ASSETS AND INTELLECTUAL PROPERTY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="ixform10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>00000013 - Disclosure - COMMITMENTS AND CONTINGENCIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://regenerexpharmainc.com/role/CommitmentsAndContingencies</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="ixform10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>00000014 - Disclosure - OPERATING LEASES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://regenerexpharmainc.com/role/OperatingLeases</Role>
      <ShortName>OPERATING LEASES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="ixform10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>00000015 - Disclosure - STOCKHOLDERS??? DEFICIT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://regenerexpharmainc.com/role/StockholdersDeficit</Role>
      <ShortName>STOCKHOLDERS??? DEFICIT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="ixform10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>00000016 - Disclosure - SUBSEQUENT EVENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://regenerexpharmainc.com/role/SubsequentEvents</Role>
      <ShortName>SUBSEQUENT EVENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="ixform10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>00000017 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://regenerexpharmainc.com/role/SignificantAccountingPoliciesPolicies</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="ixform10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>00000018 - Disclosure - NATURE OF OPERATIONS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://regenerexpharmainc.com/role/NatureOfOperationsDetailsNarrative</Role>
      <ShortName>NATURE OF OPERATIONS (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://regenerexpharmainc.com/role/NatureOfOperations</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="ixform10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>00000019 - Disclosure - GOING CONCERN (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://regenerexpharmainc.com/role/GoingConcernDetailsNarrative</Role>
      <ShortName>GOING CONCERN (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://regenerexpharmainc.com/role/GoingConcern</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="ixform10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>00000020 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://regenerexpharmainc.com/role/SignificantAccountingPoliciesDetailsNarrative</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://regenerexpharmainc.com/role/SignificantAccountingPoliciesPolicies</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="ixform10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>00000021 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://regenerexpharmainc.com/role/RelatedPartyTransactionsDetailsNarrative</Role>
      <ShortName>RELATED PARTY TRANSACTIONS (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://regenerexpharmainc.com/role/RelatedPartyTransactions</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="ixform10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>00000022 - Disclosure - INTANGIBLE ASSETS AND INTELLECTUAL PROPERTY (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://regenerexpharmainc.com/role/IntangibleAssetsAndIntellectualPropertyDetailsNarrative</Role>
      <ShortName>INTANGIBLE ASSETS AND INTELLECTUAL PROPERTY (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://regenerexpharmainc.com/role/IntangibleAssetsAndIntellectualProperty</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="ixform10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>00000023 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://regenerexpharmainc.com/role/CommitmentsAndContingenciesDetailsNarrative</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://regenerexpharmainc.com/role/CommitmentsAndContingencies</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="ixform10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>00000024 - Disclosure - OPERATING LEASES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://regenerexpharmainc.com/role/OperatingLeasesDetailsNarrative</Role>
      <ShortName>OPERATING LEASES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://regenerexpharmainc.com/role/OperatingLeases</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="ixform10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>00000025 - Disclosure - STOCKHOLDERS??? DEFICIT (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://regenerexpharmainc.com/role/StockholdersDeficitDetailsNarrative</Role>
      <ShortName>STOCKHOLDERS??? DEFICIT (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://regenerexpharmainc.com/role/StockholdersDeficit</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="ixform10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>00000026 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://regenerexpharmainc.com/role/SubsequentEventsDetailsNarrative</Role>
      <ShortName>SUBSEQUENT EVENTS (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://regenerexpharmainc.com/role/SubsequentEvents</ParentRole>
      <Position>26</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" isDefinitelyFs="true" isUsgaap="true" original="ixform10q.htm">ixform10q.htm</File>
    <File>rgpx-20230930.xsd</File>
    <File>rgpx-20230930_cal.xml</File>
    <File>rgpx-20230930_def.xml</File>
    <File>rgpx-20230930_lab.xml</File>
    <File>rgpx-20230930_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>regenerexlogo.gif</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="315">http://fasb.org/us-gaap/2023</BaseTaxonomy>
    <BaseTaxonomy items="28">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>44
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "ixform10q.htm": {
   "nsprefix": "RGPX",
   "nsuri": "http://regenerexpharmainc.com/20230930",
   "dts": {
    "inline": {
     "local": [
      "ixform10q.htm"
     ]
    },
    "schema": {
     "local": [
      "rgpx-20230930.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "rgpx-20230930_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "rgpx-20230930_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "rgpx-20230930_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "rgpx-20230930_pre.xml"
     ]
    }
   },
   "keyStandard": 138,
   "keyCustom": 7,
   "axisStandard": 10,
   "axisCustom": 0,
   "memberStandard": 10,
   "memberCustom": 17,
   "hidden": {
    "total": 42,
    "http://fasb.org/us-gaap/2023": 35,
    "http://regenerexpharmainc.com/20230930": 2,
    "http://xbrl.sec.gov/dei/2023": 5
   },
   "contextCount": 83,
   "entityCount": 1,
   "segmentCount": 28,
   "elementCount": 264,
   "unitCount": 4,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 28,
    "http://fasb.org/us-gaap/2023": 315
   },
   "report": {
    "R1": {
     "role": "http://regenerexpharmainc.com/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "From2023-04-01to2023-09-30",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ixform10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-04-01to2023-09-30",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ixform10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://regenerexpharmainc.com/role/BalanceSheets",
     "longName": "00000002 - Statement - BALANCE SHEETS (UNAUDITED)",
     "shortName": "BALANCE SHEETS (UNAUDITED)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "AsOf2023-09-30",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ixform10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-09-30",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ixform10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://regenerexpharmainc.com/role/BalanceSheetsParenthetical",
     "longName": "00000003 - Statement - BALANCE SHEETS (UNAUDITED) (Parenthetical)",
     "shortName": "BALANCE SHEETS (UNAUDITED) (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "AsOf2023-09-30",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ixform10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-09-30",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ixform10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R4": {
     "role": "http://regenerexpharmainc.com/role/StatementsOfOperations",
     "longName": "00000004 - Statement - STATEMENTS OF OPERATIONS (UNAUDITED)",
     "shortName": "STATEMENTS OF OPERATIONS (UNAUDITED)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "From2023-07-012023-09-30",
      "name": "us-gaap:GeneralAndAdministrativeExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ixform10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-07-012023-09-30",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ixform10q.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://regenerexpharmainc.com/role/StatementsOfCashFlows",
     "longName": "00000005 - Statement - STATEMENTS OF CASH FLOWS (UNAUDITED)",
     "shortName": "STATEMENTS OF CASH FLOWS (UNAUDITED)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "From2023-04-01to2023-09-30",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ixform10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-04-01to2023-09-30",
      "name": "us-gaap:Depreciation",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ixform10q.htm",
      "unique": true
     }
    },
    "R6": {
     "role": "http://regenerexpharmainc.com/role/StatementsOfStockholdersDeficit",
     "longName": "00000006 - Statement - STATEMENTS OF STOCKHOLDERS' DEFICIT (UNAUDITED)",
     "shortName": "STATEMENTS OF STOCKHOLDERS' DEFICIT (UNAUDITED)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "AsOf2022-03-31_us-gaap_CommonStockMember",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ixform10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2022-04-012022-06-30_us-gaap_RetainedEarningsMember",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ixform10q.htm",
      "unique": true
     }
    },
    "R7": {
     "role": "http://regenerexpharmainc.com/role/NatureOfOperations",
     "longName": "00000007 - Disclosure - NATURE OF OPERATIONS",
     "shortName": "NATURE OF OPERATIONS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "7",
     "firstAnchor": {
      "contextRef": "From2023-04-01to2023-09-30",
      "name": "us-gaap:NatureOfOperations",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ixform10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-04-01to2023-09-30",
      "name": "us-gaap:NatureOfOperations",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ixform10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://regenerexpharmainc.com/role/BasisOfPresentationOfInterimFinancialStatements",
     "longName": "00000008 - Disclosure - BASIS OF PRESENTATION OF INTERIM FINANCIAL STATEMENTS",
     "shortName": "BASIS OF PRESENTATION OF INTERIM FINANCIAL STATEMENTS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "From2023-04-01to2023-09-30",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ixform10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-04-01to2023-09-30",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ixform10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://regenerexpharmainc.com/role/GoingConcern",
     "longName": "00000009 - Disclosure - GOING CONCERN",
     "shortName": "GOING CONCERN",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "From2023-04-01to2023-09-30",
      "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ixform10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-04-01to2023-09-30",
      "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ixform10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://regenerexpharmainc.com/role/SignificantAccountingPolicies",
     "longName": "00000010 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "From2023-04-01to2023-09-30",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ixform10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-04-01to2023-09-30",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ixform10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://regenerexpharmainc.com/role/RelatedPartyTransactions",
     "longName": "00000011 - Disclosure - RELATED PARTY TRANSACTIONS",
     "shortName": "RELATED PARTY TRANSACTIONS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "From2023-04-01to2023-09-30",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ixform10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-04-01to2023-09-30",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ixform10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://regenerexpharmainc.com/role/IntangibleAssetsAndIntellectualProperty",
     "longName": "00000012 - Disclosure - INTANGIBLE ASSETS AND INTELLECTUAL PROPERTY",
     "shortName": "INTANGIBLE ASSETS AND INTELLECTUAL PROPERTY",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "From2023-04-01to2023-09-30",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ixform10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-04-01to2023-09-30",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ixform10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://regenerexpharmainc.com/role/CommitmentsAndContingencies",
     "longName": "00000013 - Disclosure - COMMITMENTS AND CONTINGENCIES",
     "shortName": "COMMITMENTS AND CONTINGENCIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "From2023-04-01to2023-09-30",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ixform10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-04-01to2023-09-30",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ixform10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://regenerexpharmainc.com/role/OperatingLeases",
     "longName": "00000014 - Disclosure - OPERATING LEASES",
     "shortName": "OPERATING LEASES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "From2023-04-01to2023-09-30",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ixform10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-04-01to2023-09-30",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ixform10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://regenerexpharmainc.com/role/StockholdersDeficit",
     "longName": "00000015 - Disclosure - STOCKHOLDERS\u2019 DEFICIT",
     "shortName": "STOCKHOLDERS\u2019 DEFICIT",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "From2023-04-01to2023-09-30",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ixform10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-04-01to2023-09-30",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ixform10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://regenerexpharmainc.com/role/SubsequentEvents",
     "longName": "00000016 - Disclosure - SUBSEQUENT EVENTS",
     "shortName": "SUBSEQUENT EVENTS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "From2023-04-01to2023-09-30",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ixform10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-04-01to2023-09-30",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ixform10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://regenerexpharmainc.com/role/SignificantAccountingPoliciesPolicies",
     "longName": "00000017 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "17",
     "firstAnchor": {
      "contextRef": "From2023-04-01to2023-09-30",
      "name": "us-gaap:RevenueRecognitionPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ixform10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-04-01to2023-09-30",
      "name": "us-gaap:RevenueRecognitionPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ixform10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://regenerexpharmainc.com/role/NatureOfOperationsDetailsNarrative",
     "longName": "00000018 - Disclosure - NATURE OF OPERATIONS (Details Narrative)",
     "shortName": "NATURE OF OPERATIONS (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "18",
     "firstAnchor": {
      "contextRef": "From2023-04-01to2023-09-30",
      "name": "dei:EntityIncorporationDateOfIncorporation",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:NatureOfOperations",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ixform10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-04-01to2023-09-30",
      "name": "dei:EntityIncorporationDateOfIncorporation",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:NatureOfOperations",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ixform10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://regenerexpharmainc.com/role/GoingConcernDetailsNarrative",
     "longName": "00000019 - Disclosure - GOING CONCERN (Details Narrative)",
     "shortName": "GOING CONCERN (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "19",
     "firstAnchor": {
      "contextRef": "AsOf2023-09-30",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ixform10q.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R20": {
     "role": "http://regenerexpharmainc.com/role/SignificantAccountingPoliciesDetailsNarrative",
     "longName": "00000020 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "20",
     "firstAnchor": {
      "contextRef": "AsOf2023-09-30",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ixform10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-09-30",
      "name": "us-gaap:FiniteLivedIntangibleAssetUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:ResearchDevelopmentAndComputerSoftwarePolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ixform10q.htm",
      "unique": true
     }
    },
    "R21": {
     "role": "http://regenerexpharmainc.com/role/RelatedPartyTransactionsDetailsNarrative",
     "longName": "00000021 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative)",
     "shortName": "RELATED PARTY TRANSACTIONS (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "21",
     "firstAnchor": {
      "contextRef": "From2023-04-01to2023-09-30",
      "name": "us-gaap:RelatedPartyTransactionRate",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ixform10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-04-01to2023-09-30",
      "name": "us-gaap:RelatedPartyTransactionRate",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ixform10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://regenerexpharmainc.com/role/IntangibleAssetsAndIntellectualPropertyDetailsNarrative",
     "longName": "00000022 - Disclosure - INTANGIBLE ASSETS AND INTELLECTUAL PROPERTY (Details Narrative)",
     "shortName": "INTANGIBLE ASSETS AND INTELLECTUAL PROPERTY (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "22",
     "firstAnchor": {
      "contextRef": "From2021-11-012021-11-15",
      "name": "us-gaap:BusinessCombinationContingentConsiderationArrangementsDescription",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ixform10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2021-11-012021-11-15",
      "name": "us-gaap:BusinessCombinationContingentConsiderationArrangementsDescription",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ixform10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://regenerexpharmainc.com/role/CommitmentsAndContingenciesDetailsNarrative",
     "longName": "00000023 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)",
     "shortName": "COMMITMENTS AND CONTINGENCIES (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "23",
     "firstAnchor": {
      "contextRef": "AsOf2021-11-15",
      "name": "us-gaap:AssetAcquisitionContingentConsiderationLiability",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:NatureOfOperations",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ixform10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-03-31_custom_AssetPurchaseAgreementLiabilityMember",
      "name": "us-gaap:AccruedLiabilitiesCurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ixform10q.htm",
      "unique": true
     }
    },
    "R24": {
     "role": "http://regenerexpharmainc.com/role/OperatingLeasesDetailsNarrative",
     "longName": "00000024 - Disclosure - OPERATING LEASES (Details Narrative)",
     "shortName": "OPERATING LEASES (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "24",
     "firstAnchor": {
      "contextRef": "AsOf2023-09-30",
      "name": "us-gaap:PrepaidExpenseCurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ixform10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-04-01to2023-09-30",
      "name": "us-gaap:LesseeOperatingLeaseDescription",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ixform10q.htm",
      "unique": true
     }
    },
    "R25": {
     "role": "http://regenerexpharmainc.com/role/StockholdersDeficitDetailsNarrative",
     "longName": "00000025 - Disclosure - STOCKHOLDERS\u2019 DEFICIT (Details Narrative)",
     "shortName": "STOCKHOLDERS\u2019 DEFICIT (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "25",
     "firstAnchor": {
      "contextRef": "AsOf2023-09-30",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ixform10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-04-01to2023-09-30",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ixform10q.htm",
      "unique": true
     }
    },
    "R26": {
     "role": "http://regenerexpharmainc.com/role/SubsequentEventsDetailsNarrative",
     "longName": "00000026 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)",
     "shortName": "SUBSEQUENT EVENTS (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "26",
     "firstAnchor": {
      "contextRef": "AsOf2023-09-30",
      "name": "us-gaap:NotesPayable",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ixform10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-11-01_us-gaap_SubsequentEventMember_custom_ReissuedNotesMember",
      "name": "us-gaap:NotesPayable",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ixform10q.htm",
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://regenerexpharmainc.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://regenerexpharmainc.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated deficit",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r74",
      "r282",
      "r290",
      "r291",
      "r294",
      "r311",
      "r386"
     ]
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrepaidExpenseCurrent",
     "crdr": "debit",
     "calculation": {
      "http://regenerexpharmainc.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://regenerexpharmainc.com/role/BalanceSheets",
      "http://regenerexpharmainc.com/role/OperatingLeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid expenses",
        "verboseLabel": "Prepaid Expense, Current",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r100",
      "r145",
      "r146",
      "r374"
     ]
    },
    "us-gaap_SharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharesIssued",
     "presentation": [
      "http://regenerexpharmainc.com/role/NatureOfOperationsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares, Issued",
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://regenerexpharmainc.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changes in operating assets and liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeLossFromContinuingOperationsPerBasicShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperationsPerBasicShare",
     "presentation": [
      "http://regenerexpharmainc.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basic and Diluted Loss per Common Share",
        "documentation": "The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r79",
      "r80",
      "r108",
      "r119",
      "r121",
      "r122",
      "r123",
      "r124",
      "r129",
      "r131",
      "r132",
      "r231",
      "r278",
      "r450"
     ]
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AmortizationOfIntangibleAssets",
     "crdr": "debit",
     "presentation": [
      "http://regenerexpharmainc.com/role/SignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization of Intangible Assets",
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r29",
      "r31"
     ]
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://regenerexpharmainc.com/role/StatementsOfOperations": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://regenerexpharmainc.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Operating Expenses",
        "label": "Operating Expenses [Default Label]",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "RGPX_ShareholderMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://regenerexpharmainc.com/20230930",
     "localname": "ShareholderMember",
     "presentation": [
      "http://regenerexpharmainc.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://regenerexpharmainc.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shareholder [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://regenerexpharmainc.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings per Share",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r28"
     ]
    },
    "us-gaap_IntangibleAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IntangibleAssetsDisclosureTextBlock",
     "presentation": [
      "http://regenerexpharmainc.com/role/IntangibleAssetsAndIntellectualProperty"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "INTANGIBLE ASSETS AND INTELLECTUAL PROPERTY",
        "documentation": "The entire disclosure for all or part of the information related to intangible assets."
       }
      }
     },
     "auth_ref": [
      "r148"
     ]
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionDomain",
     "presentation": [
      "http://regenerexpharmainc.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://regenerexpharmainc.com/role/StockholdersDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transaction between related party."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfWarrants",
     "crdr": "debit",
     "calculation": {
      "http://regenerexpharmainc.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://regenerexpharmainc.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from sale of common stock and warrants",
        "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt)."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertySubjectToOrAvailableForOperatingLeaseAxis",
     "presentation": [
      "http://regenerexpharmainc.com/role/OperatingLeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property Subject to or Available for Operating Lease [Axis]",
        "documentation": "Information by property that could be leased or is available for lease."
       }
      }
     },
     "auth_ref": [
      "r86"
     ]
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://regenerexpharmainc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r411"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightOutstanding",
     "presentation": [
      "http://regenerexpharmainc.com/role/SignificantAccountingPoliciesDetailsNarrative",
      "http://regenerexpharmainc.com/role/StockholdersDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right, Outstanding",
        "documentation": "Number of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "RGPX_ServicesRenderedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://regenerexpharmainc.com/20230930",
     "localname": "ServicesRenderedMember",
     "presentation": [
      "http://regenerexpharmainc.com/role/StockholdersDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Services Rendered [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://regenerexpharmainc.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://regenerexpharmainc.com/role/StatementsOfCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://regenerexpharmainc.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (decrease) in cash and equivalents",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r64"
     ]
    },
    "us-gaap_InterestPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestPaid",
     "crdr": "credit",
     "presentation": [
      "http://regenerexpharmainc.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest",
        "documentation": "Amount of cash paid for interest, including, but not limited to, capitalized interest and payment to settle zero-coupon bond attributable to accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount; classified as operating and investing activities."
       }
      }
     },
     "auth_ref": [
      "r421"
     ]
    },
    "RGPX_AffiliatesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://regenerexpharmainc.com/20230930",
     "localname": "AffiliatesMember",
     "presentation": [
      "http://regenerexpharmainc.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Affiliates [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "RGPX_PurchaseIntellectualPropertyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://regenerexpharmainc.com/20230930",
     "localname": "PurchaseIntellectualPropertyMember",
     "presentation": [
      "http://regenerexpharmainc.com/role/NatureOfOperationsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase Intellectual Property [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://regenerexpharmainc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://regenerexpharmainc.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cash and cash equivalents, beginning of period",
        "periodEndLabel": "Cash and cash equivalents, end of period",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r64",
      "r110"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://regenerexpharmainc.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders\u2019 Deficit"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TemporaryEquityContractTerms": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TemporaryEquityContractTerms",
     "presentation": [
      "http://regenerexpharmainc.com/role/StockholdersDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary Equity, Contract Terms",
        "documentation": "Significant terms of equity contract classified as temporary equity to issue additional shares. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://regenerexpharmainc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r410",
      "r412",
      "r413"
     ]
    },
    "us-gaap_NatureOfOperations": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NatureOfOperations",
     "presentation": [
      "http://regenerexpharmainc.com/role/NatureOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "NATURE OF OPERATIONS",
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward."
       }
      }
     },
     "auth_ref": [
      "r89",
      "r91"
     ]
    },
    "RGPX_ReissuedNotesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://regenerexpharmainc.com/20230930",
     "localname": "ReissuedNotesMember",
     "presentation": [
      "http://regenerexpharmainc.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://regenerexpharmainc.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reissued Notes [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://regenerexpharmainc.com/role/StockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "STOCKHOLDERS\u2019 DEFICIT",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r73",
      "r112",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r229",
      "r357",
      "r359",
      "r368"
     ]
    },
    "RGPX_ChiefExecutiveOfficerAndChiefFinancialOfficerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://regenerexpharmainc.com/20230930",
     "localname": "ChiefExecutiveOfficerAndChiefFinancialOfficerMember",
     "presentation": [
      "http://regenerexpharmainc.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://regenerexpharmainc.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Chief Executive Officer And Chief Financial Officer [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://regenerexpharmainc.com/role/CommitmentsAndContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "COMMITMENTS AND CONTINGENCIES",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r150",
      "r151",
      "r369",
      "r430"
     ]
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockPricePerShare",
     "presentation": [
      "http://regenerexpharmainc.com/role/StockholdersDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock, Price Per Share",
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "RGPX_PromissoryNotesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://regenerexpharmainc.com/20230930",
     "localname": "PromissoryNotesMember",
     "presentation": [
      "http://regenerexpharmainc.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Promissory Notes [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "RGPX_Promissory1NotesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://regenerexpharmainc.com/20230930",
     "localname": "Promissory1NotesMember",
     "presentation": [
      "http://regenerexpharmainc.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Promissory 1 Notes [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertySubjectToOrAvailableForOperatingLeaseDomain",
     "presentation": [
      "http://regenerexpharmainc.com/role/OperatingLeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A descriptive title of whether the property is subject to or available for operating lease."
       }
      }
     },
     "auth_ref": [
      "r86"
     ]
    },
    "RGPX_AggregateInterestExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://regenerexpharmainc.com/20230930",
     "localname": "AggregateInterestExpenseMember",
     "presentation": [
      "http://regenerexpharmainc.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Interest Expense [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "RGPX_BoardMembersAndConsultantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://regenerexpharmainc.com/20230930",
     "localname": "BoardMembersAndConsultantsMember",
     "presentation": [
      "http://regenerexpharmainc.com/role/StockholdersDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Board Members And Consultants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "RGPX_OfficeLeaseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://regenerexpharmainc.com/20230930",
     "localname": "OfficeLeaseMember",
     "presentation": [
      "http://regenerexpharmainc.com/role/OperatingLeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Office Lease [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://regenerexpharmainc.com/role/SubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SUBSEQUENT EVENTS",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r259",
      "r261"
     ]
    },
    "RGPX_AssetPurchaseAgreementLiabilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://regenerexpharmainc.com/20230930",
     "localname": "AssetPurchaseAgreementLiabilityMember",
     "presentation": [
      "http://regenerexpharmainc.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Purchase Agreement Liability [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestExpense",
     "crdr": "debit",
     "calculation": {
      "http://regenerexpharmainc.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://regenerexpharmainc.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://regenerexpharmainc.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Interest expense",
        "label": "Interest Expense",
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r82",
      "r107",
      "r136",
      "r244",
      "r338",
      "r396",
      "r453"
     ]
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionAxis",
     "presentation": [
      "http://regenerexpharmainc.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://regenerexpharmainc.com/role/StockholdersDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Axis]",
        "documentation": "Information by type of related party transaction."
       }
      }
     },
     "auth_ref": [
      "r256",
      "r257",
      "r439"
     ]
    },
    "RGPX_MonthlyRentalPaymentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://regenerexpharmainc.com/20230930",
     "localname": "MonthlyRentalPaymentsMember",
     "presentation": [
      "http://regenerexpharmainc.com/role/OperatingLeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Monthly Rental Payments [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1",
     "crdr": "debit",
     "presentation": [
      "http://regenerexpharmainc.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issued for the acquisition of intellectual property",
        "documentation": "The amount of intangibles that an Entity acquires in a noncash (or part noncash) acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r25",
      "r26"
     ]
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "presentation": [
      "http://regenerexpharmainc.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies (Note 7)",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r44",
      "r280",
      "r309"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://regenerexpharmainc.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://regenerexpharmainc.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and equivalents",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r96",
      "r373"
     ]
    },
    "RGPX_SecurityDepositMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://regenerexpharmainc.com/20230930",
     "localname": "SecurityDepositMember",
     "presentation": [
      "http://regenerexpharmainc.com/role/OperatingLeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Deposit [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://regenerexpharmainc.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to reconcile net loss to cash flows used in operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NonoperatingIncomeExpenseAbstract",
     "presentation": [
      "http://regenerexpharmainc.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Income (Expense)"
       }
      }
     },
     "auth_ref": []
    },
    "RGPX_PlantFacilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://regenerexpharmainc.com/20230930",
     "localname": "PlantFacilityMember",
     "presentation": [
      "http://regenerexpharmainc.com/role/OperatingLeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plant Facility [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://regenerexpharmainc.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://regenerexpharmainc.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Other Income (Expense)",
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": [
      "r61"
     ]
    },
    "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock",
     "presentation": [
      "http://regenerexpharmainc.com/role/BasisOfPresentationOfInterimFinancialStatements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "BASIS OF PRESENTATION OF INTERIM FINANCIAL STATEMENTS",
        "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r67",
      "r68"
     ]
    },
    "us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain",
     "presentation": [
      "http://regenerexpharmainc.com/role/StockholdersDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred compensation related to equity-based payment arrangements. Includes, but is not limited to, employment contracts with one or more selected officers or key employees. Excludes broad group equity-based compensation plans, defined benefit pension plans, defined benefit other postretirement benefit plans and other deferred compensation that is not equivalent to a defined benefit pension plan or a defined benefit other postretirement benefit plan."
       }
      }
     },
     "auth_ref": [
      "r38"
     ]
    },
    "RGPX_OperatingLeaseCostMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://regenerexpharmainc.com/20230930",
     "localname": "OperatingLeaseCostMember",
     "presentation": [
      "http://regenerexpharmainc.com/role/OperatingLeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease Cost [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherNotesPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherNotesPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://regenerexpharmainc.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://regenerexpharmainc.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current portion of notes payable to shareholder",
        "documentation": "Amount of long-term notes classified as other, payable within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "us-gaap_LongTermNotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermNotesPayable",
     "crdr": "credit",
     "presentation": [
      "http://regenerexpharmainc.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Notes Payable, Noncurrent",
        "documentation": "Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://regenerexpharmainc.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://regenerexpharmainc.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Website, net of accumulated amortization of $27,834 and $26,397, as of September 30, 2023 and March 31, 2023, respectively",
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r265"
     ]
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://regenerexpharmainc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r413"
     ]
    },
    "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ForeignCurrencyTransactionGainLossBeforeTax",
     "crdr": "credit",
     "calculation": {
      "http://regenerexpharmainc.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 2.0
      },
      "http://regenerexpharmainc.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://regenerexpharmainc.com/role/StatementsOfCashFlows",
      "http://regenerexpharmainc.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Foreign currency gain (loss)",
        "negatedLabel": "Foreign currency adjustments",
        "documentation": "Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction."
       }
      }
     },
     "auth_ref": [
      "r233",
      "r234",
      "r235",
      "r236",
      "r351"
     ]
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://regenerexpharmainc.com/role/SignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SIGNIFICANT ACCOUNTING POLICIES",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r111"
     ]
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://regenerexpharmainc.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Recent Accounting Pronouncements",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "crdr": "debit",
     "calculation": {
      "http://regenerexpharmainc.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://regenerexpharmainc.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization of ROU assets, net of liabilities",
        "documentation": "Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease."
       }
      }
     },
     "auth_ref": [
      "r420"
     ]
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Depreciation",
     "crdr": "debit",
     "calculation": {
      "http://regenerexpharmainc.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://regenerexpharmainc.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r32"
     ]
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeLeaseDescriptionLineItems",
     "presentation": [
      "http://regenerexpharmainc.com/role/OperatingLeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Lease, Description [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r250"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://regenerexpharmainc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r401"
     ]
    },
    "us-gaap_PaymentsToAcquireIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquireIntangibleAssets",
     "crdr": "credit",
     "presentation": [
      "http://regenerexpharmainc.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-cash research and development expenses",
        "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill."
       }
      }
     },
     "auth_ref": [
      "r63"
     ]
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://regenerexpharmainc.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://regenerexpharmainc.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://regenerexpharmainc.com/role/StatementsOfCashFlows",
      "http://regenerexpharmainc.com/role/StockholdersDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party, Type [Axis]",
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "auth_ref": [
      "r197",
      "r256",
      "r257",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r327",
      "r329",
      "r361",
      "r439"
     ]
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://regenerexpharmainc.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://regenerexpharmainc.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Current Liabilities",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r95",
      "r113",
      "r142",
      "r156",
      "r157",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r164",
      "r220",
      "r221",
      "r222",
      "r232",
      "r386",
      "r431",
      "r440",
      "r441"
     ]
    },
    "us-gaap_OtherDepreciationAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherDepreciationAndAmortization",
     "crdr": "debit",
     "presentation": [
      "http://regenerexpharmainc.com/role/SignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Depreciation and Amortization",
        "documentation": "Amount of expense charged against earnings to allocate the cost of tangible and intangible assets over their remaining economic lives, classified as other."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r32",
      "r59"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromNotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromNotesPayable",
     "crdr": "debit",
     "calculation": {
      "http://regenerexpharmainc.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://regenerexpharmainc.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from notes payable to shareholder",
        "documentation": "The cash inflow from a borrowing supported by a written promise to pay an obligation."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://regenerexpharmainc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://regenerexpharmainc.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://regenerexpharmainc.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by financing activities",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r109"
     ]
    },
    "us-gaap_NotesAndLoansPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NotesAndLoansPayable",
     "crdr": "credit",
     "presentation": [
      "http://regenerexpharmainc.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Notes and Loans Payable",
        "documentation": "Including the current and noncurrent portions, carrying value as of the balance sheet date of all notes and loans payable (with maturities initially due after one year or beyond the operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r77",
      "r449"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "presentation": [
      "http://regenerexpharmainc.com/role/StockholdersDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum",
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://regenerexpharmainc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "presentation": [
      "http://regenerexpharmainc.com/role/StockholdersDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum",
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://regenerexpharmainc.com/role/SignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsSoldUnderAgreementsToRepurchaseTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsSoldUnderAgreementsToRepurchaseTypeDomain",
     "presentation": [
      "http://regenerexpharmainc.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is the type of such assets (for example, US Treasury Obligations, US Government agency obligations and loans, and so forth). This item may be presented as an element in the table that is disclosed when the carrying amount (or market value, if higher than the carrying amount) of securities or other assets sold under repurchase agreements exceed 10 percent of total assets, as of the most recent balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r114"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://regenerexpharmainc.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flows from Financing Activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://regenerexpharmainc.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://regenerexpharmainc.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net cash used in investing activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r109"
     ]
    },
    "us-gaap_AssetsSoldUnderAgreementsToRepurchaseAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsSoldUnderAgreementsToRepurchaseAxis",
     "presentation": [
      "http://regenerexpharmainc.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Securities or Other Assets Sold under Agreements to Repurchase [Axis]",
        "documentation": "Information by securities or other assets sold under repurchase agreements. Repurchase agreements are agreements under which the transferor (repo party) transfers a security to a transferee (repo counterparty or reverse party) in exchange for cash and concurrently agrees to reacquire that security at a future date for an amount equal to the cash exchanged plus a stipulated interest factor."
       }
      }
     },
     "auth_ref": [
      "r114"
     ]
    },
    "us-gaap_NotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NotesPayable",
     "crdr": "credit",
     "calculation": {
      "http://regenerexpharmainc.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://regenerexpharmainc.com/role/BalanceSheets",
      "http://regenerexpharmainc.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://regenerexpharmainc.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Notes payable, net of current portion",
        "verboseLabel": "Notes Payable",
        "documentation": "Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r77",
      "r449"
     ]
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://regenerexpharmainc.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flows from Investing Activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://regenerexpharmainc.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://regenerexpharmainc.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net cash used in operating activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r65",
      "r66"
     ]
    },
    "us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis",
     "presentation": [
      "http://regenerexpharmainc.com/role/StockholdersDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity-Based Arrangements, Individual Contracts, Type of Deferred Compensation [Axis]",
        "documentation": "Information by type of deferred compensation related to equity-based payment arrangements. Includes, but is not limited to, employment contracts with one or more selected officers or key employees. Excludes broad group equity-based compensation plans, defined benefit pension plans, defined benefit other postretirement benefit plans and other deferred compensation that is not equivalent to a defined benefit pension plan or a defined benefit other postretirement benefit plan."
       }
      }
     },
     "auth_ref": [
      "r38"
     ]
    },
    "us-gaap_AssetsSoldUnderAgreementsToRepurchaseLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsSoldUnderAgreementsToRepurchaseLineItems",
     "presentation": [
      "http://regenerexpharmainc.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets Sold under Agreements to Repurchase [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r114"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://regenerexpharmainc.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInPrepaidExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInPrepaidExpense",
     "crdr": "credit",
     "calculation": {
      "http://regenerexpharmainc.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://regenerexpharmainc.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Prepaid expenses",
        "label": "Increase (Decrease) in Prepaid Expense",
        "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_LeaseContractualTermDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseContractualTermDomain",
     "presentation": [
      "http://regenerexpharmainc.com/role/OperatingLeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual term of lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r419"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://regenerexpharmainc.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://regenerexpharmainc.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current portion of lease liabilities",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r248"
     ]
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeLeaseDescriptionTable",
     "presentation": [
      "http://regenerexpharmainc.com/role/OperatingLeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Lease, Description [Table]",
        "documentation": "Disclosure of information about lessee's leases."
       }
      }
     },
     "auth_ref": [
      "r250"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://regenerexpharmainc.com/role/BalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://regenerexpharmainc.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Assets",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r99",
      "r113",
      "r135",
      "r138",
      "r140",
      "r142",
      "r156",
      "r157",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r164",
      "r219",
      "r221",
      "r232",
      "r279",
      "r322",
      "r386",
      "r398",
      "r431",
      "r432",
      "r440"
     ]
    },
    "us-gaap_ScheduleOfAssetsSoldUnderAgreementsToRepurchaseTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAssetsSoldUnderAgreementsToRepurchaseTable",
     "presentation": [
      "http://regenerexpharmainc.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Assets Sold under Agreements to Repurchase [Table]",
        "documentation": "Schedule, as of the most recent balance sheet date, of securities or other assets sold under repurchase agreements when this amount exceeds 10 percent of total assets. Disclosure may include the following: the type of securities or assets sold under agreements to repurchase, the carrying amount, market value (including accrued interest plus any cash or other assets on deposit. The information is segregated into securities maturing (1) overnight; (2) term up to 30 days; (3) term of 30 to 90 days; (4) term over 90 days; (5) demand."
       }
      }
     },
     "auth_ref": [
      "r114"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "presentation": [
      "http://regenerexpharmainc.com/role/SignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseContractualTermAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseContractualTermAxis",
     "presentation": [
      "http://regenerexpharmainc.com/role/OperatingLeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease Contractual Term [Axis]",
        "documentation": "Information by contractual term of lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r419"
     ]
    },
    "us-gaap_RepaymentsOfNotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RepaymentsOfNotesPayable",
     "crdr": "credit",
     "presentation": [
      "http://regenerexpharmainc.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://regenerexpharmainc.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Repayment of notes payable to shareholder",
        "label": "Repayments of Notes Payable",
        "documentation": "The cash outflow for a borrowing supported by a written promise to pay an obligation."
       }
      }
     },
     "auth_ref": [
      "r20"
     ]
    },
    "srt_ChiefFinancialOfficerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ChiefFinancialOfficerMember",
     "presentation": [
      "http://regenerexpharmainc.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Chief Financial Officer [Member]"
       }
      }
     },
     "auth_ref": [
      "r427"
     ]
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://regenerexpharmainc.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://regenerexpharmainc.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://regenerexpharmainc.com/role/StatementsOfCashFlows",
      "http://regenerexpharmainc.com/role/StockholdersDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "auth_ref": [
      "r197",
      "r256",
      "r257",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r327",
      "r329",
      "r361"
     ]
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://regenerexpharmainc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r416"
     ]
    },
    "us-gaap_ProceedsFromRelatedPartyDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromRelatedPartyDebt",
     "crdr": "debit",
     "calculation": {
      "http://regenerexpharmainc.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://regenerexpharmainc.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Related party advances",
        "label": "Proceeds from Related Party Debt",
        "documentation": "The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://regenerexpharmainc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfStockholdersEquityAbstract",
     "auth_ref": []
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfCashFlowsAbstract",
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://regenerexpharmainc.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://regenerexpharmainc.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease liabilities, net of current portion",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r248"
     ]
    },
    "srt_ChiefExecutiveOfficerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ChiefExecutiveOfficerMember",
     "presentation": [
      "http://regenerexpharmainc.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Chief Executive Officer [Member]"
       }
      }
     },
     "auth_ref": [
      "r427"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockMember",
     "presentation": [
      "http://regenerexpharmainc.com/role/StatementsOfStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r388",
      "r389",
      "r390",
      "r392",
      "r393",
      "r394",
      "r395",
      "r424",
      "r425",
      "r435",
      "r451",
      "r454"
     ]
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://regenerexpharmainc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://regenerexpharmainc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r401"
     ]
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://regenerexpharmainc.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information \u2013 Cash Paid For:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdditionalCashFlowElementsOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalCashFlowElementsOperatingActivitiesAbstract",
     "presentation": [
      "http://regenerexpharmainc.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flows from Operating Activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "presentation": [
      "http://regenerexpharmainc.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Cash Investing and Financing Activities:"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://regenerexpharmainc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r401"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://regenerexpharmainc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r401"
     ]
    },
    "us-gaap_NotesPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NotesPayableCurrent",
     "crdr": "credit",
     "presentation": [
      "http://regenerexpharmainc.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current portion of notes payable",
        "documentation": "Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://regenerexpharmainc.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-Based Compensation",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r199",
      "r200",
      "r202",
      "r203",
      "r204",
      "r205",
      "r208",
      "r212",
      "r213",
      "r214",
      "r215"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://regenerexpharmainc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r401"
     ]
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://regenerexpharmainc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://regenerexpharmainc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://regenerexpharmainc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r412"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://regenerexpharmainc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elected Not To Use the Extended Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r418"
     ]
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://regenerexpharmainc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://regenerexpharmainc.com/role/StatementsOfStockholdersDeficit",
      "http://regenerexpharmainc.com/role/StockholdersDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Shares and warrants sold for cash",
        "label": "Stock Issued During Period, Value, New Issues",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r50",
      "r51",
      "r74",
      "r298",
      "r354",
      "r367",
      "r397"
     ]
    },
    "us-gaap_OtherAffiliatesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAffiliatesMember",
     "presentation": [
      "http://regenerexpharmainc.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Affiliates [Member]",
        "documentation": "A category that identifies other affiliates."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestExpenseDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestExpenseDebt",
     "crdr": "debit",
     "presentation": [
      "http://regenerexpharmainc.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Expense, Debt",
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r178",
      "r182",
      "r382",
      "r383"
     ]
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://regenerexpharmainc.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://regenerexpharmainc.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Current Assets",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r94",
      "r101",
      "r113",
      "r142",
      "r156",
      "r157",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r164",
      "r219",
      "r221",
      "r232",
      "r386",
      "r431",
      "r432",
      "r440"
     ]
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://regenerexpharmainc.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Right of Use Assets and Lease Liabilities",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r249"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://regenerexpharmainc.com/role/StockholdersDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r38"
     ]
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://regenerexpharmainc.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://regenerexpharmainc.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts payable",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r386"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://regenerexpharmainc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://regenerexpharmainc.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Assets-"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://regenerexpharmainc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentCarryingAmount",
     "crdr": "credit",
     "presentation": [
      "http://regenerexpharmainc.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://regenerexpharmainc.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt, Gross",
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r77",
      "r181"
     ]
    },
    "us-gaap_LesseeOperatingLeaseDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseDescription",
     "presentation": [
      "http://regenerexpharmainc.com/role/OperatingLeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Description",
        "documentation": "Description of lessee's operating lease."
       }
      }
     },
     "auth_ref": [
      "r251"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://regenerexpharmainc.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares, Issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r51"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://regenerexpharmainc.com/role/StockholdersDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r206"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://regenerexpharmainc.com/role/StatementsOfStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares and warrants sold for cash",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r50",
      "r51",
      "r74",
      "r293",
      "r354",
      "r367"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://regenerexpharmainc.com/role/StockholdersDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r205"
     ]
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementTable",
     "presentation": [
      "http://regenerexpharmainc.com/role/NatureOfOperationsDetailsNarrative",
      "http://regenerexpharmainc.com/role/StatementsOfStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed."
       }
      }
     },
     "auth_ref": [
      "r116",
      "r117",
      "r118",
      "r134",
      "r264",
      "r292",
      "r299",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r310",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r329",
      "r331",
      "r332",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r354",
      "r391"
     ]
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueRecognitionPolicyTextBlock",
     "presentation": [
      "http://regenerexpharmainc.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue Recognition",
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources."
       }
      }
     },
     "auth_ref": [
      "r331",
      "r372",
      "r375"
     ]
    },
    "us-gaap_BusinessCombinationContingentConsiderationArrangementsDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationContingentConsiderationArrangementsDescription",
     "presentation": [
      "http://regenerexpharmainc.com/role/IntangibleAssetsAndIntellectualPropertyDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Contingent Consideration Arrangements, Description",
        "documentation": "For contingent consideration arrangements recognized in connection with a business combination, this element represents a description of such arrangements."
       }
      }
     },
     "auth_ref": [
      "r39"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://regenerexpharmainc.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://regenerexpharmainc.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock: $0.001 par value: 675,000,000 shares authorized: 277,915,910 and 277,112,660 issued and outstanding at September 30, 2023 and March 31, 2023, respectively",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r281",
      "r386"
     ]
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CountryRegion",
     "presentation": [
      "http://regenerexpharmainc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://regenerexpharmainc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetAcquisitionContingentConsiderationLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetAcquisitionContingentConsiderationLiability",
     "crdr": "credit",
     "presentation": [
      "http://regenerexpharmainc.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://regenerexpharmainc.com/role/NatureOfOperationsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Acquisition, Contingent Consideration, Liability",
        "documentation": "Amount of liability recognized from contingent consideration in asset acquisition."
       }
      }
     },
     "auth_ref": [
      "r434"
     ]
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://regenerexpharmainc.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://regenerexpharmainc.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued compensation",
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://regenerexpharmainc.com/role/BalanceSheetsParenthetical",
      "http://regenerexpharmainc.com/role/StockholdersDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares Authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r310"
     ]
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MachineryAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MachineryAndEquipmentGross",
     "crdr": "debit",
     "calculation": {
      "http://regenerexpharmainc.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://regenerexpharmainc.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Furniture and computer equipment, net of accumulated depreciation of $735 and $197 as of September 30, 2023 and March 31, 2023, respectively",
        "documentation": "Amount before accumulated depreciation of tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment."
       }
      }
     },
     "auth_ref": [
      "r71"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://regenerexpharmainc.com/role/BalanceSheetsParenthetical",
      "http://regenerexpharmainc.com/role/StatementsOfStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares, Outstanding",
        "periodStartLabel": "Common Stock, Shares, Outstanding, Beginning Balance",
        "periodEndLabel": "Common Stock, Shares, Outstanding, Ending Balance",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r51",
      "r310",
      "r328",
      "r454",
      "r455"
     ]
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Extension",
     "presentation": [
      "http://regenerexpharmainc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventLineItems",
     "presentation": [
      "http://regenerexpharmainc.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Line Items]",
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event."
       }
      }
     },
     "auth_ref": [
      "r243",
      "r260"
     ]
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://regenerexpharmainc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r401"
     ]
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://regenerexpharmainc.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://regenerexpharmainc.com/role/StatementsOfCashFlows",
      "http://regenerexpharmainc.com/role/StockholdersDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-based compensation",
        "verboseLabel": "Share-Based Payment Arrangement, Noncash Expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://regenerexpharmainc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedBenefitPlanDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanDisclosureLineItems",
     "presentation": [
      "http://regenerexpharmainc.com/role/StatementsOfCashFlows",
      "http://regenerexpharmainc.com/role/StockholdersDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Benefit Plan Disclosure [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTable",
     "presentation": [
      "http://regenerexpharmainc.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Table]",
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued."
       }
      }
     },
     "auth_ref": [
      "r243",
      "r260"
     ]
    },
    "dei_EntityIncorporationDateOfIncorporation": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationDateOfIncorporation",
     "presentation": [
      "http://regenerexpharmainc.com/role/NatureOfOperationsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, Date of Incorporation",
        "documentation": "Date when an entity was incorporated"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://regenerexpharmainc.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r243",
      "r260"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "presentation": [
      "http://regenerexpharmainc.com/role/StockholdersDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r201"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://regenerexpharmainc.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://regenerexpharmainc.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts payable and accrued liabilities",
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable",
     "presentation": [
      "http://regenerexpharmainc.com/role/StatementsOfCashFlows",
      "http://regenerexpharmainc.com/role/StockholdersDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Defined Benefit Plans Disclosures [Table]",
        "documentation": "Disclosures about an individual defined benefit pension plan or an other postretirement defined benefit plan. It may be appropriate to group certain similar plans. Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r34",
      "r35",
      "r36",
      "r37"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://regenerexpharmainc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://regenerexpharmainc.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://regenerexpharmainc.com/role/BalanceSheets",
      "http://regenerexpharmainc.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://regenerexpharmainc.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other accrued liabilities",
        "verboseLabel": "Accrued Liabilities, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://regenerexpharmainc.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r243",
      "r260"
     ]
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://regenerexpharmainc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://regenerexpharmainc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r400"
     ]
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeasesFutureMinimumPaymentsDue",
     "crdr": "credit",
     "presentation": [
      "http://regenerexpharmainc.com/role/OperatingLeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Leases, Future Minimum Payments Due",
        "documentation": "Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r85"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://regenerexpharmainc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r401"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentPreproductionDesignAndDevelopmentCosts": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentPreproductionDesignAndDevelopmentCosts",
     "presentation": [
      "http://regenerexpharmainc.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Furniture and Computer Equipment",
        "documentation": "Disclosure of accounting policy for the preproduction design and development costs it incurs related to long-term supply arrangements, including whether such costs are capitalized or expensed as incurred. The entity also may disclose the aggregate amount of (1) assets recognized for agreements that contractually reimburse the entity for its pre-production design and development costs (2) assets recognized for molds, dies and other tools that the entity owns and (3) assets recognized for molds, dies and other tools that the entity does not own."
       }
      }
     },
     "auth_ref": [
      "r147"
     ]
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://regenerexpharmainc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://regenerexpharmainc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://regenerexpharmainc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://regenerexpharmainc.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://regenerexpharmainc.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Right of use asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r247"
     ]
    },
    "us-gaap_InterestPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestPayableCurrent",
     "crdr": "credit",
     "presentation": [
      "http://regenerexpharmainc.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://regenerexpharmainc.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Payable, Current",
        "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "us-gaap_LesseeFinanceLeaseDiscountRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeFinanceLeaseDiscountRate",
     "presentation": [
      "http://regenerexpharmainc.com/role/SignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Finance Lease, Discount Rate",
        "documentation": "Discount rate used by lessee to determine present value of finance lease payments."
       }
      }
     },
     "auth_ref": [
      "r438"
     ]
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://regenerexpharmainc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock",
     "presentation": [
      "http://regenerexpharmainc.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development",
        "documentation": "Tabular disclosure of the nature and amounts of capitalized costs of a research and development nature that were acquired in a transaction other than a business combination, the amount of such assets charged to expense during the period, and identification of the income statement caption in which the charges are included."
       }
      }
     },
     "auth_ref": [
      "r30"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://regenerexpharmainc.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r243",
      "r260"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://regenerexpharmainc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r414"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://regenerexpharmainc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://regenerexpharmainc.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Common Shares Outstanding",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r128",
      "r133"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://regenerexpharmainc.com/role/StatementsOfStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r209",
      "r210",
      "r211",
      "r298",
      "r424",
      "r425",
      "r426",
      "r435",
      "r454"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeAxis",
     "presentation": [
      "http://regenerexpharmainc.com/role/SignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r152",
      "r153",
      "r154",
      "r155",
      "r196",
      "r198",
      "r205",
      "r206",
      "r207",
      "r262",
      "r263",
      "r286",
      "r300",
      "r301",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r370",
      "r371",
      "r378",
      "r384",
      "r385",
      "r387",
      "r390",
      "r429",
      "r433",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://regenerexpharmainc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r403"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice",
     "presentation": [
      "http://regenerexpharmainc.com/role/StockholdersDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Exercise Price",
        "documentation": "Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://regenerexpharmainc.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ASSETS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CapitalLeaseObligationsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CapitalLeaseObligationsCurrent",
     "crdr": "credit",
     "presentation": [
      "http://regenerexpharmainc.com/role/OperatingLeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Capital Lease Obligations, Current",
        "documentation": "Amount of capital lease obligation due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r87",
      "r88"
     ]
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://regenerexpharmainc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12gTitle",
     "presentation": [
      "http://regenerexpharmainc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r404"
     ]
    },
    "us-gaap_DebtInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentAxis",
     "presentation": [
      "http://regenerexpharmainc.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://regenerexpharmainc.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument [Axis]",
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r48",
      "r49",
      "r76",
      "r77",
      "r115",
      "r165",
      "r166",
      "r167",
      "r168",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r245",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r422"
     ]
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://regenerexpharmainc.com/role/SignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MaximumMember",
     "presentation": [
      "http://regenerexpharmainc.com/role/SignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r152",
      "r153",
      "r154",
      "r155",
      "r198",
      "r263",
      "r286",
      "r300",
      "r301",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r370",
      "r371",
      "r378",
      "r384",
      "r385",
      "r387",
      "r433",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447"
     ]
    },
    "RGPX_RelatedPartyAdvances": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://regenerexpharmainc.com/20230930",
     "localname": "RelatedPartyAdvances",
     "crdr": "credit",
     "calculation": {
      "http://regenerexpharmainc.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://regenerexpharmainc.com/role/BalanceSheets",
      "http://regenerexpharmainc.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related party advances",
        "verboseLabel": "[custom:RelatedPartyAdvances-0]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeasesTextBlock",
     "presentation": [
      "http://regenerexpharmainc.com/role/OperatingLeases"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "OPERATING LEASES",
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r246"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeMember",
     "presentation": [
      "http://regenerexpharmainc.com/role/SignificantAccountingPoliciesDetailsNarrative"
     ],
     "auth_ref": [
      "r152",
      "r153",
      "r154",
      "r155",
      "r196",
      "r198",
      "r205",
      "r206",
      "r207",
      "r262",
      "r263",
      "r286",
      "r300",
      "r301",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r370",
      "r371",
      "r378",
      "r384",
      "r385",
      "r387",
      "r390",
      "r429",
      "r433",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://regenerexpharmainc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r412"
     ]
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://regenerexpharmainc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r417"
     ]
    },
    "us-gaap_RelatedPartyTransactionRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionRate",
     "presentation": [
      "http://regenerexpharmainc.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction, Rate",
        "documentation": "Identify the stated interest rate per the agreement, for example, leasing and debt arrangements between related parties."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchDevelopmentAndComputerSoftwarePolicyTextBlock",
     "presentation": [
      "http://regenerexpharmainc.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Website",
        "documentation": "Disclosure of accounting policy for its research and development and computer software activities including the accounting treatment for costs incurred for (1) research and development activities, (2) development of computer software for internal use, (3) computer software to be sold, leased or otherwise marketed as a separate product or as part of a product or process and (4) in-process research and development acquired in a purchase business combination."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r1",
      "r45"
     ]
    },
    "RGPX_WarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://regenerexpharmainc.com/20230930",
     "localname": "WarrantsMember",
     "presentation": [
      "http://regenerexpharmainc.com/role/StockholdersDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://regenerexpharmainc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r408"
     ]
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://regenerexpharmainc.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      },
      "http://regenerexpharmainc.com/role/StatementsOfOperations": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://regenerexpharmainc.com/role/StatementsOfCashFlows",
      "http://regenerexpharmainc.com/role/StatementsOfOperations",
      "http://regenerexpharmainc.com/role/StatementsOfStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net Loss",
        "label": "Net loss",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r66",
      "r81",
      "r93",
      "r102",
      "r103",
      "r106",
      "r113",
      "r119",
      "r121",
      "r122",
      "r123",
      "r124",
      "r126",
      "r127",
      "r130",
      "r135",
      "r137",
      "r139",
      "r141",
      "r142",
      "r156",
      "r157",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r164",
      "r231",
      "r232",
      "r285",
      "r330",
      "r352",
      "r353",
      "r377",
      "r396",
      "r431"
     ]
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MinimumMember",
     "presentation": [
      "http://regenerexpharmainc.com/role/SignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r152",
      "r153",
      "r154",
      "r155",
      "r198",
      "r263",
      "r286",
      "r300",
      "r301",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r370",
      "r371",
      "r378",
      "r384",
      "r385",
      "r387",
      "r433",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementLineItems",
     "presentation": [
      "http://regenerexpharmainc.com/role/NatureOfOperationsDetailsNarrative",
      "http://regenerexpharmainc.com/role/StatementsOfStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r116",
      "r117",
      "r118",
      "r134",
      "r264",
      "r292",
      "r299",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r310",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r329",
      "r331",
      "r332",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r354",
      "r391"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateDuringPeriod": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentInterestRateDuringPeriod",
     "presentation": [
      "http://regenerexpharmainc.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Interest Rate During Period",
        "documentation": "The average effective interest rate during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r40",
      "r177"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://regenerexpharmainc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r409"
     ]
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://regenerexpharmainc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r415"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "crdr": "credit",
     "presentation": [
      "http://regenerexpharmainc.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r98",
      "r149"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://regenerexpharmainc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r412"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://regenerexpharmainc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "presentation": [
      "http://regenerexpharmainc.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Related Party Transactions, by Related Party [Table]",
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r43",
      "r333",
      "r334",
      "r337"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "presentation": [
      "http://regenerexpharmainc.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r166"
     ]
    },
    "RGPX_NotesPayableShareholder": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://regenerexpharmainc.com/20230930",
     "localname": "NotesPayableShareholder",
     "crdr": "credit",
     "calculation": {
      "http://regenerexpharmainc.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://regenerexpharmainc.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Notes payable to shareholder, net of current portion"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://regenerexpharmainc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r399"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://regenerexpharmainc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r407"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://regenerexpharmainc.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://regenerexpharmainc.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://regenerexpharmainc.com/role/OperatingLeasesDetailsNarrative",
      "http://regenerexpharmainc.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Selling, general and administration",
        "verboseLabel": "General and Administrative Expense",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r332"
     ]
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "presentation": [
      "http://regenerexpharmainc.com/role/RelatedPartyTransactions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "RELATED PARTY TRANSACTIONS",
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r253",
      "r254",
      "r255",
      "r257",
      "r258",
      "r295",
      "r296",
      "r297",
      "r335",
      "r336",
      "r337",
      "r358",
      "r360"
     ]
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "presentation": [
      "http://regenerexpharmainc.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r97",
      "r284"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://regenerexpharmainc.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://regenerexpharmainc.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Liabilities",
        "label": "Liabilities",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r113",
      "r142",
      "r156",
      "r157",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r164",
      "r220",
      "r221",
      "r222",
      "r232",
      "r308",
      "r376",
      "r398",
      "r431",
      "r440",
      "r441"
     ]
    },
    "RGPX_NotesPayableRelatedParties": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://regenerexpharmainc.com/20230930",
     "localname": "NotesPayableRelatedParties",
     "crdr": "credit",
     "calculation": {
      "http://regenerexpharmainc.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://regenerexpharmainc.com/role/BalanceSheets",
      "http://regenerexpharmainc.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Notes payable to related parties",
        "verboseLabel": "[custom:NotesPayableRelatedParties-0]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://regenerexpharmainc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r406"
     ]
    },
    "us-gaap_PaymentsToAcquireFurnitureAndFixtures": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquireFurnitureAndFixtures",
     "crdr": "credit",
     "calculation": {
      "http://regenerexpharmainc.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://regenerexpharmainc.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchase of furniture and computer equipment",
        "label": "Payments to Acquire Furniture and Fixtures",
        "documentation": "The cash outflow for acquisition of furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r63"
     ]
    },
    "us-gaap_DebtInstrumentMaturityDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentMaturityDate",
     "presentation": [
      "http://regenerexpharmainc.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Maturity Date",
        "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r90",
      "r379",
      "r436"
     ]
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionLineItems",
     "presentation": [
      "http://regenerexpharmainc.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r333",
      "r334",
      "r337"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://regenerexpharmainc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "RGPX_OperatingLeasesRouAssetAndLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://regenerexpharmainc.com/20230930",
     "localname": "OperatingLeasesRouAssetAndLiabilities",
     "presentation": [
      "http://regenerexpharmainc.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating leases, ROU asset and liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://regenerexpharmainc.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://regenerexpharmainc.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Operating Loss",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r135",
      "r137",
      "r139",
      "r141",
      "r377"
     ]
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://regenerexpharmainc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r405"
     ]
    },
    "RGPX_AccruedInterestConvertedIntoNotePayableToShareholder": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://regenerexpharmainc.com/20230930",
     "localname": "AccruedInterestConvertedIntoNotePayableToShareholder",
     "crdr": "credit",
     "presentation": [
      "http://regenerexpharmainc.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued interest converted into notes payable"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://regenerexpharmainc.com/role/NatureOfOperationsDetailsNarrative",
      "http://regenerexpharmainc.com/role/StatementsOfStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r18",
      "r92",
      "r104",
      "r105",
      "r106",
      "r116",
      "r117",
      "r118",
      "r120",
      "r125",
      "r127",
      "r134",
      "r143",
      "r144",
      "r195",
      "r209",
      "r210",
      "r211",
      "r217",
      "r218",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r230",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r252",
      "r287",
      "r288",
      "r289",
      "r298",
      "r354"
     ]
    },
    "RGPX_NoncashOrPartNoncashAcquisitionOfIntangibleAssetsExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://regenerexpharmainc.com/20230930",
     "localname": "NoncashOrPartNoncashAcquisitionOfIntangibleAssetsExcludingGoodwill",
     "crdr": "debit",
     "presentation": [
      "http://regenerexpharmainc.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note payable issued for acquisition of intellectual property"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://regenerexpharmainc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueIssuedForServices",
     "crdr": "credit",
     "presentation": [
      "http://regenerexpharmainc.com/role/StatementsOfStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Stock-based compensation",
        "label": "Stock Issued During Period, Value, Issued for Services",
        "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://regenerexpharmainc.com/role/BalanceSheetsParenthetical",
      "http://regenerexpharmainc.com/role/StockholdersDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r51"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://regenerexpharmainc.com/role/StatementsOfStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r92",
      "r116",
      "r117",
      "r118",
      "r120",
      "r125",
      "r127",
      "r143",
      "r144",
      "r209",
      "r210",
      "r211",
      "r217",
      "r218",
      "r223",
      "r225",
      "r226",
      "r228",
      "r230",
      "r287",
      "r289",
      "r298",
      "r454"
     ]
    },
    "RGPX_DisclosureOperatingLeasesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://regenerexpharmainc.com/20230930",
     "localname": "DisclosureOperatingLeasesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Leases"
       }
      }
     },
     "auth_ref": []
    },
    "RGPX_StockBasedCompensationUnrecognizedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://regenerexpharmainc.com/20230930",
     "localname": "StockBasedCompensationUnrecognizedCompensationCost",
     "crdr": "debit",
     "presentation": [
      "http://regenerexpharmainc.com/role/StockholdersDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "[custom:StockBasedCompensationUnrecognizedCompensationCost-0]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesIssuedForServices",
     "presentation": [
      "http://regenerexpharmainc.com/role/StatementsOfStockholdersDeficit",
      "http://regenerexpharmainc.com/role/StockholdersDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, Issued for Services",
        "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubstantialDoubtAboutGoingConcernTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubstantialDoubtAboutGoingConcernTextBlock",
     "presentation": [
      "http://regenerexpharmainc.com/role/GoingConcern"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "GOING CONCERN",
        "documentation": "The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern."
       }
      }
     },
     "auth_ref": [
      "r47"
     ]
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://regenerexpharmainc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentNameDomain",
     "presentation": [
      "http://regenerexpharmainc.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://regenerexpharmainc.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r115",
      "r165",
      "r166",
      "r167",
      "r168",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r245",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r422"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://regenerexpharmainc.com/role/BalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://regenerexpharmainc.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Liabilities and Stockholders\u2019 Deficit",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r78",
      "r283",
      "r386",
      "r423",
      "r428",
      "r437"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://regenerexpharmainc.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://regenerexpharmainc.com/role/BalanceSheets",
      "http://regenerexpharmainc.com/role/GoingConcernDetailsNarrative",
      "http://regenerexpharmainc.com/role/StatementsOfStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Stockholders\u2019 Deficit",
        "periodStartLabel": "Beginning balance, value",
        "periodEndLabel": "Ending balance, value",
        "negatedLabel": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r54",
      "r55",
      "r69",
      "r312",
      "r328",
      "r355",
      "r356",
      "r386",
      "r398",
      "r423",
      "r428",
      "r437",
      "r454"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "presentation": [
      "http://regenerexpharmainc.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development",
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r216",
      "r448"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://regenerexpharmainc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://regenerexpharmainc.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "LIABILITIES AND STOCKHOLDERS\u2019 DEFICIT"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://regenerexpharmainc.com/role/SignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Useful Life",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://regenerexpharmainc.com/role/NatureOfOperationsDetailsNarrative",
      "http://regenerexpharmainc.com/role/StatementsOfStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r92",
      "r104",
      "r105",
      "r106",
      "r116",
      "r117",
      "r118",
      "r120",
      "r125",
      "r127",
      "r134",
      "r143",
      "r144",
      "r195",
      "r209",
      "r210",
      "r211",
      "r217",
      "r218",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r230",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r252",
      "r287",
      "r288",
      "r289",
      "r298",
      "r354"
     ]
    },
    "us-gaap_MajorityShareholderMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MajorityShareholderMember",
     "presentation": [
      "http://regenerexpharmainc.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Majority Shareholder [Member]",
        "documentation": "Owner that controls more than 50 percent of the voting interest in the entity through direct or indirect ownership."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://regenerexpharmainc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r413"
     ]
    },
    "us-gaap_IncomeTaxesPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxesPaid",
     "crdr": "credit",
     "presentation": [
      "http://regenerexpharmainc.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes",
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r23"
     ]
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://regenerexpharmainc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r413"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://regenerexpharmainc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r402"
     ]
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://regenerexpharmainc.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://regenerexpharmainc.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional paid-in capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r386",
      "r452"
     ]
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://regenerexpharmainc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r412"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "4",
   "SubTopic": "50",
   "Topic": "350",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482610/350-50-25-4"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "1",
   "SubTopic": "40",
   "Topic": "350",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482633/350-40-30-1"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "20",
   "Topic": "715",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.20)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.21)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.22)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.25)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-3"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-4"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-5"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-2"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-2"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-3"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-4"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-2"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03.17)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "985",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//205/tableOfContent"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//205-40/tableOfContent"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-1"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.8)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//235/tableOfContent"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "275",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//275/tableOfContent"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//440/tableOfContent"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//505/tableOfContent"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04.9)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "840",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "40",
   "Subparagraph": "(Note 3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481418/840-10-55-40"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "840",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481501/840-20-50-2"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "840",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481501/840-20-50-4"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "840",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481192/840-30-45-2"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "840",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481161/840-30-50-1"
  },
  "r89": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r90": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.22(a)(2))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r91": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//275/tableOfContent"
  },
  "r92": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r93": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7"
  },
  "r94": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r95": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5"
  },
  "r96": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r97": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r98": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r99": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r100": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r101": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r102": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r103": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r104": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(210.5-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482955/340-10-05-5"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483032/340-10-45-1"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480341/340-10-S99-3"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//350-30/tableOfContent"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-6"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//718/tableOfContent"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481839/830-10-45-17"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482014/830-20-35-1"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481956/830-20-45-1"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481926/830-20-50-1"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483013/835-20-50-1"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//842-20/tableOfContent"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-1"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//850/tableOfContent"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-6"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//855/tableOfContent"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483154/926-20-50-5"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "35A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "35A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-2"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-5"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-6"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  },
  "r419": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r420": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r421": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2"
  },
  "r422": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r423": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r424": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r425": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r426": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r427": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-13"
  },
  "r428": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r429": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10"
  },
  "r430": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//450/tableOfContent"
  },
  "r431": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r432": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r433": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r434": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "15",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480123/805-50-15-3"
  },
  "r435": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r436": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r437": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r438": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r439": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r440": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r441": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r442": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r443": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r444": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r445": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r446": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r447": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r448": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1"
  },
  "r449": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r450": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r451": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r452": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r453": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r454": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r455": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>45
<FILENAME>0001472375-23-000142-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001472375-23-000142-xbrl.zip
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MP?G(<!LW^,L9WWY9_&K/PDN% %*B?NF>7_>N_R:IY=',?=*D53XOU7XAA_Y
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MFZ"[%1&4R\7T@7SC6C"#:W&@WAMPB."G30%=+26O9+AS)=O#>\M\UE2N?IL
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MOJ?3JY%7_,\C"_ _]$"Z&,Y!8+M4.BU>'!AL13J'<SG=0#"%]TW"0#I$ HP
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MIS97T#EW^-@RGY$RHMI1T'K; ,(<>[1)=VI<@7/@6),K4P50W?%G695C;3S
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M3YM9Z-"XO #FQ%ASR-<)94$C; W.50I]2&$M)HP2XXG2[W*(ARU - !U^45
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M#%FEM$/XKV.2OL%QJ^ZRV>V&Y.#RW26)Y90%2"H<\9X!D2!IYF#/ 9$I^L-
ML[AE#\9MVC9W[--<(N84F31%+@YTH)%7:<!?M=HG# :0)>^UQRG%1I+6[7]#
M13S4 / O5WN6=5$EL&9C^9C82)@"5MO?ZC#_6X(+))MPD];X\](BM@V^:Y\^
MR?+X"\*Y::CX3VL*Z:9S)5L67N7S3[PW8$$W_)B;519VPR^&>N$_=J]/+L\+
MQ8OE+? 7<D$B8-GPKH*<I-(EJ<III;0I294*I4HM4R2UB<Q-0YK>6WPL:VK0
M<VZW"G(+#_D-:DZ*9#WXM 1X_"N,4Y!ZI4JA7-M0[&7;"LH$DL--\_ BSU/M
M]72HJ2J'5U[5U[+VVK?T8K%Z+N[0*)7#/?0.P/I:6R3U3&PDZ7L+PE=8B2Z2
M5F1[HYX=*#P!UC2E1J-0J21H+*6(R)R&4J2A]VX<95L#;J:SCB8,DNGM[TG]
M_L[[MN;P DQH<+K72584=X1MB+G*Y!'>HOWO(&WL;\M%Q(T&#,UOM6>NM@U'
M-IZTOLZ%W&A.1VV&!DU#%Y7KA8M*=4Z04*QF9QO81A"6SPN51GUN _X%HM&C
M3''7(VTN>KY&=X2,19]_??&-UWM4A]G5=4OHX(ZG8D"5"_7S\TPIOYQ*TJ&2
M;21#M5 N5C)%)6F:2#?8M)LN'J KC,S1V,7.SQAOIZL?"K[*8A&EI?*Q!2!<
M56F%!/MUZ$WX6>?X0].("/Q["QMS.Y-[738<^*[EKR8-J5"/,8A7T6-I[VDK
M,S]&M<5JMAF]QK;1;/N61DF)G!]X@Z'!K4D82]\MT[;3.0%IG)>/,11X<%C<
MSJ\N%TN[Q^*>')H'1!L*$Q<O.T!EG$6C9K>1H&TVLIR2O=YGQM,MEVU.L.\,
M'FUA!:4ADAK%2J%VD5O*!TY4*QZ#G)<W.@;)L*WK'9I6ZF?U1NAP=-V[E_K>
MN8E_7K(DM6K#/($D,@!B";("U*B:+KA*>S]4%=!+14Q5RH7SZGP0:K>V4X[Z
M#5&_C;EU7JA5&N_&W,JN-DP\&+3&04 .VD,#[1X*16[;S6_MVW:OW>K2M42,
M=7N=J[__UKF];CUT@P;BK9OV5;NW^^SI3)^6O?/MY\+^^"52#MI#$/;+2E]N
MM>"*^EQ\Y^([*X4NB];95!08GGJ$CN4)%LCGM0<II-%Y4+X7($XQ)_.B4;BH
MY@4L.1%M$\VHUPJEZJ%G96XG%Q^XR"M L6@Y$^RF0W=$OXLCRX?O]W]\\2!P
MC]MO>KM/)PGJO#*?'' $ULBA(&^K8^9*J7!QL0?T9=::LER2&IBXQ W;:]J<
M/0<ONVJN-1KKYH1SCX1#_E2*9E.E=%$HUC>DXR./!1PAJ6R5J%TN%4J-#3.D
MCL0Z\CO3RYZ\T\-!CW>@8T,F.>Y_-S+JHEPHQI0XY);2SK&XE<54KA7JN<7D
MKW/:,6B,J<DB>=N@:UF]>!0VR[6'LL7%);NYAEPK50\%-=URFW[HJ0P"JIYG
MZ1TYA6QG.@&%U#=,2SX2T^EM@?>N=.^N9%.A6BP6BL6C['&2F08F%XT#;6"R
M$ZM&QVSYM5VEHTXG3UJ710H3?'M^DF8+E/-RH=S(UE%)3DJ)"K7&T94C+)I-
M5!<P%IO*\NZ:=BV5-#N*2A<JE7KA_'P/F>4YDM=!\E:'[?5S<)OW4'&;YY,N
M21\[DJ3''+0'J8G)*V9L00@T:(&A>(K:<S*.S>M<G-X0CAITIX!)I[%4K= H
M;FCA9UL#'Q &MU&PE5*U4"_NX>!L3PHV1GA87C8;YK)E-/"0O:C"')V&DJJT
M='+AJIN'*(_<@#@:\MA*DEUDCCYV: 6]:[,G[KPDE8#F1;50KN3]GU(\)BD5
MJP=Z3+*VO* X/,P6.O38BHN/.H*]JX9-P;G(G6DHZ04OZ^?50BECA_TY8:74
MM*E4K!_;*4G"39O8?BN##RK:GHYK53NO%1J;YOAGV[0Y"NQN>8U$N5&H;II]
M>("F57:5VQ'&^G/09EI5+TS#,D<CS<$^NQA&P*[25_ (V,'<4$ 0L8_H3;/Z
MI^QWJ8B1T\$\*UIHI?+)Y>FN_,WCA6)EAU#,5<OQR[\<M >I6L"OZSJF\E,<
M6]I!XSX^T!3-R3L_'8 V>">=G]:^XAR,)A-5(5#WE[?N'!$/$R?<RU;'ZCIX
M!$97*=]SBP[V$W#FVW<W48?OGD:VWW(ZMUC=&L[HXM45SXJQES#,7H0REBWV
MC*OZPE;>D)BCZ3I#TP+LJ8F#>6T0K[JBC4'KK^B\7L-ST 5GH;/ I<0ILO^#
ME7TA[MR23]:$2]NVW>Q@J>,ZM@,.$0B/U)94KM<+C5(-_JR")O3.$@7IUF26
M/$BW7A*"%!RYPOGY*B#5"#X$67.Z..0$9_FM2_EM@ML'/$/T00HGG=Q$Y+"\
MXOHX*6.K2FL2%(=^:V Z!FX3AD1@R#H,KZFGFL$4>:PYLGYL^2C+NYX$8+@'
M*+2-*P&#5)**"J5JO5!O7!SCV=MAH7&K2T[JI4+C?$.A\GX<Z&;D6E(O'I0]
M!7DX.2@?EW/  W=DS>!J2[8,P*4=N0>5P)^,3+-AO[^>G,YR!?BBM4:A6%TC
ML6 17!-7PJN=;.6$MVO"6T\*+R"\<J%8AS_E-01R.H0W0V>[*%%?&GM_;YDW
M;Y!I&%9X\:PS254>5@KG%2Q<3Y@LDQ9Z.06D)I@P&:M<:"2M$=.2/FL)O#2S
M0BD"M^FI8N8O5DCK<L@=1&Q".&H::EKR-,'+1/.;/-XGP>WI"M,5(3*7C;5(
M>!+0%\K3Q1$"^+MOJA/Z 0OD+B5I 3["*/Z7:SO:8+*4 U8::.&]C[TAQU;9
MYF@L&Q,\@A']'F6+2[+!-'CKR:)HI$654<Z0VQRP([NJAD&$@6;(AJ+!$S8>
M8%,^XYFW*MHGS*SK7BB#,*OHL@TXEM7G/\<R+):N(3BAQ^RQK/B/"0X1JCR:
M1U$L?HC)G@OCJT28($4K8$XJ=Y%P@%>BL$(U>K*(J"J5#TG'_"K5#W'(HFD\
M: &D.+!+'[L0K#1SZ<U)*Q]B4PZWC83%T;D@A!!&9Y$]2R-Q&$<0G/8M+O\\
ME0< GB],UE_DB3V/Z-6D;=6W@6/WO.6.%X3IG!B9$10R::K \Y_E"),, 2\Z
MX@;X;&A:;(9Q+D,)G[&28/%.^@N%7QPQ^MOO+YYJ9:$#-N9#ZWOKKO70^H/=
M_]9\^-$LL/;=U5EBPW=[S5[K1^NNUV6=&]:Y;STT>^W.73>Q"3X^WC4?K]N]
MUO4G&C.<H[N0=)9C:N7I([(_$>;R. 3THRZ/;9C(_REF]C?9;=M R@*IF:YQ
MF++M^3Z&7RXY$L9G-K:<#Y\!>D@SK+O3<UL0NZ@C?CVIGBQ?_V;1N 5FYB)#
M +T#BW/V SX>VJQEJ%Q=+7T\NR?C68-P5WO=/7SWR"\KA*131_@68?'=T$0X
M 7+W#)>C*(LH>D\\NR,B6-77*]-!]M&S8?:@7LZA_CYH_=A!NAM"/AHW:,=K
MSCPEYX#( 7&0@$BYS#UH'LA:KWBE^3ZZEQT()G) Y(#( ;&/5C:A HY-<_*Z
M7-=!RA78$S<XIF-@-IZLCC1#LQU+7MJC-L%<J+4SB18G0&4WO^F[ ''34)LA
M #]S3\-$TYMN+',DTIOJI\52 K=J7=0*C76RY@\XLRZGI@745 ZHJ;QE#7:I
M4-OT<I&<F(Z#F$ @58&8''-[X52KGA>*C0V;U.;T=!ST5!;TM+UPJEP4ZA?I
M)O7NPUM-P-I[X#:G7B>B+ZC*G[ENCC&U]F#BISLJ,/<A!11\/8723BRUH[ZU
M/1.87['K:6VS.Y!S!.R!]9*R1'+FRPKS58_MNB!/?Y>KF^MOOWPR+CJ]8<N#
M_5O*N[)) Z#Y,$M;C=>S'G+):6,]VG@WX9.<,-86&LD9((VL!T-RZEA;;.2!
MC0-)#%H]22^;7==S".40RB%TX)[B2GE)MZ:]>D[2@:GI%-O7!0!L&XHYX@C%
MI/W A9WKUG8(#Z!E8DY%RZAH"X]Q$16MZ3KF)'3@)+25;[E0%.W?R?QTO%YF
M!JAF"Y]S48?+-9W/_0B>8_-',VT&Y]O/M_]NM[]''] 9<HL)!< ^>J''3YGR
M!1./PZZ!U&,,@>?PS.&9P_/@3C822-EL8_4WMQU8 !>2/@N55KOKXN[O?R>I
MEZ5&X2+V[M(M?)RD(RCO"K.)95R4S@OGQ=VTYL\QNR+/)I4R4;DH5-;!;8[#
MY+@SH<2&<J%4KF6".[-?LGMC6ARFAZ4IKF5Q0YFP)UDSV$?=M.W\[JNM-K*<
M)SS(7WE@[UFR88L'OP,",!;[C0,#\)[\FJZ=4BV4ZVNP2]:\CYS44B>UY RG
M1N$\I[4#I[4W='T"<BV%(\KS\H9%./DEDONGN-2E6S*&9[D!FC1;B?@)QIW*
M%V=)%!LM.&YX3][0G6F8T9/WE.)1BRX7K!5JY?-,.$A'@.PD<9V8H54I%,_S
MJ^*SP+N)VS+58J%1S@-4^T1K\OE0Y<)%+1M'!7O*1,C8$>2:-04[MMRSYA;G
MT,^AGT,_AWYF7-9%L]UQQRMU2LP.6=,.VOU=R\G92-S90YG31;%4J%833A5/
MP@[.264;4DF^EJET4:A6,AC5R.ED2Y&21L'21;U0+&\8JLV)8M]$D;S_72T5
MSJMKG!#E#GB> YS#,X=G#L\<GOMP9+_V+[_)MJ90Y^5K37<=KI)G"].,N<6N
MS-$(%&MW*%M\:2U7;H@LRUKUK1"T.Z[@;<UP->/)*YLV#?N>6X0&@G.B+G'[
M[F:!L7)/D]DGE\6S+%87Y 25+D%MZCBO1E#9,(%S@MJMA-K0PTY<1N6D<UBD
MLZD??DBR:'^5^;]S1#_8=4V81W[B[,ZEF]P9,P<1 \]F'=>Q'3 % 7];5>[O
M.MLT 8;806-6'Q$>'@0:.@,!^Q#HB5N2MP(#_O!YHURO%VJE\T*EMF&*5Q8<
MR)S4TB&UK>S#6%(KE<J%\_-]IL_GI)9)4MO2<HPEMDH%_A37.,;+B>U]$-M6
MMN;!R#5A;<+??5.=T \R8/92DA8,&<:LPK'*>NDTVXW3&W(F*^ VC&5C@EV#
M#=,!XQ,@*LD&T^"M)[ST=RQ;#IJHSI#;'$ ONZJ&9NQ ,V1#T> )P+;#\1XF
M^VS[58&E[&]06+XP'$$-7M'UL:PB7='9GZ++-E"$K#[_.99A%G)S3N@Q>RPK
M_F."S<1I830X72Q^F%M M" &/GD]$>Z"P" Y#HO\!7@ENDFLM#E91'>5RH>D
MI5BE^B$.RC2-!RV %#>(74]6F[G\YJ25#S$B*1VN$800PN@LLF=I) [C"(+3
MOL7EGZ?R ,#SA<GZBSRQYQ&]FLBN^JE\.Y$4?J66$U.IA5"G*[0T56#ZSTJ$
M38: &1VQ XP[-"TVPSJ7H<NT5F+B?[FVHPTF*<HHD 8/K>^MN]9#ZP]V_UOS
MX4>SP-IW5V<AZ;#=\-U>L]?ZT;KK=5GGAETUN[^QF]O.[]W$)OCX>-=\O&[W
M6M>B#5_XCK.%<%L/#ZNIBD28Q^, 4)&Z/+9A(O^GF-G?9*>4FJZF6\62<I',
M^Q@^7DTEC\\T#VT3R_Q.J/8*.!'%QJ\GU9,UUO!&K'6M*/4"XZ._4-S=@!("
MNY)UM5?V [X<VJQEJ%Q=+>JY\R:M&:VEC$'\7K':Y6/P!S"V#8YSCLK=]G)8
M"<.KVBX8"=H) M\52,L'SQ.PCRO9'K(;W7RQV< R1Z%K9QEK*H[VK#D:M[^L
M?'Z5$</DB#JD'P@@]G0BB[5CC.F;5(]%8\8QT=@$EK<X%6$5*976JHZE_B,#
M%Q_EQ/5.ZT@.ZUZ;IHI!/@KNP\".R2P.D%<TG3,#)"C*3_Q406M@0-: :W.5
M:08+&G P.6P.[%(#;I9I=30&0*:WG[+:]WOIULZJY[BB:/#\=<4V9]=\#/2N
M47@\,[45^Y31RT5T&%QI-_8N%1J'W'HT)XKD&S:6"O7&T?9KW%*2=1U3^7G:
MEU$YXY$_-^S5I=J^J30I4J1TD6\(@ZL0"%*75)5*H7+QKMKW)8?/\&GIJ<V5
M4^WU=*BI*H=77M77LO;:M_1BN53%M5Z42^7PX6ENP-R9QBG:YI+%;2Y;RI J
M#%7^S'5SC%:]?W'0XBA(KLE\\7$O3\@1ZIE-Y2]7LWC;<&3C2>OKO&G;W$DA
MY#$;Z:@6BX7B.J44N=V3(K6L*ISJ&PFGH[=)FB,3IOLW*6',,'SH/#*9&*E
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M8LL59Y(J?<WG31!I9?CVD)RLULMFVY"@IE8W6LMMPS.3MR.N\WJIT#C/B>N
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M^6:>CYI>/FK*G34KE3P?]<"2;9+*M4FON>9:98DY01TE0:42E+QHG!?*ZS1
MS(EKW\256&K@3NX3P]+60JUQD?7,P9SH=D=T211-7U0*C?/,4]778[T=('=0
M<@<E5_G9H+'<0<D)*@L$E3LH.7'E#DKNH!P^T;U+!R4OF,MTMG\].+!;H^_8
M@FS_6@6D7EXNLS,44RK:FAA.WDX'M.<H/PB4IV))(]<7-[6DWSL)K)@652\=
M85K4\3#8-JRS%X69E\=ET=?817E<@N9>-:^/.W#:6:^4(6T[LIH7R+UW6DK%
M0&U<%*K%;!7/O%_26M7@K><%<EE UZXEP18\?E')%H_OJ$#NW54IY)5Q^XA
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MP:2H3+E%MK@JH7%E&0*1DS!XSW8CH6:LVA0\K6\>3U_#0Y8V1KIN&NHWV=;
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M3XA)? U1*51BR-)'=@")#VO!JA<0"V2#AYT6I&F9UA@G&36'/ '^2D:W[D6
MD!?0MI0\0QY>?B/$E)DC8U\*>R0!GX)O(%FR9D>=4SR>![,:>256A(3<#@]%
M/(0/R<?'](@ 0(ARZ3(_0=WC"6HM,R>H1)@^3<12R$$=K28)BJU.6<\3/65=
M7RG%Z<4$PH5+W>UH]!BD*]I_*!FU 7 TALPQ  622I?!'AN2LQ8)WH%^<#'P
M@#$9$>'V8SL_9 .@BJHRD'P8/Q"Y)'B"HZ"%#!K0YORGI(C$2!&8)2*>"=<"
MS8*'\3*-\L+LGP$O7E2#S&*PL4&^.S H^$Q#C3]3L&,:Z3ECOYDO\*E5 'KP
M5X<!([ 8_;!(*&9$IC,L8R)A3,D7] . C";>$TNFIGA#3@' \*(I*#)=$O.6
M% T^%<""P"J6::3/BP ^<XHKBEGE((T4=!@J%]J[Q$D=^@OQ]5,[JNK!SG8)
MHA) :&XX?Q.>]6&@=>Q%,6'V$>>.;_R J>!1")D_!2D$0N'+V '$HC P.!@1
MJ.U<#+CJ$1N"D!^S'C #=*2Q@?QL6H(>N#421@>B?>Q:-NA-$7;%):F@>J41
ME\F%.=M;#L0;EF2\\Z*:Z$/Z_@<C RWDD%M<IY-GX?B!QZJ@!>6;$10F1KE%
M+.L;>[YY)4A2'J$-:L<\BP?58=M,>*@H]] ?F[KTGH\6QJU'N*['KJ848\VP
M&6LFHW[.5. U W/]'C06,+J=M(]3]7V<;OO[7?NF?=6\Z['FU57G\:Z'/L]]
MY[9]U6YM&Z=+'DH/(E+_ &@'<"'Q$(@FB0%(N_2F8*$YZ%!K_T<?),B0\RPU
M.++ H+G%FMTK=EX\QS!WZ1-8$\"R,)Q_7H2 1P=B&L80F0#P8OF3-/NT%S\7
M)Q9]6)\0D[YT#@:K? (]@ )1,[Q7)?C"L#T'"AQ-!=1']1/&]DR% ETBN#7[
MD!],\B2[&EZ!M&0%POFK?2*0 *;^+=2#@ LH0P,ECVQ[?BB"$(4+=AZS!Q0.
M6;#5?<4#?_?C<2C'A'/N\&!#Y/D.A99>\2 E.#J6ID<I!2]IZ ?'^*"FLGO+
M?++D$:4HT7&)IP1_X[(.U$*G-M-G_HD8EPW?F@*MB>BGPVZ*X]Y;FHT9'!,;
M]$I!'/S,C"26*Y G5*=WBH_F@5B6A=O61GW0K]Q+:%"Y'CYQER(\H?(!:>
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M)NLSX[\=E!=,?$/96H*7KS6;4H,>X/VD0O)8D0*3GI9#9M,].)/8U&#.</I
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M:XX)NP_T!EHNL18*6]U"D2(6B@R.G\E&FJY3IR6LQ1^"*J BG?FX5+E0%6;
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MAN,B4AUY%?*1YELR%3XCV6@K4B[43E 8RA60X['?3Y3L7(H@0W]BJN6]3A&
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MO5 5>AH8JQ'A'/&G[-7['J+1O.&3E%/SM(NT>DO [!JB@/NW3C)P8%L*F4H
M [YM?$E_<61%32$QOF/^E-?*:0?9P5Y&>V"$]F'DA4KTCE=1?H.7CU+O/<(9
M..NJ:TZ"(!'!,G)[A5@3E@4E50;ZL2XDLEI8@5)BU#GE7XI))QX+*0EZ?N9#
M_(091DB#L$1N/--DBK)#D 3/40^#I-<A )(!.Z-#$X>721Z)!2GO#V^9Y"P
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M>WY?VU;WL0#*FWK3TW\1"]OV,_KW@@O\,2)!")0MN,#N@)FO/]&O:(U>H[M
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MJ8R21!8?.A1?(UC/GADZ-?O72D869U&6\S-)''@:W40I(%8[ELXY!^P+S)V
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M]B \"9'*SC(7N]#"MR=[G=;SO1WGVMW^I"Y35W=;KUZ^:-$YY\W_TBP<8^D
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M/M903:.AH#B[%YHHWZUVJ)C7YWXTEA+S;9KFS?'11MS>)U\9"),N8^<@6%D
MY 9N,NXY,7O==^[K!UV7/=?5JFBE .RL2@A#(..<(LB61#;"=DMP213B?*3I
MS47M03+T?QX9EB <KW= ;/25MSX)E!'K'@=Z64SO(,J(=!,@B.NC94C+(0W:
M66=S[X,TC>C965J274S6A/M*VRV)= '8F[LV5+<4\ @HM^IQ"<<39<'\@16(
M#]-KB41QZ=?7&ZQC\X]\'T9H-"\:DA?,!*;#^Z('[!=[6J^MED$FLHHK:Y4
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M($"PA5_25QX;4.'^O@Z#=Y219RB[D1*H9OP/8/JEJ BYP;#??;*,LOR2CY3
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M7F)T!430L68K?GMMOIWJNMU$-$9]^Q%,$V.*V7A#M5G=;V]:ZM^<O_%&0:4
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M7>2[H5])=&??,<E->S*DYQGK1^3+16HO,!8\'O-TD]+8W\" VS!L>#/XC_I
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M31;!,MU0HG+C2)3%!/IQJI@<!0^()%_ 98\C)2P2IE%4LW$<2@&""%1VVF&
MZ#B!XEQ5%*6#L;@:"\JQ^UUA^OCU&D>>!!R(NK>JX\)0JJA<*+5 ZJ@^450
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M&!!U] @5#")*J*OEDTBS)$RS7=I*=YBD>^( #Y-TK8Y0#%IN2675A"ZUM"J
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MU^3W5B5X;L?722-A2#=$\*@\60>9C$(Z8>>GCB@!"V>/")(@B&2$ISZ'I-9
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MS6%X34=ACA W@$H+J#*!B U/T1,MS1Y$ZS(:T$SX207A14IZF.)F5";=9!U
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M'XJ6N -/3./B:*N_+9#70']@JA+I&B#PF2HV<L?C;4P>X[^8WP=DJZ._-=7
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MN;7") .K\E9450?;O[[2S"D2W\A4N?^+^+][*R#\D_\'4$L! A0#%     @
M U]H5SJ_)J:+!P  0"L   \              ( !     &5X:&EB:70S,2TQ
M+FAT;5!+ 0(4 Q0    (  -?:%?E ,S,S@<  /XM   /              "
M ;@'  !E>&AI8FET,S$M,BYH=&U02P$"% ,4    "  #7VA7"*!UO ($   _
M$   #P              @ &S#P  97AH:6)I=#,R+3$N:'1M4$L! A0#%
M  @  U]H5QLQ--TC!   C1    \              ( !XA,  &5X:&EB:70S
M,BTR+FAT;5!+ 0(4 Q0    (  -?:%=<:=6<>9@  +4I!@ -
M  "  3(8  !I>&9O<FTQ,'$N:'1M4$L! A0#%     @  U]H5U8TW9M'%0
M5!8  !$              ( !UK   ')E9V5N97)E>&QO9V\N9VEF4$L! A0#
M%     @  U]H5V1^!!UT"   C$P  !$              ( !3,8  ')G<'@M
M,C R,S Y,S N>'-D4$L! A0#%     @  U]H5R&'V$ 6"@  BW(  !4
M         ( ![\X  ')G<'@M,C R,S Y,S!?8V%L+GAM;%!+ 0(4 Q0    (
M  -?:%>@=WG.\Q<  &)L 0 5              "  3C9  !R9W!X+3(P,C,P
M.3,P7V1E9BYX;6Q02P$"% ,4    "  #7VA7\O-_[2(Q  #0FP( %0
M        @ %>\0  <F=P>"TR,#(S,#DS,%]L86(N>&UL4$L! A0#%     @
M U]H5R.K)>:V)   .#X" !4              ( !LR(! ')G<'@M,C R,S Y
@,S!?<')E+GAM;%!+!08     "P + +D"  "<1P$    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>